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General introduction
PART 1
Nutritional care for the preterm infant
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INTRODUCTION
Definition of preterm birth
Prematurity is defined as being born alive before 37 weeks of pregnancy are completed. 
The subcategories of preterm birth are based either on weeks of gestational age or 
weight at birth. Moderate to late preterm infants are born 32 up to 37 weeks of 
gestation, while very preterm infants have a gestation at birth ranging from 28 to 
below 32 weeks and extremely preterm infants are born below 28 weeks of gestation. 
For categorization according to birth weight, the following subcategories are used: 
low birth weight (LBW < 2500 grams), very low birth weight < 1500 grams), and 
extremely low birth weight (ELBW < 1000 grams). (1) A subdivision is important since 
lower gestational age and birth weight are associated with greater risk of developing 
both, short and long-term health complications, or even death. The major cause of 
neonatal mortality, which is defined as death within the first 28 days after birth, is 
preterm birth.(2)
Prevalence and outcome of preterm birth
Figure 1 presents the global rates of preterm birth with distribution of subcategories 
of prematurity. Despite a reduction in live births over the past decades, the number of 
preterm births is still increasing. (1) Approximately five million children are born every 
year in the EU, of whom about half a million are preterm infants requiring care in the 
Figure 1   Estimated numbers and rates of preterm births by region and by 
gestational age grouping for the year 2010 (1, 5)
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CHAPTER 1 INTRODUCTION
neonatal period.(3) In 2008 the incidence of prematurity varied from 5.5 %  to 11.1% of 
all births among European  Countries. (4) 
 Between 2004 and 2010 neonatal mortality declined in Europe by 29% (95% CI 
23% to 39%) with a range of 9 to 67% by country. This was mainly based on increase 
of survival of preterm infants with similar changes for all subcategories of prematurity 
as described above. (6) Despite this progress, prematurity has been recognized as 
a severe public health problem with an increasing impact on the annual societal 
economic costs caused by long hospital stays, high first year medical costs, educational 
and lost productivity costs. According to Petrou et al ‘neonatal costs tended to be 
higher for preterm infants who survive compared to those who die’ and are related 
to the need for surgical intervention and the level of assisted ventilation needed by 
the infant. (3, 7-12) Table 1 presents a summary of long-term impact of preterm birth.  
 The most comprehensive information with regard to long-term outcomes of 
survivors in Europe has been collected in a number of cohort studies such as the 
Dutch nationwide prospective study (POPS), certain regions of France (EPIPAGE), the 
United Kingdom (EPICURE) and Sweden (EXPRESS). (20-29) The EPIPAGE and EPICURE 
study were repeated and thus included infants during two time periods.  All of these 
studies followed high risk preterm infants up to the age of five years and evaluated 
survival, morbidity and neurodevelopmental outcomes. Summarizing the results of 
the cohort studies of different European countries showed that, despite the high 
level of health care available in these countries, preterm birth still bears a high risk of 
unfavorable outcome. On the other hand these studies also showed, that improvement 
of outcome over the years was possible, that a substantial number of infants achieved 
a normal development and outcome differed among countries. (26, 30-32) The evaluation of 
different treatment strategies among different countries could be helpful to improve 
treatment for preterm infants. 
 The care for very preterm infants implies a complex treatment concept taking 
into account the immaturity of all organ systems but also the rapid growth and 
maturation at that stage of the development, demanding adequate nutritional 
supply. With regard to the long-term consequences of preterm birth, it should be 
taken into consideration that the immature gastrointestinal system may prohibit the 
supply of adequate nutritional intake, leading to undernutrition with consecutively 
growth retardation affecting not only growth of the body but also the brain. Over the past 
30 years, neonatal care has become highly technical and sophisticated leading to fully 
equipped intensive care units. The use of antenatal steroids, respiratory support with 
mechanical ventilation, surfactant replacement therapy as well as hemodynamic 
support, treatment with antibiotics among other things caused a significant decrease 
in neonatal mortality and improved outcomes for ill born and very preterm infants. 
(33) Nevertheless with regard to optimal treatment concepts, the recent EPICE study, 
that evaluated clinical practices in European NICU centers, found that treatment 
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CHAPTER 1 INTRODUCTION
Skimmed cow’s milk enriched with dextrose-maltose proved to reveal the greatest 
weight gain. This was thought to be the result of higher protein content in the cow’s 
milk feedings. (43) Furthermore studies showed that human milk, even after enrichment 
with vitamin D, was inferior compared to skimmed cow’s milk for adequate bone 
mineralization leading to the general recommendation that artificial feeding was 
preferred for preterm infants. (44) This led to the development of special formulas for 
preterm infants, providing more protein and fat. Clinical studies showed that these 
preterm formulas improved weight gain without metabolic abnormalities as reported 
with previous formulations. (39) Finally, the use of breast milk was reinvented because 
a number of studies suggested that the protein quality may play an important role in 
feeding tolerance. Further human milk fortifiers were developed to enrich human 
milk. (45-47) 
 Necrotizing enterocolitis (NEC), an acute disease of the gastrointestinal tract, has 
determined the treatment strategies of enteral feeding in preterm infants for many 
years. (48, 49) Since most infants have received some enteral nutrition at the onset of 
the disease, the fear for NEC led to a tendency to withhold enteral feedings. On the 
contrary, more recently the idea emerged that human milk may have beneficial effects 
on the prevention of this disease. (50) The development of parenteral nutrition for 
preterm infants provided the opportunity to treat sick infants who were unable to 
tolerate enteral feedings, and currently parenteral nutrition is standard of care for 
extremely preterm infants. (39) Nevertheless the optimal composition has yet not 
been determined. The most recent European guidelines for parenteral nutrition in 
preterm infants were published more than 10 years ago, although an update is 
planned to be published very soon. (51) 
 During the last century techniques to provide nutrition to preterm infants, as well 
as the knowledge concerning nutritional needs have improved. However, there are 
still controversies in recommendations and clinical practice. Knowledge on specific 
requirements are often derived from clinical observations, animal experiments, 
short-term observational or interventional studies. The recommendations based on 
these results may not always have contributed to the improvement of long-term 
outcome of preterm infants. (52)  As an example, fluid restriction and delayed feedings 
that were proposed in the 40ies of the last century, revealed to be associated to 
dehydration, electrolyte disturbances and finally serious growth retardation with 
impaired neurodevelopment. (42, 53-57) Despite the fact that these practices were 
revisited twenty years later, nowadays, the fear of fluid overload and feeding 
intolerance still exists. (58-60) Fluid restriction often implies a reduction in the amount 
of nutritional intake. Consecutively many preterm infants born nowadays develop 
postnatal growth retardation, remain growth retarded and perform less in later life 
compared to their term born pears. This impaired development has been associated 
with early postnatal growth retardation.(61) Most early studies looked at more mature 
protocols varied greatly and consensus on best practices appeared to be lacking, as 
well as standardized protocols or guidelines on national or regional levels. (34) This 
study showed that  outcome was improved when evidence based treatments were 
applied. Thus, to optimize the treatment of preterm infants, and thereby improve 
long-term outcome, uniform treatment guidelines based on adequate research should 
have a priority. 
 This thesis will focus on nutritional aspects for the very low birth weight preterm 
infant, including very and extreme preterm infants, with the aim to provide more 
knowledge with regard to the efficacy of current recommendations for nutritional 
supply.
Historical perspective of preterm infant nutrition
The history of neonatology shows that in the first place the survival of preterm infants 
was related to the awareness that thermoregulation on the one hand was an important 
factor for survival, while on the other hand feeding was necessary to keep preterm 
born infants alive. (33, 35-37) At the end of the 19th century Pierre Budin, a French 
obstetrician, combined the incubator care with the focus on mother-child bonding to 
improve breastfeeding, very likely to currently reestablished practices. According to 
his ideas, warmth and the ability to provide own mother’s milk, were the key-principles 
for preterm infant survival. (38) He became an international authority on the care of 
preterm infants. (36) His colleague introduced gavage feedings for preterm infants 
who were too weak to receive breast milk from a spoon or the breast. (39) 
 The energy content of human milk was first determined in 1887. The first energy 
requirements for preterm infants were based on a number of studies at the beginning 
of the 20th century and recommended a range between 95 and 160 kcal/kg/day, while 
most infants received intakes between 150 and 200 kcal/kg/d, because it was believed that 
rapid weight gain would be beneficial. (40) Twenty years later the energy requirements 
were reevaluated based on 11 preterm infants with a birth weight ranging from 1130 
to 2220 grams between 10 and 44 days after birth. The daily energy requirement was 
determined to be 120 kcal/kg/day with an average daily weight gain of 16 g/kg/day.(41) 
Recommendations used nowadays, are mainly based on these early calculations, 
while it is not known whether this is valid for the extremely preterm infants treated in 
modern neonatal intensive care units. (39) 
 During the last century the ideas and recommendations for nutritional requirements 
for preterm infants have changed in all directions, indicating a lack of knowledge with 
regard to optimal nutritional requirements. Practice changed from early feedings of 
high volumes using exclusively breast milk to delayed feeding only after the first 72 
hours with restricted volumes and different kinds of cow milk formulas. Delayed 
feedings were thought to prevent aspiration pneumonia and necrotizing enterocolitis 
(NEC) and were regarded to prevent edema based on immature kidney function. (42) 
20 21
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CHAPTER 1 INTRODUCTION
activity. Energy provided by carbohydrates, protein and fat is converted to ATP by 
oxidation in mitochondria or lost as heat production, while ATP is hydrolyzed to ADP 
to maintain vital functions, growth and storage of energy. Energy loss can occur 
through losses in stool, mostly as fat and in small proportions through carbohydrates 
and protein, and through urine as urea. Energy stores comprise primarily fat as 
adipose tissue, protein as structural component of all organs, and in small amounts as 
glycogen derived from glucose and other carbohydrates. 
 Glucose is the major carbohydrate and the most important energy substrate for 
the fetus and newborn infant. (67, 68, 73) Glucose is particularly necessary as primary 
energy source for the brain but also for the heart, liver and kidney. Furthermore, 
glucose serves as a source of carbon for the de novo synthesis of fatty acids and a 
number of non-essential amino acids. Fetal energy requirements are high and the 
driving force for glucose transfer is a constant fetal glucose concentration to ensure a 
constant supply. (74-76) Glucose utilization rate is twice as high in very preterm 
compared to term born infants, mainly as a result of the decreasing contribution of 
brain and heart to the metabolic rate in older infants. (77) Alternative substrates, such 
as ketones, are low in concentrations in the fetus and preterm infant and glycogen 
synthesis and storage does not develop before the third trimester and is low in the 
preterm infant. Immediately after birth hormonal changes occur that stimulate 
glycogenolysis and gluconeogenesis. (78) In a term born newborn glycogen stores are 
depleted after 10 hours. (79) After this time glucose production is dependent on 
 gluconeogenesis from precursors such as pyruvate, lactate, glycerol and alanine. (80) 
The preterm infant is prone for hypo- as well as hyperglycemia.  Low substrate stores, 
intolerance of full enteral feeding and probably rate- limiting gluconeogenic enzymes 
regulating gluconeogenesis may lead to hypoglycemia. (81-83) Therefore in clinical 
practice, glucose supplementation should be started directly after birth in all preterm 
infants, either as parenteral infusion or early enteral feedings. Hypoglycemia in 
newborn infants has been related to impaired neurodevelopmental outcome, while 
hyperglycemia has been associated with increased morbidity and mortality.  (84-88)
 Protein is the major structural and functional component of all cells of the body. 
Proteins are macromolecules composed of one or more chains of amino acids. Amino 
acids are composed of an amino (NH2) group, a carboxyl group ( COOH) and a specific 
side chain attached to the central α-carbon. Functional differences among amino 
acids are based on differences in the structure of their side chains. All proteins are 
polymers of only 20 different amino acids. These amino acids are usually grouped into 
essential, non-essential or conditionally amino acids. Essential amino acids cannot  be 
synthesized by the body and if these amino acids are not sufficiently supplied the 
protein synthesis will be reduced. A number of amino acids are called ‘conditionally 
essential’ based on the temporarily metabolic and physiologic immaturity of the 
preterm infant to provide adequate endogenous synthesis and thereby increased risk 
infants with probably different needs than the group of very and extreme preterm 
infants currently seen in the neonatal intensive care units. The specific needs of the 
very immature infants still need to be defined. (54,62-64) Irrespective of nutritional 
requirements, the aim of nutritional support, as first defined by the American 
Academy of Pediatrics Committee of Nutrition in 1985, namely to achieve a postnatal 
growth rate similar to fetal growth combined with satisfactory functional development, 
is still valid. (65, 66)
Nutrients – The ingredients
Nutrition in general is an agglomeration (collective term) of all constituents or 
nutrients the body needs for optimal functioning, growth, metabolism and repair. 
Nutrients are subdivided into macronutrients and micronutrients. Carbohydrates, 
protein and fat are the primary macronutrients, while micronutrients comprise 
minerals, trace elements and vitamins.
 The requirements of macro- and micronutrients as well as the amount of fluid not 
only depend on the weight of a child, but gestational age, immature gastrointestinal 
and renal function have to be taken into consideration to guarantee adequate 
nutritional supply. The common recommendation for postnatal nutrition of very 
preterm infants is that the nutritional intake should meet the nutritional requirements of 
the growing human fetus and lead to a comparable growth as term born infants. (65, 67, 68) 
Fetal requirements have been estimated by the factorial method based on analyses of 
carcasses of deceased fetuses and from animal studies. (68-70) These  recommendations 
are insufficient since postnatal nutritional requirements exceed the fetal needs by 
energy needed for thermoregulation, respiratory work load, illness and other adverse 
conditions. (71) Furthermore the way of nutrient administration differs, as the fetal 
nutrient supply occurs as a constant flow through the umbilical cord influenced 
by maternal nutrition, endocrinology, placental metabolism and perfusion. Fetal 
nutrition is a complex interaction between genetic growth potential, the ability of the 
maternal-placental system to transfer nutrients to the fetus and the endocrine 
environment determining whether the fetus will follow this growth potential through 
intra-uterine life. (72) In contrast, during the postnatal situation the nutritional supply 
to the preterm infant is dependent on intake based on standard nutritional guidelines, 
impaired by incomplete nutrient absorption through the gastrointestinal tract and 
suboptimal composition of either enteral or parenteral nutrition. 
Macronutrients
Macronutrients provide energy to all organs to sustain various functions of the body 
including thermoregulation, growth, pulmonary function, circulation, and physical 
22 23
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AA and DHA have been found in high concentrations in structural lipids of the cerebral 
cortex and in the outer segment of the retinal photoreceptors. (120, 121) DHA also is 
important for neuronal and cellular signal transmission and a number of immune 
functions. AA and eicosapentaenoic acid ( C20:5n-3) are both precursors of eicosanoids, 
which can be subdivided into prostaglandins, prostacyclins, thrombaxanes, and 
leucotrienes. (118) De-novo synthesis of DHA and AA has been shown to be insufficient 
in preterm infants, while supplementation of these fatty acids in term infants seemed 
to lead to improvement in visual acuity and psychomotor development. (122) Thereby 
AA and DHA may be regarded as conditionally essential fatty acids for preterm and 
term newborn infants. 
 Preterm birth and thereby cessation of essential fatty acid supply, directly leads 
to insufficiency in essential fatty acids and consecutively failure of the lipid metabolism. 
(123) The preterm infant lacks adipose tissue and thereby has no stores to produce 
energy. This may result in lipolysis of available long-chain polyunsaturated fatty acids 
and fatty acid oxidation to produce the necessary energy and potentially lead to 
abnormal structural brain development with consequence for long-term outcome. (67) 
Micronutrients
All electrolytes such as sodium, potassium, chloride, magnesium as well as the trace 
elements and vitamins belong to the group of micronutrients. As part of this thesis 
focuses on nutritional interventions to improve bone mineralization, this description 
is limited to the electrolytes and hormonal regulation that play a crucial role for the 
development of bone tissue namely the metabolic homeostasis of calcium and 
phosphorus.
 The primary constituents of skeletal tissue are calcium, phosphorus and magnesium. 
They compose 0.07 to 2.7% of the body weight of an appropriate for gestational age 
term newborn infant. (69, 70) These minerals are also important components of extra- 
cellular fluid, intracellular structures, cell membranes, and soft tissue. The circulating 
fraction of calcium and phosphorus as measured in blood is less than 1% of the total 
amount of the mineral. (Table 2)
Fetal bone mineral homeostasis
The fetal bone formation starts around the second part of the gestation and mainly 
follows two stages: 1. Proliferation and growth of mesenchymal structures and 
cartilage 2. Progressive ossification and mineralization of these structures. Growth is 
directly related to protein and energy supply, but also to the hormonal environment 
including insulin and IGF 1 and 2, while bone formation and mineralization are related 
to mineral supply of calcium and phosphorus as well as hormonal factors, like 
parathyroid hormone (PTH) and vitamin D. (128) The process of bone mineralization 
increases rapidly only in the later stages of pregnancy, leading to significant increase 
of impaired protein synthesis. The non-essential amino-acids can be synthesized by 
the body from intermediates of the tricarboxylic acid cycle and other metabolic 
pathways. 
 The formation of protein is a process of synthesis and degradation of amino acids 
with no storage pool but continuous turnover of proteins. Shortage of a certain amino 
acid will impair protein synthesis, while a surplus of amino acids can either be used 
for glycogenesis and energy production or will lead to renal losses. Protein synthesis 
exceeds five times the rate of protein accretion, meaning that one gram of protein 
synthesis requires the accretion of 5 gram of protein. (89, 90) This also means that 
protein synthesis is a highly energy consuming activity. Depending on the calculation 
used, protein metabolism requires approximately 40% of the resting energy expenditure. 
Amino acid requirements have been estimated based on animal studies, veno-arterial 
differences in amino acids in the umbilical cord, the factorial method, stable isotope 
tracer method or human milk analysis. (90 – 101) 
 Quantitative balance studies showed that amino acid uptake exceeds the amount 
necessary for protein accretion, indicating that the human fetus oxidizes amino acids 
to generate energy. (99) Fetal amino acid requirements are high to provide sufficient 
substrate to enable a high protein synthesis rate with adequate growth during early 
gestation. (102) The preterm infant has amino acid requirements comparable to the 
fetal requirements but in contrast, the continuous flow of nutrients has ceased and 
the preterm infant is dependent on exogenous administration, either enteral or 
parenteral. A number of studies found a negative nitrogen balance in case of 
insufficient supply of amino acids. Further studies suggested that nitrogen excretion 
may be inversely related to gestational age leading to renal losses with 180 mg/kg/d 
nitrogen (1.1 gram/kg/d protein) at 26 weeks of gestation and 135mg/kg/d nitrogen 
(0.85 mg/kg/d protein) at 29 weeks gestation. (103-106) Also, studies have demonstrated 
that administration of a sufficient amount of amino acids can reverse a negative 
nitrogen balance. A positive nitrogen balance is seen as indicative for protein 
accretion. (105-116) In the absence of  parenteral nutrition and insufficient enteral 
feeding the preterm infant will use its own protein stores for protein turnover and 
thereby achieve a catabolic state, finally leading to growth retardation and death. (117)
 Fat plays an important role in infant nutrition since it is a major source of energy, 
a component of cellular membranes, a carrier for fat-soluble vitamins and a source of 
essential fatty acids that play an important role in a variety of physiologic processes. 
(118) The long chain polyunsaturated fatty acids α-linolenic acid (ALA, 18:3n-3) and 
linoleic acid (LA, 18:2n-6) are called essential fatty acids because the human body 
does not possess the enzymes to produce the double bonds in the n-3 and n-6 
position. These two fatty acids need to be obtained from diet to prevent fatty acid 
deficiencies. Arachidonic acid (AA, C20:4n-6) and docosahexaenoic acid (DHA, 
C22:6n-3) play an important role in the fetal and neonatal brain development. (119) 
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supplement in parenteral nutrition. The circulating concentrations of calcium and 
phosphorus in blood are regulated within narrow limits through changes in intestinal 
absorption, renal excretion or reabsorption, mainly under influence of PTH and 
calcitriol. (138) PTH is activated as a result of low extracellular concentration of ionized 
calcium (Ca2+). PTH stimulates the resorption of calcium in bone tissue and increases 
the renal tubular reabsorption of calcium, while on the other hand tubular reabsorption 
of phosphorus is reduced leading to increase of phosphaturia. Furthermore PTH 
stimulates the enzyme 25(hydroxy) cholecalciferol-1-alpha hydroxylase in the kidney 
that regulates the hydroxylation of 25-hydroxy cholecalciferol (calcidiol) into the 
active 1,25-dihydroxy cholecalciferol (calcitriol). Calcitriol stimulates the intestinal 
absorption of calcium and  phosphorus, the resorption of calcium and phosphate 
from bone tissue and indirectly the renal reabsorption of phosphorus. The hormonal 
regulation of the bone mineral homeostasis of the preterm infant is functionally 
comparable to the adult regulation. (139) 
Intestinal absorption of calcium and phosphorus
The intestinal absorption of calcium occurs through passive and active mechanisms. 
The passive absorption is not hormonally regulated while the active absorption of 
calcium is regulated by calcitriol mainly in the duodenum. More than half of the 
nutritional intake is passively absorbed by the jejunum. This means that directly after 
birth, even for preterm infants, intestinal calcium absorption is  effective. Bile salts and 
lactose stimulate the intestinal absorption of calcium, while some medications such 
as xanthine derivates reduce absorption. About 80 - 90% of the administered amount 
of phosphorus is absorbed through the passive pathways. In case of low serum 
concentration this amount can be increased by activation of intestinal absorption 
through calcitriol. (137)
Renal excretion and reabsorption of minerals
In general, 98% of the calcium excreted by the glomeruli is reabsorbed by the renal 
tubuli. Increasing nutritional intake will lead to an increase of calcium excretion. A 
number of drugs enhance calcium excretion such as furosemide and xanthine 
derivates, while thiazide diuretics limit excretion. Renal calcium excretion depends on 
the acid base status. Metabolic acidosis will increase calcium excretion while it is 
reduced with metabolic alkalosis. Renal excretion of phosphorus is primarily regulated 
by the amount of phosphorus in the nutritional intake. A reduction in nutritional 
intake can lead to renal tubular reabsorption of more than 90% of phosphorus 
excreted by the glomeruli. Phosphorus depletion leads to increase in renal calcium 
excretion in favor of phosphorus reabsorption while an increase in nutritional supply 
of phosphorus will decrease the calcium excretion. (140, 141)
in mineral requirements. (128) Fetal mineral accretion occurs through placental 
transport. The active transport of calcium uses mechanisms similar to those active 
within intestinal cells. Mechanisms used for the trans-placental absorption of 
phosphorus have not been established. (129) Fetal calcium accumulation mostly occurs 
during the third trimester trough active transport across the placenta leading to 
greater fetal than maternal calcium concentrations. (130) Fetal calcium needs are 
primarily met by increased calcium absorption during pregnancy. (131) Fetal calcium 
derives from both maternal dietary intake as well as maternal skeleton. The human 
fetus accumulates about 30 grams of calcium by term, with 80% obtained during the 
last trimester. (69, 132-135) Phosphorus is important for the endochondral bone 
development. It induces apoptosis of hypertrophic chondrocytes and is incorporated 
into osteoid before calcium binds to it. Therefore phosphorus is an important factor 
of the formation and mineralization of bone during fetal development. Comparable 
to calcium, the fetal phosphorus concentrations are significantly higher than maternal 
concentration. (136) 
Postnatal hormonal regulation
After birth the regulation of mineral metabolism changes significantly. (137) The loss of 
the placental mineral pump means that calcium and phosphorus have to be 
administered by nutrition, either enteral as human milk,  infant formula or as 
Table 2  Distribution and function of Calcium and Phosphorus
Mineral Distribution Function
Calcium Bone (99%)
Extracellular fluid
Intracellular structures
Cell membranes
Skeletal structural integrity
Receptor activation for metabolic events
Neuromuscular excitability
Blood coagulation
Cell division
Excitation-contraction coupling muscles
Secretion (hormones, neurotransmitters)
Enzyme activation
Membrane stability
Phosphorus Bone (80 -85%)
Skeletal muscle (ca 9%)
Viscera, extracellular fluid (ca 11%)
Skeletal structural integrity
Component lipoproteins cell membrane
Bone mineralization – matrix formation
Energy metabolism
Cell signaling, nucleic acid synthesis
Adapted from(124-127)
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continue fetal growth in the postnatal period. The disorganized gastrointestinal 
motility may cause a delayed passage. (147-149) 
 Even the extremely preterm intestine is capable of digesting and absorbing milk 
feeds but not as well as term infants. (150) Protein digestion is not limited, while lipid 
digestion and absorption are relatively inefficient caused by low concentrations of 
lipolytic enzymes as lingual and pancreatic lipases as well as bile acids. While human 
milk improves lipid digestion and absorption, because of the presence of two human 
milk lipases, this may be less effective with tube feeding. (151,152) Short and medium 
chain fatty acids are absorbed and transported more readily than long-chain fatty 
acids. Lipid absorption has been estimated to vary between 58 to 89 % of the intake 
in preterm infants compared to 72 to 95% for term infants. (153) High intake of calcium 
impairs digestion of fat, but high intake of fat impairs the absorption of calcium. 
(154-156) Carbohydrates such as lactose and sucrose need to be hydrolyzed by lactase 
and sucrase. Lactase activity has been found to be very low in preterm infants while 
other disaccharidases seemed to be higher. (157-159) This led to the assumption that 
preterm infants are lactose intolerant. Later studies showed that, even in preterm 
infants, lactase activity increased soon after the introduction of human milk and was 
sufficient to digest human milk carbohydrates sufficiently. (160) The activity to absorb 
monosaccharides is available in early gestation.
 The initiation and increment of volumes of enteral feeding for preterm infants 
has been a matter of debate for many years. There have been concerns about feeding 
intolerance, gastrointestinal reflux, and necrotizing enterocolitis (NEC). (161) A number 
of studies suggested a link between NEC and rapid advancement of enteral feeding 
rates. (162-167) The undigested content was thought to function as a chemoattractant 
for neutrophils and thus might initiate an inflammation cascade, which was proposed 
to increase the risk of necrotizing enterocolitis. (168-170) Consecutively, this led to delay 
in introduction of enteral feeds for the first postnatal days or even until the end of the 
first week in combination with very cautious increments. (161) Numerous studies 
suggested disadvantages in the delay of enteral nutrition. Withholding enteral feeds 
has been shown to impair gastrointestinal motility, hormonal activity, diminish 
structural integrity and growth of the intestinal mucosa and thus can delay the time 
to achieve full enteral feeding, while on the contrary the introduction of enteral feeds 
has been shown to promote the development of the intestinal mucosa. (148,146,171) 
Several studies have shown that specifically human milk increases the epithelial 
proliferation of the immature intestine and the intestinal function. (172-174)
 Up to date there is a great variation in clinical practice in the initiation of the first 
enteral feeding. (175) Meta-analyses of available studies by Cochrane reviews 
concluded that delayed introduction of enteral feeding and moderate advancing of 
enteral feed volumes did not reduce the risk of NEC, while slow advancement delayed 
the time to full enteral feeding and increased the risk of infection. It is not known 
Postnatal supply of minerals and vitamin D 
After birth, human milk is the major source for bone minerals and vitamin D. For the 
preterm infant human milk does not provide the quantity of minerals as during fetal 
development, and necessary for adequate bone mineralization. Insufficient supply of 
nutrients will lead to bone resorption to maintain stable blood concentrations of 
calcium and phosphorus. In preterm infants the insufficient supply of nutrients leads 
low bone mineralization called ‘osteopenia of the premature’ with an increased risk of 
bone fractures. Vitamin D needs to be supplemented postnatally since the exposure 
to sunlight is negligible and vitamin D content of human milk is low. The postnatal 
vitamin D stores are dependent on the maternal vitamin D concentrations. (142) Recent 
studies showed that an increasing number of pregnant women, especially if veiled 
and dark skinned, are vitamin D deficient. (143) Placental insufficiency and preeclampsia 
are also associated with impaired placental- fetal transfer of vitamin D. (144) In 
conclusion, after preterm birth, the infant is at risk of impaired bone mineralization 
and supplementation of calcium, phosphorus and vitamin D is necessary directly 
after birth. (144) 
Enteral and parenteral nutrition
The natural way to provide and ingest food for any infant is the gastrointestinal tract, 
or enteral pathway. The alternative route is the parenteral route via venous access 
through application of liquid nutrients. Both ways of administration bare benefits and 
risks that should be taken into account prescribing nutritional intake for the individual 
patient. The preterm infant lacks stores of all nutrients. (69) An extremely preterm 
infant is composed of more than 85% of water, with no adipose tissue, low stores of 
liver glycogen, very few amounts of minerals, while proteins available in muscles and 
organs may function as the only source of energy.  The potential energy stores merely 
comprise enough energy to meet the basal metabolic energy requirements for more 
than 24 hours while in contrast the energy requirements exceeds those of the term 
born infant based on energy needed for heat loss, respiratory distress and loss of 
stools. (69, 145, 146) Therefore separating the preterm infant from the placental 
circulation means that full supply of all nutrients should be started immediately after 
birth to prevent catabolism. 
Enteral nutrition
In preterm infants the enteral pathway is partly compromised in the early postnatal 
period, based on immature gastrointestinal motility and immature intestinal 
epithelium with impaired digestion and absorption of food. (146) Initially, most preterm 
infants tolerate only small volumes, insufficient to provide all nutrients necessary to 
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subsequently led to restricted or delayed use of parenteral lipid emulsions. Parenteral 
lipid emulsions have been associated with increased pro-inflammatory eicosanoid 
production and lipid peroxidation and consecutively with chronic lung disease, increase 
in pulmonary vascular resistance and retinopathy of prematurity as well as impaired 
immune response with increased risk for nosocomial infections. (203-208) Cholestatic liver 
disease is frequently recognized with long-term PN and has been associated with an 
accumulation of phytosterols that can be found in vegetable oil. (209-212) 
 Parenteral lipid emulsions have predominately been based on soybean oil that 
contains a high amount of n-6 fatty acids (52-55%). (213) Due to the adverse effects, 
subsequently different lipid emulsions were developed aiming at a reduction of the 
amount of n-6 fatty acids and a more physiologic fatty acid profile. (202)  The optimal 
composition has not been developed yet, neither the optimal time to initiate 
parenteral lipids nor the optimal requirements. Systematic reviews and meta-analyses 
did not find benefits of early introduction of lipid emulsions with regard to postnatal 
growth but also no differences in adverse effects such as chronic lung disease, 
duration of supplemental oxygen, retinopathy of prematurity and sepsis. (214-216) 
Further the alternative lipid emulsions in comparison with soybean emulsion showed 
no statistically significant differences in clinically important outcomes including 
death, growth, chronic lung disease, sepsis, retinopathy of prematurity ≥ grade 3 and 
PN associated  liver disease. (215, 217) 
 The third macronutrient and major source of non-protein calories in PN is 
D-glucose (dextrose) that contributes most to the osmolality of the PN solution, 
thereby a risk factor for adverse effects of venous access. (51) While glucose provides 
about 40 - 60% of the energy in nutrition and is utilized by all cells, administration of 
an excess of glucose may be responsible for hyperglycemia, and will lead to 
mitochondrial damage with lipogenesis, fat deposition with finally development of 
steatosis and cholestasis. Excessive glucose intake causes increased CO2 production 
which may result in respiratory distress. (218,219) Glucose administration affects the 
hormonal regulation of the glucose metabolism and may lead to impaired sensitivity 
for insulin.  Adding lipid emulsions to PN decreases the need of carbohydrates as 
non-protein energy, while in combination with a high amount of amino acids the 
amount of carbohydrates should be adequately high enough to allow optimal protein 
synthesis. The combination of macro-nutrients may affect the hormonal and 
metabolic regulation. The optimal amount and combination of macro-nutrients in PN 
solutions is still a matter of debate. For enteral nutrition it has been demonstrated 
that the composition of the feeding affects the body composition of the infant. (220, 221) 
Abnormal deposition of fat mass may have adverse consequences in later life with 
increased risk of type II diabetes, hypertension and cardiovascular disease. (‘postnatal 
origin hypothesis’) (222-224) 
whether this holds true specifically for the group of extremely preterm infants, since 
only few studies included infants below 1000 grams. (176, 177) Furthermore, a number 
of studies have shown that irrespective of the details of recommendations, having a 
standardized feeding protocol will reduce necrotizing enterocolitis and improve 
outcome of patients. (161, 166, 178-181)
Parenteral nutrition
Nowadays parenteral nutrition (PN) is able to provide all nutrients necessary to achieve 
adequate growth and functional development. (182) Thereby parenteral nutrition is of 
vital importance for all preterm infants and sick neonates who are unable to tolerate 
enteral nutrition. The availability of adequate PN has contributed to a decrease in 
mortality and improvement of outcome of very preterm infants. (183) However, there is 
no consensus on the optimal composition and requirements of fluid nutrients, and the 
way to administer parenteral solutions. (184) Furthermore, the application of PN bares 
a number of risks, such as increased prevalence of infections, thrombosis and hepatic 
failure that may have life-long consequences for the individual patient. (183)
 In the early years of PN, protein was supplemented as hydrolysate of fibrin or 
casein and later as synthetic amino acids solutions. (185) A number of studies reported 
side-effects in combination with these solutions like hyperammonaemia, hyper- 
chloremic metabolic acidosis, hepatic failure, hyperphenylalaninemia and other 
imbalances of plasma amino acids and mineral concentrations. (186-192) Despite 
the fact that studies showed that early commencement of more recent amino acid 
solutions was safe and led to a positive nitrogen balance, the fear of adverse events 
caused a delayed introduction and supplementation of restricted amounts of amino 
acids. (105,106,108,110) Current available amino acid formulations have been designed to 
result in blood concentrations of amino acids similar to either cord blood or breast-milk 
fed infants.(193-197) Nevertheless, the optimal composition, the ideal preparation of 
the solution, as well as the daily requirements have not been found for all parenteral 
amino acids. All 20 amino acids are required equally for a normal protein synthesis, 
but the utilization rate may be different. If one amino acid is not sufficiently available, 
specifically the essential or conditionally essential amino acids, this will be the rate 
limiting factor for protein synthesis. A number of amino acids have a low solubility or 
low stability in parenteral solutions which can be improved by acetylation. However, 
studies have shown that infants are not fully capable to use acetylated amino acids. 
Acetylated amino acids were excreted in high amounts in the urine and consequently 
led to low concentrations of deacylated plasma amino acids. (194, 198) 
 Supply of parenteral lipids to infants who are unable to receive enteral nutrition is 
necessary to prevent deficiencies of essential fatty acids (EFA). (199-201) Further, lipid 
emulsions provide a concentrated source of energy. (202) However, there are concerns 
about a number of adverse effects related to the administration of lipid emulsions that 
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Breast milk or Formula
Human milk
Human milk has a unique composition of nutrients and is recognized as the preferred 
nutrition for all newborn infants. (251) Human milk contains functional nutrients that 
help provide the optimal microenvironment for protection and maturation of the gut 
and passively provide protection from infections. (252-254) (see table 3) Human milk 
contains bacteria. This has been interpreted as a source of commensal and a potential 
probiotic inducing a mother-to- infant bacterial transfer via breast milk of maternal 
gut bacteria. (255, 256) The composition of the bioactive factors of human milk differs 
not only among women but also during the lactation period from colostrum with 
the highest concentrations, through transitional to mature milk. The amount of 
these factors also seems to be dependent on the degree of prematurity. Depending 
somewhat on the agent investigated, colostrum of preterm infants seems to have 
higher concentrations of immuno-active substances than colostrum from term 
mothers, while colostrum of mothers of extremely preterm infants has the lowest 
concentrations. (255, 257-259)
 Besides its contribution to host defense and trophic effects on the gastrointesti-
nal tract, it is generally accepted that human milk contains all nutrients necessary for 
optimal growth and development of newborn infants. Human milk has a high amount 
of lactose and polyunsaturated fatty acids. The benefits of both nutrients for optimal 
digestion and development of the child have been described above. However, the 
exact composition of breast milk is usually unknown and is dependent on gestational 
age and time of lactation. (261, 262) The amount of carbohydrates, protein and fat of 
breast milk of mothers who deliver preterm is usually higher compared to mothers of 
term infants during the transitional phase of the lactation period. In both groups the 
content of protein decreases with lactation duration while carbohydrates and fat 
seem to increase. (261, 262) Nevertheless, the overall nutritional content of human milk 
has been shown to be inadequate for very preterm infants. A number of clinical trials 
showed that feeding pure human milk led to impaired postnatal growth in very 
preterm infants. (263-266) On the other hand, Polberger et al. found in a randomized 
trial that enrichment of human milk with protein in very preterm infants improved 
growth in weight and length. (267) This study also found large fluctuations in daily 
nutrient intake due to a varying content of protein and fat content in human milk. This 
has also been found in a number of studies that evaluated the composition of human 
milk. (262, 268) Overall, regarding the high nutritional needs of preterm infants, human 
milk has an insufficient content of protein and minerals namely sodium, calcium and 
phosphorus. Finally, this may lead to nutritional deficiencies in very preterm infants 
and consecutively result in growth retardation and impaired bone mineralization. 
The supplementation of calcium and phosphorus in PN has been a challenging 
subject since the introduction of PN solutions, because both minerals combined in 
solution easily precipitate, in quantities necessary to meet the requirements of 
preterm infants. (225-227) Alternate infusion of both minerals, cyclic infusions but also 
low quantities of both minerals have been used to prevent central venous line 
occlusions seen as  result of calcium phosphate crystal formation. (228-230) These 
practices led to metabolic disturbances with hyper- and hypocalcaemia or - 
phosphataemia. Metabolic bone disease and rickets have been reported in 
combination with long-term parenteral nutrition. (228, 231, 232) The solubility of calcium 
and phosphorus depends on the source of mineral that is used for the preparation of 
the PN solution. Organic calcium and phosphorus compounds, such as calcium 
gluconate or sodium glycerol-phosphate, are more stable in PN solutions than 
inorganic minerals like calcium chloride, potassium or sodium phosphate. (233-240) 
More recent studies have shown that high concentrations of calcium in combination 
with sodium-glycerol-phosphate safely can be provided in PN solutions without 
precipitation. (241, 242) A number of studies demonstrated that adding calcium and 
phosphorus to the PN solution caused a positive nutrient balance, and increasing the 
amount increased the retention of both minerals. (226, 243-247) None of these studies 
provided amounts that would equal the fetal accretion rate. Current recommenda-
tions of daily requirements of mineral intake by international committees are based 
on either the factorial approach or balance studies and aim to achieve a postnatal 
mineral accretion equivalent to that of the intrauterine gain of a normal fetus. (142) In 
contrast to enteral nutrition, parental supply of minerals is independent of intestinal 
absorption and the amount of minerals is directly available for the metabolic needs. 
Consecutively parenteral daily requirements are assumed to be lower than enteral 
needs. Furthermore in comparison, the recommendations for enteral Ca/P intake 
ratios  differ compared to parenteral. The recommended Ca/P intake ratios have not 
been evaluated systematically. Only few studies evaluated the effect of parenteral 
mineral supplementation on bone status in preterm infants. Although these studies 
showed a positive effect on bone mineralization, the intervention period was short, 
the amount of minerals supplied was below current recommendations, the numbers 
of infants evaluated was small, and infants were either at term age or at higher 
gestational age than that of infants currently cared for in NICUs. (226, 243-250) Up to date 
it has not been proven that mineral supplementation in PN will lead to normal bone 
mineralization in preterm infants. 
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Preterm formula
Special preterm formulas were developed several decades ago since the nutritional 
adequacy of human milk for preterm infants was questioned. These special preterm 
formulas were enriched with protein as well as relatively high amounts of 
carbohydrates, fat, sodium, calcium, phosphorus and vitamins. (269) A number of 
clinical trials demonstrated that postnatal weight gain improved with preterm 
formula compared to human milk. (270-274) Meta-analyses of Cochrane reviews 
concluded that higher protein intake with formula accelerated weight gain and 
formula compared to donor breast milk resulted in higher rates of short-term growth. 
(275, 276) 
 The advantage of formula feeding is the ability to provide a guaranteed and 
standardized nutritional intake of all nutrients.  However, the composition of preterm 
formulas is artificial and has been developed according to the nutritional requirements 
as defined by Ziegler based on the reference fetus. (69) Over the years the formula 
composition has been adapted to improve feeding tolerance. Initially high doses of 
protein led to elevated blood urea nitrogen, blood ammonia, urine osmolarity and 
metabolic acidosis while weight gain did not further improve above an intake of 4.5 
g/kg/d of protein. (45, 277) Longitudinal studies to determine the effects of high protein 
intake on long-term outcome of growth, body composition, neurodevelopment and 
possible adverse conditions of obesity, diabetes and cardiovascular disease are still 
needed. (278) Short-term studies have shown that body composition can be altered by 
changes in the composition of preterm formula. (220) The protein source of preterm 
formulas is cow’s milk. Milk proteins can be divided into caseins and whey proteins 
with a ratio of 80 : 20 for cow’s milk and 40 : 60 for human milk.  Casein easily coagulates 
when acidified and therefore is more difficult to digest, leads to slower gastric 
emptying and amino acid absorption. More recent preterm formulas have a 
whey-dominant composition that aims at more rapid gastric emptying and production 
of free amino acids that are comparable to those produced by human milk.  (279, 280) 
The fat source of formula usually is a blend of vegetable oils and medium chain 
triglycerides (MCT) and is less complex than human milk fat. (281) Human milk contains 
‘bile-salt-stimulated lipase and palmic acid in the β position that increase the 
bioavailability of milk fat and increase digestion and absorption of nutrients. (282) 
The latter is currently added to most formula feedings. Intestinal absorption of fat of 
preterm formula is impaired, partly because of  lower quantities of lingual and gastric 
lipases and lower pool of bile salts in preterm infants. Medium chain triglycerides are 
more easily absorbed but the energy content of MCT is about 15% lower than long 
chain triglycerides. (278, 281) Intestinal absorption of fat, as well as calcium is also 
depending on the source of triacyclglycerols used in formula. (283) Currently sucrose is 
replaced as carbohydrate source by lactose in formula because lactose promotes 
growth of bifido- and lactobacillus organisms, decreases intestinal pH and thereby is 
Table 3  Immun agents in human milk
Immune 
functions
Agents Functions
Anti-microbial SIgA Interferes attachment of microbial pathogens 
to epithelium, neutralizes bacterial toxins
Lactoferrin Blocks multiplication of siderophiles by chalting 
Fe+++
Lysozyme Digests peptidoglycans from certain bacterial 
cell walls 
Alpha-lactalbumin Destroys streptococcus pneumoniae
Lactadherin Blocks binding rotavirus to intestinal 
epithelium
MUC1 Blocks binding E. coli to intestinal epithelium
C3 Precursor of opsonins C3b and C3bi
Fibronectin Opsonin
CCL28 Destroys C albicans and certain bacteria
MIF Supports killing M. tuberculosis
Defensins Inhibits HIV-1 replication, and destroys E.coli
Oligosaccharides Interferes attachment of microbial pathogens 
to epithelium
Anti-
inflammatory 
Prostaglandins E2, F2α Cytoprotectives 
EGF, Lactoferrin, polyamines Epithelial growth factors
Cortisol Maturational factor
PAF -acetylhydrolase Degradation inflammatory mediators
α-1antichymotrypsin Binder of enzymes
Lysozym to elastin Binder of substrates of enzymes
Lactoferrin to lipid A of LPS Binders of toxin
IL-10, TGF-β1 Modulators of inflammatory leukocytes
Uric acid, β-carotene, 
ascorbate
Anti-oxidants
Immun-
modulatory
IL-7 Stimulates T-cell production
Interferon-γ, TNF-α, IL-12, 
IL-18
Enhancement of cellular immunity
TGF-β, IL-4, IL-10 Enhancement of humoral immunity
IL-β1,IL-6, MIF Macrophage stimulation
IL-8, RANTES, MIP-1, CCL28 Chemokine activities
IP-10, MIG Interferon inducible proteins
TGF-β1, IL-10 Anti-inflammatory actions 
EGF, M-CSF, G-CSF, 
erythropoietin
Growth stimulation
Adapted from (253, 260)
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fortification has been shown to increase the osmolality of human milk. (306) Both 
factors are assumed to increase the risk of feeding intolerance, specifically impaired 
gastric emptying and increased risk for necrotizing enterocolitis. (287, 307) Though 
recent systematic reviews did not find an increase in adverse effects among infants 
who received HMF, the available data are limited to small trials and usually more 
stable infants. (308) It is not known whether these statements are applicable for 
extremely preterm infants, the ones that should mostly take advantage of human 
milk fortification.  
Outcome measures in relation to nutritional practices
The key processes of intra-uterine as well as postnatal development of preterm born 
infants are growth, neurodevelopment and bone development. All three have been 
shown to be associated with nutritional intake and thereby are often used as outcome 
parameters for the evaluation of nutritional interventions. 
Growth
For growth assessment the optimal expected postnatal growth of a preterm infant 
needs to be defined. In general, pediatric societies recommend that postnatal growth 
of preterm infants should approximate the fetal intra-uterine growth. (65, 305) Clinical 
measures of growth commonly compare weight, length and head circumference. 
Estimates of fetal growth may be obtained from large population studies. Uniform 
standardized fetal growth charts are not available currently. For the analyses of 
postnatal growth evaluation as performed for this thesis, the Dutch references by 
gestational age, the Swedish growth reference from 24 weeks of gestation to 24 
months by gender and the revised Fenton growth chart for preterm infants were 
used. (309-311)
 The period of fastest human growth occurs between 22 and 40 weeks of gestation 
requiring the comparatively highest nutritional supply during lifetime for achievement 
of optimal fetal growth. While after preterm birth the energy expenditure exceeds 
the fetal needs, the infant is physically unable to tolerate the full required amount of 
enteral nutrition and technically it can be difficult to provide the high requirements as 
described above. Many clinical studies have demonstrated  that most very preterm 
infants develop a severe growth retardation in the postnatal period. (60, 312-314)  Dancis 
et al. who developed one of the first growth curves for preterm infants, reported 
nearly 70 years ago that ‘the chief variable in determining the weight curve of ….a 
premature is the feeding policy’. (315) Embleton et al. demonstrated that most very 
preterm infants did not receive the recommended nutritional intake during the first 
two postnatal weeks and consecutively developed a cumulative nutritional deficit 
able to suppress the growth of opportunistic bacteria. However,  preterm formulas 
also contain glucose polymers, like maltodextrin, to reduce the osmolality load. In 
animal studies maltodextrin in formula was associated with increased risk of 
necrotizing enterocolitis. (159, 284)  
 The greatest concern with regard to preterm formula is the association of formula 
feeding with necrotizing enterocolitis (NEC) and late-onset sepsis. (50) It has been 
suggested that this may be related to an inflammatory response in relation to cow’s 
milk protein but also to changes in the intestinal microbiome in relation to formula 
feeding. (285, 286) A number of studies found that exclusive diets with human milk 
shortened the duration of parenteral nutrition, decreased the incidence of  NEC 
including the need for surgical intervention. (287, 288) Formula feeding does not provide 
the immunological protection of human milk. A retrospective study found that the 
amount of own mother’s milk during the first 10 days of life was associated with 
decreased morbidity and mortality in very preterm infants.(289, 290)
Fortified Human milk
The alternative way to provide the required higher amount of nutrients to very 
preterm infants is to enrich own mother’s milk specifically with nutrients insufficient 
available in human milk such as protein and minerals especially sodium, calcium and 
phosphorus as well as several trace elements and vitamins. The idea was to combine 
the advantages of non-nutritional factors of human milk with an extra amount of 
nutrients. Consecutively a number of powdered and liquid human milk supplements 
or ‘fortifiers’ (HMF) were developed. A number of small studies evaluated the effect of 
fortification of human milk on biochemical mineral status, weight gain and bone 
mineralization in comparison to either pure human milk or preterm formula. (267, 
291-304) Most studies found improved mineral balances with fortified human milk 
compared to pure human milk and improved weight gain and a few found improved 
bone mineralization. Some of the studies reported that the use of HMF led to growth 
equivalent to growth seen in infants fed formula feeding. This led to the 
recommendation that human milk for very preterm infants needed to be enriched 
with supplements. (305) However, the above mentioned studies used different 
products, the initiation and duration of the fortification were divers and most infants 
evaluated were more stable than preterm infants currently treated in the NICU. 
Studies that could not demonstrate an improvement in bone mineralization with 
higher mineral intake had a short intervention period. (292, 293, 295) There is no evidence 
based recommendation available with regard to either the optimal time to start or the 
optimal volume of human milk to commence fortification. Early enrichment at low 
volumes of enteral intake may accelerate the enteral nutritional intake and thereby 
support postnatal growth and decrease the duration of parenteral nutrition. On the 
other hand most multi-nutrient fortifiers are based on cow’s milk protein and 
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myelinization. (330) Recent functional MRI studies have shown that preterm birth will 
have impact on this complex process of brain development with potentially effects 
on the brain architecture. Studies found that preterm birth, at term equivalent age, 
was associated with reduced brain volumes, diminished cortical gyrification and 
delayed maturation in gray matter structures. (330) These deficits were found in the 
absence of focal brain injury and seemed to persist throughout childhood. (330-333) 
These recent morphological findings seem to confirm the results of many international 
follow up studies that evaluated the neurobehavioral outcome of very preterm infants 
up to childhood and school age. Very preterm infants showed more behavioral 
problems, attention problems, less academic achievements and impaired executive 
functions compared to term born infants. (334-336) Until now it has been difficult to 
prove a causative relationship between nutritional support and neurodevelopment. 
A number of studies demonstrated that more aggressive nutritional support led to 
improved extra-uterine weight gain for very preterm infants and this seemed to be 
associated with improved neurodevelopment in childhood. (61, 337)  Ehrenkranz et al 
and Belfort et al found that postnatal weight gain was positively associated with 
mental and psychomotor development at 12 and 18 month corrected age. (61, 338) 
Furthermore, head growth seemed to be positively associated with neurodevelop-
ment. (339-342) This improvement has specifically been related to higher amino acids 
intake. (340, 343, 344) However, there is always more than one single determinant of neu-
rodevelopmental outcome. Risk factors for adverse development include antenatal 
conditions like maternal illness, prenatal drug exposure, reduced fetal oxygen and 
nutrient supply as a result of placental insufficiency, while furthermore socioeconomic 
status and maternal education have been associated with neurodevelopmental 
outcome. Perinatal events such as asphyxia, intra-ventricular hemorrhage, infectious 
diseases and other prematurity related morbidities have been associated to impaired 
neurodevelopmental outcome.(345) All of these determinants may contribute to the 
overall outcome of a child and therefore may hamper the determination of the effect 
of nutritional support.
 Besides perinatal conditions gender has been reported to be a factor for outcome 
after preterm birth. In general, long-term follow-up evaluations of preterm infants 
have shown that boys are more at risk for unfavorable outcome than girls. (319, 346, 347) 
Hintz et al evaluated risk factors for adverse neurodevelopmental outcomes of 
preterm born children and found male gender to be an independent risk factor for 
severe impairment of psychomotor development at two years of age. (348) On the 
other hand, nutritional intervention studies have indicated that boys probably may 
take more advantage of improvements of nutritional intake than girls. (62,322,349)  
 Placental insufficiency, the most common cause of small for gestational age, 
implies a period of fetal undernutrition and thereby also an increased risk of altered 
brain development that consecutively may cause altered neurodevelopment. (350) 
that was not regained during the following weeks. (60) The same infants demonstrated 
an increasing growth retardation during the same period which led to the assumption 
that the postnatal growth retardation as seen in these infants could be associated 
with insufficient nutritional intake. The postnatal growth retardation has been shown 
to persist until early childhood.(316, 317) The ELGAN study, a prospective cohort study 
evaluating nutritional practices and postnatal growth of extremely preterm infants, 
found that first week nutritional practices were positively associated with weight gain 
during the first month.(318) While follow up studies showed that postnatal morbidities 
such as intraventricular hemorrhage and cerebral palsy, chronic lung disease, 
infectious diseases and necrotizing enterocolitis was negatively associated with 
growth, several studies indicated that improved growth specifically was associated 
with higher protein intake in the early postnatal period. (274, 317, 319-323) 
 Irrespective of nutritional intake or other co-variables, infants may follow different 
growth trajectories depending on either being born as appropriate or small for 
gestational age. The size of a newborn infant is determined by the genetic potential 
of each parent but is also dependent on the intra-uterine environment or chromosomal 
abnormalities. The term ‘appropriate for gestational age’ describes a newborn whose 
size is appropriate for gestational age according to a standardized growth chart, while 
small for gestational age generally is considered if the weight falls below the tenth 
percentile. The optimal postnatal nutritional treatment of intra-uterine growth 
restricted preterm infants is a matter of debate. Most follow up studies have shown 
that small for gestational age born infants do not catch up and remain smaller than 
infants born with appropriate weight at the same gestational age. (317, 319, 324) This 
impaired postnatal growth could be a result of a persisting postnatal undernutrition 
as seen in appropriate for gestational age preterm infants, indicating increased 
nutritional requirements compared to infants with appropriate fetal growth. On the 
other hand, intra-uterine growth restriction may have programmed fetal growth 
towards adaptation to poor nutritional environment. (325, 326) Accelerated postnatal 
growth may have adverse consequences for the growth restricted preterm infant, 
setting the stage for long-term obesity and metabolic problems. (327) Currently it is 
not known whether small for gestational age preterm infants have a window of 
opportunity to catch-up to normal growth during the early postnatal period or that 
moderate postnatal growth should be accepted to prevent obesity, diabetes and 
cardiovascular disease. (328, 329)
Neurodevelopment
Satisfactory functional development is the second important goal of nutritional 
management.(65) This implies optimal growth and development of the brain. The 
human brain is the most complex system of the body and at the time of preterm birth 
in a rapid developmental process of synaptogenesis and axonal growth and beginning 
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is caused by either insufficient deposition or increased resorption of organic bone 
matrix. In contrast to osteomalacia, the incorporation of calcium and phosphate into 
organic bone matrix is not affected and the mineralization of the growth plate 
cartilage proceeds normally, thus there is no sign of rickets.  Bone mineral density and 
bone mineral content are physically and radiological decreased. 
Osteoporosis
Osteoporosis has only been defined for adults and reflects a situation where the areal 
bone mineral density is below -2.5 standard deviations from the mean of young 
healthy adults. (362, 363) This definition has been shown to predict a future fracture risk. 
In large epidemiological studies a reduction of 1 standard deviation score predicted a 
two-to threefold increase in the risk of fractures.(364) The areal bone mineral density 
depends on bone size and therefore this definition cannot be used in neonatology, 
since all infants would be diagnosed as having osteoporosis.(357) Currently there is no 
definition of osteoporosis available in pediatrics. It has been suggested to use the 
term osteoporosis if bone stability is not adapted to mechanical requirements 
because bone mass is inadequately low and fractures occur after minor trauma. (357)
Osteopenia of prematurity
Preterm infants are at significant risk to develop reduced bone mineral content (BMC) 
with subsequent development of osteopenia of prematurity or metabolic bone 
disease (MBD). (365, 366) Osteopenia results from diminished synthesis and/or increased 
Most studies found lower cognitive scores, or neurological abnormalities in small for 
gestational age children compared to children with appropriate birth weight. (351-355) 
It is not known whether postnatal nutritional interventions in preterm infants are able 
to ameliorate the unfavorable intra-uterine development. Overall, studies looked 
only at term born small for gestational age infants. A systematic review reported of 
two randomized trials that found no effect of nutrient enriched formulas on neuro- 
cognition, whereas early growth increased fat mass, lean mass and blood pressure. 
Most observational studies consistently found a positive association between post- 
natal weight gain and neurocognitive outcomes, but also adiposity, insulin resistance 
and blood pressure. (356) It is not known whether preterm infants are born within a 
window of opportunity for favorable catch up in growth and neurodevelopment. 
A systematic review evaluating prognostic factors for poor neurodevelopment in 
children born very preterm found that low birthweight was a significant prognostic 
factor in early infancy with lack of an association in later years. (353) This could indicate 
a ‘catch -up’ in neurodevelopment but currently it is not known whether this is related 
to nutritional interventions. 
Bone development
Bone mineralization
The formation of bone occurs in several steps. Bone matrix is synthesized and deposited 
by osteoblasts. Minerals are incorporated into the pre-existent bone matrix, the cortex 
or trabeculae may be thickened or new trabeculae may be synthesized. Bone 
mineralization can only occur when bone matrix has previously has been deposited. 
(357) Decreased bone mineralization may reflect two situations: either not enough 
organic matrix has been deposited or not enough mineral has been incorporated. 
Both conditions correspond to the most common pathological situations seen in the 
development of the preterm skeleton – either osteomalacia or osteopenia. (357-359) 
(Figure 2)
Osteomalacia
Osteomalacia describes the situation of accumulation of un-mineralized bone matrix 
with osteoblasts continuing to secrete osteoid. Therefore the average mineral content 
is low and the bone is soft. A clinical example for this situation may be seen in the 
occipital flattening of preterm infants. If this process involves the growth plate it is 
called rickets. Bone mineral density and bone mineral content are decreased in 
osteomalacia and trabecula have a washed out appearance on radiographs. (357, 360, 361)
Osteopenia
This term describes a decreased amount of bone tissue with a decreased thickness or 
number of trabeculae and/or decreased thickness of the bone cortex. (357) Osteopenia 
Figure 2   Conditions of bone development in preterm infants. Black: mineralized 
bone matrix; grey speckled: unmineralized bone matrix adapted from (357)
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adolescence. (376, 382-389) Their findings were diverse, but most of the studies showed 
that these former preterm infants remained smaller later in life, some with lower bone 
mineralization, others with low mineralization but normal in proportion to their small 
body size. Several studies found impaired bone mineral content in boys compared to 
girls as well as for small for gestational age born children compared to children born 
with appropriate weight. (390, 391) Despite the low content of minerals, human milk 
seemed to have a positive effect on bone development. (377, 392) All of the participants 
of these studies received diets that provided nutrients markedly below the current 
recommendations and therefore the results may not be representative for the 
population of preterm infants treated nowadays.
Screening methods
Metabolic bone disease is often defined as decreased bone mineral content relative 
to the expected level of mineralization for a fetus or of an infant of a comparable size 
in combination with either biochemical or radiographic changes. (393) As MBD is 
asymptomatic in most infants, screening seems necessary for a timely diagnosis. 
Despite the recognition of the importance of early intervention to prevent MBD there 
is a lack of consistency and practices concerning screening and monitoring. (366,394) 
Currently there is no consensus on diagnosis, treatment or timing of initiation of 
treatment. This is partly based on the lack of evidence based parameters to evaluate 
bone status. (395,396) Standard screening methods currently used, comprise 
determination of biochemical parameters of the calcium - phosphorus homeostasis 
including serum and urine analysis as well as imaging methods. 
Biochemical parameters
Evaluation of electrolyte disturbances is standard of care in many neonatal units 
assuming that biochemical parameters of Ca-P homeostasis within a normal range 
will lead to optimal bone mineralization. (140,141,397-410) However, there is currently 
neither a consensus on the appropriateness of either parameter nor the frequency of 
measurements. (395,396) Reference values in relation to adequate nutritional intake 
have not been developed. Urinary excretion of minerals in spot urine samples has 
been shown to be an easy tool for routine evaluation. Pohlandt proposed to aim for a 
small ‘surplus of minerals’ in urine samples, while Aladangady et al developed 
reference values for urinary Ca-/P-creatinine ratios for preterm infants. (400,406) Staub 
et al compared both methods with regard to an agreement between their results and 
found neither method to be superior. (411)  None of the studies evaluated the direct 
effect of nutritional intake on biochemical parameter of Ca-P homeostasis.
resorption of organic bone matrix. (357) There are numerous reasons for impaired 
bone development in preterm infants but adequate supply of substrate is obviously a 
prerequisite for synthesis of bone tissue. Up to 80 % of the body calcium of a term 
infant is accrued during the last trimester of pregnancy. (367) Infants born preterm miss 
this active foetal mineralization in the third trimester and instead are reliant on 
parenteral and enteral sources of minerals. (368) In clinical practice it is difficult to meet 
the high foetal needs either because of limited solubility of parenteral fluids, low 
content of calcium and phosphate in human milk and impaired intestinal absorption 
of calcium or phosphorus through formula feeding. (142, 241) Besides insufficient supply 
of nutrients, impaired organic bone matrix formation can be caused as a result of 
severe systemic disease, drug side effects (corticosteroids, sedativa), increased losses 
of minerals based on immature renal function, suboptimal calcium/phosphate intake 
ratio, diuretics and vitamin D deficiency based on renal or hepatic disease. (357, 365) 
Intra-uterine growth restriction has been associated with increased risk of osteopenia. 
(369) Furthermore, it has been suggested that skeletal development is driven by 
functional requirements, meaning that bone strength increases when and where it is 
required to maintain bone stability, resulting mainly from muscle contraction and not 
from passive gravity. (357, 370) Nutritional and mechanical factors seem to have different 
roles in bone development and cannot substitute for each other, meaning that lack of 
mechanical challenge posed by muscle contractions will decrease the need for bone 
formation and therefore high amounts of minerals may not be used. On the other 
hand inadequate supply of minerals will prevent mineralization of bone matrix. (357)
Metabolic bone disease has declined since the 1980’s, probably due to improved 
nutritional management. (365) However, the incidence of MBD still is increasing with 
decreasing gestational age and birth weight. The infants most at risk are those under 
28 weeks and less than 1500 gram. For infants less than 1000 gram an incidence of 
55% has been reported. (128) Depending on the severity, MBD may remain clinically 
silent or result in fractures. (371)  Postnatal development of MBD has been related to 
myopia of prematurity, and impaired respiratory function as a result of bone softening 
and poor growth in childhood. (372-374) For the long-term development preterm 
infants have been shown to be smaller in length with significantly lower lumbar spine 
bone mass compared to population reference data. (375-377) Inadequate bone 
mineralization is seen as a risk factor for the development of osteoporosis in later life, 
which is an important cause of morbidity and mortality in elderly people and a 
considerable factor of healthcare expenditure. (378-380) The peak bone mass is attained 
before skeletal maturity. (381) Any factor that influences the acquisition of peak bone 
mass may represent a mechanism to affect later osteoporosis risk. Although medical 
treatment of preterm infants has improved over the years, the optimal treatment to 
prevent bone mineral disease is still a matter of debate. Only a few studies have 
evaluated long-term bone development of VLBW children until childhood and 
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Imaging
Osteopenia can be discovered on a plain radiograph, but this usually only provides 
visible changes of ‘thin bones’ if bone mineral content has decreased by at least 
20 - 40%. These radiographic signs occur late and furthermore are not quantifiable. 
Since it also uses radiation this method is not suitable for routine practice. Dual-
Energy- x-ray absorptiometry (DEXA) currently is recognized as the gold standard for 
bone measurements in adults and is currently also used in infants. This method is 
sensitive to detect small changes in bone mineral content. (412) Nevertheless, the 
availability is limited, it is not suitable for daily screening and it also uses a small 
amount of radiation. (413) Although the use is validated for preterm and term infants, 
the reference values depend on the method used. (414) Therefore it may be difficult to 
compare the results of different studies. Quantitative ultrasound is a promising new 
method based on the idea that changes in ultrasound are related to changes in bone 
mineral density and bone structure. (415) This method is a non-invasive, cheap bedside 
test, and suitable for repeated measurements. Depending on the method used, 
changes in ultrasound are measured at the tibia, calcaneus, radius of metacarpal 
phalanges. It is not known whether this method can replace DEXA. 
Outline of the thesis
2
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The overall purpose of the work presented in this thesis is to determine the effect of 
nutritional intake during the first two weeks of life in very low birth weight infants 
with regard to three key processes of postnatal development, namely growth, neuro-
development and bone mineralization. 
 In 2003 the department of Neonatology of the Radboudumc introduced a 
standard nutritional protocol for all infants admitted to the NICU. This protocol mainly 
provided recommendations concerning the initiation and increment of enteral nutrition. 
The use of human milk was strongly advised and otherwise preterm formula was 
used. In 2004 the regular use of human milk fortifier was introduced. A standard 
protocol for registration of feeding tolerance, growth and mineral status including 
blood and urine samples was introduced. During the same time the composition of 
the standard parenteral solution was adapted according to the recommendations of 
international guidelines.(416) The new parenteral nutrition provided a higher amount 
of amino acids, carbohydrates and minerals, specifically calcium and phosphorus 
and was introduced and used from January 1st in 2005 onwards. Furthermore, the 
parenteral nutrition protocol was adapted to achieve the full amount of parenteral 
intake earlier than compared to the previous guideline, while at the same time more 
emphasis was put on fast increment of enteral nutrition. The aim of the new nutritional 
protocol was to provide the full nutritional requirements for all infants as soon as 
possible after birth. 
 The studies presented in this thesis are based on two cohort studies. The first 
study is observational and included the data collection of two consecutive year 
cohorts (2004, 2005) of very preterm infants admitted to the neonatal intensive care 
unit of the Radboudumc. The two cohorts differed with regard to the composition of 
parenteral nutrition provided after birth. After the second week of life infants of both 
cohorts usually received the same nutritional intake, mainly fortified human milk or 
preterm formula. The surviving infants of both cohorts who fulfilled the criteria for 
the national follow-up were included for a long-term follow up of growth and neuro-
development. The same infants were finally invited at the age of nine to 10 years for 
an evaluation of growth and bone mineralization. 
 The second study was performed in combination with the multi-center double- 
blind randomized controlled trial the ‘Early Nutrition Study’ (ENS) that evaluated 
the effect of human milk on sepsis, necrotizing enterocolitis and death. This study 
randomized preterm infants with a birth weight below 1500 gram to receive either 
donor milk in addition to mother’s own milk or preterm formula if mother’s milk was 
not available. According to the study protocol human milk was not fortified until day 
10 of life. For participants of the Radboudumc the study protocol was extended  (Early 
Supplementation Study; ESS).  A third group was included in a randomized fashion. 
This third group received enteral nutrition according to the nutritional protocol of the 
NICU of the Radboudumc. Further, this group received early fortification of human 
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clinical parameters. In chapter 8 we analyzed growth and bone mineralization at term 
corrected age of participants of the randomized ESS in relation to enteral nutritional 
intake during the first 10 days of life. Chapter 9 presents a study that investigated 
whether the method of phalangeal quantitative ultrasound is able to replace the 
method of dual-energy-x-ray absorptiometry for determination of bone mineralization 
in children born as very-low birth weight infants.  
Part 4 | Discussion and Summary
Chapter 10 will summarize the results of all studies, put them into perspective and 
provide recommendations for further studies or improvements. Chapter 11 summarizes 
all parts of the thesis.
milk and preterm formula if mother’s own milk was not available and thereby had a 
higher enteral nutritional intake of protein, calcium and phosphorus during the first 
10 days compared to infants who received unfortified human milk during the same 
period. The aim of this study was to evaluate the effect of higher enteral mineral 
intake during the first 10 days, on growth and bone mineralization in preterm born 
infants at term corrected age. 
The following hypotheses were tested:
• Increase in protein and energy intake during the first postnatal week improves 
postnatal weight gain and leads to improved long-term growth at nine to 10 years 
of age
• Early enteral feeding improves weight gain
• The nutritional intake of calcium and phosphorus during the first two weeks of life 
of very low birth weight infants affects biochemical parameters of the calcium – 
phosphorus homeostasis 
• Higher amount of enteral supplementation of calcium and phosphorus during the 
first 10 days of life leads to improved growth and bone mineralization at term 
corrected age of very low birth weight infants 
• Nutritional intake during the first week affects head growth and neurodevelop-
mental outcome of very low birth weight infants at 24 months
• Increase in calcium and phosphorus intake during the first postnatal week improves 
long-term growth and bone mineralization at nine to 10 years of age 
• Boys take more advantage of nutritional improvements than girls 
• Phalangeal quantitative ultrasound can replace dual-x-ray absorptiometry for 
determination of bone mineralization in children born very preterm 
Part 2 | Different amino acid and mineral intakes
 In chapter 3 the effect of different nutritional intake of the two observational cohorts 
(2004, 2005) are evaluated with regard to weight gain and length for the short-term 
outcome until term corrected age. In chapter 4 the effect of early nutritional intake on 
long-term growth and bone mineralization of former preterm infants is evaluated. In 
chapter 5 the effect of early nutritional intake on neurodevelopmental outcome at 24 
months corrected age is evaluated. 
Part 3 | Calcium and Phosphorus metabolism and bone mineralization  
in preterm infants 
Chapter 6 presents an observational study describing the longitudinal changes of 
biochemical parameters of the calcium-phosphorus metabolism during the first five 
postnatal weeks based on data collected from the 2005 cohort. In chapter 7 data 
recorded during the ESS, were used to quantify changes in biochemical parameters of 
the calcium-phosphorus homeostasis in relation to nutritional intake and other 
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Abstract
Aim
To evaluate whether increasing the amount of amino acids and energy in parenteral 
nutrition combined with rapid increment of enteral feeding improves postnatal 
growth in preterm infants. 
Methods 
Observational study; two consecutive year-cohorts of preterm infants; Cohort 2 received 
higher supplementation of parenteral amino acids and energy with more rapid 
enhancement of enteral feeding than Cohort 1. Nutritional intake, weight and  head 
circumference (HC) were compared. 
Results
Cohort 2 (N:79, gestational age (GA): 29.8±2.2 weeks, birth weight (BW):1 248±371g) 
achieved full enteral feeds earlier (p < 0.001) and had a higher protein/energy intake 
during the first week (p < 0.001) than Cohort 1 (N: 68, GA: 29.5±2.3 weeks, BW: 
1261±339g). Both cohorts developed cumulative protein/energy deficits, but less in 
Cohort 2 (p < 0.01). Appropriate for gestational age infants (AGA) of Cohort 2 improved 
weight gain until week 5 (p < 0.01) compared to AGA of Cohort 1, nevertheless all 
infants demonstrated a decline in mean standard deviation score (>1) for weight at 
term. Small for gestational age infants failed to improve HC.
Conclusions
Improved parenteral intake may lead to improved short-term postnatal weight gain. 
Faster increase of enteral nutrition was well tolerated but failed to prevent nutritional 
deficits. Practising early enteral feeding with higher supplementation of nutrients 
may be needed and requires further study. 
Introduction
The main goal of nutrient supply to preterm infants is to achieve growth similar to 
intrauterine fetal growth combined with satisfactory functional development. (1) 
Many preterm infants face long-term detrimental effects. (2,3) Even first week parenteral 
nutritional management seems pivotal in determining long-term outcomes. (4)
 Protein intake and enteral feeding have been considered important growth- 
promoting factors in very low birth weight (VLBW) infants. Several trials have 
demonstrated that increasing protein intake can lead to a positive nitrogen balance, 
albumin synthesis, whole body protein synthesis and improved postnatal weight 
gain. (5) 
 Recently it was demonstrated that early aggressive nutrition directly after birth 
led to reduced postnatal weight loss and reduced postnatal growth restriction. (6, 7) 
Nutrients can be provided by either parenteral or enteral route. Central venous 
catheters and parenteral nutrition (PN) allow administration of adequate nutrients 
soon after birth but both have been shown to be significant risk factors for late-onset 
sepsis. (8,9) Early establishment of enteral feeding, especially of human milk, may be 
protective against infection. (10) Several studies demonstrated that rapid advancement 
of enteral feeding in preterm infants led to an earlier regain of birth weight and a 
shorter hospital stay. (11,12)
 To improve our nutritional management of preterm infants, we increased the 
amount of amino acids and energy provided by parenteral nutrition in combination 
with the intention to rapidly increase enteral feeding. We compared the new feeding 
regimen to the previous standard protocol, hypothesizing that the increase in protein 
and energy intake as well as early full enteral feeds would lead to improved postnatal 
weight gain. 
Method
Study design 
This prospective cohort study was conducted during two consecutive years, 2004 
(Cohort 1) and 2005 (Cohort 2). The study was approved by the local ethics committee. 
Informed consent of parents was not necessary according to our institutional review 
board because the parenteral nutrition solution was a standard medical prescription 
that was changed to improve quality. The nutritional protocol and record-keeping 
were part of the standard care applied in our department.  
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Nutritional intake of human milk was calculated assuming a protein content of 1.4 g/dL, 
a fat content of 3.2 g/dL, and a carbohydrate content of 7 g/dL as used for comparable 
studies (6, 7) and published previously (13). To evaluate nutritional intake in relation to 
recent recommendations, a mean daily intake of 3.8g protein and 120 kcal/kg/d was 
assumed to be adequate. (1) Actual intake was subtracted from the recommended 
intake to calculate the daily deficit, which was then summed to calculate the 
cumulative deficit. Because intake during weeks 3, 4, and 5 was only recorded once a 
week, the mean daily intake was considered as the weekly intake divided by 7. 
 A BW below the 10th percentile of the Dutch reference curves for BW by gestational 
age was defined as small for gestational age (SGA).(14) We performed analyses 
between subgroups of GA and between appropriate for gestational age (AGA) and 
SGA infants. 
 The mean daily weight gain was calculated weekly from birth for the first 5 weeks 
and until TCA. Postnatal weight gain was calculated using the exponential formula 
described by Patel et al. (15). To quantify postnatal growth, we calculated the standard 
deviation score (SDS) for weight changes using the Dutch reference curves as a 
reference for fetal growth and, thus, the estimated optimal postnatal growth. (14) The 
head circumference was recorded during the first week, at TCA, 6 months, 1 and 2 
years of corrected age. The SDS for HC were calculated using the Swedish growth 
reference for preterm infants and the Dutch reference of the nationwide growth 
study. (16,17)
Study population
Preterm infants born below 34 weeks gestational age (GA), admitted to our tertiary 
neonatal intensive care unit (Radboud University Nijmegen Medical Center, The 
Netherlands) were recruited on the first day of life if it was assumed that PN was 
needed for at least 5 days. Infants with major congenital malformations or asphyxia 
were excluded from evaluation. 
Nutritional protocol
During both time periods, all infants received nutrition according to standard 
institutional nutritional protocols. No other major changes in clinical practice occurred 
during either period. 
Parenteral nutrition
Parenteral nutrition was started directly after birth in both cohorts. Nutritional intake 
was increased by daily increment of the amount of fluid. Our PN consisted of standard 
prepared components. The cohorts differed for the intake schedule. Cohort 2 achieved 
full parenteral nutrition earlier than Cohort 1 (4 vs. 6 days). At full PN Cohort 2 received 
more amino acids  (21 vs.17.5 gram/kg/week) than Cohort 1. Carbohydrate intake of 
Cohort 2 exceeded Cohort 1 if the total fluid intake increased above the recommended 
150 ml/kg/day (C1: 95.9 vs. C2: 96.6 – 117.6 gram/kg/day). The total amount of parenteral 
lipid intake was not changed. (Table 1). Details are presented in Table 1.
Enteral nutrition 
In both cohorts enteral feeding was started on the first day of life. The amount was 
increased daily, while the PN was gradually reduced to maintain a daily fluid intake 
within the protocol range. The maximum enteral fluid intake was the same as for the 
PN (Table 1). The stepwise increase of enteral volume was left at the discretion of the 
neonatologist in charge. For the second cohort we intended to increase the enteral 
amount of nutrition as soon as possible. Gastric residuals up to 3 ml per feeding were 
generally accepted. Human milk was enriched using a commercially available fortifier 
(Nutrilon Nenatal BMF, Nutricia, Zoetermeer, NL) above an intake of 50 mL/d.  The fortifier 
(HMF) added 0.8 g/dL of protein. If human milk was not available, infants received 
preterm formula (Nutrilon Nenatal Start, Nutricia, Zoetermeer, NL) with a protein 
content of 2.5 g/dL. 
Data collection and Analysis
The intake of all nutrients via both, PN and enteral feeding as well as growth charac-
teristics was recorded daily during the first 2 weeks, weekly until week 5 and at term 
corrected age (TCA), calculated and analysed according to the information in the 
patient charts. 
Table 1  Parenteral nutritional intake
D0 D1 D2 D3 D4 D5 D6
Cohort 1 Fluid ml/kg/d 60 80 100 120 140 160 180
CH g/kg/d 4.9 5.9 6.8 7.8 8.83 11.7 13.7
AA g/kg/d 0.5 1 1.5 2 2.25 2.5 2.5
Lipids g/kg/d 0.5 1 1.5 2 2.5 3 3
EQ kcal/kg/d 26 37 47 57 67 86 92
Cohort 2 Fluid ml/kg/d 80 100 125 150 150 150 150 -180
CH g/kg/d 8 9.6 11.7 13.8 13.8 13.8 13.8-16.8
AA g/kg/d 0.75 1.5 2.25 3 3 3 3
Lipids g/kg/d - 1 2 3 3 3 3
EQ kcal/kg/d 35 53 74 94 94 94 94 -106
Standard protocol for parenteral nutrition of Cohort 1 and Cohort 2 with different standardized 
parenteral solutions. CH: carbohydrates; AA: amino acid; EQ: energy quotient. The parenteral nutrition 
consisted of two standard prepared components, a mixture of amino acids/glucose/minerals and lipid 
emulsion plus vitamins. Amino acid solutions and lipid emulsion: Cohort 1 : Aminovenos N paed 10% 
(Fresenius Kabi), Intralipid 20% (Fresenius Kabi) Cohort 2: Primene (Clintec, Brussels), Intralipid 30% 
(Fresenius Kabi).
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protein/kg/d was reached earlier in Cohort 2 than Cohort 1 (12.3 ± 7.4 vs.14.7 ± 8.0 
days; non-significant), a considerable number of infants in both cohorts never 
achieved this intake during the first five postnatal weeks (14/68 (20.5%) vs. 13/79 
(16.5%)). Energy intake increased continuously. At the end of the five week follow up 
Cohort 1 received a mean energy intake of 117 ± 24 kcal/kg/d whereas  cohort 2 
received 123 ± 24 kcal/kg/d (Figure 2). 
 Infants of both cohorts developed cumulative deficits of protein and energy 
intake compared to the recommended intake (Figure 2). Nevertheless, these deficits 
were significantly lower in Cohort 2 during the observational period (p < 0.01). Protein 
deficits were not compensated, whereas the cumulative energy deficit tended to 
catch-up from the third week on. (Figure 2). 
Postnatal growth 
Maximum weight loss was 9.5% in both cohorts. The day that infants reached the 
nadir for weight was achieved earlier in Cohort 2 than Cohort 1 at mean 3.3 ± 0.6 days 
vs. 4.1 ± 1.2 days (p < 0.001). The mean number of days to regain birth weight was not 
different between both cohorts (8.9 ± 0.7 days vs. 8.3 ± 1.3 days). 
Statistics
The primary outcome of our study was postnatal growth. The power calculation to 
determine the size of the study group, was based on the study of Pauls et al., who 
investigated postnatal weight gain in VLBW infants on a comparable feeding regimen. 
(18) A difference in weight change of 0.5 SD was assumed to be clinically relevant. We 
calculated that each group should contain at least 66 patients to find a statistical 
difference with an α of 0.05 and a power of 0.80 between the 2 cohorts. Data are 
presented as the mean ± SD, except otherwise mentioned. Paired Student t-tests 
were performed to compare the mean variables between subgroups of each cohort. 
Fisher’s exact test was used to evaluate categorical data. The level of significance was 
set at p < 0.05
Results
Patient selection and characteristics
The patient recruitment and cohort inclusion are presented in Figure 1. Finally, 68 infants 
in Cohort 1 and 79 infants in Cohort 2 were evaluated. The mean GA (29.5 ± 2.3 weeks vs. 
29.8 ± 2.2 weeks) and mean BW (1261 ± 339 g vs. 1248 ± 371 g) were not different 
between the 2 cohorts. In Cohorts 1 and 2, respectively, 7.5 and 11% of  infants were 
classified as SGA (Table 2). Mortality before day 8 was unrelated to nutritional intake. 
Morbidity and mortality before discharge are described in Table 2. The incidence of 
common diseases related to prematurity and mortality were not significant different 
between both cohorts. 
Nutritional intake
Both cohorts started PN directly after birth, but the mean duration was significantly 
shorter and full enteral feeding was achieved significantly earlier in Cohort 2 (p < 0.001) 
(Table 3). Ninety-six and 91% of infants in Cohorts 1 and 2, respectively, received 
human milk, which was generally supplemented with human milk fortifier by day 5.
 Daily changes in protein and energy intake are presented in Figure 2. The mean 
daily protein intake (g/kg/d) was higher in Cohort 2 up to day 5 (p < 0.005), whereas 
energy intake (kcal/kg/d) was higher up to day 7 (p=0.01) (Figure 2). This difference 
was mainly caused by the increased parenteral intake (Figure 3). Cohort 2 had a 
significant increased protein and energy intake during the first week (protein: 14. 5 ± 
4 vs. 18. 1 ± 4 g/kg/week; energy: 512 ±93 vs. 609 ± 127 kcal/kg/week; p < 0.001) This 
difference was reduced during the second week of life (Table 3).  The mean  maximum 
protein intake was higher in cohort 2 (4.0 ± 0.5 vs. 4.3 ± 0.9 g/kg/d; p < 0.01) whereas 
the day to achieve the maximum intake demonstrated a wide range in both cohorts 
(Table 3). Although the achievement of the assumed recommended intake of 3.8g 
Figure 1   Patient recruitment and cohort inclusion
PN = parenteral nutrition; TCA = term corrected age
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At birth the mean SDS for weight was positive and similar between AGA infants 
of both cohorts (Table 2). SGA infants had a significant lower mean SDS for weight than 
AGA infants of their respective cohort. (p < 0.0001) (Table 2).
 For AGA infants daily weight gain (g/kg/d) increased from the second week on 
but was significantly higher in Cohort 2 (p < 0.01). However, at TCA, the daily weight 
gain was no longer different between both cohorts (Figure 2). SGA infants demonstrated 
a higher growth velocity from birth until week 5 and until term age compared to 
AGA infants of the same cohort (birth - week 5: SGA C1/C2: 12.2 ± 3.1 / 12.2 ± 2.1 g/kg/d 
vs. AGA C1/C2: 8.9 ± 2.7 / 10.7 ± 3.0; p = 0.03; birth – term corrected age: SGA C1/C2: 
15.5 ± 4.2 / 14.5 ± 1.5 vs. AGA C1/C2: 11.1± 2.3 / 11.8 ± 2.3 g/kg/d; p < 0.001) (Figure 2). 
Weight gain was not different between SGA infants of Cohort 1 and Cohort 2. 
 Despite the positive weight gain from the second week onward, all infants 
demonstrated a steady decrease in SDS for weight during the 5-week follow up, 
which continued until TCA (Figure 2).  For AGA infants this decrease resulted in a mean 
Table 2  Cohort characteristics
Cohort 1 Cohort 2 p-value
Infants, No. 68 79
AGA 57 65
SGA
GA, mean (SD), weeks
11 14
AGA 29.1 (2.0) 29.5 (2.7) 0.33
SGA 31.3 (2.3) 30.9 (2.7) 0.70
p-value 0.01 0.10
BW, mean (SD), g
AGA
SGA
p-value
1200 (337)
875 (148)
<0.0001
1271 (350)
881 (258)
<0.0001
0.26
0.94
BW SDS, mean (SD)
AGA
SGA
p-value
0.32 (0.7)
-1.69 (0.69) 
<0.0001
0.26 (0.94)
-1.79 (0.5)
<0.0001
0.69
0.69
HC SDS, mean (SD)
AGA -0.89 (0.93) -1.24 (0.71) 0.04
SGA -2.73 (1.06) -2.52 (0.72) 0.94
p-value <0.0001 <0.0001
AGA Female Male Female Male
Number 29 28 30 35
GA, mean (SD), weeks 29.3 (2.3) 28.8 (1.7) 29.4 (3.6) 29.5 (1.9)
BW, mean (SD), g 1129 (319) 1272 (351) 1207 (340) 1325 (359)
BW SDS, mean (SD) 0.11 (0.6) 0.53 (0.7) 0.15 (0.9) 0.36 (1.0)
SGA Female Male Female Male
Number 9 2 7 7
GA, mean (SD),weeks 32.2 (2.1) 28.3 (0.4) 31.5 (2.5) 30.4 (3.2)
BW, mean (SD), g 906 (154) 732 (101) 837 (165) 924 (351)
BW SDS, mean (SD) - 1.8 (0.8) - 1.35 (0.3) -1.82 (0.6) -1.76 (0.5)
Table 2  Continued
Cohort 1 Cohort 2 p-value
Mortality and Morbidity
IRDS, No. (%) 45 (66.1) 47 (59.5)
Mechanical ventilation, No.(%) 40 (60) 51 (65)
Duration of ventilation, days, med 
(interquartile range)
4 (2 – 7) 4 (4 – 7)
> 20 days on ventilator, No 1 1
CLD, No. (%) 11 (16) 8 (10)
GI symptoms, No. (%) 16 (23) 15 (19)
NEC ≥ IB, No. (%) 5 (7) 5 (6)
Sepsis, No. (%) 32 (47) 38 (48)
PDA, No. (%) 31 (45) 24 (30)
IVH III-IV, No. (%) 5 (7.3) 3 (3.8)
Mortality before discharge, No. (%) 1 (1.5) 4 (5)
Cohort characteristics concerning patient selection, morbidity and mortality. AGA = appropriate for ges-
tational age; BW = birth weight; GA = gestational age; SGA = small for gestational age. SGA was defined 
as birth weight below the 10th percentile in the Dutch reference (14). HC = head circumference  during 
the first postnatal week (16). Chronic lung disease (CLD) was defined as need for supplemental oxygen for 
more than 28 days. Sepsis was defined as clinical signs in combination with positive results from blood 
cultures ≥ 48 hours after birth, and necrotizing enterocolitis (NEC) was defined according to the criteria 
given by Bell et al. (32). IRDS = Infant respiratory distress syndrome; PDA = Patent ductus arteriosus; IVH 
III-IV = Intra-ventricular hemorrhage grade III-IV. None of the items were significantly different between 
the cohorts. None of the parameters were significantly different.
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loss of 2.0 ± 1 SDS from birth until term corrected age in Cohort 1 and 1.9 ± 1.2 SDS in 
Cohort 2 (not significant). In contrast, SGA infants demonstrated a lower decline in 
mean SDS for weight than AGA infants (C1/C2: 1.16 (± 1.2)/1.64 (± 0.7) (not significant). 
 At birth the mean SDS for HC was significant lower in AGA infants of C2 compared 
to AGA C1 (Table 2). At term corrected age this difference did no longer exist (AGA TCA 
C1/C2: -1.05 ± 1.25/ -0.35 ± 1.96; p < 0.11) and by 6 months both groups demonstrated 
a complete catch up in mean SDS for head circumference compared to the normal 
Dutch population at 6 months (AGA 6m C1/C2: 0.09 ± 1.01/ 0.12 ± 1.07; p< 0.88). AGA 
infants of C2 had a significant greater increase of mean SDS for head circumference 
than AGA infants of C1 by 6 months (C1/C2: 1.12 ± 0.74/ 1.57 ±  0.78; p < 0.01). The mean 
SDS for HC of SGA infants was not different at birth between both cohorts but 
significant lower than their respective AGA group (Table 2). Both cohorts of SGA 
infants showed an improvement of mean SDS for head circumference by 6 months, 
but the difference remained significant compared to AGA infants (p < 0.02) (SGA term 
corrected age C1/C2: -2.1 ± 1.91/-2.69 ± 1.78; p < 0.69; SGA 6m C1/C2: -2.07 ± 1.69/-0.73 
± 0.77; p <0.11). While AGA infants achieved a catch up to normal head circumference 
within 6 months the mean SDS of SGA infants remained below 1 SD for the normal 
Dutch population at the age of two years. (SGA 1y C1/C2: -1.36 ± 1.49/ -1.07 ± 1.19; 
p< 0.49; 2y C1/C2: -1.32 ± 1.68/-0.98 ±0.98). 
 Subgroup analyses within a cohort revealed no differences between subgroups 
of GAs of AGA infants (data not shown). The number of SGA infants was too small to 
perform sub analyses. Fi
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Table 3  Nutritional Characteristics
Cohort 1 Cohort 2
PN, mean (SD) days, (range) 12.8 (3.8) (7-25) 10.6 (3.6) (6-25)*
Full enteral feeding, mean (SD), days 13.6 (3.4) 11.6 (3.6)*
Protein week 1, mean (SD),  g/kg/week 14.5 (3.7) 18.1 (4.0)*
Protein week 2, mean (SD), g/kg/week 21.3 (4.8) 22.4 (5.5)
Energy week 1, mean (SD), kcal/kg/week 512 (93) 609 (127)*
Energy week 2, mean (SD),  kcal/kg/week 718 (165) 768 (178)
Age at protein intake ≥ 3.8 g/kg/d, days, mean (SD), 
(med, min, max) 
14.7 (8.0)
(12; 5; 35)
12..3 (7.4)
(10; 4; 35)
Intake never above ≥ 3.8g/kg/d, No. (%) 14 (20.5) 13 (16.5)
Max protein intake, g/kg/d, mean (SD) 4.0 (0.5) 4.3 (0.9) **
Age at max protein intake, days, mean (SD)
(med, min, max)
18.2 (9.0)
(14; 4; 35)
16.7 (9.7)
(13; 4; 35)
PN = parenteral nutrition; * =  p < 0.001; ** = p < 0.01
82 83
3
CHAPTER 3 FEEDING STRATEGIES AND POSTNATAL GROWTH
nutritional improvement cannot be explained by differences in the incidence of 
major morbidities. 
 Appropriate for GA and SGA infants in this study demonstrated a different growth 
pattern (Figure 2). AGA infants, in general, have demonstrated a normal growth 
potential until birth, and therefore ideally should be able to continue this growth 
thereafter. For AGA infants in this study, the nutritional deficits led to growth 
retardation of body weight with brain sparing with even catch up in the cohort with 
improved intake. Tan and Cooke evaluated nutritional intake and head growth in a 
randomized trial and demonstrated a positive correlation between head growth and 
nutritional intake but failed to demonstrate a significant improvement. (22)  This study 
did not separate between AGA and SGA infants. Our SGA infants of both cohorts 
mainly used energy for weight gain. The same phenomenon has been described in 
other studies. (6) There is increasing evidence that SGA infants follow a different 
growth  trajectory with negative long-term consequences.(23) Therefore, the postnatal 
weight changes in growth parameter we observed  in our study can be related to 
nutritional changes. We speculate that further improvement of nutritional intake 
might have improved head growth  in SGA infants and weight gain in AGA infants. We 
are aware that our cohort of SGA infants is too small for further conclusions, but we 
suggest that with regard to probably different utilization of nutritional supply, future 
studies should evaluate differences in nutritional requirements between AGA and 
SGA infants. 
 The protein requirement of preterm infants includes the amount required for 
growth plus replacement of inevitable losses and ‘catch-up’ growth caused by 
morbidity or a failure to provide sufficient intake. (24) Analysis of data collected in the 
NICHD glutamine supplementation study revealed that significantly improved 
growth occurred in infants who received at least 3 g/kg/d of parenteral protein by the 
fifth day of life. (25) In our study, Cohort 1 had a mean intake of 3 g/kg/d by day 8, 
whereas in Cohort 2, this was achieved by day 5. (Figure 2) According to recent 
international recommendations, enteral protein intake for preterm infants should 
range between 3.5 and 4.5 g/kg/d (1). Nevertheless, our assumed optimal intake of 
3.8 g/kg/d was never achieved by a considerable amount of infants in both cohorts. 
The significant improved intake in Cohort 2 occurred mainly as a result of higher 
parenteral protein intake. Early introduction of human milk fortifier did not prevent 
cumulative protein and energy deficits, resulting in growth retardation at term age in 
both cohorts. (26) 
 Senterre and Rigo demonstrated improved postnatal growth with minimal loss 
of SDS by  providing  the recommended intake, especially amino acids, by continuation 
of long-term parenteral nutrition. (6) In their study infants received parenteral nutrition 
for more than 21 days whereas our Cohort 2 achieved full enteral feeding at a mean of 
11.6 days (Table 3). These differences in clinical practice reveal the essential scientific 
Discussion
Our data show that despite significantly improved protein and energy intake during 
the first week of life, infants developed cumulative protein and energy deficits at the 
same time that were not resolved within the observational period. For AGA infants 
the improved nutritional intake was associated with an improved gain in weight and 
head circumference but weight gain during the first five weeks was not sufficient to 
prevent a substantial decrease in the mean SDS for weight of more than 1.9 SDS  at 
term corrected age. In contrast, SGA infants had a lower decline in mean SDS for 
weight but less improvement of mean SDS for head circumference. 
Postnatal growth is influenced by morbidity. (19) The incidence of major morbidities 
in our cohorts was comparable to that of other epidemiological studies. (20,21) 
The small, short-term difference in postnatal growth between both cohorts after 
Figure 3   Amino acid intake separated in parenteral and enteral intake according  
to patient charts
(mean ± SEM); * = p < 0.01
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according to a standardized protocol, data were recorded in the same standardized 
manner and patient characteristics were comparable. In accordance to our results, the 
randomized trial performed by Tan and Cooke correlated  impaired head growth to 
persisting cumulative protein and energy deficits caused by insufficient supply  with 
current available formulas and human milk fortifiers. (22) 
 In conclusion, we confirm  that  VLBW infants develop protein and energy deficits 
during the first two weeks of  life. Aggressive enteral nutrition  is well-tolerated but 
not sufficient for adequate postnatal growth. Practising early enteral feeding with 
higher supplementation of nutrients may be needed and requires further study.
question concerning optimal feeding for preterm infants. It is obvious that provision 
of sufficient nutrients is necessary to achieve optimal growth and development in 
preterm infants. It is not known what the optimal way of feeding is, either by parenteral 
or enteral route. Both ways have their (dis-) advantages. In contrast, we assumed that 
human milk is the optimal source for feeding preterm infants. Nearly all studies 
demonstrate that human milk stimulates gastrointestinal maturation, supports infant 
host defense, improves neurodevelopmental outcome and may be protective against 
the development of necrotizing enterocolitis. (27,28) We therefore provided an 
aggressive enteral feeding regimen with fast increment of enteral nutrition and early 
fortification of human milk. This was well- tolerated and did not lead to increased 
morbidity but unfortunately did not prevent growth retardation. The optimal intake 
for enteral nutrition as recently recommended cannot be achieved even with an 
aggressive enteral feeding regimen. (1) 
 For the use of early enteral feeding, especially with human milk, we suggest that 
the currently available HMFs do not contain enough protein. Assuming an average 
protein content of less than 2 g/dl in human milk over a longer period of lactation in 
combination with a fluid intake of 150 ml/kg/d, a minimum of at least 0.5 g/dL of 
protein is needed as an extra supplement for fortified human milk to achieve the 
currently recommended intake. 
 Our study has several limitations. Firstly, for this study, human milk was not 
analysed. Therefore, our calculations concerning human milk are mainly based on 
assumptions and therefore remain hypothetical. Different studies have reported 
varying milk compositions depending on infant prematurity and the time at which 
samples were collected. Milk composition differs between the mothers of infants 
born preterm or at term and the composition changes during the lactation period. 
(13,29-31) We decided to use assumptions that have been used by Senterre and Rigo for 
evaluation of comparable studies with different results. (6) Using different assumptions 
may influence the results. Bauer and Gerss found a higher content of macronutrients 
than usually found in most other studies. (31) To rule out an underestimation of 
nutritional intake we also calculated the intake using the data provided by Bauer et al. 
with a varying protein intake between 2.5 and 2.0 g/dL. (31) (data not shown) Although 
with this calculation the nutritional intake was higher and the optimal intake was 
achieved earlier, both cohorts still had cummulative deficits that were not resolved by 
the end of the observational period. Furthermore, since infants of both cohorts had 
similar GA, it is not plausible that differences in growth were caused by general 
differences in human milk content between cohorts. 
 A second limitation of our study is that patients were not randomly assigned to 
one treatment, but rather were recruited over two consecutive time periods. We 
reasoned that attempting two different feeding protocols in one department might 
pose an increased risk for patient safety. In both cohorts, all patients received nutrition 
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In reply: 
Sir, 
We appreciate the commentary made by C. Maas and coworkers and fully agree that 
a comparison of recent cohort studies demonstrates that the first week nutritional 
intake is a major determinant for further postnatal development. (1-3)
 Nevertheless we remain at our conclusion that enteral formulas and supplements 
may not provide sufficient nutrients for preterm infants. We disagree that the ‘near 
adequate’ growth as described by Maas et al. was predominately achieved by 
accelerated enteral nutrition. (1)   
 Both our studies aimed for early full enteral feeding, provided predominantly by 
human milk, but resulted in different outcome.  In contrast to our study, fortification 
of human milk in the Maas cohorts added more protein and energy (protein: 1.1 -1.6 
vs. 0.8 g/dL; energy: 15- 20 vs. 15 kcal/dL). (1, 3) This may have improved early growth. 
On the other hand, Maas et al started fortification only at 140/100 ml/kg/day, thus 
nearly full enteral feeding. This occurred around  the end of the first week. Therefore 
parenteral amino acids were the major contributor to the total protein intake during 
the first week. In contrast to our study, they also provided by far earlier and higher 
amounts of parenteral amino acids. Theoretically, this, may have led to less cumulative 
deficit with minimal loss of SDS in the early postnatal period. 
 We would like to point at the significant increased postnatal weight gain in 
our SGA infants compared to AGA infants. This seems to indicate different growth 
trajectories with different nutritional requirements for certain groups. With regard to 
long-term developmental outcome the optimal postnatal growth has still not been 
defined. 
 We agree that optimal growth and development is mainly dependent on sufficient 
supply of nutrients which can be provided as parenteral nutrition. While there are many 
advantages to provide feeding through the enteral route, no study has demonstrated 
that the recommended intake for preterm infants during the first week can be 
provided by enteral nutrition.  Nevertheless, our studies show that rapid advancement 
of enteral nutrition is feasible, well tolerated and that small differences in nutritional 
protocols may have a remarkable effect on postnatal growth.  Further improvement 
may be achieved by advanced or individualized fortification of human milk and 
optimization of the composition of fortifiers 
 In conclusion, we agree that it is possible to improve postnatal growth in preterm 
infants with enteral nutrition, but further studies are required to improve nutritional 
protocols, preferably as randomized controlled trials.
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CHAPTER 4 FOLLOW UP GROWTH AND BONE MINERALIZATION
Abstract
Background
Preterm infants are at risk for impaired bone mineralization and growth in length later 
in life due to inadequate nutritional intake in the early postnatal period. 
Objective
To investigate whether increased nutritional supplementation of calcium, phosphate and 
protein in Very Low Birth Weight (VLBW) infants during the first 14 days after birth was 
associated with improvement in length and bone development until 9-10 years of age. 
Design
Observational follow-up study of VLBW infants (birth weight < 1500 grams or 
gestational age < 32 weeks) born in two consecutive years (eligible infants: 2004 n: 63 
and 2005: n: 66). Cohort 2005 received higher intake of calcium, phosphate and 
protein with parenteral nutrition compared to Cohort 2004. Anthropometric data 
were collected during standard follow-up visits until five years, and additionally at 9 
-10 years of age including measurements of bone mineral content, bone mineral 
density of the whole body and lumbar spine determined by  dual-energy X-ray 
absorptiometry. Long-term growth trajectories of both cohorts were evaluated 
separately for participants born appropriate (AGA) and small for gestational age 
(SGA), stratified by gender. Multivariate linear regression was used to examine the 
effect of nutritional intake and clinical covariates on length and bone mineralization.
Results
Both cohorts achieved a catch-up in length to SDS within the normal range by 6 
months (length SDS: estimated mean (95% confidence interval (CI): 6 months: Cohort 
2004: -0.7 (-1.1, -0.3) Cohort 2005: -0.5 (-0.8, -0.2)).  Bone mineral content and density 
were within the normal range and not different between the cohorts. SGA children 
achieved a catch-up in length at 5 years with bone mineralization comparable to AGA 
children.  Only for girls birth weight was significantly associated with length SDS (per 
gram: β 0.001; 95% CI (0.000, 0.003); p = 0.03)  There was no evidence of an association 
between early nutritional intake and bone mineralization.
Conclusion
Children born as appropriate or small for gestational age preterm infants are able to 
catch up in length after the postnatal period, and achieve a normal length and bone 
mineralization at age nine - ten years. An improvement of calcium and phosphate 
intake during the first 14 days after birth was not associated with improvement in 
length and bone development. 
Introduction
Achieving growth and development comparable to healthy term born infants has 
been a challenge for the treatment of preterm born infants for many decades. (1) 
As the survival of Very Low Birth Weight (VLBW) infants has increased significantly 
during the last years, it is important to evaluate their long-term outcomes, especially 
since recommendations and policies with regard to nutritional intake have been 
changed to improve postnatal growth. (2-4)
 While early cohort studies demonstrated that VLBW infants experienced a significant 
growth retardation during the early postnatal period without catch-up to the initial 
birth percentile, more recent studies showed that improvement of early nutritional 
intake diminishes the cumulative nutritional deficit and thereby may prevent growth 
retardation. (5-7)  Growth and skeletal development seem to be closely related. (8-10) 
Adequate bone mineralization is necessary for optimal  development of the bones. 
(11-13) Given the difficulties associated with meeting the nutritional needs of VLBW 
infants and to provide sufficient nutritional supply of minerals, VLBW infants are 
especially at risk of impaired bone mineral content.  (14-17) While early studies showed 
that exclusive feeding of human milk in preterm infants leads to deficiencies of 
calcium and phosphate, it is nowadays generally recommended to fortify human milk 
with additional minerals, protein and vitamins. (18-20) Furthermore, parenteral supple-
mentation of calcium and phosphate has been improved through the inclusion of 
organic phosphate in parenteral nutrition (PN). (21)
 Only a few studies have evaluated long-term bone development of VLBW children 
until childhood and adolescence. (22-30)  Their findings were diverse but most of the 
studies showed that these former preterm infants remained smaller later in  life, some 
with lower bone mineralization, others with low mineralization but normal in 
proportion to their small body size. Several studies found impaired bone mineral 
content in boys compared to girls. (22,31) Despite the low content of minerals, human 
milk seemed to have a positive effect on bone development. (32,33) All of the 
participants of these studies received diets that provided nutrients markedly below 
the current recommendations and therefore the results may not be representative for 
the population of preterm infants treated nowadays. A more recent randomized trial 
in VLBW infants found a positive effect of post- discharge feeding on BMC in 
comparison to human milk and term formula at the corrected age of 6 months, 
irrespective of gain in weight and length. (34)
 Previously we reported the short-term outcome results for two consecutive 
year-cohorts of VLBW infants that differed with regard to the nutritional intake during 
the first two weeks of life. (35) The second cohort received a higher intake of protein, 
energy as well as calcium and phosphate and this was associated with improved 
weight gain during the early postnatal period and at the corrected age of two years 
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there was a tendency of improved growth in length. A secondary analysis revealed 
that this was mainly based on improvement in boys. Small for gestational age (SGA) 
infants had a higher postnatal weight gain than appropriate for gestational age (AGA) 
born infants. (35) For the current study we describe the long-term growth in length for 
the surviving infants of the original cohorts and analyze the effect of  the postnatal 
nutritional intake on length  and bone mineralization at the of age 9 to 10 years. 
We hypothesized that increased nutritional intake would lead to improved length 
and bone mineralization. 
Methods
Study population and design 
This observational follow-up study evaluated the long-term outcomes of growth and 
bone mineralization of a previously described prospective cohort study that was 
conducted in 2004 and 2005, in order to evaluate changes in the composition of 
parenteral nutrition (PN). (35,36) Surviving participants of both cohorts who were 
eligible for the standard follow-up schedule provided to VLBW infants born prior to 32 
weeks of gestation, or those with a birth weight below 1500 grams were included in 
the study. (Eligible children: Cohort 2004: n = 63; Cohort 2005: n = 66). These children 
were invited for an additional outpatient clinic visit that included an evaluation of 
bone mineralization by dual energy X-ray absorptiometry (DEXA). The parents of 
all participants provided written informed consent for the additional investigation. 
The study was approved by the local ethics committee (2013/594) and registered 
within the Dutch Trial Registry (NTR=TC4842). 
 In accordance with the standard follow-up program, growth and general health 
status were recorded at the corrected ages of six months, and 1, 2  and 5 years. For the 
current study, we extended the follow-up by inviting children who were previously 
seen during the national follow-up program to return for further testing around the 
ages of nine and 10 years. 
Nutritional protocol 
The 2004 and 2005 cohorts included preterm infants admitted to the level III neonatal 
intensive care unit (Radboud university medical center, The Netherlands) on the first 
day of life after it was estimated  that parenteral nutrition would be needed for at least 
5 days. Infants with major congenital malformations or asphyxia were excluded. 
The nutritional protocols for the two cohorts primarily differed in terms of the parenteral 
nutritional intake with higher amounts of protein, calcium and phosphate provided to 
the 2005 Cohort. (Table 1) Following the recommendation of the European Society of 
Pediatric Gastroenterology, Hepatology and Nutrition the 2005 PN provided 3 mmol 
per kg per day of calcium and 1.92 mmol per kg per day of glycerophosphate. (4,37) 
According to the nutritional protocol of 2005, full PN was achieved four days following 
birth, while the maximum amount of PN in Cohort 2004 was achieved later, at day six. 
For both cohorts, enteral feeding was started on the first day of life and human milk 
was enriched with a commercially available fortifier (HMF) (Nutrilon Nenatal BMF, 
Nutricia, Zoetermeer, The Netherlands) from an intake of 50 ml per day onwards. 
HMF added 1.6 mmol/dL of calcium and 1.95 mmol/dL of phosphate. If human milk 
was not available, infants received a preterm formula (Nutrilon Nenatal Start, Nutricia, 
Zoetermeer, The Netherlands). The formula contained 2.5 mmol per dL of calcium and 
1.6 mmol per dL of phosphate and  200 IE per dL of Vitamin D. The full nutritional 
protocol has previously been described in detail. (35,36) No major changes in clinical 
practice occurred and all infants received nutrition according to standard institutional 
protocols.
Table 1  Parenteral nutritional intake
D0 D1 D2 D3 D4 D5 D6
2004 Fluid ml/kg/d 60 80 100 120 140 160 180
CH g/kg/d 4.9 5.9 6.8 7.8 8.83 11.7 13.7
AA g/kg/d 0.5 1 1.5 2 2.25 2.5 2.5
Lipids g/kg/d 0.5 1 1.5 2 2.5 3 3
EQ kcal/kg/d 26 37 47 57 67 86 92
Ca mmol/kg/d 0.17 0.17 0.33 0.50 0.66 0.83 1.08
P mmol/kg/d 0.04 0.04 0.08 0.12 0.16 0.20 0.26
2005 Fluid ml/kg/d 80 100 125 150 150 150 150 -180
CH g/kg/d 8 9.6 11.7 13.8 13.8 13.8 13.8-16.8
AA g/kg/d 0.75 1.5 2.25 3 3 3 3
Lipids g/kg/d - 1 2 3 3 3 3
EQ kcal/kg/d 35 53 74 94 94 94 94 -106
Ca mmol/kg/d 0.75 1.5 2.25 3.00 3.00 3.00 3.00
P mmol/kg/d 0.48 0.96 1.44 1.92 1.92 1.92 1.92
Standard protocol for parenteral nutrition of Cohort 2004 and Cohort 2005 with different standardized 
parenteral solutions. CH: carbohydrates; AA: amino acid; EQ: energy quotient. Ca: calcium; P: phospha-
teThe parenteral nutrition consisted of two standard prepared components, a mixture of amino acids/
glucose/minerals and lipid emulsion plus vitamins. Amino acid solutions and lipid emulsion: Cohort 
2004 : Aminovenos N paed 10% (Fresenius Kabi), Intralipid 20% (Fresenius Kabi), Ca gluconate 10% 
(Braun Melsungen), Potassium phosphate (Braun melsungen) Cohort 2005: Primene (Clintec, Brussels), 
Intralipid 30% (Fresenius Kabi) Ca gluconate 10% (Braun Melsungen), Sodium-glycerophosphate (Gly-
cophos; Fresenius Kabi).
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Anthropometric measurements and questionnaire
At the last visit length and weight were determined, and the  health condition 
evaluated using a questionnaire. We specifically focused on morbidities and the use 
of medication that could have affected growth and bone mineralization, for example 
corticosteroids, asthma and fractures. For the preceding follow-up visits anthro-
pometric measurements were collected either from the patient charts or requested 
from the local pediatric out-patient clinics specifically for measurements at term 
corrected age (TCA). Body weight was measured to the nearest 0.1 kg using an 
electronic digital scale (SECA MOD701) and body height to the nearest 0.1 cm by a 
wall-tapered height meter (SECA MOD240). 
Dual energy X-ray absorptiometry 
Bone mineralization of the whole body and lumbar spine (L1-L4) was evaluated using 
dual energy X-ray absorptiometry (QDR Discovery 85606, Hologic, Inc., USA) (DEXA). 
The measurements of this DEXA-scan were analyzed using the APEX system software 
version 3.3. The DEXA estimated the bone mass at the measurement site as Bone 
Mineral Content (BMC) in grams. Bone Mineral Density (BMD) is an aerial measurement 
and was recorded as grams per square centimeter. BMC and BMD were measured for 
the Whole Body (WB) and the Lumbar Spine (LS). For both sites, the BMD standard 
deviation scores (SDS) were calculated. The SDS of the WB were based on the reference 
data of the National Health and Nutrition Examination Survey (NHANES 2008)(38), 
while the  SDS of the LS were based on reference data from the Bone Mineral Density 
in Childhood Study (BMDCS)(39).
Data handling
Patient characteristics including growth, clinical course and intake of all nutrients via 
both parenteral nutrition and enteral feeding were recorded daily for the first two 
weeks, and then weekly until week five, as described previously. (35) The amounts of 
daily intake of all nutrients were calculated for each patient. From term age onwards 
the SDS were calculated for length and BMI using the Dutch reference of the 
nationwide growth study. (40,41) A birth weight below the 10th percentile of the Dutch 
reference curves for birth weight by gestational age was defined as small for 
gestational age (SGA). A birth weight above the 10th percentile was defined as 
appropriate for gestational age (AGA). (42) Differences in patient characteristics 
between responders and non-responders at corrected age of 5 years and at nine to 10 
years are presented in the supplementary materials. (Table 5a, Table 5b, Table 6a, 
Table 6b).
Statistical analysis 
The required sample size was not estimated for the current study as the study involved 
the follow-up of surviving children who were included in the original two cohorts and 
fulfilled the criteria for standard follow-up. The average length at each time point was 
estimated separately for the 2004 and 2005 cohorts, as well as for the subgroups of 
SGA/AGA at birth and gender within the cohorts. Age related differences in growth 
and bone mineralization were accounted for by using age and gender specific 
standard deviation scores. Associations between nutritional intake and the outcomes 
of length SDS, whole body and lumbar spine BMD  and BMD SDS at 9-10 years of age 
were examined using multivariable linear regression for all eligible children and 
separately for boys and girls. As potential confounders cohort, sex, gestational age, 
birth weight, SGA/AGA status, and use of corticosteroids at 5 years of age were 
included as co-variables in the analyses. 
 Not all children who were eligible for follow-up had data collected at each time 
point (Figure 1). Missing data were handled using multiple imputation. We generated 
100 imputed datasets using the method of chained equations. (43) The imputation 
model included length at each time point, BMD and BMD SDS measurements for 
whole body and lumbar spine, and the full set of nutrition variables and potential 
confounders included in the regression models. All estimates were obtained by 
averaging results across the 100 imputed datasets with inferences under multiple 
imputation obtained using Rubin’s rules. (44) Statistical analyses were conducted 
using Stata Corp (2015). Stata Statistical Software: Release 14. StataCorp LP,: College 
Station, TX and IBM SPSS statistics, version 22 for Windows (IBM SPSS Inc., IL, USA). 
Results
Cohort description
Recruitment 
Figure 1 presents the number of children for whom length could be measured. Two 
infants in the 2004 cohort and four infants in the 2005 cohort had died before 
discharge, while three and nine infants of the respective cohorts did not fulfill the 
criteria for the follow-up program, thus 63 and 66 children of 2004 and 2005 
respectively were eligible for the current analysis . Since the national follow up 
program aimed at the evaluation of health care and had a more scientific character, 
participation was voluntary, thereby not all parents followed the invitation and a 
varying number of children were seen over the time period. At term corrected age, 
measurements of length were available for about half of the participant sample. At 
the age of five years, 52 (83%) and 54 (82%) children were seen in the 2004 and 2005 
cohorts respectively. Finally, at 9-10 years of age, growth was evaluated for 32 and 30 
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children, and bone mineralization in 31 and 29 children (49 and 43%) of the 2004 and 
2005 cohorts respectively. 
Characteristics and morbidity 
Table 2 presents the characteristics of the children of both cohorts seen at 9 -10 years 
of age. The postnatal characteristics of the children were similar between the cohorts. 
However, SGA born children of both cohorts had a higher gestational age at birth and 
a significant lower birth weight compared to their respective AGA group. Cohort 2005 
also had a significant higher weight gain during the first five weeks. With the exception 
of AGA/SGA status, patient characteristics of those who responded to the invitation 
for further follow-up at 9-10 years were similar to those for the full cohort. Comparisons 
of the characteristics of responders and non-responders at five years of age, and at 
9-10 years are provided in tables 5a and 5b and tables 6a and 6b in the supplementary 
materials. 
 In agreement with the original full sample postnatal cohorts, children of Cohort 
2005 seen at the follow-up, had received a significant higher amount of calcium, 
phosphate, protein and energy during the first 14 days of life, with a shorter duration 
of  parenteral nutrition, compared to Cohort 2004. (Table 2)  AGA born children of 
Cohort 2005 also had a greater weight gain during the first five weeks of life compared 
to children of Cohort 2004, which was significant for the AGA boys, while all SGA 
infants demonstrated the highest weight gain. (35,45) Since children of both cohorts 
differed by one year of age at the last visit, the mean length and BMI of cohort 2004 
were higher. For both groups the respective SDS were within the normal range for the 
Dutch reference population. More than one third of the children in both cohorts 
reported bronchial hyper reactivity including the use of medication, while 22% in 
Cohort 2004 and 14 % Cohort 2005 reported to have had at least one incident with 
bone fractures. These incidences and the use of other medication were similar 
between both cohorts. None of the children received growth hormone therapy.
Length and bone mineralization
Longitudinal development of length and BMI
Figure 2 presents the estimation of change in length SDS from TCA until 9 -10 years 
after multiple imputation. Both cohorts were severely growth retarded by the time 
they had reached term corrected age (TCA) (SDS length: estimated mean (95% CI) 
TCA: Cohort 2004 versus Cohort 2005: -3.0 (-3.8, -2.2) vs. -3.0 (-3.7, -2.2)).  Both cohorts 
showed a catch-up in length within the first 6 months with an improvement in mean 
SDS up to the normal range for the reference population (SDS  length: estimated 
mean (95% CI) 6 months: Cohort 2004: -0.7 (-1.1, -0.3) Cohort 2005: -0.5 (-0.8, -0.2)). 
Children of Cohort 2005 seemed to have slightly improved length SDS compared to 
Cohort 2004 until the age of two years. This was more pronounced for the group of 
children born as AGA and specifically for the AGA girls at five years. The group of AGA 
boys of Cohort 2005 showed a decrease in length SDS from two years onwards and 
remained below the SDS of AGA boys of Cohort 2004. The SGA groups did not achieve 
a normal length at corrected age of six months but in contrast to AGA children 
continuously improved their  SDS for length until the end of the observational period 
reaching the normal range for the reference population. 
 BMI developed in the same manner as the length with a major catch-up during 
the first six months. There were no differences seen between both cohorts or among 
subgroups of AGA and SGA children. For the group of SGA children SDS BMI developed 
within the same range as SDS length with mean lower values.
Table 2  Patient characteristics at 9 – 10 years
Cohort 2004 Cohort 2005
Numbers 32 30
Sex (boy/girl), n 18/14 15/15
Exact age, years 10.3 (0.3) 9.5 (0.3)*
Postnatal characteristics
Gestational age, weeks, 29.4 (1.9) 29.4 (1.4)
Appropriate / small for gestational age, n 29/3 27/3
Birth weight, grams 1182 (254) 1160 (328)
Birth weight SDS 0.2 (1.0) 0.04 (1.1)
GV week 1-5, gram/kg/day 8.6 (2.6) 11.1 (2.8)*
Nutrition
PN days, median (IQR) 26.0 (14.0 – 38.8) 10 (8.0 – 16.0)*
Phosphate, mmol/kg/14 days 16.0 (8.8) 35.7 (9.3)*
Calcium, mmol/kg/ 14 days 22.6 (10.1) 40.9 (7.4)*
Protein, grams/kg/ 14 days 35.3 (7.7) 41.6 (6.2)*
Energy, kcal/kg/14 days 1185 (238) 1403 (205)*
Growth
Weight, kg 32.2 (5.6) 30.2 (5.5)
Length, cm 141 (6) 137 (5)*
BMI 16.1 (2.2) 16.0 (2.5)
SDS length -0.6 (0.9) -0.5 (0.7)
SDS BMI -0.4 (1.2) -0.2 (1.2)
Data presented as mean (SD); SDS: standard deviation score; GV: growth velocity from postnatal week 1 
until week 5 according to Patel’s formula [58]; PN days: number of days of parenteral nutrition; BMI: body 
mass index; * : p- value < 0.01
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Figure 2   Follow up in length SDS using imputed data 
AGA: appropriate for gestational age at birth; SGA: small for gestational age at birth; SDS: standard deviation 
scores;  bars represent estimates of the mean and 95% confidence intervals; The analysis represents the full 
sample of children who were eligible for standard follow up.
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CHAPTER 4 FOLLOW UP GROWTH AND BONE MINERALIZATION
Bone development 
The results of the Whole Body (WB)  and Lumbar spine (LS) scan for the sub-groups of 
both cohorts are presented in Table 3. Comparing the total cohorts, the mean bone 
mineral content (BMC) of both, WB and LS, tended to be higher for Cohort 2004 
(n = 31), which is likely to be related to the average younger age and lower weight of 
Cohort 2005 (n = 29). The mean whole body BMC of Cohort 2004 was on average 
90.0 gram higher compared to Cohort 2005 (95% confidence interval (CI): (8.1, 161.8); 
p-value = 0.015). The mean whole body BMD only differed by 0.032 g/cm2 (95% 
CI: (0.00, 0.06); p-value = 0.049). The mean lumbar spine BMC and BMD were only 
slightly higher for Cohort 2004 compared to 2005 respectively, with 2.1 gram (95% 
CI: (0.05, 4.3); p-value = 0.045) and 0.026 g/cm2(95% CI: (-0.02,0.07); p-value = 0.230). 
While the differences for the lumbar spine were relatively small, the more relevant age 
dependent mean BMD SDS for both measurement sites were similar between both 
cohorts and within the normal range for the reference population (2004 versus 2005: 
mean WB BMD SDS 0.43 vs. 0.35 (mean diff: 0.08; 95% CI: (-0.43, 0.58); p-value = 0.75); 
mean LS BMD SDS -0.036 vs. -0.15 (mean diff: 0.11; 95% CI: (-0.48, 0.71); p-value = 0.70). 
 The evaluation of subgroups of children (Table 3) showed that the lower bone 
mineral content  (WB and LS)  of Cohort 2005 was specifically associated with a lower 
mean BMC of AGA boys of 2005, while in contrast the mean BMC of AGA girls of 2005 
nearly attained the same amount as the respective subgroup of 2004. Thus, of Cohort 
2005, girls had a non-significant higher BMC than boys despite a comparable body 
weight. This was also seen for the BMD. The subgroup of SGA girls was found to have 
the highest BMC and BMD compared to all other subgroups.
The effect of early nutrition on length and bone mineralization
Table 4 presents the results of the adjusted associations between nutritional intake 
during the first 14 days of life, clinical characteristics and length SDS and  BMD and 
BMD SDS for whole body and lumbar spine, separately for boys and girls. For the total 
eligible group,  there was some evidence that birth weight was associated with length, 
with a 1 gram increase associated with 0.001 SDS increase in length (95% CI: 0.0002, 
0.002; p-value 0.046), (table 4a, supplementary material).  This was mainly based on 
the association between birth weight and length for girls with 0.001 SDS increase in 
length (95% CI: 0.000, 0.003; p-value 0.03).   For boys as well as for girls, there was no 
evidence of an association between length at nine to 10 years of age and nutritional 
intake of the first 14 days or any of the potential confounders.  
 For the total group as well as both sexes, there was no evidence that mean BMD 
of the whole body and lumbar spine and BMD SDS was associated with nutritional 
intake or any of the other clinical characteristics that were measured. 
Table 3  Bone mineralization  at 9 -10 years
Appropriate for gestational age Boys Girls
2004 
(n = 17)
2005 
(n = 12)
2004 
(n = 11)
2005 
(n = 14)
Exact age, years 10.3 (0.3) 9.5 (0.26) 10.5 (0.3) 9.5 (0.3)
Whole Body: BMC g 1208.8 (156.1) 1042.7 (117.6) 1103.7 (132.1) 1096.4 (146.7)
   BMD g/cm2 0.882 (0.06) 0.831 (0.05) 0.843 (0.07) 0.834 (0.07)
   BMD SDS 0.73 (1.09) 0.19 (0.84) -0.2 (1.0) 0.49 (0.95)
Lumbar spine: BMC g 25.6 (4.9) 22.3 (3.5) 25.1 (4.5) 24.1 (4.0)
   BMD g/cm2 0.606 (0.08) 0.548 (0.09) 0.608 (0.06) 0.616 (0.09)
   BMD SDS 0.06 (0.08) -0.64 (1.31) -0.37 (0.74) 0.17 (1.15)
Small for gestational age Boys Girls
2004 
(n = 0)
2005 
(n = 2)
2004 
(n = 3)
2005 
(n = 1)
Exact age, years 9.7 (0.16) 10.2 (0.37) 9.6
Whole Body: BMC g 1106.0 (32.9) 1173.2 (151.9) 1159.0
  BMD g/cm2 0.829 (0.033) 0.857 (0.08) 0.874
  BMD SDS 0.05 (0.63) 0.40 (0.98) 1.00
Lumbar spine: BMC g 23.5 (2.1) 26.7 25.8
  BMD g/cm2 0.574 (0.047) 0.677 (0.04) 0.722
  BMD SDS -0.25 (0.64) 0.67 (0.23) 1.5
Data presented as  mean (SD); SDS: standard deviation score; BMC: bone mineral content; BMD: bone mineral 
density
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Discussion
Our evaluation of two cohorts of VLBW infants suggested that growth retardation 
achieved in the postnatal period returned to a normal range length within the first 
6 months. At nine to 10 years the mean BMD SDS measured for Whole Body and  Lumbar 
Spine was within the normal range and seemed not related to nutritional intake. 
Only birth weight appeared to be associated with length at 9-10 years of age for girls.
 While a number of previous studies found a decreased length and bone 
mineralization in former preterm infants, both cohorts in our study had SDS for 
length, and BMD SDS for whole body and lumbar spine within the normal range for 
age. (29-31,46) Several studies pointed at the positive effect of human milk on bone 
mineralization despite the low mineral content. (27,28) More than 90 % of  all infants in 
both cohorts received own mother’s milk. For Cohort 2004 the use of human milk may 
have compensated for the low parenteral mineral intake. (35) 
 Although both cohorts had achieved mean SDS for length and BMI within the 
normal range for the reference population, this was still below the initial SDS for 
weight at birth.  Any long-term effect of early nutrition in our study may be questioned, 
as in both cohorts a substantial growth retardation was observed by the time infants 
were discharged. Besides postnatal illness, this phenomenon can be explained by the 
fact that fortification of human milk at levels that were used more than 10 years ago 
did not prevent nutritional deficits. A considerable number of infants of both cohorts 
never achieved the recommended enteral intake. (4,35) It is possible that further 
improvement of early postnatal nutritional intake may have prevented postnatal 
growth retardation and consecutively may have led to childhood growth SDS 
equivalent to growth at birth.
 In contrast to our hypothesis, the significant different nutritional intake did not 
lead to a higher bone mass. The results from the linear regression showed no effect of 
mineral intake on bone mineralization, neither for boys nor for girls. The nutritional 
increment of  calcium, phosphate in combination with more protein may not have 
been adequate for bone development. Recently, studies demonstrated that high 
protein intake may be related to hypophosphatemia indicating an increased need for 
phosphate supplementation. (47,48)  Despite the significant increased amount of 
phosphate supplementation, Cohort 2005 had hypophosphatemia during the first 
week of life. (36) This may have been the result of an imbalanced nutritional intake of 
amino acids and phosphate. (49) On the other hand the mean BMD SDS was within the 
normal range of the reference population for both cohorts. As mentioned above this 
may have been the positive effect of human milk, but it may also indicate that preterm 
infants have the capability for catch-up for bone mineralization. Follow up studies of 
a randomized trial in preterm infants evaluating post-discharge feeding showed that 
higher nutritional intake positively affected BMC at six months corrected age, while 
this was not maintained until the age of eight years suggesting a catch up in children 
who received a lower mineral intake in the post-discharge period. (34,50) 
 A varying number of children could not be evaluated at the standard follow up 
visits, leading to lower numbers of patients than originally eligible and thereby 
questioning the representativeness of the current data.  Patient characteristics of the 
responders to follow up at five and nine to 10 years were comparable to the respective 
original cohorts and characteristics of non-responders differed only slightly compared 
to responders. We used multiple imputation to reduce the potential for bias from due 
to missing data and  thus calculated estimates for the total eligible cohorts (2004: n = 
63; 2005: n = 66). This narrowed the differences between the groups but the results 
based on analyses using observed data and those from multiple imputation were 
generally consistent. The original postnatal evaluation of growth revealed a significant 
higher weight gain until week 5 for AGA infants of Cohort 2005, mainly based on 
improved growth in boys. (35,45) The same group of boys of 2005 seemed to deteriorate 
with regard to length from two years of age onwards in contrast to  the respective 
AGA girls and AGA boys of 2004. This was in contrast to the early reported Dutch 
follow up study of VLBW infants where boys showed a significant improved catch-up 
between 5 to 10 years compared to girls. (51) The repeated use of inhaled corticoste-
roids has been shown to negatively affect linear growth and bone mineralization. 
(52-54) Further, an increasing obstructive airway disease from childhood into 
adolescence has been demonstrated in follow up studies of VLBW infants. (55) While a 
considerable number of children of both cohorts reported bronchial hyper-reactivity, 
for the current study corticosteroid use seemed not to affect length and bone 
mineralization. Nevertheless, we cannot exclude effects of childhood morbidities that 
were not accounted for in the current analysis.
 The Dutch nationwide prospective study found stunting of SGA children at 10 
years of age, while a 20 year follow up of SGA preterm born young adults found lower 
SDS for height and lumbar spine bone mineralization. (51,56) In contrast, our SGA 
children of both cohorts demonstrated the highest growth velocity during the first 5 
postnatal weeks, had a lower decline in SDS for weight compared to AGA infants at 
TCA, and continuously improved growth with a full catch-up in height at the last visit 
at age nine to 10 years. (35) Bone mineral density of the whole body and lumbar spine 
were higher than the respective AGA groups. According to the multivariate regression 
analysis being SGA did not significantly affect SDS for length and BMD. It has been 
suggested that SGA infants are not able to compensate the intra-uterine incomplete 
bone mineral accretion in the postnatal period, we speculate that the first postnatal 
weeks may represent the critical window for SGA infants to start the catch-up growth 
and thereby indicating the need for sufficiency of nutritional intake directly after 
birth. (57) 
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This study has several limitations. First, the patients were not randomly assigned 
to a treatment, but recruited over two consecutive time periods. However, nutritional 
protocols and data collection were standardized, patient characteristics were comparable 
even for the follow-up. For the last visit we were unable to invite all children at the 
same age which led to age dependent differences in growth and bone mineralization. 
We accounted for these differences by using age dependent standard deviation 
scores for comparisons. The major limitation of this study was the fact that the power 
calculation was not performed for differences in bone development or morbidities 
in childhood. We tried to overcome a considerable loss of follow up by evaluating 
characteristics of responders and non-responders to evaluate the representativeness 
of the children seen at follow up and used the method of multiple imputation. 
The latter may even be seen as a strength of this study since the few recent studies 
that evaluated long-term bone mineralization in former preterm infants mostly 
evaluated lower numbers of patients. However, unknown morbidities during the 
childhood period and individual lifestyles that were not accounted for may have 
biased the results. 
Conclusions
Children born preterm as appropriate or small for gestational age are able to catch 
up in length after the postnatal period, and achieve a normal length and bone 
mineralization. An improvement of calcium and phosphate intake during the first 
14 days of life was not associated with improvement in length and bone development. 
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Table 4a   Effect of clinical and nutritional characteristics on length  
and bone mineralization
SDS Length at 9 - 10 years β 95% Confidence Interval p-value
Cohort 2005 (versus 2004) -0.331 (-0.974, 0.312) 0.307
Sex (being girl) -0.070 (-0.510, 0.369) 0.751
Gestational age at birth, weeks 0.034 (-0.119, 0.187) 0.658
Birth weight, grams 0.001 (0.0002, 0.002) 0.046
Small for gestational age 0.211 (-0.607, 1.030) 0.607
Any corticosteroids (5 years) -0.229 (-0.873, 0.415) 0.479
Phosphate mmol/kg/14 days 0.019 (-0.015, 0.055) 0.274
Calcium mmol/kg/14 days -0.006 (-0.050, 0.038) 0.783
Protein grams/kg/14 days -0.001 (-0.047, 0.046) 0.974
Whole Body BMD SDS β 95% Confidence Interval p-value
Cohort 2005 (versus 2004) -0.400 (-1.331, 0.532) 0.391
Sex (being girl) -0.052 (-0.702, 0.599) 0.873
Gestational age at birth, weeks 0.147 (-0.086, 0.380) 0.210
Birth weight, grams 0.001 (-0.0004, 0.002) 0.147
Small for gestational age -0.068 (-1.28, 1.148) 0.910
Any corticosteroids (5 years) 0.038 (-0.759, 0.836) 0.923
Phosphate mmol/kg/14 days 0.019 -0.032, 0.070) 0.450
Calcium mmol/kg/14 days -0.011 (-0.085, 0.064) 0.766
Protein grams/kg/14 days 0.005 (-0.070, 0.080) 0.900
Lumbar Spine BMD SDS β 95% Confidence Interval p-value
Cohort 2005 (versus 2004) -0.627 (-1.800, 0.544) 0.285
Sex (being girl) 0.140 (-0.621, 0.901) 0.714
Gestational age at birth, weeks 0.172 (-0.134, 0.477) 0.263
Birth weight, grams 0.0002 (-0.002, 0.001) 0.786
Small for gestational age 0.179 (-1.289, 1.648) 0.806
Any corticosteroids (5 years) -0.253 (-1.254, 0.747) 0.613
Phosphate mmol/kg/14 days 0.018 (-0.055, 0.092 0.612
Calcium mmol/kg/14 days -0.004 (-0.114, 0.107) 0.946
Protein grams/kg/14 days 0.006 (-0.100, 0.112) 0.908
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Table 4a   Continued
Whole Body BMD β 95% Confidence Interval p-value
Cohort 2005 (versus 2004) -0.046 (-0.106, 0.014) 0.128
Sex (being girl) -0.009 (-0.052, 0.033) 0.661
Gestational age at birth, weeks 0.009 (-0.006, 0.024) 0.245
Birth weight, grams 0.0001 (-0.00003, 0.0001) 0.182
Small for gestational age -0.004 (-0.084, 0.075) 0.913
Any corticosteroids (5 years) 0.004 (-0.046, 0.055) 0.865
Phosphate mmol/kg/14 days 0.002 (-0.002, 0.005) 0.361
Calcium mmol/kg/14 days -0.001 (-0.006, 0.004) 0.556
Protein grams/kg/14 days 0.001 (-0.004, 0.006) 0.773
Lumbar Spine BMD β 95% Confidence Interval p-value
Cohort 2005 (versus 2004) -0.067 (0.148, 0.014) 0.103
Sex (being girl) 0.033 (-0.021, 0.088) 0.228
Gestational age at birth, weeks 0.013 (-0.008, 0.035) 0.220
Birth weight, grams -0.00002 (-0.0001, 0.0001) 0.791
Small for gestational age 0.012 (-0.091, 0.116) 0.811
Any corticosteroids (5 years) -0.012 (-0.083, 0.059) 0.740
Phosphate mmol/kg/14 days 0.002 (-0.004, 0.007) 0.507
Calcium mmol/kg/14 days -0.0005 (-0.008, 0.007) 0.898
Protein grams/kg/14 days 0.0003 (-0.007, 0.008) 0.930
SDS: standard deviation score; BMD: bone mineral density
Table 5a  Follow up at 5 years; Responders and Non-responders to Follow – up
Appropriate for gestational age 2004 2005
Responder Yes No Yes No
Number 44 8 43 11
Gender (F/M) 22/22 4/4 21/22 3/8
Gestational age; weeks, mean (SD) 28.6 (1.7) 30.0 (1.7) 29.4 (1.5) 28.7 (2.0)
Birth weight; grams, mean (SD) 1115 (251) 1352 (371) 1218 (301) 1210 (389)
Birth weight SDS 0.3 (0.7) 0.4 (0.7) 0.3 (1.1) 0.22 (0.8)
Growth until week 5; g/kg/day, mean (SD) 8.9 (2.7) 9.4 (2.2) 11.3 (3.1) 8.7 (2.4)
PN; days, mean (SD) 28.4 (13.4) 18.7 (9.2) 14.0 (9.1) 15.2 (7.9)
P 14 days; mmol/kg/day; mean (SD) 15.4 (8.1) 23.2 (11.6) 35.4 (8.2) 33.2 (8.1)
Ca_14 days; mmol/kg/day; mean (SD) 22.8 (9.3) 32.1 (14.1) 41.4 (8.0) 40.3 (9.9)
Protein_14 days; grams/kg/day; mean (SD) 34.6 (6.8) 40.5 (6.5) 41.7 (7.9) 39.0 (11.4)
Energy_14 days; kcal/kg/day; mean (SD) 1202 (218) 1333 (248) 1403 (273) 1367 (298)
IRDS; n (%) 36 (82) 5 (65) 28 (65) 6 (55)
CLD; n (%) 8 (18) 2 (25) 4 (9) 1 (9)
PDA treatment; n (%) 23 (52) 1 (13) 11 (26) 6 (55)
Late onset sepsis; n (%) 25 (57) 2 (25) 21 (49) 6 (55)
Cortico_5y; n (%) 6 (13) - 5 (12) -
Bronchial hyper reactivity at 5y; n (%) 11 (25) - 6 (14) -
Data presented as  mean (SD); SDS: standard deviation score; GV: growth velocity from postnatal week 1 
until week 5 according to Patel’s formula [58]; PN: parenteral nutrition; P_14 days: total phosphate intake 
during the first 14 days; Ca_14 days: total calcium intake during the first 14 days; IRDS: infant respiratory 
distress syndrome; CLD: chronic lung disease defined as oxygen dependency at 28 days; PDA treatment: 
medical and or surgical treatment for patent ductus arteriosus; Cortico_5y: any treatment with steroids 
post discharge until 5 years of age.
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Table 5b  Follow up at 5 years; Responders and  Non-responders to Follow – up
Small for gestational age 2004 2005
Responder Yes No Yes No
Number 8 3 11 1
Gender (F/M) 7/1 2/1 6/5 1/0
Gestational age; weeks, mean (SD) 31.9 (1.9) 30.0 (3.6) 30.5 (2.6) 33.4
Birth weight; grams, mean (SD) 915 (162) 766 (80) 817 (168) 970
Birth weight SDS -1.7 (0.6) -1.7 (1.1) -1.8 (0.6) -2.0
Growth until week 5; g/kg/day, mean (SD) 12.8 (3.4) 12.2 (1.5) 11.9 (2.0) 16.0
PN; days, mean (SD) 15.9 (7.8) 18.6 (14.5) 12.7 (6.1) 7.0
P_14 days; mmol/kg/day; mean (SD) 18.4 (11.6) 9.9 (9.3) 38.9 (10.0) 30.4
Ca_14 days; mmol/kg/day; mean (SD) 26.2 (11.4) 13.3 (2.1) 35.9 (7.3) 47.5
Protein_14 days; grams/kg/day; mean (SD) 37.6 (7.6) 27.3 (1.0) 37.6 (4.7) 42.0
Energy_14 days; kcal/kg/day; mean (SD) 1227 (286) 1099 (75) 1314 (119) 1453
IRDS ; n (%) 1 2 4 0
CLD; n (%) 1 0 2 0
PDA treatment; n (%) 2 2 0 0
Late onset sepsis; n (%) 1 2 5 0
Cortico_5y; n (%) 0 - 3 -
Bronchial hyper reactivity at 5y; n (%) 0 - 3 -
Data presented as  mean (SD); SDS: standard deviation score; GV: growth velocity from postnatal week 1 
until week 5 according to Patel’s formula [58]; PN: parenteral nutrition; P_14 days: total phosphate intake 
during the first 14 days; Ca_14 days: total calcium intake during the first 14 days; IRDS: infant respiratory 
distress syndrome; CLD: chronic lung disease defined as oxygen dependency at 28 days; PDA treatment: 
medical and or surgical treatment for patent ductus arteriosus; Cortico_5y: any treatment with steroids 
post discharge until 5 years of age.
Table 6a  Follow up at 9 - 10 years; Responders and  Non-responders to Follow – up
Appropriate for gestational age 2004 2005
Responder Yes No Yes No
Number 29 23 27 27
Gender (F/M) 11/18 15/8 14/13 10/17
Gestational age; weeks, mean (SD) 29.0 (1.6) 28.5 (1.9) 29.2 (1.4) 29.2 (1.8)
Birth weight; grams, mean (SD) 1199 (258) 1092 (305) 1197 (322) 1235 (315)
Birth weight SDS 0.4 (0.8) 0.3 (0.6) 0.2 (1.0) 0.4 (1.0)
Growth until week 5; g/kg/day, mean (SD) 8.5 (2.7) 9.6 (2.6) 10.8 (2.8) 10.6 (3.5)
PN; days, mean (SD) 29.4 (15.5) 23.8 (8.8) 13.4 (7.7) 15.1 (9.9)
P_14 days; mmol/kg/day; mean (SD) 15.9 (8.8) 17.5 (9.4) 34.7 (8.1) 35.3 (8.3)
Ca_14 days; mmol/kg/day; mean (SD) 22.2 (10.3) 26.7 (10.7) 41.2 (7.4) 41.2 (9.2)
Protein_14 days; grams/kg/day; mean (SD) 34.5 (7.7) 36.8 (6.1) 41.4 (6.3) 41.0 (10.7)
Energy_14 days; kcal/kg/day; mean (SD) 1174 (240) 1283 (191) 1408 (213) 1383 (331)
IRDS ; n (%) 24 (83) 17 (74) 16 (60) 18 (67)
CLD; n (%) 6 (21) 4 (17) 6 (22) 2 (7)
PDA treatment; n (%) 16 (55) 8 (34) 3 (11) 7 (26)
Late onset sepsis; n (%) 12 (42) 15 (65) 10 (37) 12 (44)
Cortico_5y; n (%) 6 (21) - 5 (19) -
Bronchial hyper reactivity at 5y; n (%) 10 (35) - 6 (22) -
Cortico_10y; n (%) 12 (42) - 8 (31) -
Bronchial hyper reactivity at 10y; n (%) 18 (64) - 17 (65) -
Fractures at 10y; n (%) 22 (79) - 23 (89) -
Data presented as  mean (SD); SDS: standard deviation score; GV: growth velocity from postnatal week 1 
until week 5 according to Patel’s formula; (58) PN: parenteral nutrition; P_14 days: total phosphate intake 
during the first 14 days; Ca_14 days: total calcium intake during the first 14 days; IRDS: infant respiratory 
distress syndrome; CLD: chronic lung disease defined as oxygen dependency at 28 days; PDA treatment: 
medical and or surgical treatment for patent ductus arteriosus; Cortico_5y: any treatment with steroids 
post discharge until 5 years of age.
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CHAPTER 5 EARLY NUTRITION AND NEURODEVELOPMENTAL OUTCOME
Abstract
Aim
This study assessed whether increased amino acid and energy intake in preterm 
infants during the first week of life was associated with improved neurodevelopment 
at the corrected age (CA) of 24 months.
Methods
We evaluated preterm infants from two consecutive cohorts in 2004 (Cohort 1) and 
2005 (Cohort 2) with different nutritional intakes in The Netherlands. Nutritional intake 
and growth was recorded until week five and after discharge. Neurodevelopment 
was determined using the Bayley Scales of Infant Development – Second Edition at 
a CA of 24 months. 
Results
Compared to Cohort 1(n = 56), Cohort 2 (n = 56) received higher nutritional intake 
during week one (p < 0.001), The weight gain in Cohort 2 was higher until week 5, 
especially among boys (p < 0.002). The mean Mental Developmental Index (MDI) 
scores did not differ, but Cohort 2 was associated with an increased chance of having 
an MDI ≥ 85, with an odds ratio of 6.4 and 95% confidence interval (CI) of 1.5-27.4, 
among all girls with a higher protein intake (5.3, 1.2-23.3). The Psychomotor Developmental 
Index increased with increasing nutritional intake, especially among boys (β-coefficient 
3.1, 95% CI 0.2-6.0). 
Conclusion
Higher nutritional intake was associated with different improvements in growth and 
neurodevelopment in boys and girls. 
Introduction
In addition to promoting growth similar to intra-uterine foetal growth, adequate 
functional development is the main goal of nutritional supplementation for preterm 
infants. (1) Postnatal growth has been associated with neurodevelopmental outcomes 
in very low birth weight (VLBW) infants. (2,3) In addition to postnatal weight gain, head 
growth may serve as a predictor of brain growth and therefore of neurodevelopmen-
tal outcomes. (4) Follow-up studies of children born preterm have indicated that 
subnormal head growth predicted poorer intelligence quotient scores at three and 
eight years of age. (5,6) Poindexter et al associated low early amino acid intake with 
increased risks of having a small-for-age head circumference (HC) at 18 months of age, 
specifically in boys. (7) 
 In a retrospective study, Stephens et al determined that higher nutritional intake 
in the first week of life was associated with higher Mental Developmental Index (MDI) 
scores and related this increase to higher protein and energy intakes. (8) Van den Akker 
et al suggested that the effects of nutritional interventions in the first few days 
following birth may be gender specific. (9) VLBW boys, but not girls, were affected by 
low amino acid and energy intakes when assessed at a corrected age of 24 months. 
Previously, we demonstrated that increased amino acid and energy intakes during the 
first week of life were associated with a statistically significant short-term improvement 
in weight gain in VLBW infants. (10) A secondary analysis of these data revealed that 
this was mainly based on improvement in male infants.
 In the current study, we investigated the neurodevelopment of the surviving 
infants of the original cohorts in relation to early nutritional intake. We hypothesised 
that nutritional supplementation during the first week would not only improve weight 
gain in the early postnatal period, but would also lead to improved head growth and 
 neurodevelopmental outcomes at a corrected age of 24 months, specifically in boys.
Methods
This study evaluated the long-term outcome data of a previously described 
prospective cohort study that was conducted during two consecutive years, 2004 
(Cohort 1) and 2005 (Cohort 2), to evaluate a change in the composition of standard 
parenteral nutrition (PN). (10) The study was approved by the local ethics committee. 
The cohort characteristics, the nutritional protocol and its modification and the 
short-term results were described in detail in the previous paper. (10) The original 
study included preterm infants born before 34 weeks of gestation who were admitted 
to our tertiary neonatal intensive care unit at the Radboud university medical center 
in The Netherlands on the first day of life on the assumption that PN would be needed 
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for at least five days. Infants with major congenital malformations or asphyxia were 
excluded from the study. During both time periods, no major changes in clinical 
practice occurred and all infants received nutrition according to standard institutional 
protocols. The two cohorts primarily differed in PN intake which consisted of standard 
components, with higher amounts of amino acids and carbohydrates for Cohort 2. 
According to the new protocol, Cohort 2 achieved full PN two days earlier than Cohort 1, 
at postnatal day four versus six, respectively. (10) 
 The intake of all nutrients via both PN and enteral feeding, as well as growth 
 characteristics, were recorded daily during the first two weeks, weekly until week five 
and at term corrected age. Based on the information in the patient charts, the mean 
daily weight gain was calculated weekly for the first five weeks, according to Patel’s 
formula. (11)  
 This study included the surviving participants of the original cohorts who 
received standard follow-up care provided for VLBW infants born prior to 32 weeks of 
gestation or with a birth weight of less than 1,500 grams. In accordance with the 
national follow-up programme, anthropometric data were recorded at the corrected 
ages of six, 12 and 24 months. The head circumference standard deviation score (HC 
SDS) was calculated using the Swedish growth reference for preterm infants and the 
Dutch reference of the nationwide growth study from term corrected age onwards. 
(12,13) Standard deviation scores for weight and length were calculated using the 
Dutch reference. (12) In addition, a neurodevelopmental assessment using the Bayley 
Scales of Infant Development - Second Edition (BSID-II) was performed at 24 months 
of corrected age, resulting in Mental and Psychomotor Developmental Indices (MDI 
and PDI). Scores of 85 or above were categorised as normal outcomes, whereas scores 
between 70 and 85 reflected moderate impairment and scores below indicated 70 
severe impairment. (14) We assumed the diagnosis of normal neurodevelopmental 
outcome as clinically relevant and therefore dichotomised the MDI and PDI scores 
with a cut-off score of  ≥ 85 reflecting normal outcome and as score of below 85 
reflecting neurodevelopmental impairment.
 The original cohort study was powered to assess differences in postnatal growth. 
Since this study only evaluated the surviving infants of these cohorts, no power 
calculation was carried out. The statistical analyses were performed using IBM SPSS 
statistics, version 22.0 for Windows (IBM SPSS Inc., Chicago, Illinois, USA). As the values 
of the continuous variables were normally distributed, mean differences with 95% 
confidence intervals (95% CI) were calculated between the two cohorts. For 
dichotomous data, odds ratios (OR) with 95% CIs were calculated. Subsequently, 
linear regression analyses were performed to assess the effects on the continuous 
MDI and PDI scores of belonging to Cohort 1 or 2. These analysis were also used for 
protein and energy intake in week one, separately and simultaneously, adjusted for a 
potential confounder set that included gender, gestational age, birth weight, maternal 
education, infant respiratory distress syndrome, days on ventilator, indomethacin 
treatment and late onset sepsis. This confounder set was reduced if the model was 
unstable or when interpretation issues called for greater precision, by manually 
excluding those variables that did not change the effect estimate by more than 10% 
when they were excluded. Logistic regression analyses were performed for the 
dichotomous outcomes MDI ≥ 85 and PDI ≥ 85. All analyses were performed for the 
total study population and separately for the subgroups of boys and girls.
Results
The original Cohort 1 comprised 68 infants (38 girls), while Cohort 2 comprised 
79 infants (37 girls). The detailed cohort characteristics have previously been reported. (10) 
For the current study, we evaluated all 112 surviving children who visited the routine 
follow up at the corrected age of 24 months. A further six infants had died, two from 
Cohort 1 and four from Cohort 2, while three and nine infants from the two respective 
cohorts were not invited, according to the criteria of the follow-up programme, and 
seven and 10 infants did not participate in the 24-month follow up. (Figure 1)
Cohort characteristics
The cohort characteristics for the participating children, and the potential determinants 
of the outcomes, are presented in Table 1. Mean gestational age (GA) and birth weight 
did not differ between the two cohorts, but the duration of mechanical ventilation 
was 1.4 days shorter for infants in Cohort 2.  Concerning nutritional intake, Cohort 2 
received 3.3 (95% CI 2.0-4.6) grams/kg/week more protein than Cohort 1 and had a 92 
(54-131) kcals/kg/week higher energy intake during the first week. These differences 
were slightly smaller during the second week. 
 Only small differences were seen between the two cohorts with regard to gender, 
the numbers of infants with prematurity-related morbidities and maternal education. 
The only exception was patent ductus arteriosus (PDA), and its treatment, which 
occurred more frequently among infants in Cohort 1. Independent of cohort status, 
male infants seemed to have had an increased risk of infant respiratory distress 
syndrome (IRDS) and chronic lung disease (CLD) compared to female infants (OR 2.5, 
95% CI 1.1-5.6 and 3.1, 1.0-9.6, respectively).  
Growth and neurodevelopmental outcomes
The outcome parameters postnatal growth velocity, head circumference standard 
deviation scores (HC SDS) and BSID-II scores are presented in Table 2. The infants in 
Cohort 2 exhibited a higher mean daily weight gain from birth through to week five 
compared to Cohort 1, with a mean difference of 1.8 (95% CI 0.7-3.0) grams/kg/day 
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that was mainly due to a 3.1 (1.3-4.8) grams/kg/day higher weight gain in male infants. 
The HC SDS in week one was lower in Cohort 2 than Cohort 1, but at the corrected age 
of six months the HC SDS was normal compared to the Dutch population for both 
cohorts. This means that infants in Cohort 2 achieved a greater catch-up growth for 
HC (0.6 SDS; 0.2-0.9) compared to Cohort 1. At the corrected age of 24 months, the 
weight, length and head circumference were not different between the cohorts and 
within the normal range compared to the reference population.
 In Cohort 1, 10 infants could not be tested for MDI adequately, because they were 
unable to complete the tests or were easily distracted. As their parents reported 
concerns regarding their behavior, and they all had PDI scores of less than 70, these 
infants were categorised into the group with an MDI of less than 85. One infant refused 
to cooperate with MDI testing and was excluded from the analysis. The mean MDI and 
Figure 1   Consort diagram
PN = parenteral nutrition; VLBWI = very low birth weight infants (GA < 32 weeks or birthweight < 1500 
grams; BSID-II = Bayley Scales of Infant Development – Second Edition.
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PDI scores were not different between the two cohorts, either in the total group or in 
the subgroups of boys and girls. However, the girls in both cohorts achieved higher 
scores than the boys, especially in Cohort 1 with a mean difference MDI of 12.7, (95% 
CI 5.2-20.2), PDI of 9.4 (0.8-18.0). In Cohort 2, the differences between boys and girls 
were smaller, with a mean difference for MDI of 6.3 (95% CI 1.2-13.8) and 5.5 (-4.1-14.9) 
for PDI.  
 The children in Cohort 1 also seemed to be at increased risk of having an MDI 
below 85 (OR 2.1, 95% CI 0.9-5.4) compared to Cohort 2. Subgroup analyses by MDI 
revealed that children with an MDI below 85 had a lower mean protein intake during 
the first week of life compared to children with an MDI of ≥85: 14.9 versus 16.8 grams/
kg/week with a mean difference of 1.8 (95% CI 0.1-3.5). Furthermore, an MDI below 85 
seemed to be associated with having had a PDA (OR 1.9, 95% CI 0.8-4.7), IRDS (2.2, 
0.8-6.0) or CLD (3.3, 1.1-10.1) and with ≤ 10 years of maternal education (4.0, 1.3-13.8). 
For children with a PDI below 85, the same associations were seen but with slightly 
lower effect estimates: PDI < 85 PDA (OR 1.6, 95% CI 0.8-3.8), IRDS (2.2, 1.0-4.8), CLD 
(2.6, 0.8-8.8) and maternal education (2.5, 0.8-7.6)). Compared to girls, boys seemed to 
have increased risks of having an MDI below 85 (OR 5.1, 95% CI 1.8-14.0) and a PDI 
below 85 (1.9, 0.9-4.0).    
Effect of early nutrition on neurodevelopmental scores and outcomes
Table 3 presents the results of the linear regression analysis of the effects of early 
nutritional intake on the continuous neurodevelopmental outcome scores adjusted 
for confounders. Table 4 presents the results of the logistic regression analysis of the 
chance to achieve a normal neurodevelopmental outcome in relation to early 
nutritional intake adjusted for confounders. The different nutritional protocols in 
Cohorts 1 and Cohort 2 did not influence the mean MDI scores, either in the total 
study population or in the subgroups of boys and girls. However, a one gram/kg 
higher intake of protein adjusted for energy in week one was associated with an 
increase in the PDI score of 2.4 (95% CI 0.6-4.3), especially among the boys (3.1, 0.2-6.0). 
This led to an approximately 1.5 higher chance of having a PDI ≥ 85 per gram/kg 
higher protein intake (OR 1.4, 95% CI 1.1-1.8) and this was also more pronounced 
among the boys (Table 4). Cohort 2 was associated with a markedly higher chance of 
having an MDI ≥ 85 in the total study population (6.4; 1.5-27.4), as well as for boys and 
girls separately. Among girls, a positive influence of protein intake on the chance of 
having an MDI ≥ 85, with or without an adjustment for energy intake, was also 
observed (5.3, 1.2-23.3 and 2.8, 1.1-6.8, respectively). 
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Discussion 
Our evaluation of two cohorts at the corrected age of 24 months indicated that infants 
who received more protein and energy during the first week of life demonstrated a 
short-term improvement in postnatal weight gain, especially among male infants, 
while catch-up growth in head circumference   seemed to be improved as well.  The 
mean BSID-II scores were not different between the two cohorts and the MDI scores 
did not seem to be influenced by the nutritional protocol. However, we found 
differences in the subgroups of children, namely boys and girls. Children in Cohort 2 
were more likely to have an MDI ≥ 85, which was clearly associated with a higher 
protein intake among girls, while higher protein intake had a positive effect on the 
PDI score among boys. 
 While head circumference growth has been related to neurodevelopmental 
outcome, two randomised trials demonstrated that impaired head growth was 
associated with the persistence of cumulative protein and energy deficits and that 
postnatal abnormal head growth was ameliorated via the optimisation of nutritional 
intake, especially parenteral intake. (15,16) The improved catch-up in head circumference 
we saw with improved nutrition was in accordance with the results of the above 
mentioned trials. 
 A systematic review evaluated the effects of increased nutritional intake in the 
neonatal period on neurodevelopmental outcomes in VLBW infants and the results 
were comparable to our cohorts. (17) This review evaluated 15 studies with regard to 
differences in neurodevelopmental scores and survival without impairment. The 
relationship between increased nutrition and neurodevelopmental outcomes 
remained unclear, probably due to the variety of nutritional interventions and neuro-
developmental outcome measures. In contrast, we not only compared the differences 
between the cohorts, but evaluated the mental developmental and psychomotor 
indices in relation to the individual nutritional intake of the first week, adjusting for a 
number of confounders of neurodevelopment and evaluated subgroups of children. 
In general, preterm infants have been shown to be at risk for adverse neurodevelop-
mental outcomes associated with socioeconomic status and gender, as well as with a 
number of clinical factors that may be related to each other. (18) Therefore, it is difficult 
to evaluate the effect of a single determinant, such as nutritional intake. In our study, 
for instance, the diagnosis and treatment of PDA seemed to be important risk factors 
for adverse outcome, but children with a PDA also had a lower protein and energy 
intake during the first two weeks compared to children without PDA. However, by 
including treatment for PDA in our confounder set, we were able to estimate the 
effects of protein and energy intake independent of PDA and other determinants of 
neurodevelopmental outcomes in preterm born children. The same holds true for the 
other relevant confounders included in our analyses. However, some residual 
confounding by maternal education may still have been present in our results due to 
the relatively large number of missing values for this variable.   
 There is no consensus on whether improvements in postnatal weight gain and 
neurodevelopment are a result of a higher intake of amino acids. (2,3,19)  A Cochrane 
review found no evidence that high doses of amino acids had a positive effect on 
neurological outcomes. (20) In contrast, van den Akker et al presented the long-term 
outcome results of a randomised trial that evaluated the early administration of amino 
acids and indicated that the intervention group, especially the male infants who 
received amino acids immediately after birth, experienced fewer disabilities at the 
corrected age of 24 months. (9)  Vlaardingerbroek et al demonstrated that high levels 
of amino acids and non-protein energy sources were needed to achieve an anabolic 
state in VLBW infants. (21) Our findings are in accordance with the latter study because 
Cohort 2 received not only more amino acids, but also an increase in energy. (9) 
 Gender seemed to be an important factor that determined the consequences of 
nutritional interventions, both in our study on short-term growth effects, as in other 
studies. (9,10,22-24) While the general male disadvantage regarding mortality, morbidity 
and neurodevelopmental outcomes among VLBW infants is well-established, the 
above mentioned nutritional intervention studies found that higher intake was 
specifically advantageous for male infants. (25,26) Male vulnerability in outcomes have 
been related to higher perinatal testosterone and cortisol concentrations and an 
impaired adaptive response to stress that may have an influence on brain development. 
(27,28) Also, studies have demonstrated gender-specific differences in early brain 
maturation. (29,30) All of this may indicate different requirements of nutritional intake 
for male and female infants in the early postnatal period and this could explain the 
different effects on neurodevelopmental outcomes for boys and girls that we 
observed. 
 In accordance with the study of van den Akker et al, our results indicate that both 
male and female infants were vulnerable to nutritional deficits, but may have had 
different needs. (9) Even short-term interventions may have significant effects for male 
and female infants, either inducing harm if the nutritional intake is inadequate or 
preventing poor neurological outcomes if the nutritional needs are met. 
 In addition to the strengths mentioned above, this study also had some 
limitations. First, the patients were not randomly assigned to a treatment, but were 
recruited over two time periods. However, all patients received nutrition according to 
a standardised protocol, the data were recorded in the same standardised manner 
and the results were corrected for disparities in patient characteristics and morbidities. 
Second, although we improved the nutritional intake in Cohort 2, these infants did 
still not receive the intake recommended by guidelines issued after the two study 
periods. (1,10) This factor may have attenuated our results, for both boys and girls. 
Furthermore, this study was not designed and powered to evaluate gender 
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differences. Nevertheless, our data are consistent with recent studies and thus indicate 
that it may be necessary to develop different nutritional strategies for specific 
subgroups of preterm infants. 
Conclusion
This study showed that an increase in the intake of amino acids and energy during the 
first week of life was associated with improved short-term weight gain, possibly 
improved catch-up of head growth and several specific long-term neurodevelop-
mental outcomes among preterm born boys and girls at the corrected age of two 
years. Our findings indicate a need for adequately powered and randomised studies 
to evaluate gender-specific nutritional needs in preterm infants.
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EARLY NUTRITION AND NEURODEVELOPMENTAL OUTCOME
To the editor, 
With interest we read the article by Weisz et al evaluating the association between 
ductal ligation and neurodevelopmental outcome in preterm infants.1 We fully agree 
that postnatal events may affect outcome. Although the authors included an extensive 
list of morbidities and therapies as possible confounders, we suggest nutritional 
intake should be considered as a covariate for neurodevelopmental outcome. 
 We previously evaluated neurodevelopmental outcomes of 112 preterm infants 
at two years of corrected age, but related this to protein and energy intake of the first 
two weeks of life.2 Male sex and patent ductus arteriosus were found to be the 
greatest negative determinants of neurodevelopment, with an increased risk for 
adverse outcome (Bayley Scales of Infant Development II: Mental and Psychomotor 
Developmental Indices (MDI and PDI) below 85) for patients with PDA: (MDI Odds 
Ratio 1.9; 95% CI; 0.8 - 4.7, PDI (1.9; 0.9 - 4,0). Infants with patent ductus arteriosus (n = 
45) received statistically significant less protein and energy during the first two weeks 
compared to infants without patent ductus arteriosus (n = 67) (protein (g/kg/week) 
week 1: (mean diff: -3.0; 95% CI -4.4, -1.6) week 2: (-2.3; -4.1, -0.41); energy (kcal/kg/
week) week 1: (-84; -124, -44); week 2: (-84; -148, -20).  
 While a number of studies,  as mentioned by Weisz et al, associated ductal ligation 
with impaired outcome, none of these studies accounted for nutritional intake. 1 
Wickremasinghe et al discontinued enteral feedings in the ‘early ductal ligation’ 
group, while with the more ‘selective approach’ enteral feedings were continued. 3 
Fluid restriction and cautious increment of enteral feeding is a generally accepted 
measure of conservative treatment of patent ductus arteriosus. In many cases this is at 
the expense of the daily required nutritional intake. Ductal ligation usually serves as 
the last treatment option and thereby prolonging the period of low nutritional intake. 
 We speculate that the impaired outcome after ductal ligation, as mentioned in 
many studies, is not only a result of surgery itself, but also the consequence of 
undernutrition in a period of rapid brain growth. Weisz et al1 did not report nutritional 
intake; therefore, any effect of nutrition on their positive outcome for ductal ligation 
compared to other studies remains speculative.   
 In light of the previously mentioned data, we suggest that future studies should 
evaluate outcome of prematurity related clinical conditions, such as treatment of 
patent ductus, in relation to nutritional intake. 
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Abstract
Objectives
Bone mineralisation in preterm infants is related to supply of calcium (Ca) and 
phosphorus (P). We increased the amount of minerals in parenteral nutrition (PN) for 
preterm infants and  evaluated postnatal Ca and P metabolism in relation to mineral 
and vitamin D (vit D) intake.  
Methods
Preterm infants, included on their first day of life, received standard parenteral nutrition 
providing a maximum Ca/P intake of 3/1.92 mmol/kg/d on day 3. Ca/P content of 
formula was 2.5/1.6 mmol/dl, and fortified human milk supplied 2.4/1.95mmol/dl. 
PN supplied 80 IU/kg/d vit D. Formula and fortified human milk contained 200 IU 
vitamin D/dl. Over a 5-week period serum concentrations and urinary excretion of Ca/P 
were registered and related to intake of minerals and vit D.
Results
During twelve months 79 infants (mean gestational age: 29.8 ± 2.2 weeks, mean birth 
weight: 1248 ± 371 grams) were included. The recommended intake for minerals was 
achieved by day 5 and for vitamin D by four weeks. Infants developed hypercalcaemia, 
hypercalciuria, and hypophosphataemia during the first postnatal week, leading to 
additional phosphorus supplementation in 49 infants . The renal tubular reabsorption 
of phosphorus was > 95% until day 9 but decreased below 70% after the second 
week. Alkaline phosphatase was normal at birth, increased to a maximum of 450 IU/l 
by day 14 and remained above the normal range for the remaining period. 
Conclusions
Parenteral intake of phosphorus appeared to be too low leading to mineral imbalances 
in the early postnatal period, while also vitamin D intake was below recommendations. 
Introduction
Preterm infants are at risk for the postnatal development of impaired bone 
mineralisation. (1) This is primarily caused by an insufficient supply of calcium (Ca) and 
phosphorus (P) at the developmental stage during which these infants exhibit the 
fastest mineral accretion and thus have the highest requirements during their lifetime. (2,3) 
Therefore minerals should be supplemented in preterm infants directly after birth, 
either through parenteral nutrition (PN), formula feeding or as supplement to human 
milk. (4) In addition to minerals, vitamin D (vitD) needs to be supplemented because 
human milk contains only low amounts of vitD, and infants usually do not obtain 
enough through contact with sunlight during the first months of life. Vitamin D is 
essential for the adequate regulation of mineral homeostasis and bone mineralisation. (5) 
During the last decennia international guidelines presented  recommendations of 
optimal supplementation of calcium and phosphorus and vitamin D (6-12)(Table 1). 
Daily requirements of minerals have been determined either using the factorial 
approach or balance studies in stable growing preterm infants. (13-15) International 
recommendations concerning vitD requirements are subject of debate but there 
is consensus that the daily intake should be increased in comparison to former 
 recommendations. (11, 16) Studies evaluating these recommendations in the early 
postnatal period of very low birth weight infants have not been performed recently.
 In 2005, we implemented a parenteral solution (PN) that contained more Ca and 
P to improve the mineral supply for preterm infants. At that time, the Dutch 
 recommendations for vitD supplementation were 80 IU/kg/d with PN and 400 IU/d 
with enteral feeding. (17)  
 As a quality control in relation to the implementation of the revised PN solution, 
we performed an observational study evaluating mineral homeostasis during the first 
five postnatal weeks. In this study, we evaluated mineral homeostasis in relation to 
postnatal mineral and vitD intake. We hypothesised that the use of this PN solution 
would not lead to disturbances in calcium and phosphorus metabolism.
Methods
Study population
This prospective cohort study was conducted throughout 2005. Preterm infants born 
at less than 34 weeks of gestational age (GA) who were admitted to our level III 
neonatal intensive care unit (Radboud University Nijmegen Medical Centre, Nijmegen, 
the Netherlands) were recruited on the first day of life. Infants with major congenital 
malformations or asphyxia were excluded from evaluation. 
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Nutritional protocol
Our PN consisted of standard prepared components. The PN solution contained 
2.5 mmol/dl calcium gluconate (calcium gluconate 10%; B. Braun, Melsungen, Germany) 
and 1.6 mmol/dl sodium-glycerophosphate (Glycophos; Fresenius Kabi BV, Zeist, NL). 
All of the infants received nutrition according to the standard institutional nutritional 
protocol. PN was started directly after birth. Mineral intake was increased daily by 
incremental increases in the amount of PN (Table 2). The maximum parenteral intake 
according to the European Society of Pediatric Gastroenterology, hepatology, and 
Nutrition (ESPGHAN) recommendations in 2005 was achieved at day 3 with 3 mmol/
kg/d Ca and 1.92 mmol/kg/d P. (10)  The recommendations provided by Tsang et al 
were used for enteral intake (9). Vitamin D was supplemented with PN using Vitintra 
infant (40 IE/ml vitamin D, Fresenius Kabi‘s Hertogenbosch, NL). The infants received 
the generally advised doses of 2 ml/kg/day, resulting in a parenteral intake of 80 IE/
kg/d by day 4. (10)
 Enteral feeding was started on the first day of life with daily increments, while PN 
was gradually reduced to maintain a daily fluid intake within the protocol range. 
The maximum enteral fluid intake for enteral nutrition and PN was the same (Table 2). 
The stepwise increase in the enteral volume was left to the discretion of the attending 
neonatologist. Human milk was enriched with a commercially available human milk 
fortifier (HMF) (Nutrilon Neonatal BMF, Nutricia, Zoetermeer, NL) from an intake of 
50 ml/d onwards. HMF added 1.6 mmol/dl Ca, 1.5 mmol/dl P and 200 IE/dl vitD, 
therefore fortified human milk was assumed to contain 2.4 mmol/dl Ca and 1.95 
mmol/dl P. The HMF provided minerals as calcium glycerophosphate and calcium 
lactate. If human milk was not available, the infants received a preterm formula 
(Nutrilon Nenatal Start, Nutricia, Zoetermeer, NL). The formula contained 2.5 mmol/dl 
Ca, 1.6 mmol/dl P and 200 IE/dl vitD. Because fortified human milk and preterm formula 
were both supplemented with vitD, the infants received no further supplements. 
 Additional Ca and P were administered using 10% calcium gluconate or sodium 
glycerophosphate for PN or a potassium phosphate (KPO4) and calcium chloride 
(CaCl2) suspension for enteral supplementation. The decision to start additional sup-
plementation of minerals was left to the discretion of the attending neonatologist 
and based on serum mineral concentrations, urinary excretion of Ca and P in spot 
urine samples and serum alkaline phosphatase (18). We aimed for sP ≥2.0 mmol/l, sCa 
≥2.0 mmol/l, sAF < 300 IU/l and urinary excretion of uP > 0.4 mmol/l and uCa >1.2 
mol/l and a tubular reabsorption of P (trP) > 80%.  If one of the parameter was below 
or beyond the target this could lead to changes in additional supplementation of Ca 
and/or  P. Usually 0.5 -1.0 mmol/kg/d were added.
Data registration
Nutritional intake was registered on a daily basis during the first two weeks and 
weekly until week five. Serum values of calcium (sCa, mmol/l), phosphorus (sP, mmol/l), 
alkaline phosphatase (AF, IU/l) and creatinine (sCreat, µmol/l) were measured according 
to a standard protocol. Spot urine samples were used to evaluate Ca (uCa, mmol/l), 
P (uP, mmol/l) and Creat (uCreat, mmol/l) excretion.
Data analysis
Nutritional intake was calculated according to notations in the patient charts, 
including parenteral or enteral intake and additional supplementation of Ca, P and 
vitD. Ca and P metabolism was evaluated by comparing the concentrations in blood 
(sCa and sP) and urinary excretions (uCa and uP). Our laboratory reference served as 
the normal range for sCa (2.2 – 2.6 mmol/l), sP (2.03 - 2.9 mmol/l) and AF (80 – 280 IU/l). 
Table 1  Recommended intake of calcium and phosphorus for preterm infants
AAP 
‘85
ASCN 
‘87
ESPGHAN  
‘87
LSRO 
‘02
Tsang 
‘05
ESPGHAN 
‘05
ESPGHAN  
‘10
Parenteral
Ca  (mmol/kg/d) 1.5 – 2.25 1.5 – 2.0 1.0 – 4.0
P (mmol/kg/d) 1.6 – 2.25 1.5 – 2.0 0.75 – 3.0
Ca : P (molar) 1:1 1.1:1–1.3:1 1.3:1 - 1.7:1
Enteral 
Ca (mmol/kg/d) 4.5 – 5.25 1.75 – 3.5 3.7 – 5.5 3.0 – 5.0 3.0 – 3.5
P (mmol/kg/d) 4.1– 4.6 1.6 – 3.0 3.3 – 4.4 2.0 – 3.5 2.0 – 3.0
Ca : P (molar) 1.1:1–1.3:1 1.4:1 – 2.0:1 1.7:1–2.0:1 1.4:1–1.6 1.5.–2.0
Recommended intake of calcium and phosphorus for preterm infants according to international guidelines 
(6-12) AAP = American Academy of Pediatrics, ASCN = American Society for Clinical Nutrition; 
Ca = calcium; ESPGHAN = European Society of Pediatric Gastroenterology, Hepatology, and Nutrition; 
LSRO = Life Sciences research office, American Society of Nutritional Sciences; P = phosphorus
Table 2  Parenteral intake of fluid, calcium and phosphorus
D0 D1 D2 D3 D4
Fluid (ml/kg/d) 80 100 125 150 150
Calcium (mmol/kg/d) 0.75 1.5 2.25 3.00 3.00
Phosphorus (mmol/kg/d) 0.48 0.96 1.44 1.92 1.92
Parenteral intake of fluid, calcium and phosphorus. D0 was defined as day of the admission, and day 1 
was defined as the next morning, when the nutritional intake regimen was routinely started.
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The tubular reabsorption of P (trP) was used as an indicator of P availability (normal 
range: 85 -95%). The ratios of Ca and P to creatinine (uCa/Creat and uP/Creat) were 
calculated retrospectively and compared with the percentiles based on the data 
presented by Aladangady et al (19). AF was used as a marker for changes in bone 
metabolism. All of the data were categorised into subgroups of infants according 
to GA.
Statistics
The data were collected within a cohort study evaluating weight gain in relation to 
different nutritional intakes. For the primary objective of weight gain, we determined 
that a study group size of 66 patients was required to identify a significant difference 
with an α = 0.05 and a power of 0.80. The data are presented as the mean ± SD, unless 
otherwise indicated. 
Ethical considerations
The study was approved by the local ethics committee. The informed consent of 
parents was not necessary according to our institutional review board because the PN 
solution was a standard medical prescription that was changed to improve quality. 
The nutritional protocol, record keeping, and blood and urine sampling were part of 
the standard care used in our department.
Results
Patient recruitment and cohort inclusion are presented in Figure 1. A total of 79 infants 
were evaluated. The mean GA was 29.8 ± 2.2 weeks, and the mean birth weight was 
1248 ± 371 g. The nutritional characteristics are presented in Table 2. Only the total 
group data are presented.
 The nutritional intake of Ca, P, vitD and protein is shown in Figure 2. The daily 
intake increased with time according to the nutritional protocol. The mean duration 
of PN was 10.6 ± 3.6 (range 6 – 25) days (Table 3). The highest mean daily intake of 
calcium was 3.3 ± 1.5 mmol/kg, which was achieved at week 3. The mean total calcium 
intake was within the recommended range. (9, 10) Only seven infants received 
additional calcium supplementation over short periods to treat hypocalcaemia 
(Figure 2A). The mean total P intake was within the lower range of the ESPGHAN PN 
recommendations at day 2 but increased to just above the maximum intake for PN 
(2.3 mmol/kg/d) after day 6 when enteral and parenteral nutrition provided a similar 
amount of intake. The maximum daily intake including parenteral , enteral  and the 
additional supplement (3.3 ± 1.2 mmol/kg) occurred in week 3 (Figure 2B). The total 
Ca and P intake was slightly above the more recent ESPGHAN recommendations for 
enteral nutrition. (11) Infants received a total protein intake of mean (SD) 2.6 ± 0.6 and 
3.2 ± 0.7 gram/kg per day during the first and second week (Figure 2C).
 Vitamin D intake was calculated according to the recorded intake. Human milk 
was provided to 91% of our infants and reached a mean enteral intake of >50 ml per 
day at day 4. Subsequently, human milk was fortified and enriched with vitD. After day 5, 
the daily vitD intake increased above 160 IU. The recommended daily intake of 400 IU 
was only reached four weeks after birth (Figure 2D).
 The calcium, phosphorus and alkaline phosphatase (sAF) concentrations in blood 
and urine are presented in Figure 3. Directly after birth, the mean sCa was 2.2 ± 0.24 
mol/l, which continuously  increased to a maximum of 2.7 ± 0.24 mmol/l on day 5. 
Between days 4 and 8, the mean sCa remained above the upper reference limit of 2.6 
mmol/l. Forty-five percent of all infants had a sCa >2.6 mmol/l on day 5. At the same 
time 34% infants had a sP level below 1.8 mmol/l. For the remaining observational 
period, the mean sCa remained below the upper normal range. The mean sP 
concentration was below the lower reference range of 2 mmol/l from birth until day 9 
and increased to within the normal range for the remaining observational period. 
At birth, the mean sAF was within the normal range (mean 194 ± 62 IU/l), but thereafter, 
it steadily increased to a maximum of 480 IU/l by day 7 and remained above 300 IU/l 
for the remaining observation period, thus exceeding the upper reference limit. 
 The mean uP, evaluated with spot urine samples was low until day 9, but generally 
above the recommended surplus of 0.4 mmol/l. The urinary excretion of P increased 
Figure 1   Cohort inclusion
PN = parenteral nutrition
Expected PN < 5 d
Asphyxia, cong. malformation.
N = 111
Admissions < 34 weeks 
N = 226
Inclusion 
N = 115
Follow up
N = 79
Transfer < d 10: N = 21
Death < d 8: N = 7
Incomplete data: N = 8 
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steadily until week 5. The mean urinary excretion of Ca was below the recommended 
surplus of 1,2 mmol/l until day 2. The mean uCa remained above the surplus for the 
rest of the observational period  and tended to increase towards the end of the 
observational period. The highest uCa excretion occurred between day 3 and day 8 
(Supplemental Digital Content 1: jpeg; Figure S1 Urinary excretion of calcium and 
phosphorus determined from spot urine samples). 
 The mean uCa/Creat ratio increased steadily after day 3, remaining above 3.8 
mmol/mmol (the 95th percentile) between days 4 – 8 and above 2 mmol/mmol (the 
75th percentile) for the rest of the follow-up (Figure 3)(18). The mean uP/Creat ratio 
remained below 0.5 mmol/mmol (the 10th percentile) until day 9 and increased above 
16 mmol/mmol (75th percentile) after the second week (Figure 3) (19). In accordance 
with the low mean uP/Creat ratio, the tubular reabsorption of phosphate (trP) 
remained above 95% during the first week. After the second week, the mean trP 
decreased to below 70% (range 58 – 68%).
 During the second week 49 of 79 infants received additional supplementation of P. 
This was continued in 25 infants until week 5. Infants who received additional P until 
week 5 had a significant lower gestational age, and lower birth weight (p < 0.001) and 
received enteral nutrition earlier. They had lower sP concentrations and lower urinary 
excretion of P during the first week, and higher sAF concentrations compared to 
infants without additional P. The trP was low in all infants during the last three weeks 
independent of any P supplementation (Supplemental Digital Content 2: doc; Word 
File S1: Sub- analysis additional phosphorus supplementation). 
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Table 3  Nutritional characteristics
PN, mean (SD) days, (range) 10.6 (3.6) (6-25)
First enteral feeding, mean (SD) day 0.91 (0.22)
Full enteral feeding, mean (SD) days 11.6 (3.6)
Infants receiving human milk, (n) (%) 72 (91%)
Nutritional characteristics. Full enteral feeding was defined as an enteral intake of 150 ml/kg/day; 
PN: parenteral nutrition
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Discussion
Our results demonstrate that the mineral intake of our infants met the recent recom-
mendations for parenteral and enteral nutrition for preterm infants. (9-11) (Table 1) 
Nevertheless, we observed hypercalcaemia, hypophosphataemia, hypercalciuria, and 
high tubular phosphate reabsorption during the first week and hyperphosphaturia 
with a low trP during the second half of the study period. Furthermore, the sAF 
increased above the normal range. The recommended vitD intake was only achieved 
by week 5. These data indicate a great need for phosphorus supplementation in the 
early postnatal period and a mineral imbalance in the second half of the observation 
period, probably related to low vitD intake.
  Increasing Ca and P intake in PN has been shown to improve bone mineral 
content in preterm infants. (20) The use of sodium-glycerophosphate in PN offers the 
opportunity to increase the mineral contents of standard PN solutions. (10, 21) 
Despite the increased need for minerals, the supplementation of high amounts of 
minerals is often regarded as a potential risk factor for the development of 
hypercalcaemia, hypercalciuria and, thereafter, nephrocalcinosis. (22) We observed 
hypercalcaemia, a high urinary excretion of Ca between days 4 and 8 and a uCa/Creat 
ratio above the 95th percentile in the same period. Hypercalcaemia can be caused by 
either high calcium intake or hypophosphataemia. High nutritional Ca intake will 
increase urinary Ca excretion. Furthermore, several medications, metabolic  acidosis, 
renal disease and vitD deficiency  are known to have a calciuretic effect. (23-25) 
Aladangady et al. demonstrated a significant relationship between a high Ca/Creat 
ratio and the use of xanthine derivatives, such as caffeine.  (19, 23) All of the infants 
received caffeine directly after birth or shortly before extubation from ventilation. 
Additionally, hypophosphataemia will lead to increased urinary Ca excretion. (25) Our 
cohort had low sP concentrations and high renal P retention during the first week. 
Balance studies have demonstrated improved calcium retention after increasing 
phosphate intake.(26, 27) Aladangady demonstrated that a low uP/Creat ratio is related 
to P insufficiency and is independent of medication. (19) The decrease in the uCa/creat 
ratio and the increase in the uP/creat ratio after day 8 in our cohort may be the result 
of P supplementation. Therefore our results reflect an increased need of phosphorus 
during the early postnatal period. Several studies recently suggested that this 
increased need may be related to a higher amount of amino acids administered with 
parenteral nutrition nowadays, in comparison to older studies used for current 
guidelines. (28 - 30)   
 During the second half of the observation period, we recognised a different 
pattern with still elevated uCa excretion, an increasing phosphaturia, low trP, and 
elevated AF, whereas the mineral intake mainly remained the same. Since many 
infants received additional P at that time this may be interpreted as a result of an Fi
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unnecessary supplementation. Furthermore, we used potassium phospate as oral 
supplement, while organic salts probably may have had an improved bioavailability. 
(11) Nevertheless, infants who did not receive additional P during the last week, 
demonstrated the same increase in urinary excretion of phosphorus and calcium 
(Supplemental Digital Content 2: doc; Word File S1: Sub- analysis additional 
phosphorus supplementation).  At that time, the mean vitD intake was below the 
recommended daily intake of 400 IU vitD. Insufficient vitamin D may explain the high 
Ca excretion while indirectly this may have inhibited the renal tubular reabsorption of 
phosphorus. (5) Our data are in accordance with previously performed balance studies 
in preterm infants that demonstrated that vitD is absorbed well and positively 
influences mineral homeostasis. (31) In these studies, infants received 1200 IU vitD/d. 
 Present recommendations concerning nutritional intake and mineral homeostasis 
are developed for either parenteral or enteral nutritional intake and the recommended 
Ca : P ratio encloses  a wide range. There is a discrepancy between the guidelines 
presented by Tsang et al and the ESPGHAN ESPEN recommendation. (9, 10) According 
to Tsang et al the lower limit of parenteral P intake is higher and the range of Ca : P 
ratio lower than recommended by the ESPGHAN. (Table 1). Looking at our data the 
American recommendations seem to be more appropriate.  
 Nowadays, most very low birth weight infants receive a combination of parenteral 
and enteral nutrition with an increased amount of protein and energy directly after 
birth. Current recommendations are based on studies performed in stable growing 
infants of several weeks old, whereas recent studies indicate that nutritional deficits 
developed during the first postnatal weeks may have a long-lasting effect for future 
development. (32, 33)  
 Our study has several limitations. We evaluated mineral homeostasis but did not 
evaluate bone mineral content using Dual-energy X-ray absorptiometry. Nevertheless 
mineral imbalance, especially hypercalciuria, has been related to impaired bone 
mineralisation. (34, 35) We observed a high urinary excretion of minerals in our patients. 
Therefore we believe that despite the high mineral intake, our patients were at risk of 
developing suboptimal bone mineralisation, with the long-term consequence of 
reduced length. (36) In addition, we did not measure vitD concentrations although the 
intake could be calculated from charts and a positive relationship between enteral 
vitD intake and the vitD concentration in blood has been demonstrated in preterm 
infants. (31) The latest ESPGHAN guidelines recommend a daily intake of 800 – 1000 IU 
vitD/day in enterally fed preterm infants. (11) This recommendation does not state at 
what time enteral vitD supplementation should be initiated. Furthermore, the 
recommendation for parenteral supplementation has not been re-evaluated with 
regard to the revised target value of 75 mmol/l (30 ng/ml) 25-hydroxy vitamin D. (37) 
 Early postnatal mineral homeostasis with high mineral intake and high doses of 
vitamin D in preterm infants has not yet been investigated. Our data suggest that 
optimal dosing of minerals and vitamin D should be re-evaluated in very low birth 
weight infants in the early postnatal period in combination with more aggressive 
parenteral and enteral nutritional intake. 
 In conclusion, our data demonstrate that the parenteral intake of phosphorus 
appeared to be too low, leading to mineral imbalances in the early postnatal period, 
while also vitamin D intake was below recommendations. 
164 165
6
CHAPTER 6 POSTNATAL CALCIUM AND PHOSPHORUS METABOLISM
Supplemental Digital Content 2
Word File S1: Sub analysis additional phosphorus supplementation 
Sub analysis of infants who received additional phosphorus 
supplementation
We performed a sub analysis to clarify our conclusion that the hyperphosphaturia we 
saw in our patients after the second week cannot solely be explained by our regimen of 
phosphorus supplementation.
From the end of the first week onwards an increasing number of infants received 
additional phosphorus supplementation. During week 3, 4 and 5 the number of 
infants who received additional supplementation steadily declined. During the 5th 
week 25 of 79 infants still received additional phosphorus supplementation. For the 
sub analysis we divided our cohort into a group without phosphorus supplementation 
(P- ; n=54) and with phosphorus supplementation (P+; n=25) during week 5.
 Infants who did not receive P suppl had a significant higher GA and higher birth 
weight than the group of infants who did receive supplementation (P-:  GA 30.5 ± 2 
wks; BW: 1293 ± 358gram vs. P+: 28.3 ± 1.5 wks; BW: 1004 ± 302gram; p< 0.001). 9/54 
and 4/25 infants were SGA at birth (16% both).
Intake:
Group P+ received enteral nutrition somewhat faster than group P- and therefore also 
received  somewhat less parenteral nutrition (both non-significant). In both groups 
additional supplementation of phosphorus was started by day 2 and 3 but from day 9 
on group P+ received significant more extra P  compared group P- for rest of the 
observational period. 
Serum control:
Serum P: The  sP concentration was below 2 mmol/l until day 7 in P-, and until day 8 
in P+. Between day 4 and day 8, sP in P+ remained between mean 1.5±0.2  and mean 
1.7±0.5 mmol/l.  During this period serum phosphate concentrations were significant 
lower than phosphate concentrations of P+(p < 0.005). After day 9 sP in both groups 
remained within the reference range (2.0 -2.9 mmol/l).
Serum Ca: Serum calcium concentrations were not different between both groups, 
but slightly higher until day 4 in group P- (non-significant). Data are presented in 
Figure 3.
sAlkaline Phosphatase (sAF): sAF was not different and within the normal range (80 
-280 IU/L) until day 3 in both groups.  In P+ the AF increased up to 665 ± 38 IU/l by day 
7 whereas in P- the sAF was 434±123 at the same time (p=0.01). In P- the AF achieved 
a maximum level by day 10 of 447 ±95 IU/l. After the peak level the sAF slowly declined 
in both groups, but somewhat slower in P+ than in P-.
Urinary excretion
uP: Group P+ excreted  more P than group P- between d0 and day2 (4.7 vs. 1.1 – 3.1 
mmol/l ), while at that moment the nutritional intake was not different and below 
recommended optimal intake. Group P+ had a lower urinary excretion of P (0.1 – 1.2 
mmol/l) than in group P- (0.5 -2.5 mmol/l) between day 4 -8. Between W3 and W5 the 
urinary excretion of P was not different between both groups. 
uCa: The urinary excretion of Ca was not different between both groups. 
Table S1 number of infants who received additional P
d0 d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 d11 d12 d13 d14 w3 w4 w5
0 0 1 7 22 34 45 47 48 49 49 46 47 49 47 46 31 25
Table S2  serum alkaline phosphatase (sAF U/L; mean±SD)
sAF U/L W3 W4 W5
P- 321 ± 114 338 ± 91 305 ± 112
P+ 380 ± 152 352 ± 128 323 ± 120
Table S3 urinary excretion of phosphorus from spot urine (mmol/L; mean±SD)
uP mmol/l W3 W4 W5
P- 20.3 ± 15 16.3 ± 18.4 14.4 ± 3.9
P+ 18.4 ± 10 25.5 ± 18.4 22.9 ± 23.5
Table 4 urinary excretion of calcium from spot urine (mmol/L; mean±SD)
uCa mmol/l W3 W4 W5
P- 1.95 ± 1.4 2.24 ± 1.8 3.18 ± 3.16
P+ 2.56 ± 1.6 1.85 ± 1.12 3.3 ± 3.33
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Renal tubular reabsorption:
Tubular reabsorption of P was not different between both groups and remained 
between 88 and 99% between d0 and day10. From day 11 on, in both groups the Tr P 
declined simultaneously.
Summarizing: 
Infants in group P+ were of significant lower GA and BW and received enteral nutrition 
somewhat  earlier. The group P+ had lower sP levels and a faster increase in sAF and 
also a slightly lower mean uP excretion during the first two postnatal weeks in 
comparison to group P-. Both groups had initially a high renal tubular reabsorption. 
This, in combination with elevated sAF, was interpreted as insufficient P supplementation 
and therefore additional P was subscribed. Additional supplementation was reduced 
in the following period in relation to laboratory results. Nevertheless phosphaturia 
remained high and trP low in both groups, even without supplementation.
 We therefore believe that unnecessary supplementation is not the main cause of 
our results.  
 
Table S5 renal tubular reabsorption of phosphorus (TrP %)
Tr P % W3 W4 W5
P- 61 ± 18 70 ± 16 67 ± 24
P+ 56 ± 21 49 ± 23 70 ± 23
Figure S1   Urinary excretion of Ca and P (mmol/l; mean ±SD)
black line: P -; grey line: P+; dotted line: surplus: P: 0.4 mmol/l; Ca 1.2 mmol/l (18)
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Abstract
Preterm infants are at significant risk to develop reduced bone mineralization based 
on inadequate supply of calcium and phosphorus (Ca-P). Biochemical parameters 
can be used to evaluate the nutritional intake. The direct effect of nutritional intake 
on changes in biochemical parameters has not been studied. Our objective was 
to evaluate the effect of Ca-P supplementation on biochemical markers as serum 
(s)/urinary (u) Ca and P; alkaline phosphatase (ALP); tubular reabsorption of P (TrP) 
and urinary ratios for Ca/creatinin and P/creatinin in Very-Low-Birth-Weight infants 
on postnatal day 1, 3, 5, 7, 10, and 14. This observational study compared two groups 
with High (n=30) and Low (n=40) intake of Ca-P. Birth weight: median (IRQ) 948 
(772-1225) vs. 939 (776-1163) grams; Gestational age: 28.2 (26.5-29.6) vs. 27.8 (26.1-29.4) 
weeks. Daily median concentrations of biochemical parameter were not different 
between the groups but linear regression mixed model analyses showed that Ca 
intake increased the uCa and TrP (p = 0.04) and decreased ALP (p = 0.00). Phosphorus 
intake increased sP, uP and uP/creat ratio and ALP (p ≤ 0.02) and caused decrease 
in TrP (p =0.00). Protein intake decreased sP (p = 0.000), while low gestational age 
and male gender increased renal excretion of P (p < 0.03). Standardized repeated 
measurements showed that biochemical parameters were affected by nutritional 
intake, gestational age and gender. 
Introduction
Bone development is one of the key processes of intrauterine and postnatal growth. (1) 
Preterm infants are at significant risk to develop reduced bone mineral content based 
on inadequate supply of calcium and phosphorus (Ca-P). (2,3) During normal 
pregnancies in healthy mothers, there is an active, placental transfer of Ca-P to the 
fetus leading to a high mineral accretion during the last trimester, while after birth 
the infant is dependent on nutritional supply of minerals. (4,5) In clinical practice, 
postnatally it is difficult to meet the high fetal needs, either because of limited 
solubility of parenteral fluids, low content of Ca-P of human milk and impaired 
intestinal absorption through formula feeding. (6-9) Balance studies tried to define 
nutritional requirements but, in clinical practice it is often uncertain whether the 
nutritional intake of Ca-P provided to preterm infants is sufficient and is actually used 
for bone mineralization. (10-12)
 Assuming that biochemical parameters of Ca-P homeostasis within a normal 
range will lead to optimal bone mineralization, evaluation of electrolyte disturbances 
is standard of care in many neonatal units. (13-28) However, there is currently neither 
a consensus on the appropriateness of either parameter or the frequency of 
measurements. (29,30) A recent survey among U.S. neonatologists showed a great lack 
of consensus and variation in practices regarding definition and screening methods 
for metabolic bone disease. (31) Reference values in relation to adequate nutritional 
intake have not been developed. Urinary excretion of minerals in spot urine samples 
has been shown to be an easy tool for routine evaluation. Pohlandt proposed to aim 
for a small ‘surplus of minerals’ in urine samples, while Aladangady et al developed 
reference values for urinary Ca-P / creatinine ratios for preterm infants. (17,23) Staub 
et al compared both methods with regard to an agreement between their results and 
found neither method to be superior. (32) None of the studies evaluated the direct 
effect of nutritional intake on biochemical parameter of Ca-P homeostasis. It is not 
sure whether biochemical parameters are able to indicate sufficiency of nutritional 
intake. 
 The aim of this study was to evaluate changes in biochemical parameters of the 
Ca-P homeostasis in blood and urine in relation to different nutritional intake during 
the first 14 days of life in Very Low Birth Weight (VLBW) infants. Our hypothesis 
was that the nutritional intake of calcium and phosphorus would have an effect on 
biochemical parameters of the calcium – phosphorus homeostasis. 
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Materials and Methods 
Study design and randomization 
The current study (Early Supplementation Study (ESS)) was part of the Early Nutrition 
Study (ENS), a multi-center double-blinded randomized controlled trial. (CMO file 
number: NL37296.029.11, Dutch Trial Registry: NTR 3225) While the ENS evaluated the 
effects of human milk on postnatal outcome, the primary objective of the ESS was 
bone mineralization in relation to early and late enteral supplementation of minerals. 
(33) The studies were approved by the Ethical Committee of the VU University Medical 
Center (Amsterdam, The Netherlands). Patients were distributed into three groups 
through two steps of randomization. The first step randomized eligible infants either 
into the early supplementation group (High) or the late supplementation group (Low) 
being part of the ENS. The second step of the randomization was only performed if 
infants were assigned to late supplementation and randomized them to either ‘ENS A’ 
or ‘ENS B’ as part of the ENS. Both randomization steps were performed before the 
first enteral nutrition was administered resulting in basically three groups. 
Study population 
Participants for the ENS/ESS were recruited at the level III neonatal intensive care unit 
of the Radboud university medical center (Radboudumc), Nijmegen, The Netherlands. 
The inclusion criteria were a birth weight below 1500 grams and written informed 
consent of both parents. The exclusion criteria were maternal drugs and/or alcohol 
use during pregnancy, birth defects, congenital infection within 72 hours after birth, 
perinatal asphyxia with a pH < 7.0 and any intake of cow’s milk based products prior 
to randomization. For the current study infants who died or were discharged before 
the end of the study period of 14 days were excluded from analysis. 
Intervention and Nutritional protocol
Parenteral nutrition (PN) was started directly within the first hour after birth. The PN 
solution consisted of 2.5 mmol/dL calcium-gluconate (calcium-gluconate 10%; B. 
Braun, Melsungen, Germany) and 1.6 mmol/dL sodium-glycerophosphate (Glycophos; 
Fresenius Kabi BV, Zeist, The Netherlands) and 2.25 grams/dL amino acids (Primene; 
Clintec, Brussels). Additional parenteral supplementation with 10% calcium- gluconate 
or sodium glycero-phosphate was administrated depending on biochemical parameters. 
Table A1 presents the standard protocol for PN. The decision to start additional 
 supplementation was left to the attending neonatologist based on biochemical 
parameter as being a standard procedure of our department.
 Enteral feeding was started on the first day of life with daily increments, while PN 
was gradually reduced to maintain a daily fluid intake within the protocol range. 
Late supplementation was assumed to provide a low intake of nutrients because 
‘Group Low’, comprising of group ENS A and ENS B, received no additional enteral 
supplementation or fortification of human milk during the first 10 days of life. Group 
ENS A received donor milk if mother’s own milk (MOM) was not available. Group ENS 
B received preterm formula (Hero Baby Prematuur Start; Hero Kindervoeding, Breda, 
The Netherlands) if MOM was not available, containing 2.4 mmol/dL calcium, 1.7 mmol/dL 
phosphorus and 2.6 grams/dL proteins. The additional nutrition in ENS A and ENS B 
was blinded to all caretakers and parents. After 10 days all infants received nutrition 
according to the standard protocol of the Radboudumc. 
 Early supplementation was assumed to provide a high intake (Group High). 
This group received enteral nutrition from day 1 onwards according to the local 
protocol. They received additional enteral supplementation and human milk fortifier 
(Nutrilon Neonatal BMF; Nutricia, Zoetermeer, The Netherlands; BMF) by the time the 
enteral intake was 50 ml per day. The human milk fortifier added 1.65 mmol/dL 
calcium, 1.22 mmol/dL phosphorus and 0.8 grams/dL protein to human milk. They 
received preterm formula if MOM was not available. The decision to start additional 
enteral supplementation was left to the attending neonatologist based on bio- 
chemical parameter and postnatal growth as being a standard procedure of our 
department. The additional enteral supplementation could comprise of either a 
supplement of protein (Nutrilon Nenatal Protein Fortifier; Nutricia, Zoetermeer, The 
Netherlands) or a potassium phosphate (KPO4) and calcium chloride (CaCl2) suspension 
for enteral supplementation. 
 Group ENS A received 100% human milk during the first 10 days and reflected a 
group with low intake of minerals and protein, because human milk has a very low 
nutrient content. Group High reflected a high intake of nutrients, because human 
milk was enriched with minerals and protein as soon as possible. Group ENS B could 
be considered as intermediate depending on the amount of MOM or preterm formula 
an infant received, since preterm formula contained approximately the same amount 
of minerals as fortified human milk. 
Biochemical parameters of bone mineralization
For this study, blood and urine samples were analyzed according to the local protocol 
of the department. Samples were taken on days 1, 3, 5, 7, 10 and 14 after birth. Urine 
was collected through spot samples. (25) The following parameters were analyzed: 
serum calcium (sCa), serum phosphorus (sP), serum alkaline phosphatase (ALP), urine 
calcium (uCa), urine phosphorus (uP), urine calcium/creatinin ratio (uCa/Creat), urine 
phosphorus/creatinin ratio (uP/Creat), and tubular reabsorption of phosphorus (TrP).
Data registration and handling
Patient characteristics, clinical course, growth and intake of all nutrients were recorded 
daily from the patient records and abstracted for this study. Amounts of enteral, 
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parenteral and additional supplementation (parenteral and enteral) of all nutrients 
were calculated separately for each patient. The total intakes were calculated per kg 
per day per infant. The intake through human milk was calculated based on the 
reference of Gidrewicz et al. .(34) The calcium/phosphorus ratio was calculated per day 
by dividing the daily intake of calcium in mmol/kg through the daily intake of 
phosphorus in mmol/kg.
 After closure of patient enrollment and de-blinding of the ENS, we performed a 
reallocation procedure for the intermediate group ENS B. Infants who received more 
than 90% MOM were considered to reflect a low intake of minerals and were allocated 
to group Low together with the infants of group ENS A. Infants who received more 
than 90% of preterm formula were considered to reflect a high intake of minerals and 
were allocated to High. Infants in between these extremes were not included in the 
analyses.
Statistical analysis 
The primary objective of the ESS was bone mineralization in relation to mineral sup-
plementation, and the original power calculation was based on bone mineral content 
at term corrected age.  For the evaluation of changes in biochemical parameters in 
relation to nutritional intake the power calculation was based on sP. In a previous 
evaluation of our nutritional protocol performed at our department, we found a mean 
1.7 mmol/l of sP during the first week. (35) A concentration of 2.0 mmol/l was defined 
as target for optimal bone mineralization by Hellstern et al. (20)  Assuming an expected 
mean of 1.7 mmol/l, we determined that 24 infants were required in each group to 
find a difference of 0.3 mmol/l in sP between High and Low with α=0.05 (two-sided) 
and a power of β=0.80.
 The statistical analyses were performed using IBM SPSS statistics 22.0 for Windows 
(IBM SPSS Inc., Chicago, IL, USA). Differences in patient characteristics, nutritional 
characteristics and biochemical parameters between the High and Low group were 
determined using the Mann-Whitney U test or the chi-square test, depending on the 
variable under examination. Due to non-normality of the continuous variables, the 
data were presented as median (with interquartile range (IQR)), unless otherwise 
indicated. A p-value <0.05 was considered statistically significant.
 To account for repeated outcome measurements, we used a mixed model analysis 
to determine the effects of daily nutritional intake of calcium and phosphorus on each 
biochemical parameter. We included the total intake of Ca/P and protein, the 
percentage of enteral amount of Ca/P intake, and a number of clinical parameter that 
could affect the Ca/P homeostasis such as birth weight, gestational age, gender, 
caesarian section, multiple births, sepsis, and days of caffeine, furosemide, steroids, 
and sedation during the first two weeks as co-variables in the initial models. 
Necrotizing enterocolitis was not included as co-variable because of small numbers. 
Using manual backward selection, variables were kept in the model when they 
contributed statistically significantly with a p value < 0.1.
Results
Patient characteristics
Enrollment of patients occurred between January 2013 and December 2014. The 
distribution of the infants is presented in the consort diagram (Figure 1). Finally, 
109 infants were randomized, either to Late Supplementation (Low; n = 72; distributed 
into Group ENS A (n = 40) and ENS B (n = 32) or Early Supplementation (High; n = 37). 
 The characteristics of all infants included in the three groups of the ENS/ESS study 
are presented in Table A2. After de-blinding of group Low, 4 infants of group ENS B 
were reallocated to High and 13 to Low so that, Low and High consisted of 53 and 
41 infants, respectively. Infants who died or were discharged before postnatal day 14 
(13 in Low, 11 in High) were excluded. Finally, data of 40 infants of Low and 30 of High 
were analyzed. The baseline patient characteristics, morbidity, medication and nutritional 
characteristics for these patients are presented in Table 1. Infant characteristics were well 
balanced between the groups Low and High and comparable to the original groups.
Nutritional intake
The nutritional characteristics and intake of calcium, phosphorus and protein during 
week 1 and 2 are presented in Table 1. The median and interquartile range (IQR) for 
the duration of PN was 12.0 (10.0–14.0) versus 11.0 (9.0–14.0) days for High versus Low, 
while the median day of reaching an enteral intake of 150 ml/kg was day 13.0 
(10.5–20.0) versus day 12.0 (9.8–17.0), respectively. In accordance with the study 
protocol Low received a higher amount of human milk. The median start day of BMF 
in group High and Low was 7.9 (5.0–10.0) and 11.0 (11.0–13.0) respectively.  As a result, 
High received a significant higher total intake of calcium and phosphorus during the 
first two weeks and of protein during week 2 compared to Low. Table A3 presents the 
nutritional intake divided into 4 routes of administrations: parenteral, enteral and 
additional supplementation either par- or enteral. This shows that differences in 
intake were mainly based on differences in enteral intake. Further, both groups 
received additional parenteral supplementation of phosphorus, based on low sP 
concentrations. 
 Figure 2 presents the daily changes in nutritional intake during the first 14 days. 
Figures 2A, 2B and 2D demonstrate the total calcium, phosphorus and protein intake. 
High had a steady increase in intake during the study period, whereas Low showed a 
temporary decrease, and plateau at the end of the observational period, probably 
due to the decreasing amount of PN and increasing amount of unfortified human 
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Figure 1   Consort diagram
Assessed for eligibility
(n = 210 ) 
Excluded:
Not meeting inclusion criteria (n= 36)
Declined to participate (n= 65)
First Randomization ( n= 109)
Late Supplementation (n = 72)
Early Nutrition Study (ENS)
Second randomization
Early Supplementation (n = 37)
Protocol Radboudumc
Group ENS A (n = 40)
Donormilk in addition to MOM
No enteral supplements until day10
Group ENS B (n = 32)
Preterm formula in addition to MOM
No enteral supplements until day10
Group C (n = 37)
Preterm formula in addition to MOM
Fortification of MOM if > 50 ml/day
Reallocation
> 90% MM → Low (n = 13)
> 90% formula → High (n = 4)
Low (n=53) Intermediar (n = 15) High (n = 41)
Excluded from analysis:
Death < day 14 (n = 7)
Discharge < day 14 (n = 6)
Excluded from analysis: 
Death < day 14 (n = 3)
Discharge < day 14 (n = 8)
Low (n = 40) Not used for analysis High (n = 30)
MOM = mother’s own milk
Table 1  Patient characteristics, morbidity, medication, and nutritional characteristics
Low (n=40) High (n=30) p-Value
Characteristics
Birth weight, grams; median (IQR)  948 (772 – 1225) 939 (776 – 1163) 0.85
< 1000 gram, n (%) 22 (55.0) 16 (53.3) 0.89
Gestational age, median (IQR) 28.2 (26.5 – 29.6) 27.8 (26.1 – 29.4) 0.76
SGA,n (%) 8 (20.0) 4 (13.3) 0.46
Male, n (%) 19 (47.5) 15 (50.0) 0.84
Singletons, n (%) 28 (70.0) 16 (53.3) 0.15
Cesarean section, n (%) 18 (45.0) 20 (66.7) 0.07
Apgar score (5 min), median (IQR) 7.0 (6.3 – 9.0) 7.5 (7.0 – 8.0) 0.71
Apgar score (5min) <7, n (%) 10 (25.0%) 6 (20.0%) 0.62
Morbidity
Sepsis, n (%) 8 (20.0%) 9 (30.0%) 0.33
NEC ≥ stage 2, n (%) 1 (2.5%) 2 (6.7%) 0.39
IVH Grade 3 – 4 n (%) 5 (12.5) 3 (10) 0.75
Medication
Caffeïne; n (%) 39 (97.5%) 28 (93.3%) 0.39
Furosemide, n (%) 3 (7.5%) 4 (13.3%) 0.42
Corticosteroids 3 (7.5) 1 (3.3) 0.46
Sedation, n (%) 8 (20.0%) 9 (30.0%) 0.33
Nutritional characteristics
PN, days, median (IQR) 11.0 (9.0-14.0) 12.0 (10.0-14.0) 0.10
150 ml/kg enteral, studyday, median (IQR) 12.0 (9.8 – 17.0) 13.0 (10.5 – 20.0) 0.59
Start day of BMF, median (IQR) 11 (11.0-13.0) 7.9 (5.0-10.0) 0.00
Human milk in ml/kg/day*, median (IQR) 50.9 (24.0 – 82.2) 30.0 (8.5 – 54.6) 0.01
Formula in ml/kg/day*, median (IQR) 0.0 (0.0 – 0.2) 1.1 (0.1 – 7.3) 0.00
Nutritional intake
Ca (total) W 1, mmol/kg; median (IQR) 10.7 (9.9-12.0) 13.1 (11.1-14.6) 0.00
Ca (total) W 2, mmol/kg; median (IQR) 16.4 (12.9-17.7) 21.7 (15.3-24.4) 0.00
P (total) W 1, mmol/kg; median (IQR) 10.8 (9.3-12.4 12.3 (11.1-14.2) 0.00
P (total) W 2, mmol/kg; median (IQR) 16.4 (12.9-19.6) 18.2 (16.0-22.1) 0.02
Prot (total) W 1, grams/kg; median (IQR) 18.6 (15.9-21.1) 20.0 (16.9-23.4) 0.16
Prot (total) W 2, grams/kg; median (IQR) 23.2 (21.0-26.6) 27.0 (24.1-30.6) 0.00
Low: no enteral supplementation of human milk before day 11; High: standard protocol: enteral supple-
mentation of human milk if intake was ≥ 50 ml/day; IQR: Interquartile range; SGA: small for gestational 
age: < p10; Sepsis: > 72 hrs postnatally and positive blood culture, prevalence within the first 14 days; 
NEC: necrotizing enterocolitis according to Bell stage [36], prevalence within the first 14 days; IVH: In-
traventricular hemorrhage (grade according to Papile) [37]; PN: parenteral nutrition; BMF: breast milk fortifier; 
* : during the intervention period; Ca: calcium; P: phosphorus; Prot: protein; W1: week 1; W2: week 2
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milk. Except for day 1, both groups received a median total calcium, phosphorus and 
protein intake according to the ESPGHAN recommendations for parenteral and 
enteral nutrition [38,39]. The calcium/phosphorus ratios were highly variable. Both 
groups showed a decrease in the calcium/phosphorus ratio on day 5 that lasted until 
day 11 (Figure 2C); most likely caused by the transition from parenteral nutrition to 
enteral nutrition. For both groups, the ratio was below the recommendations of 
ESPGHAN on all days. (38,39)
Biochemical parameters
Table A4 summarizes the median daily values of both groups for all biochemical 
parameters. The median serum concentrations of Ca en P were within the normal 
range and only showed slight differences between the two groups and an overall 
increase during the study period. (40) Except for the first day, the median sP 
concentrations remained below our target of 2 mmol/l until day 5 and 10 for High and 
Low respectively. The median uCa and uP values were above the recommended 
surplus (uCa >1.2 mmol/l, uP >0.4 mmol/l) during the entire observational period.(23) 
The median TrP values were above the lower normal range of 85% until day 5, and 
decreased thereafter, reflecting a higher loss of phosphorus. The median ALP values 
were within the normal range (80-330 U/l) until day 5, but increased steadily thereafter. (40) 
In both groups, the uCa/Creat ratios were above the reference value (0.5 mmol/mmol) 
during the complete study period. (32) The uP/Creat ratios were below the reference 
value (4.0 mmol/mmol) until day 5, but above the reference thereafter. (32)
The results of the mixed model analyses are summarized in Table 2.
• The sCa concentration was not related to intake of Ca/P and was only marginally 
affected by a number of co-variables except for daily protein intake that caused an 
increase of 0.107 mmol/L per gram/kg protein. 
• The sP concentration increased in relation to phosphorus intake (0.13 mmol/l per 
mmol/kg phosphorus) and birth weight (0.0004 mmol/l per gram birth weight), 
whereas protein intake (-0.13 mmol/l per gram/kg/day protein), gestational age 
(-0.05 mmol/l per week), furosemide (-0.11 mmol/l per day) and caffeine (-0.02 
mmol/l per day) decreased in sP concentration. 
• The urinary excretion of Ca seemed to increase in relation to Calcium intake (0.35 
mmol/l per mmol/kg calcium), and increased in relation to protein (0.36 mmol/l per 
gram/kg protein) and being born by cesarean section (0.65 mmol/l if born by 
cesarean section), whereas it was not affected by the phosphorus intake. 
• The urinary excretion of P increased in relation to daily phosphorus intake (3.18 
mmol/l per mmol/kg phosphorus), gender (1.88 mmol/l if infant was a boy), whereas 
P excretion lowered in relation to daily intake of protein (-1.18 mmol/l per mmol/kg 
protein), gestational age (-0.71 mmol/l per week) and caffeine (-0.29 mmol/l per day). 
Calcium intake did not affect the urinary P excretion. Fi
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• The TrP increased in relation the daily Calcium intake (3.10% per mmol/kg calcium), 
and gestational age (3.05% per week). The reabsorption of phosphorus lowered in 
relation to daily phosphorus intake (-6.21% per mmol/kg phosphorus), gender 
(-4.60% if infant was a boy), being born by cesarean section (-5.12%), and sepsis 
(-6.78%).
• The ALP increased in relation protein intake (30.54 U/l per mmol/kg), daily intake of 
phosphorus (23.64 U/l per mmol/kg phosphorus). A decrease in ALP was related to 
calcium intake (-44.94 U/l per mmol/kg calcium), gestational age (-20.71 U/l per 
week) and the number of days of steroid use (-23.86 U/l per day). 
• The uCa/creat ratio increased in relation to daily protein intake (0.54 l/l per gram/
day protein) and sepsis (0.66 l/l), but it was not affected by the total calcium and 
phosphorus intake. 
• The uP/creat ratio increased in relation to daily phosphorus intake (4.01 l/l per 
mmol/kg phosphorus), gender (2.31 l/l if infant was a boy), while the P/creat ratio 
seemed lower in relation to daily protein intake (-0.81 l/l per gram/kg protein), and 
decreased with gestational age (-0.94 l/l per week), and caffeine (-0.30 l/l per day). 
Discussion
In this observational study of initially three randomized groups providing different 
nutritional intake to VLBW infants during the first 10 days of life, we found no 
differences between group Low and High concerning the biochemical parameters of 
Ca-P homeostasis. However, the mixed model analysis showed that the intake of 
calcium was associated with increased urinary calcium excretion and tubular 
reabsorption of phosphorus and a decrease in the ALP, while the nutritional intake of 
phosphorus was associated with a decreased sCa and an increase in sP, uP and uP/
creat ratio. The nutritional intake of calcium and phosphorus affected the TrP and 
ALP in opposite directions. Protein intake was greatly associated with a decrease in 
sP, uP and an increase in ALP, sCa, and uCa, while in addition, gestational age and male 
gender affected especially the phosphorus metabolism.
 VLBW infants belong to one of the most vulnerable patient groups for whom 
adequate postnatal nutritional intake has life-long consequences. (41) Therefore 
intervention studies with different nutritional intakes could be seen as unethical in 
the light of the right of optimal treatment for every patient. On the other hand, in 
clinical practice a great variation in clinical guidelines has been reported, often based 
on rather low evidence. (42) While fortification of human milk is generally seen as 
necessary nowadays, there is also concern about possible risks of introducing 
cow-milk based products too early. (43,44) According to our local protocol, fortification 
is introduced early and additional mineral supplementation is provided based on 
laboratory results. The intention is to optimize postnatal growth and bone 
mineralization but the efficacy of our protocol has not been proven. The combination 
of the Early Nutrition Study and the Early Supplementation Study provided the 
opportunity to evaluate two different nutritional concepts within the range of 
nutritional guidelines and therefore within the ethical limits. On the other hand, all 
infants participating in the ESS, independent of group allocation, received the 
standard treatment according to the local practice, which frequently led to additional 
parenteral supplementation of nutrients in case of electrolyte disturbances or 
impaired growth.  This practice may have ameliorated the differences between the 
groups and therefore affected the results. By reallocating infants from group ENS B to 
either group Low or High and excluding infants with intermediate intake from further 
analysis we tried to maximize the differences in nutritional intake between the two 
remaining groups. The reallocation of infants did not change the baseline patient 
characteristics. The detailed analysis of nutritional intake showed that additional 
 supplementation was not different between the groups and differences in intake 
were mainly based on enteral nutrition. 
 Even though the two groups had a maximum difference in nutritional intake, 
the comparison of daily concentrations of the biochemical parameters showed no 
differences between group High and Low, probably by leveling out inter-individual 
differences on group level. In contrast, the linear mixed model analysis took into 
account both intra- and inter-individual fluctuations, and thereby enabled us to 
specify effects of various co-variables.   
 Despite an increasing intake of phosphorus, sP remained below our target 
concentration during the first week. Recently, a randomized trial, evaluating nutritional 
support according to current recommendations in VLBW infants, observed hypo-
phosphatemia in relation to high protein intake. (45) Jamin et al observed electrolyte 
disturbances, especially hypophosphatemia and hypokalemia, in low-birth weight 
piglets with a high protein diet. (46) Hypophosphatemia is the hallmark of the refeeding 
syndrome and a well-known complication in relation to parenteral nutrition of 
malnourished patients (47-49) Bonsante et al proposed the concept of ‘Placental 
Incompletely Restored Feeding (PI-Refeeding) syndrome for electrolyte disturbances 
found in VLBW infants. (50) This syndrome is said to be caused by an imbalanced 
nutritional intake of amino acids and phosphorus. Amino acids and energy are needed 
to maintain an anabolic state of the cell, while phosphorus is necessary for a number 
of cellular functions, energy homeostasis as well as for bone mineralization. 
Phosphorus in blood will preferably be transferred to the cell regardless of bone 
mineral status. A higher intake of amino acids will enhance the need for phosphorus 
in growing cells, and in case of low concentrations of phosphorus in blood it will be 
released from bone. Simultaneously with the release of phosphorus, calcium will also 
be released from the bone because of an unfavorable Ca/P ratio and will consecutively 
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be excreted in urine if the sP concentrations are too low. Our results are in agreement 
with this concept. According to the mixed model analyses we found that an increasing 
amount of protein was associated with an increase in the sCa, uCa, ALP and uCa/Creat 
ratio, whereas it was associated with a decrease in sP, uP and the uP/Creat ratio. 
Remarkably, in our study an increase in a sP concentration of 0.13 mmol/l occurred per 
1 mmol/kg intake of phosphorus and a decrease of -0.13 mmol/l per 1 gram/kg protein 
intake, meaning that 1 gram/kg of protein intake should be accompanied by 1 mmol/
kg of phosphorus in nutrition of VLBW infants to maintain adequate sP concentrations. 
 The role of ALP in bone mineralization is controversial, but an increase is usually 
associated with poor bone mineralization. (30,51) According to our results, an increasing 
intake of protein was associated with an increase in ALP. Again, following the above 
mentioned mechanisms higher protein intake enhanced the cellular need of 
phosphorus and thereby decreased the sP concentration and the availability of 
phosphorus for bone mineralization, leading to activation of ALP. We also found that 
an increased ALP was associated with increasing phosphorus intake, while one would 
expect lowering of ALP. An explanation for this phenomenon could be a relatively 
insufficient intake of calcium in combination with phosphorus intake, since an 
increasing calcium intake was associated with decrease in ALP concentrations. In this 
study, for both groups, the calcium/phosphorus ratio was below recommendations, 
meaning that relatively more phosphorus than calcium was administered.
 Gestational age at birth seemed to be an important determinant for the 
phosphorus metabolism in our study, meaning that infants with a lower gestational 
age had a higher renal excretion of phosphorus, irrespective of nutritional intake. 
Immaturity of the kidneys at lower gestational age has been shown to cause impaired 
tubular reabsorption of phosphorus. (15) Renal losses of minerals may then compromise 
the effect of nutritional intake on bone mineralization. However, current recommen-
dations for nutritional intake of calcium and phosphorus usually do not take into 
account differences in renal function based on gestational age. 
 Further, we found that male gender was related to low serum phosphorus 
concentrations, low tubular reabsorption and increased renal excretion of phosphorus 
and uP/creat ratio. We speculate a retardation in maturation of the renal function in 
male infants compared to females as is known for the development of the pulmonary 
function. (52)
 All parameters evaluated in this study are regularly used to monitor either 
electrolyte homeostasis or bone mineralization.  Practices among units vary greatly, 
measurements may be performed at later age and greater intervals and not 
standardized or in combination, leading to inconsistent results and handling. An 
explanation for the inconsistency in results of other studies could be the underesti-
mation of the effects of inter-relationships between various co-variates. In our opinion 
these associations can only be discovered with standardized repeated measurements 
taking into account other clinical factors. To our knowledge this is the first study 
evaluating changes in biochemical parameters of the calcium-phosphorus 
homeostasis based on standardized repeated measurements and daily changes in 
nutritional intake in a mixed model linear regression analysis including also clinical 
factors. 
 Our data show that standardized repeated measurements of blood and urine 
samples can provide useful information with regard to the Ca-P homeostasis. This 
does not result in a clear advice for nutritional intake. Nevertheless, this study is a first 
step and its importance lies in the description and quantification of changes in a more 
‘physiological way’ that will further enable us to develop new guidelines to improve 
bone mineral status in preterm infants. Notwithstanding, we confirmed the 
relationship between the intake of protein and phosphorus, and demonstrated the 
effect of renal immaturity and gender. Thus, a second step could be, to relate the 
current results to bone mineralization and provide recommendations for nutritional 
intake and a third step to develop a concept of target values for biochemical parameter 
so that these can be used to monitor nutritional intake to achieve optimal bone 
mineralization in daily practice.  
This study had several limitations. The mixed model analysis assumes that the effects 
of the different variables are linear which has not been proven yet. In addition, the 
biochemical parameters may have been influenced by factors that were not taken 
into account in our analysis.  Daily sampling of biochemical parameter would have 
been optimal, but this was judged unethical regarding the amount of blood volume 
needed. Nevertheless, measurements were performed in a standardized manner and 
therefore provided a good reflection of changes in blood and urine concentrations 
for the complete study period. Further, in comparison to other studies, both groups 
had relatively high daily intakes. This may partly explain the small variations in 
biochemical parameters. This study only investigated the biochemical parameters 
during the first 14 days of life. Maturational changes in renal function may alter the 
results; however repeated measurements will indicate these changes and thereby can 
be used as guide for optimal supplementation of minerals. 
Conclusions 
In conclusion, standardized repeated measurements showed that biochemical 
parameters of Ca-P homeostasis seemed to be affected by nutritional intake of 
calcium and phosphorus as well as protein, while immaturity of kidneys was related to 
an increase in urinary excretion of minerals irrespective of nutritional intake. Further 
studies are needed to define target values to stabilize electrolyte balances and 
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improve bone mineralization taking into account nutritional intake and gestational 
age of the patient. 
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Table A1  standard parenteral nutritional intake 
Day 1 Day 2 Day 3 Day 4
Fluid ml/kg/day 80 100 125 150
CH grams/kg/d 8 9.6 11.7 13.8
AA grams/kg/d 0.75 1.5 2.25 3
Lipids grams/kg/day 1 2 3 3
EQ Kcal/kg/day 44 62 82 94
Calcium mmol/kg/day 0.75 1.5 2.25 3.00
Phosphorus mmol/kg/day 0.48 0.96 1.44 1.92
Parenteral nutritional intake based on standardized parenteral solutions. [35,53] For infants below 1000 
grams amino acids were additionally added according to current recommendations. (12) Amino acid 
solution: Primene (Baxter, the Netherlands); Lipid emulsion including vitamins: Clinoleic (20%; Baxter, 
The Netherlands) or SMOFlipid 20% (Fresenius Kabi; The Netherlands); CH: carbohydrates, AA: amino 
acids, EQ: energy quotient.
Table A2   Cohort characteristics of all patients included in  
the Early Supplementation Study
Characteristics Group ENS A
(n = 40)
Group ENS B
(n = 32)
Group C
(n = 37)
GA, weeks; med (IQR) 28.2 (25.7-30.1) 28.3 (26.5-30.7) 27.9 (26.1-29.7)
Birth weight, grams; med (IQR) 967(753-1245) 1012 (847-1199) 1006 (771- 1220)
SGA; n (%) 9 (23) 8 (25) 6 (16)
Male; n (%) 21 (53) 20 (63) 18 (49)
Singletons; n (%) 25 (63) 24 (74) 25 (68)
Antenatal Steroids compl.; n (%) 36 (90) 31 (97) 31 (86)
Cesarean section; n (%) 19 (48) 20 (63) 25 (68)
Apgar score (5 min); med (IQR) 7.5 (6.3-9.0) 8.0 (7.0-9.0) 7.0 (7.0-8.0)
Apgar score (5min) < 7; n (%) 10 (25) 5 (16) 8 (22)
Mortality; n (%) 6 (15) 3 (9) 7 (19)
Morbidity
IRDS 24 (60) 19 (59) 23 (62)
Days of MV; med (IQR) 1,5 (0.0-4.8) 1.0 (0.0-4.0) 1.0 (0.0-7.0)
Days of N-CPAP; med (IQR) 18.0 (6.5-38.8) 28.0 (7.0-40.8) 16.0 (6.0-36.5)
CLD; n (%) 12 (30) 14 (44) 10 (27)
PDA; n (%) 20 (50) 20 (63) 21 (57)
Ductal ligation; n (%) 4 (10) 2 (6.3) 1 (3)
IVH grade ≤ 2; n (%) 15 (38) 5 (16) 5 (14)
IVH grade ³ 3; n (%) 2 (5) 7 (21) 4 (11)
Sepsis; n (%) 13 (33) 10 (32) 14 (38)
NEC; n (%) 4 (10) 5 (16) 3 (8)
Bell stage 2; n 2 3 1
Bell stage 3; n 2 2 2
Laparotomy; n 2 1 2
ROP; n (%) 4 (10) 1 (3) 5 (14)
ROP grade ³ 3 1 0 1
Medication
Caffeine; n (%) 38 (95) 30 (94) 33 (90)
Furosemide; n (%) 11 (28) 10 (31) 7 (19)
Diuretics (maintenance); n (%) 3 (8) 0 3 (8)
Corticosteroids; n (%) 1 (3) 2 (6) 4 (11)
Sedation; n (%) 13 (33) 11 (34) 15 (41)
Nutritional characteristics
Days of PN; med (IQR) 10.0 (8.0-13.0) 10.5 (9.0-14.8) 10.5 (8.3-21.0)
120 ml/kg enteral, day; med (IQR) 9.0 (7.0-12.5) 9.0 (8.0-13.0) 9.0 (7.2-14.8)
150 ml/kg enteral, day; med (IQR) 12.0 (9.0-17.0) 11.0 (10.0-17.0) 12.0 (10.0-20.0)
Start day of BMF; med (IQR) 11.0 (11.0-12.7) 12.0 (11.0-14.0) 6.0 (4.0-8.0)
ENS A: donor milk in addition to mother’s own  milk (MOM) and no supplements with enteral feeding until day 
10; ENS B: preterm formula in addition to MOM and no supplements with enteral feeding until day 10; Group C: 
preterm formula in addition to MOM and fortifier  if intake ≥ 50 ml/day; med: median; IQR: inter quartile range; 
GA: gestational age; SGA: small for gestational age according to Fenton et al, (54) IRDS: infant respiratory  distress 
syndrome; MV: mechanical ventilation; N-CPAP: nasal continuous positive airway pressure; CLD: chronic 
lung disease defined as oxygen dependency at 36 weeks gestational age; PDA: patent ductus arteriosus 
with need for treatment; IVH: intra-ventricular hemorrhage;  Sepsis: > 72 hrs postnatally and positive blood 
culture; NEC: necrotizing enterocolitis with staging according to Bell; (36) ROP: retinopathy of prematurity; 
sedation: morfine and/or midazolam > 24 hrs; PN: parenteral nutrition; BMF: breast milk fortifier
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Table A3   Nutritional intake of calcium and phosphorus by route of administration
Nutritional Intake
Mmol/kg/week
Low (n = 40)
Median (IQR)
High (n =30)
Median (IQR)
p - Value
Ca (total) W1 10.7 (9.9 – 12.0) 13.1 (11.1 – 14.6) 0.00
Ca (total) W2 16.4 (12.9 – 17.7) 21.7 (15.3 – 24.4) 0.00
Ca (enteral) W1 1.7 (1.1 – 2.2) 3.3 (1.1 – 5.7) 0.00
Ca (enteral) W2 10.8 (6.2 – 16.0) 17.5 (2.3 – 22.8) 0.07
Ca (enteral suppl) W1 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 1.0
Ca (enteral suppl) W2 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 0.22
Ca (PN) W1 9.4 (8.0 – 10.2) 9.8 (7.9 – 11.5) 0.34
Ca (PN) W2 3.1 (0.7 – 7.9) 5.1 ( 1.9 – 10.9) 0.14
Ca (PNsuppl) W1 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 1.0
Ca (PNsuppl) W2 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0) 0.74
P (total) W1 10.8 (9.2 – 12.4) 12.3 (11.1 - 14.2) 0.00
P (total) W2 16.4 (12.9 – 19.6) 18.9 (16.0 – 22.1) 0.02
P (enteral) W1 1.0 (0.6 -1.4) 2.1 (0.7 – 3.9) 0.00
P (enteral) W2 8.1 (5.0 – 12.0) 10.4 (1.7 – 17.2) 0.08
P (enteral suppl) W1 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.9) 0.03
P (enteral suppl) W2 0.0 (0.0 – 0.0) 0.0 (0.0 – 1.4) 0.33
P (PN) W1 7.5 (6.4 – 8.2) 7.8 (6.3 – 9.2) 0.34
P (PN) W2 2.5 (0.6 – 6.3) 4.1 (1.5 – 8.7) 0.14
P (PN suppl) W1 2.4 (0.5 – 3.8) 1.8 (0.0 – 2.7) 0.16
P (PN suppl) W2 2.3 (0.0 -4.2) 0.7 (0.0 – 4.3) 0.30
Low: no enteral supplementation of human milk before day 11; High: standard protocol: enteral 
supplementation of human milk if intake was ≥ 50 ml/day; IQR: inter quartile range; Ca: calcium; 
P: phosphorus; total: som of all nutritional intake; enteral: enteral intake including standard fortification; 
enteral suppl:  additional enteral supplementation; PN: parenteral intake; PN suppl: additional parenteral 
supplementation; W1: week 1; W2: week 2
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Table A4   Daily measurements of biochemical parameter of the calcium  
and phosphorus homeostasis
Day 1 Day 3 Day 5 Day 7 Day 10 Day 14
Serum Ca (mmol/l)
- Low 2.2 (2.0 – 2.4) 2.4(2.2 – 2.5) 2.5 (2.4 – 2.7)
Serum Ca (mmol/l)
- Low 2.6 (2.4 – 2.7) 2.5 (2.4 – 2.7) 2.6 (2.4 – 2.8)
- High 2.2 (2.0 – 2.4) 2.4 (2.3 – 2.6) 2.5 (2.4 – 2.7) - High 2.4 (2.3 – 2.6) 2.5 (2.3 – 2.7) 2.6 (2.5 – 2.8)
p-Value 0.94 0.17 0.34 p-Value 0.15 0.69 0.17
Urine Ca (mmol/l)
- Low 1.3 (1.0 – 1.9) 2.1 (1.5 – 3.4) 2.6 (2.0 – 3.9)
Urine Ca (mmol/l)
- Low 2.7 (1.6 – 3.8) 2.0 (1.6 – 3.3) 1.8 (1.4 – 3.5)
- High 1.5 (1.2 – 1.7) 3.3 (2.0 – 4.7) 3.1 (2.3 – 5.8) - High 2.5 (1.8 – 3.8) 2.7 (2.0 – 3.4) 2.3 (1.6 – 3.4)
p-Vvalue 0.66 0.03 0.06 p-Vvalue 0.84 0.21 0.50
Serum P (mmol/l)
- Low 1.8 (1.7 – 2.2) 1.8 (1.5 – 2.0) 1.7 (1.5 – 2.0)
Serum P (mmol/l)
- Low
1.9 (1.8 – 2.2) 2.0 (1.8 – 2.2) 2.3 (2.1 – 2.4)
- High 2.1 (1.8 – 2.3) 1.8 (1.5 – 2.0) 1.6 (1.3 – 2.2) - High 2.1 (1.8 – 2.4) 2.1 (2.0 – 2.4) 2.2 (2.0 – 2.3)
p-Value 0.22 0.88 0.71 p-Value 0.21 0.08 0.16
Urine P (mmol/l)
- Low 1.7 (0.3 – 3.8) 2.1 (0.7 – 5.5) 1.3 (0.7 – 3.5)
Urine P (mmol/l)
- Low 4.1 (0.7 – 6.8) 5.4 (2.2 – 8.2) 10.4 (6.8 – 18.4)
- High 2.3 (0.2 – 4.6) 2.6 (0.9 – 4.1) 3.1 (1.6 – 6.9) - High 5.4 (3.5 – 9.8) 7.4 (4.5 – 13.7) 9.5 (5.5 – 16.4)
p-Value 0.68 0.98 0.04 p-Value 0.02 0.04 0.46
Tubular reabsorption of P (%)
- Low 94.0 (76.8 – 98.2) 86.5 (76.1 – 95.3) 92.2 (83.8 – 96.9)
Tubular reabsorption of P (%)
- Low 83.1 (72.4 – 96.3) 80.8 (68.8 – 92.7) 75.9 (64.9 – 85.2)
- High 85.3 (76.4 – 98.1) 92.7 (73.3 – 95.7) 88.1 (80.8 – 95.1) - High 79.4 (51.9 – 87.6) 76.6 (59.1 – 83.2) 67.4 (53.9 – 82.4)
p-Value 0.59 0.62 0.21 p-Value 0.08 0.23 0.36
Alkaline Phosphatase (U/l)
- Low 167.0 (138.0 – 236.0) 213.0 (182.0 – 291.0) 263.5 (202.3 – 368.5)
Alkaline Phosphatase (U/l)
- Low 329 (261.3 – 455.0) 379 (311.0 – 503.0) 423.0 (301.8 – 506.0)
- High 203 (146.5 – 232.8) 244.0 (174.3 – 270.8) 275.5 (206.3 – 307.0) - High 304.5 (249.3 – 375.0) 342.0 (213.8 – 414.3) 380.0 (281.8 – 509.8)
p-Value 0.76 0.94 0.76 p-Value 0.22 0.10 0.66
uCa/Crea ratio (mmol/mmol)
- Low 2.1 (1.3 – 3.5) 2.5 (1.8 – 3.1) 3.6 (2.3 – 5.2)
uCa/Crea ratio (mmol/mmol)
- Low 3.8 (2.3 – 6.2) 2.9 (1.8 – 4.1) 2.3 (1.6 – 3.7)
- High 1.7 (1.4 – 3.7) 2.7 (2.0 – 6.1) 4.0 (2.9 – 6.3) - High 3.0 (2.1 – 5.4) 3.8 (2.4 – 5.0) 3.4 (1.9 – 4.8)
p-Value 0.98 0.30 0.35 p-Value 0.49 0.21 0.14
uP/Crea ratio (mmol/mmol)
 - Low 1.6 (0.5 – 5.9) 2.8 (1.0 – 6.8) 1.9 (0.8 – 5.4)
uP/Crea ratio (mmol/mmol)
- Low 5.1 (1.1 – 9.3) 7.2 (2.5 – 12.3) 11.2 (6.2 – 18.6)
- High 3.8 (0.5 – 6.7) 1.8 (1.1 – 5.8) 3.5 (1.6 – 6.1) - High 7.7 (5.0 – 10.9) 9.4 (7.0 – 16.5) 14.5 (9.3 – 18.7)
p-Value 0.64 0.72 0.15 p-Value 0.14 0.06 0.73
All data are presented as median and interquartile range; sCa: serum calcium (mmol/l); uCa: urine  calcium 
(mmol/l); sP: serum phosphorus (mmol/l); uP: urine phosphorus (mmol/l); TrP: tubular reabsorption of 
 phosphorus (%); ALP: Alkaline phosphatase (U/L); uCa/Crea ration: urine calcium/ creatinine ration (mmol/
mmol); uP/Cre ratio (mmol/mmol).
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Abstract
Preterm infants often have a reduced bone mineral content (BMC) with increased risk 
of metabolic bone disease. After birth it is difficult to supply calcium (Ca) and 
phosphorus (P) comparable to the high fetal accretion rate. It is not known whether 
high supplementation of minerals in the early postnatal period improves growth 
and bone mineralization. The aim of this study was to evaluate growth and bone 
mineralization at term corrected age (TCA) in very and extremely preterm infants who 
received different enteral Ca and P intakes during the first 10 days of life. Infants (n = 109) 
with birth weights below 1500 g were randomly assigned to one of three groups that 
differed in the nutritional protocols delivered until day 10: Group A, mother’s own 
milk (MOM) and donor milk (unfortified); Group B, MOM (unfortified) and preterm 
formula; Group C, MOM (start fortification >50 mL/day) and preterm formula. Due to 
the earlier commencement of fortification, Group C received higher intakes of calcium 
and phosphorus and protein (p < 0.001) until day 10. At TCA weight, length, BMC and 
bone mineral density (BMD), measured by dual-X-ray absorptiometry, were not 
different between the groups. Nutritional intake of P was positively associated with 
length (β; (95% confidence interval (CI): 0.20 (0.001; 0.393); p-value = 0.048), whereas 
Ca intake was negatively associated with BMC (−1.94 (−2.78; −1.09); p-value < 0.001). 
A small interaction between Ca and P intake was only found for BMD (0.003 (0.00002; 
0.00006); p-value = 0.036). The volume of human milk per kg provided during the first 
10 days was positively associated with BMC (β; (95% CI): 0.013 (0.002; 0.023); p < 0.017). 
Higher intakes of Ca and P during the first 10 days, as provided in this study, did not 
improve bone mineralization at term corrected age. 
Introduction
Very and extremely preterm infants are known to have a reduced bone mineral content 
(BMC) with increased risk of development of metabolic bone disease (MBD). (1–6) 
There are numerous reasons for impaired bone development in preterm infants, but 
an adequate supply of substrates of calcium (Ca) and phosphorus (P) is a prerequisite 
for normal bone mineral accretion, whereas vitamin D is essential for the adequate 
regulation of the mineral homeostasis and bone mineralization. (5,7) Up to 80% of 
the body Ca of a term infant is accrued during the last trimester of pregnancy. (7,8) 
Infants born preterm miss this active foetal mineralization in the last trimester, and 
instead are reliant on supplementation of minerals, provided through parenteral and 
enteral sources. (9,10) In clinical practice, it is difficult to meet the high foetal needs 
after preterm birth. Parenteral fluids have a limited solubility for high amounts of 
Ca and P, whereas human milk has low contents of calcium (Ca) and phosphorus (P) 
and formula feeding has been shown to have an impaired intestinal absorption of 
minerals. (9,11,12) 
 Nowadays, it is accepted that early enteral nutrition, and especially human milk 
(HM), has beneficial health effects. Enrichment of HM with human milk fortifiers (HMF) 
for preterm infants is the standard of care. (13) However, there is uncertainty with 
regard to the method of fortification of human milk. The timing and amount of 
mineral supplementation vary greatly, resulting in varying international practices. (14) 
Supplementation of Ca and P is often delayed because of fear of nephrocalcinosis, 
feeding intolerance and necrotizing enterocolitis. (15,16) Early mineral supplementation 
of human milk at low volumes of enteral intake accelerates the amount of enteral 
intake, decreases the duration of parenteral nutrition, and may support postnatal 
growth and bone mineralization in the early postnatal period, whereas delay of 
fortification may lead to insufficient mineral intake and consecutively impaired bone 
mineralization. Whether early postnatal high mineral intake will improve bone 
mineralization has not been evaluated. 
 The aim of this study was to evaluate bone mineralization and growth at term 
corrected age (TCA) in very and extreme preterm infants who received either unfortified 
human milk, preterm formula, or early fortified human milk during the first 10 days 
of life. We hypothesized that a higher mineral intake would lead to a higher weight 
and length as well as improved bone mineralization at term corrected age.
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Materials and Methods
Study Design and Randomization
This study (Early Supplementation Study (ESS)) was part of a larger multi-center 
double-blinded randomized controlled trial: the Early Nutrition Study (ENS). (17) The 
ENS evaluated the effects of human milk on postnatal mortality and morbidity, while 
the ESS evaluated bone mineralization and growth in relation to the timing of mineral 
supplementation. The studies were approved by the Ethical Committee of the VU 
University Medical Center, (Amsterdam, The Netherlands) 23 November 2012 (CMO 
dossier number: NL37296.029.11, Netherlands Trial Registry: NTR 3225). Participants 
were assigned into one of three groups through two steps of randomization, based 
on stratification according to birth weight, below or above 1000 g, and appropriate or 
small for gestational age status. First, infants were randomized into either late mineral 
and protein supplementation, as part of the ENS (Group A and B), or early supplemen-
tation, as part of the ESS (Group C). The second step was only performed if infants 
were randomized to the late supplementation group. This step randomized infants to 
either Group A (mother’s own milk (MOM) and/or donor milk) or Group B (MOM and/
or preterm formula). Both randomization steps were performed before the first 
enteral nutrition was administered. 
Study Population 
Infants were recruited at the level III neonatal intensive care unit of the Radboud 
University Medical Center (Radboudumc), Nijmegen, Netherlands. Preterm infants, 
with a birth weight below 1500 g, were eligible for inclusion, if both parents had given 
written informed consent before the first enteral feeding. Exclusion criteria were 
congenital malformations, congenital infection proven within 72 h after birth, 
perinatal asphyxia with a pH <7.0, maternal drugs and/or alcohol use during pregnancy 
and any intake of cow’s milk based products prior to randomization. 
Intervention and Nutritional Protocol 
The nutritional protocol and intervention have previously been described. (18) All 
infants received parenteral nutrition (PN), according to the standard institutional 
protocol. PN was started directly within the first hour after birth and consisted of 
standard components with 2.5 mmol/dL calcium gluconate (calcium gluconate 10%; 
B. Braun, Melsungen, Germany) and 1.6 mmol/dL sodium-glycerophosphate (Glycophos; 
Fresenius Kabi BV, Zeist, The Netherlands). Table A1 presents the standard protocol 
for PN. Additional parenteral mineral supplementation with 10% calcium gluconate 
or sodium-glycerophosphate was administered, according to the discretion of the 
attending neonatologist, based on blood and urine chemistry.
Enteral feeding, according to group allocation, was started within several hours after 
birth, with daily increments, while PN was gradually reduced, to maintain daily fluid 
intake within the protocol range. Where possible, MOM was used for enteral nutrition. 
If MOM was not available, Group A received donor milk and Group B and C received 
formula. Preterm formula (Hero Baby Prematuur Start; Hero Kindervoeding, Breda, 
The Netherlands) contained 2.40 mmol/dL Ca, 1.70 mmol/dL P and 2.6 g/dL proteins. 
Groups A and B started fortification of human milk or other enteral enrichment only 
after day 10. For both groups the additional nutritional intake was blinded to all 
caretakers and parents. Group C received enteral nutrition from day 1 onwards, 
according to the local protocol. This group received additional enteral supplementation 
and human milk fortifier (HMF) by the time the enteral intake was 50 mL per day. 
(Nutrilon Neonatal BMF; Nutriticia, Zoetermeer, The Netherlands) The HMF added 
1.65 mmol/dL Ca, 1.22 mmol/dL P and 0.8 g/dL protein. Additional enteral supplemen-
tation could comprise of either a supplement of protein (Nutrilon Nenatal protein 
Fortifier; Nutricia, Zoetermeer, The Netherlands) or a potassium phosphate (KPO4) 
and calcium chloride (CaCl2) suspension for enteral supplementation. The decision to 
start additional enteral supplementation was made by the attending neonatologist 
and according to the department’s protocol, based on biochemical parameters and 
postnatal growth. 
 All infants received vitamin D with parenteral nutrition (80 IE/kg/day) directly 
after birth. Enteral supplementation was 600 IE (15 micrograms) per day for infants 
with a weight below 1250 g and 400 IE (10 micrograms) per day for all infants with 
a weight above 1250 g. Human milk fortifier and preterm formula added 200 IE 
(5 micrograms)/dL vitamin D; thus, infants received, in total, between 600 and 1000 IE 
vitamin D per day. According to the local protocol (Group C), vitamin D supplementation 
was started by the day human milk fortification was started. For Groups A and B, 
enteral vitamin D supplementation was started by day 8 in combination with vitamin K 
supplementation, according to the national Dutch recommendations. 
 After 10 days, all infants received nutrition, according to the standard protocol of 
the Radboudumc, as described above. Around term corrected age (±6 weeks), all 
surviving participants were invited for an outpatient visit and scheduled for a dual 
energy X-ray absorptiometry (DXA). 
Outcome Measures
All outcome measures were taken up to term corrected age (TCA). Primary outcome 
measures were bone mineralization and growth. Bone mineralization was measured 
by dual energy X-ray absorptiometry (DXA), using a whole-body fan beam scanner 
(Hologic Discovery 85606, software APEX 3.3, Hologic, Vilvoorde, Belgium). Bone 
mineral content (BMC), bone mineral density (BMD), lean body mass (LBM) and 
fat mass were determined. Scans showing movement artifacts were classified as 
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unacceptable. Weight and length were determined from the first week onwards, at 
least weekly, until discharge. Weight was determined using an electronic scale to the 
nearest 1 g. Crown–heel length was measured to the nearest 5 mm. For participants 
who had already been transferred, the anthropometric data at TCA were collected 
from the local hospitals. 
Data Registration and Handling
Patient characteristics, clinical course, growth and intake of all nutrients were recorded 
from the patient records and extracted for this study—daily during the first 14 days 
and weekly until discharge from the department. After discharge, anthropometric 
data at TCA were collected from local hospitals. The amounts of enteral, parenteral 
and additional supplementation (parenteral and enteral) of all nutrients were 
calculated separately for each patient. For this study, the nutritional intake from the 
first 10 days was calculated, because this period comprised the intervention period 
with the maximum difference in nutritional intake. The total intakes were calculated 
per kg per day for each infant. The intake of nutrients with human milk was calculated 
using the reference from Gidrewicz et al.. (19) Postnatal growth was evaluated using 
standard deviation scores (SDS) for weight and length, based on the revised reference 
chart for preterm infants by Fenton and Kim. (20) Infants with a birth weight below the 
10th percentile were classified to be small for gestational age (SGA). 
Statistical Analysis
The primary objective of the ESS was to examine whether bone mineralization at 
TCA differed by type of mineral supplementation at term corrected age (TCA). 
We performed a power calculation before the enrollment of participants started. 
We anticipated that a higher intake of minerals would result in a BMC that would, 
on average, be 5 g higher. Lagemaat et al. found a variability in BMC of 12 g at TCA [21]. 
Based on two-sided testing with α = 0.05 and β = 0.80, 65 infants per group were 
required. The statistical analyses were performed using SPSS 22 for Windows (IBM 
SPSS INC., Chicago, IL, USA). Differences in nutritional characteristics, anthropometric 
data at TCA and DXA scan measurements were detected using the one-way ANOVA or 
Kruskal–Wallis test, as appropriate. 
 The outcomes of interest were two DXA scan measurements, (i.e., BMC and BMD) 
as well as weight and length. We used Generalized Estimating Equations with an 
independent correlation structure and robust standard errors to account for the 
correlation between twins. (22) The stratification factors of birth weight and SGA status 
as well as gestational age at the time of measurement were included in all analyses. 
For the primary analysis, separate linear regression models were fitted to examine the 
association between ESS group and the four outcomes of interest, with Group C being 
the reference. Continuous predictor variables were centered at their respective means 
for the analysis. A set of secondary analyses examined the associations between each 
of the main nutritional variables (i.e., intake of P, Ca, protein per kg per 10 days) and 
outcomes. An interaction term was included for Ca and P. Finally, the analysis also 
examined associations between the amount of human milk and the outcomes of 
interest.
Results
Patient Characteristics 
Patients were enrolled between January 2013 and December 2014. The ENS trial was 
closed when the required number of infants was included nationwide, forcing us to 
stop the ESS before the anticipated number of patients was included. The distribution 
of patients and the exact numbers of measurements are presented in the consort 
diagram (Figure 1). A total of 109 infants were randomized to either early supplementation 
(Group C, n = 37) or to late supplementation and distributed into Groups A 
(n = 40) and B (n = 32). All surviving infants (Group A, n = 34, Group B, n = 29, Group C, 
n = 30) were included in the growth analyses, but only subsets of those were included 
in the DXA analyses, either because of parent refusal to attend the follow-up visit, 
or disapproval of the DXA scan as a result of unacceptable movement artifacts. 
The baseline characteristics of all patients included and the morbidities and relevant 
medications of patients who survived to TCA are shown in Table 1. The baseline 
 characteristics, frequencies of morbidities and treatments were comparable between 
the three groups. 
Nutritional Intake
The nutritional characteristics for the first 10 days are presented in Table 2. The 
number of days with parenteral nutrition and the time to achieve full enteral feeding 
were not different between the three groups. In agreement with the study protocol, 
Group C started HMF earlier, at a median (IQR) of day 6.0 (4.0–7.0) compared to Group 
A (day 11.5 (11.0–12.5)) and Group B (day 12.0 (11.0–13.5)) (p-value < 0.001). As a result 
of the study protocol, Group C received significantly higher mean (SD) intakes of both 
Ca (Group C: 21.5 (4.8) versus Group A: 15.7 (2.6) and Group B: 17.1 (4.0) mmol/kg per 
10 days) and P (Group C: 21.6 (3.7) versus Group A: 16.5 (3.1) and Group B: 16.5 (3.0) 
mmol/kg per 10 days) during the first 10 days (p-value < 0.001). Furthermore, Group C 
received significantly higher mean (SD) intakes of protein (Group C: 32.1 (5.5) versus 
Group A: 26.8 (5.0) and Group B: 27.5 (4.3) g/kg per 10 days; p-value < 0.001) and 
carbohydrates (Group C: 114.5 versus Group A: 109.1 (10.7) and Group B: 103.6 (11.5) g/
kg per 10 days; p-value = 0.02) According to the study protocol, Group A received a 
significantly higher percentage of human milk during the first 10 days, compared to 
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Table 1   Patient characteristics, morbidity, medication
Characteristics (All Infants) Group A
(n = 40)
Group B
(n = 32)
Group C
(n = 37)
Gestational age, weeks; mean (SD) 28.3 (2.6) 28.4 (2.6) 28.1 (2.4)
Birth weight; grams; mean (SD) 1002 (275) 1012 (219) 1006 (265)
Small for gestational age; n (%) 8 (20) 8 (25) 6 (16)
Male; n (%) 21 (53) 20 (63) 18 (49)
Singletons; n (%) 25 (63) 24 (74) 17 (46)
Antenatal Steroids; n (%) 36 (92) 31 (97) 32 (87)
Cesarean section; n (%) 19 (48) 20 (63) 25 (68)
Apgar score (5 min); med (IQR) 7.5 (6.5, 9.0) 8.0 (7.0, 9.0) 7.0 (7.0, 8.0)
Apgar score (5 min); <7; n (%) 10 (25) 5 (16) 8 (22)
Death before discharge; n (%) 6 (15) 3 (9) 7 (19)
Morbidities (All Infants Discharged) Group A
(n = 34)
Group B
(n = 29)
Group C
(n = 30)
Infant respiratory distress syndrome; n (%) 19 (56) 17 (59) 17 (57)
Days of mechanical ventilation; med (IQR) 0 (0, 4.0) 1.0 (0.0, 3.0) 0.0 (0.0, 4.0)
Days of Nasal-CPAP; med (IQR) 22.5 (11.0, 40.0) 29.0 (8.0, 41.0) 22.0 (9.0, 42.0)
Chronic lung disease; n (%) 12 (35) 13 (45) 8 (27)
Patent ductus arteriosus; n (%) 14 (41) 17 (59) 16 (53)
Intra-ventricular hemorrhage grade ≥ 2; n (%) 5 (14.7) 5 (17) 3 (10)
Sepsis; n (%); 8 (24) 8 (28) 10 (33)
Necrotizing enterocolitis; Bell stage ≥ 2; n (%) 0 0 1 (3)
Retinopathy of prematurity; n (%) 4 (12) 1 (3) 5 (17)
Medication (All Infants Discharged)
Caffeine; n (%) 32 (94) 27 (93) 28 (93)
Diuretics; n (%) 9 (27) 10 (35) 6 (20)
Corticosteroids; n (%) 4 (12) 2 (7) 3 (10)
Sedation; n (%) 7 (21) 8 (28) 8 (27)
Group A: donor milk in addition to mother’s own milk (MOM) and no supplements with enteral feeding 
until day 10; Group B: preterm formula in addition to MOM and no supplements with enteral feeding until 
day 10; Group C: preterm formula in addition to MOM and fortifier if intake ≥50 mL/day; SD: standard 
deviation; med: median; IQR: inter quartile range; small for gestational age: below 10th percentile, 
according to Fenton et al. [20]; Nasal-CPAP: nasal continuous positive airway pressure; chronic lung disease 
was defined as oxygen dependency at 36 weeks gestational age; patent ductus arteriosus was classified 
as need for treatment; sepsis was included if present for >72 h postnatally with positive blood culture; 
necrotizing enterocolitis was determined with staging, according to Bell [23]; diuretics included single 
doses of furosemide and maintenance diuretics; sedation included morphine and/or midazolam >24 h.
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Group B and Group C (p-value < 0.001), although these groups received predominantly 
human milk as well. The calorie intake differed only slightly between the groups. 
Table A2 presents the distribution of the route of supplementation of Ca and P. 
This table demonstrates that differences in mineral intake between the groups were 
based on enteral intake. 
Weight and Length at Term Corrected Age
Table 3 presents the anthropometric data at birth and TCA for all groups, including 
appropriate  (AGA) and small for gestational age (SGA) infants. For both time points, 
weight and length were similar between the groups. All groups decreased in standard 
deviation score (SDS) for weight, as well as for length. The decrease in SDS for weight 
varied between −0.41 and −0.75, and for length between −0.33 and −0.69; for both 
measurements, there were no significant differences. 
DXA-Scan at Term Corrected Age
Table 4 presents the data on body composition, as measured by DXA scan. A total of 
35 scans were classified as acceptable. Not all infants were able to visit the outpatient 
clinic on the scheduled day and for logistic reasons, a number of infants were scanned 
close before discharge from hospital, therefore the gestational age and weight at 
the time of the scan varied. Nevertheless, the outcomes were similar across the groups 
for BMC and BMD with a wide interquartile range.
Determinants of Growth and Bone Mineralization
Table 5 presents the results of the analyses evaluating the effect of being a member of 
one of the three supplementation groups, and the amount of human milk provided 
during the first 10 days, on growth and bone mineralization. Groups A and B were 
analyzed with Group C as the reference. Birth weight, gestational age at measurement 
and being small for gestational age were significant determinants for all outcomes 
and thus were used as covariates in all analyses. There was little evidence of an 
association between the studied groups and the outcomes of weight, length, BMC 
and BMD. The amount of human milk was associated with a significant effect on BMC, 
with each mL/kg increase in human milk over 10 days associated with an average 
increase of 0.013 g (p-value = 0.017) in BMC. Length and weight were not associated 
with intake of human milk.
Table 2   Nutritional characteristics during the first 10 days of life
Group A 
(n = 34)
Group B 
(n = 29)
Group C
 (n = 30)
p-Value
Characteristics
Parenteral nutrition, days; med (IQR) 10.5 (8.0, 13.0) 10.0 (9.0, 14.0) 10.0 (9.0, 21.0) 0.71
Enteral (120 mL/kg/day); day; med (IQR) 10.0 (8.0, 13.0) 9.5 (9.0, 12.0) 10.5 (9.0, 16.0) 0.89
Enteral (150 mL/kg/day); day; med (IQR) 12.0 (9.0, 17.0) 11.0 (10.0, 13.0) 12.0 (10.0, 20.0) 0.89
Start day of HMF; med (IQR) 11.5 (11.0, 12.5) 12.0 (11.0, 13.5) 6.0 (4.0, 7.0) <0.001
Human milk, mL/kg; mean (SD) 552.8 (248.4) 403.1 (294.5) 432.5 (267.9) 0.06
Formula, mL/kg; med (IQR) - 33.9 (13.9, 162.9) 12.1 (1.1, 48.6) <0.001
Percentage human milk; med (IQR) 100 (100.0, 100.0) 82.6 (53.2, 97.6) 97.3 (91.8, 99.9) <0.001
Intakes
Calcium, mmol/kg; mean (SD) 15.7 (2.6) 17.1 (4.0) 21.9 (4.8) <0.001
Phosphorus, mmol/kg; mean (SD) 16.5 (3.1) 16.5 (3.0) 21.6 (3.7) <0.001
Protein; grams/kg; mean (SD) 26.8 (5.0) 27.5 (4.3) 32.1 (5.5) <0.001
Calories; kcal/kg; mean (SD) 836 (108) 838 (86) 832 (168) 0.60
Carbohydrate; grams/kg; mean (SD) 109.1 (10.7) 103.6 (11.5) 114.5 (18.5) 0.02
Enteral: represents the day infants reached an enteral intake of either 120 or 150 mL/kg/day; HMF: human 
milk fortifier; Ca: calcium; P: phosphorus. All intakes are presented as the sum of the first 10 days; SD: standard 
 deviation; med: median; IQR: inter quartile range. Missing data: Group A (n:2); Group B (n:4); Group C (n:4).
Table 3   Outcome of anthropometry at term corrected age
Growth at TCA Group A
(n = 34)
Group B
(n = 29)
Group C
(n = 30)
p-Value
Gestational age, weeks 40.1 (39.7, 40.8) 40.3 (39.8, 41.1) 40.1 (39.2, 42.6) 0.126
Weight (grams)
Birth 1050 (834, 1263) 1036 (896, 1211) 1024 (800, 1331) 0.998
Term corrected age (TCA) 2980 (2666, 3328) 3070 (2838, 3625) 3115 (2655, 3700) 0.114
SDS Weight
Birth −0.22 (−1.26, 0.47) −0.25 (−1.28, 0.50) −0.15 (−0.93, 0.51) 0.714
Term corrected age (TCA) −1.15 (−1.93, −0.40) −1.00 (−1.84, 0.18) −0.87 (−1.74, −0.06) 0.630
Difference SDS: Birth—TCA −0.65 (−1.27, −0.34) −0.41 (−1.24, 0.18) −0.75 (−1.42, 0.10) 0.707
Length (cm)
Birth 34.5 (32.9, 36.1) 35.0 (32.5, 37.0) 35.0 (32.3, 37.0) 0.704
Term corrected age (TCA) 48.0 (45.0, 49.0) 48.5 (45.0, 50.5) 49.0 (46.0, 51.5) 0.226
SDS Length
Birth −1.29 (−1.92, −0.24) −0.62 (−2.34, 0.22) −0.66 (−1.14, −0.09) 0.190
Term corrected age (TCA) −1.37 (−2.34, −0.52) −1.25 (−2.52, −0.26) −1.48 (−1.99, −0.62) 0.737
Difference SDS: Birth—TCA −0.66 (−1.64, 0.56) −0.33 (−1.17, 0.44) −0.69 (−1.08, −0.27) 0.870
All data are presented as median and inter quartile range (IQR). TCA: term corrected age; GA: gestational 
age; SDS: standard deviation score.
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Table 6 presents the results of the regression analysis for the effects of Ca, P and 
protein intake per kilogram during the first 10 days on growth, and bone mineralization 
at term corrected age, of very preterm born infants. Based on the assumption that 
these three nutrients have a complex interrelationship in the effect on growth and 
bone mineralization, we analyzed the association with weight, length, BMC and BMD 
in three models by introducing step-by-step Ca, P and protein, thereby aiming to 
provide insight into—for example, how the effect of Ca might be influenced by the 
levels of P. In this analysis, the nutritional intakes of Ca, P and protein for the first 
10 days were not associated with weight at term age. Phosphorus intake was positively 
associated with length, with a significant in increase of 0.19 cm (p-value = 0.047) 
length for each mmol/kg received over the first 10 days. This effect remained after 
inclusion of protein in the model. Calcium intake was associated with a significant 
negative effect on BMC. Our analysis showed that each mmol/kg of Ca received over 
the 10 days was associated with a decrease of 1.21 g of BMC (p-value: 0.001). The effect 
persisted and increased slightly with the introduction of phosphorus and protein in 
the model. The testing on the interaction of Ca and P over the 10 days intake was 
negative for all outcomes, except for BMD, which showed a small positive effect 
(β 0.0003 ; 95% CI (0.00002; 0.0006); p-value = 0.036).
Table 4   Body composition measured by DXA
DXA Scan Group A
(n = 14)
Group B
(n = 12)
Group C
(n = 9)
p-Value
Gestational age (weeks) 40.5 (36.7, 44.0) 42.1 (37.6, 45.7) 43.7 (36.5, 45.7) 0.569
Weight (g) 3318 (2407, 4290) 3325 (2343, 3856) 3115 (2533, 3920) 0.966
Length (cm) 48.5 (43.8, 52.8) 48.0 (44.0, 52.1) 49.5 (45.0, 53.0) 0.923
Bone area (cm2) 314.1 (263.0, 368.3) 326.7 (254.3, 353.5) 286.6 (256.8, 390.6) 0.988
Bone mineral content (gram) 47.6 (42.0, 66.1) 51.1 (35.4, 65.3) 45.4 (35.3, 63.0) 0.967
Bone mineral density (g/cm2) 0.164 (0.147, 0.177) 0.157 (0.138, 0.186) 0.157 (0.138, 0.173) 0.819
Lean body mass (gram) 2862 (2064, 3647) 3164 (2289, 3659) 2576 (2254, 3382) 0.665
Fat mass (gram) 568 (314, 888) 473 (397, 918) 641 (231, 914) 0.922
Fat (%) 16.9 (13.5, 20.4) 15.6 (11.0, 21.5) 16.7 (8.7, 23.5) 0.918
All data are presented as median (IQR); GA: Gestational age; DXA: dual energy X-ray absorptiometry.
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Discussion
This randomized cohort study evaluated the effect of different amounts of Ca and P 
intakes, during the first 10 days of life, on growth and bone mineralization of very 
preterm infants. The early stopping of patient inclusions led to lower numbers than 
the originally anticipated 65 infants per group. Thus, the study may be underpowered 
to answer the research questions. This study found no differences in weight, length, 
bone mineral content (BMC) and bone mineral density (BMD) between three different 
intake groups of very and extremely preterm infants at term corrected age. The 
regression analysis further showed that group assignment was not associated with 
the studied outcome measures; however, we found significantly positive associations 
between P intake and length, as well as the amount of human milk intake and BMC. In 
contrast, Ca intake was associated with a decrease in BMC, which further decreased 
after the addition of P and protein in the analysis. 
 Bone mineralization, at term corrected age, in relation to enteral nutrition of 
preterm infants has been evaluated in only a few studies during the last three decades. 
Studies often had an observational design and evaluated more stable infants at a 
higher gestational age than nowadays treated. (1,2,4,24–31) Eleven studies investigated 
the effect of either human milk, fortified human milk or various compositions of 
preterm formulas in randomized studies, leading to varying results. (32–42) Only two 
studies found an increase in BMC, according to gestational age changes, in 
combination with high amounts of minerals in preterm formula, while others found 
the highest weight gain and BMC specifically with preterm formula. (2,32,34,35,37,42,43) 
Since timing, amount of fortification or composition of formulas differed in all studies 
as well as the method and timing of scanning (single photon absorptiometry versus 
dual X-ray absorptiometry), it is difficult to compare these results to our findings. 
The largest double-blinded randomized study, performed by Faerk et al., did not find 
an effect of human milk fortification or preterm formula on BMC, compared to 
unfortified human milk. (39) However, infants fed preterm formula had significantly 
higher weights at TCA and the amount of supplemented phosphorus was significantly 
associated with weight at TCA. (39) All infants achieved a BMC below that of healthy 
term born infants. (31,39) This negative result may be explained by a relatively late 
timing of fortification, at a mean age of 15 days, and a low amount of fortification of 
human milk, which was below the ESPGHAN (European Society for Peadiatric Gastro-
enterology Hepatology and Nutrition) recommendation for enteral intakes of Ca and 
P. (44) In comparison, we could not demonstrate an association between P, Ca and 
protein intakes and weight in this study; nevertheless, we found that P and the 
amount of human milk were positively associated with study outcomes. The 
differences in outcomes could be explained with the fact that our infants received 
amounts of minerals within the ESPGHAN recommendations. 
According to the nutritional protocol of our hospital, the full recommended intake 
(including parenteral and enteral intakes) was provided, as soon as possible after 
birth, aiming at a postnatal growth and bone mineralization comparable to 
development in utero and to limit a postnatal nutritional deficit, as described in 
several studies. (45–47) This included parenteral mineral supplementation directly after 
birth, early fortification of human milk and additional supplementation of minerals, 
based on biochemical parameters. Group C, following the institutional protocol, 
received a significant higher amount of Ca and P during the first 10 days, compared to 
Groups A and B, who received no enteral fortifications until day 10. The highest weight 
gain and bone mineralization could be expected in group C. However, the outcomes 
of group C compared to Groups A and B were not different, and the total group in 
comparison to the reference population was still growth retarded. Probably, this may 
be explained by the short intervention period, with only a few days of significantly 
different enteral intake. Further, this study included relatively more immature and 
sicker infants, compared to infants in the previously mentioned trials, probably 
indicating even higher requirements of minerals for very and extremely preterm 
infants than currently recommended. 
 The effect of Ca and P intakes on outcomes seemed contradictory. Calcium intake 
was associated with a significant negative effect on BMC and non-significant negative 
effects on all other outcomes, while phosphorus intake had a significant positive 
effect on length, and a non-significant positive effect on BMC. In general, the effect 
sizes were small, and BMD was the only outcome that indicated a positive interaction 
between Ca and P. Again, any interpretation should be performed with caution, since 
the results may be distorted by the small number of patients investigated with DXA 
scans. However, an explanation for this phenomenon may be that both minerals are 
closely related in the formation of bone and shortage of one item may influence the 
effect of the other mineral. Based on our previous study, we have strong indications 
that the supply of at least phosphorus was insufficient. For the same cohort of infants 
evaluated in this study, we reported changes in biochemical parameters for calcium 
and phosphorus homeostasis, in relation to nutritional intake. (18) Despite a high 
intake of P, serum P concentrations remained low in all three groups. It was 
demonstrated that serum P concentrations were significantly associated with amino 
acid intake, indicating that phosphorus was preferably used for cell metabolism 
instead of bone mineralization. Hypophosphatemia, in relation to high amino acid 
intake, has previously been reported in preterm infants and currently is recognized as 
‘Placental Incompletely Restored Feeding (PI-Refeeding) syndrome’, caused by an 
imbalanced nutritional intake of amino acids and phosphorus. (18,48,49) Furthermore, 
we demonstrated that low gestational age was associated with higher renal excretion 
of phosphorus, irrespective of nutritional intake. Thus, considering the results of both 
studies, we speculate that, despite a high intake of minerals in Group C, a high cell 
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metabolism and renal phosphorus wasting prevented adequate availability of 
phosphorus for adequate bone mineralization and consecutively prevented adequate 
use of calcium for bone mineralization. Again, this indicated that mineral requirements, 
to achieve bone mineralization equivalent to term born infants, for the most immature 
infants, may be higher than currently recommended. (13,31) 
 The method of administration of minerals may have affected the outcomes 
between groups as well as the results of the regression analysis. As demonstrated in 
Table A2, the groups differed significantly in the amount of enteral supplementation 
of minerals, but all groups received more than 50% of the total intake as parenteral 
supplement. Parenteral nutrients are directly available for metabolism, while supply 
by the enteral route is also determined by the amount of intestinal absorption. (10,50) 
The parenteral supplement in our study may have compensated for the low enteral 
intakes in Groups A and B and may have ameliorated differences in outcomes and the 
analyses regarding the effects of nutritional intake. In comparison, the study of Faerk 
et al. did not provide any information on parenteral supplements, although the 
intervention period (start of supplementation) only started at a mean of 15 ± 7 days. 
(39) Nowadays, the clinical practice for nutritional support of preterm infants is to 
provide full parenteral nutrition, including mineral supplementation, shortly after 
birth. Therefore, the provision of parenteral nutrition in the study of Faerk cannot be 
excluded and one may speculate that the comparatively positive outcomes of infants 
who received unfortified human milk in this study could partly be explained by 
parenteral supplementation of nutrients. 
 Independent of group assignment, the percentage of MOM was very high in this 
study. In the studies mentioned previously, which found an improvement in bone 
mineralization, this was overall related to the use of preterm formula with a high 
amount of minerals. We did not include a group with exclusively preterm formula, 
because our general practice is to provide preferably the mother’s own milk. On the 
other hand, a positive effect of human milk on bone development has previously 
been reported. (51,52) The positive effect of the amount of human milk on BMC in this 
study supports our assumption that even for very and extreme preterm infants, it 
should be possible to achieve adequate bone mineralization at term corrected age, in 
combination with human milk. Furthermore, this study confirmed earlier findings, 
that early fortification was well-tolerated. (53) However, this study also demonstrated, 
that current concepts of mineral supplementation and fortification of human milk are 
insufficient and need to be further evaluated, while recommendations probably need 
to be adapted. 
 This study had several limitations. Firstly, this study did not evaluate the maternal 
vitamin D status, nor were vitamin D concentrations determined in the participating 
infants. Epidemiological studies have shown a high prevalence of suboptimal vitamin 
D concentrations in pregnant and lactating women, even in countries where adequate 
exposure to sunlight and sufficient dietary intakes may be expected. (54,55) The foetus 
relies on maternal vitamin D stores, and thus postnatal vitamin D insufficiency may 
have impaired intestinal calcium absorption directly after birth. However, parenteral 
vitamin D supplementation was started directly after birth in all infants and enteral 
supplementation within the first week of life, following the recommendations for very 
low birth weight infants of the ESPGHAN 2010. (13) Recently, it was demonstrated that 
doses of vitamin D, as provided in this study, led to sufficient vitamin D concentrations 
in very low birth weight infants, in the postnatal period, at 4 weeks of age. (56) The 
small differences in start day of enteral vitamin D supplementation between Groups 
A/B and C cannot explain the differences found between the groups. Furthermore, all 
infants received the same amount of parenteral intake, with relatively high amounts 
of minerals. Based on blood and urine analyses, it was permitted to provide extra 
parenteral mineral supplementation during the intervention period. The protocol for 
parenteral nutrition has been the standard of care at our department for many years 
and we felt it would be unethical to withhold the standard of care to high risk patients. 
There was room for a more individualized treatment in relation to enteral supplemen-
tation. This possibly has ameliorated the differences between the three groups and 
subsequently decreased the size of any effect of enteral supplementation. On the 
other hand, the study protocol reflected current generally accepted clinical practice, 
with a combined parenteral and enteral nutritional intake. We would like to note that 
none of our patients developed signs of rickets or fractures and that at follow up, 
around term age, our patients had achieved a median BMC comparable to 38–39 
weeks gestation, according to Lapillone et al. (31) Up to this date, most studies have 
been limited to the evaluation of enteral intake. We suggest that further improvements 
in the combined nutritional supply of parenteral and enteral intake in the early 
postnatal period are possible and that future trials should include both routes of 
administration, starting directly after birth. A limitation of our study was the fact that 
we were unable to include the intended number of patients. This may, on the one 
hand, have led to overestimation of observed effects; on the other hand, there is a 
chance of having missed certain effects. It should be noted that we only included 
three nutrients for the regression analysis, while enteral nutrition, especially human 
milk, is a complex emulsion and the composition and interactions between various 
factors that may have impacted on the digestion and absorption of nutrients were 
not included in the analysis and thus may have been missed. 
 Despite these limitations, we decided to present our data because there are 
limited studies available investigating bone mineralization in preterm infants at term 
age, specifically for the group of very and extremely low gestational age. The specific 
nutritional needs of this high-risk group need further evaluation. Often studies remain 
of a small size because it is difficult to include sufficient patients within a reasonable 
timeframe. The strength of this study is the randomized design and that reporting of 
218 219
8
CHAPTER 8 GROWTH AND BONE MINERALIZATION OF PRETERM INFANTS
data occurred accordingly to the recently proposed standardization of nutrition and 
growth outcomes. (57) This offers the opportunity to combine our data with studies of 
a comparable setting, which may add to the significance of the overall results. 
Conclusions
On the basis of this study, there is no evidence that early high mineral intake through 
early fortification of human milk further improves bone mineralization in combination 
with high parenteral mineral intake. Mineral intake, according to current recommen-
dations for preterm infants, seems to provide an insufficient amount of minerals to 
achieve bone mineral content, comparable to term born newborns. The positive 
effect of human milk on bone mineral content needs to be further evaluated. 
Acknowledgments 
All authors gratefully thank Wendy R.J.C. Jansen, research nurse of the Pediatric Drug 
Research Center Radboudumc, and Laure J.M.L. Vorstenbosch, medical student, 
for the dedicated support in patient recruitment and data collection, as well as 
Dr. Timothy A.J. Antonius, neonatologist at Radboudumc, for the development of 
the algorithm to calculate the nutritional intakes.
Appendix A
Table A1   Standard parenteral nutritional intake
Day 1 Day 2 Day 3 Day 4
Fluid mL/kg/day 80 100 125 150
Carbohydrates grams/kg/day 8 9.6 11.7 13.8
Amino acids grams/kg/day 0.75 1.5 2.25 3
Lipids grams/kg/day 1 2 3 3
Energy Quotient Kcal/kg/day 44 62 82 94
Calcium mmol/kg/day 0.75 1.5 2.25 3.00
Phosphorus mmol/kg/day 0.48 0.96 1.44 1.92
Parenteral nutritional intake based on standardized parenteral solutions [35,53]. For infants below 1000 g, 
amino acids were additionally added, according to current recommendations [12]. Amino acid solution: 
Primene (Baxter, the Netherlands); lipid emulsion including vitamins: Clinoleic (20%; Baxter, The Netherlands) 
or SMOFlipid 20% (Fresenius Kabi; The Netherlands).
Table A2   Route of supplementation
Distribution of Mineral Intake Group A
(n = 34)
Group B
(n = 29)
Group C
(n = 30)
p-Value
Calcium, mmol/kg
Total 15.0 (13.8, 17.5) 15.9 (14.1, 19.2) 22.0 (19.3, 25.5) <0.001
Enteral 3.9 (2.4, 4.8) 6.0 (2.9, 7.5) 10.3 (4.9, 14.7) <0.001
Enteral supplement 0 0 0 1.000
Parenteral 12.1 (9.4, 15.1) 10.9 (8.2, 12.5) 12.2 (9.4, 15.2) 0.309
Parenteral supplement 0 0 0 1.000
Phosphorus, mmol/kg
Total 16.4 (14.5, 18.5) 16.3 (15.1, 19.1) 21.6 (19.1, 24.1) <0.001
Enteral 3.0 (1.7, 3.7) 4.1 (2.5, 5.4) 9.4 (3.6, 14.4) <0.001
Enteral supplement 0.0 (0.0, 0.3) 0 0.0 (0.0, 3.6) 0.063
Parenteral 12.5 (9.8, 16.3) 11.8 (9.2, 14.9) 11.9 (9.0, 16.8) 0.524
Parenteral supplement 3.3 (1.5, 6.1) 3.1 (1.2, 5.1) 2.1 (0.0, 5.6) 0.498
All values are median (IQR). All intake is presented as the sum of the intake during the first 10 days. Missing 
values: Group A (n:2); Group B (n:4); Group C (n:3).
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CHAPTER 9 DIAGNOSING BONE MINERALIZATION IN PRETERM BORN CHILDREN
Abstract
Background
Preterm infants are at risk of impaired bone health in later life. Dual-energy X-ray ab-
sorptiometry-scan (DXA) is the gold standard to determine bone mineralization. 
Phalangeal quantitative ultrasound (pQUS) is an alternative technique that is 
inexpensive, easy to use and radiation-free. The aim of this study was to investigate 
whether both techniques reveal equivalent results.
Materials and Methods
Sixty former preterm infants (31 boys; 29 girls) received a DXA and pQUS at age  9 to 
10 years. DXA measured bone mineral content (BMC) and bone mineral density (BMD) 
for total body and lumbar spine (L1-4), while pQUS measured the amplitude 
dependent speed of sound (AD-SoS) and bone transit time (BTT) at metacarpals II-IV 
providing continuous values and Z-scores based on age and sex. Four statistical 
methods evaluated the association between both techniques: Pearson’s correlation 
coefficients, partial correlation coefficients adjusted for gestational age, height and 
BMI, Bland-Altman analysis and cross tabulation. 
Results
Both techniques showed a statistically significant weak correlation for continuous 
values as well as Z-scores (0.291-0.462, p<0.05). Boys had significant and relatively 
high correlations (0.468-0.585, p<0.05). In comparison, the correlations for girls were 
not significant. Correlation coefficients further decreased while calculating the partial 
correlations. The Bland-Altman plots showed poor agreement. Sensitivity ranged 
from 33% to 92% and specificity from 16% to 68%. Positive and negative predictive 
values ranged from 4% to 38% and 82% to 97%, respectively.
Conclusions
We found statistically significant weak correlations and poor agreement between 
DXA and pQUS measurements. DXA is not equivalent to pQUS and therefore not 
replaceable by this technique in former preterm born children at the age of 9 to 
10 years. 
Introduction
Bone development is one of the key processes during fetal, neonatal and infant 
development. (1) Mineralization of bone mainly starts during the third trimester of 
pregnancy based on active placental transfer of calcium and phosphorus to the fetus. 
Up to 80% of the body calcium of a term infant is accrued during the last trimester. (2) 
Preterm infants miss out the active fetal bone development and therefore are at risk 
of reduced bone mineralization and development of osteopenia. (3) Inadequate bone 
mineralization is seen as a risk factor for the development of osteoporosis in later life, 
which is an important cause of morbidity and mortality in elderly people and a 
considerable factor of healthcare expenditure. (4-6) The peak bone mass is attained 
before skeletal maturity. (7) Any factor that influences the acquisition of peak bone 
mass may represent a mechanism  to affect later osteoporosis risk. The evaluation of 
bone development in preterm born children is relevant for the determination of the 
individual health risk as well as the evaluation of medical treatment that aimed at 
improvement in bone development. 
 Currently, there are two techniques available to determine bone mineralization, 
either dual-energy X-ray absorptiometry-scan (DXA) or quantitative ultrasound (QUS). 
DXA is the most commonly used technique for assessing bone mineralization in 
children and adolescents. (8) Although DXA is a non-invasive and standardized 
method, it is not available for all medical centers and it uses a low amount of radiation. 
In recent years, QUS has been proposed as an alternative method to replace DXA for 
the evaluation of bone status, especially since it is relatively inexpensive, fast, easy to 
use, portable and radiation-free. (9-12)
 Studies investigating the association between the measurements of DXA and 
QUS revealed inconsistent results. While a number of studies showed a significant 
positive correlation between DXA and QUS (13-28, 46), others found a discrepancy 
between the measurements of the two methods (10, 28-34). This could be a result of the 
different QUS measurement sites or different patient categories investigated. Only a 
limited number of studies used the phalangeal QUS (14, 16, 18, 22-24, 28, 46) and only one 
study looked at the specific group of former preterm born children. (10)  
 The aim of this study was to investigate whether the measurements of dual-energy 
X-ray absorptiometry scan (DXA) and phalangeal quantitative ultrasound (pQUS) 
performed in preterm born children aging from 9 to 10 years reveal comparable 
results. We hypothesized that both techniques were equivalent in diagnosing the 
state of bone mineralization. Equivalent results would mean that the pQUS could 
replace the DXA for evaluation bone mineralization as a diagnostic tool. 
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Materials and Methods
Study design
This study was a cross-sectional study using the data collection of the study 
“Long-term follow up of growth and bone mineralization of former preterm infants” 
(FoBoMin). This study was approved by the Ethics committee (CMO nr 2013/594) of 
the Radboud University Medical Center. Informed consent was obtained from all 
parents after approval by the local ethics committee. 
Study population and procedure
The study included 60 former preterm infants at the age of 9 to 10 years. All subjects 
participated in the FoBoMin-study. This long-term follow-up study evaluated two 
cohorts of very preterm infants with a birth weight below 1500 grams and gestational 
age less than 34 weeks. The cohorts differed by nutritional intake during the first two 
weeks of life. The second cohort received higher intake of protein, energy as well as 
calcium and phosphate. This was associated with improved weight gain during the 
early postnatal period. (35) The aim of the FoBoMin-study was to compare long-term 
growth and bone mineralization in relation to early nutritional intake in preterm born 
children at age  9 to 10 years. All participants of the studies were evaluated by DXA 
and pQUS. The measurements were performed on the same day for the individual 
participant. Four statistical methods were used to compare both methods. 
Measurement instruments and variables
Bone mineralization of the total body and lumbar spine (L1-L4) was determined using 
the QDR Discovery A S/N 85606 (Hologic, Inc., USA). According to the International 
Society for Clinical Densitometry (ISCD), the lumbar spine (L1-L4) and whole body 
scan are the preferred skeletal sites for measurement in children. (36) The measurements 
of the DXA were analyzed using the APEX-system software version 13.3. The DXA uses 
a low dose of radiation depending on measurement site. The effective dose, reflecting 
the real radiation risk for children of 10 years old, for the whole body is 4.8 μSv and for 
the lumbar spine 7.1 μSv. (37) According to the ‘Rijksinstituut voor Volksgezondheid en 
Milieu’ (RIVM) the yearly averaged ambient dose equivalent rate for the NMR station 
in the area of Nijmegen is 74 nSv/h (38), resulting in a daily exposure in Nijmegen of 
1.78 μSv. Therefore, the radiation dose of DXA can be regarded as very low and is 
negligible. Results of the DXA were expressed as Bone Mineral Content (BMC; g), Bone 
Mineral Density (BMD; g/cm2), representing the ratio between BMC and bone area 
(cm2), and Z-scores, representing the number of standard deviations above or below 
the mean for the patients’ sex and age. The Z-scores were calculated by the DXA 
software on the basis of reference values for sex and age obtained from a large U.S. 
population provided by the manufacturer. The Z-scores of the whole body were 
calculated using the reference data of the National Health and Nutrition Examination 
Survey (NHANES, 2008) (39), while lumbar spine  Z-scores were based on the reference 
data of the Bone Mineral Density in Childhood Study (BMDCS) (40). A Z-score less than 
or equal to -2.0 SD is considered to indicate ‘low bone mineral status’. (36) 
 The quantitative ultrasound (pQUS) was performed on the second to the fifth 
metacarpals of the phalangeal bones using a DBM Sonic Bone Profiler (IGEA, Carpi, 
Italy). The mean value of the measurements per person was calculated. The transmitter 
of the pQUS generated a sound frequency of 1.25 MHz. This technique measured the 
amplitude dependent speed of sound (AD-SoS) and bone transit time (BTT), which 
were both expressed in continuous values and in Z-scores. The AD-SoS (m/s) was the 
ultrasound velocity inside the finger and was derived from the measurement of the 
time interval between emission and reception of the ultrasound signal, considering 
the first signal with a minimum amplitude of 2 mV at the receiver probe. The BTT 
(μsec) reflected the bone characteristics without the interference of the soft tissue by 
calculating the difference between transmission time in soft tissue and bone and 
transmission time in soft tissue. (14) The Z-scores were determined on the basis of the 
reference values related to sex and age (AD-SoS Z score (age); BTT- Z-score (age)) or 
sex and height (AD-SoS Z score (height); BTT Z-score (height)). The Z-scores were 
obtained from a large Italian population provided by the manufacturer. (41)  
 Additionally, age, sex, gestational age at birth, weight, height, BMI and pubertal 
development were recorded. Weight (kg) was measured using an electronic digital 
scale (SECA MOD701) to the nearest 0.1 kg. Height (cm) was determined using a 
vertical stadiometer (SECA MOD240) to the nearest 0.1 cm. Body mass index (BMI; kg/
m2) was calculated by dividing weight (kg) by the square of height (m2). Pubertal 
development was self-assessed from pictures showing the different Tanner stages. (42) 
The children were asked to indicate which picture most resembled their current 
appearance.   
Statistical analysis
The statistical analysis was performed using the Statistical Package for the Social 
Sciences (IBM SPSS Inc., Chicago, IL, USA, version 22.0). All results were expressed as 
mean ± SD. Four statistical methods were used for the analysis of the association 
between pQUS and DXA. First, the Pearson’s correlation coefficients (r) were calculated 
for evaluation of the correlation between continuous values as well as the Z-scores of 
DXA and pQUS. The correlation coefficients were determined for every outcome for 
the total group as well as for boys and girls separately. Secondly, the partial correlation 
coefficients were determined to correct for possible confounders on the original 
correlation between DXA and pQUS.  Possible confounders of bone development, 
such as age, sex, gestational age, weight, height, BMI and Tanner stages at follow-up 
were included in the analysis. Only three of these confounders, namely gestational 
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age, height and BMI were used to calculate partial correlation coefficients, because of 
the limited number of participants in this study. The three confounders were chosen 
based on calculating whether they correlated significantly with DXA and pQUS 
measurements. Thirdly, a Bland-Altman analysis was performed to evaluate the 
agreement between both techniques using the Z-scores of either DXA and pQUS. 
Plots were created with the mean of two Z-scores within the same subject resulting 
from the two techniques on the horizontal axis and the difference of the Z-scores on 
the vertical axis. Finally, a cross tabulation was performed and the sensitivity, 
specificity as well as positive and negative predictive values were calculated, where 
DXA was considered as the gold standard. In agreement with the ISCD, a DXA Z-score 
less than or equal to -2.0 SDS should be considered as low bone mineralization. (36) A 
Z-score between -1.0 and -2.0 was considered as reduced (43) and a Z-score above -1.0 
SDS is normal. For the current study a cut-off value of -1.0 SDS was used for the 
assessment of low or normal bone mineralization, in the absence of participants with 
a Z-score less than -2.0.
A two tailed p- value of < 0.05 was considered statistically significant.
Results
Patient characteristics
The baseline characteristics of the participants (total group as well as boys and girls 
separately) are presented in Table 1. Anthropometric characteristics, gestational age 
at birth and pQUS measurements at follow-up were comparable between boys and 
girls. No statistically significant differences were found.  
Correlation
Table 2 presents the correlation coefficients of DXA and pQUS measurements for the 
continuous values. The correlation coefficients between the DXA and both pQUS 
measurements (BTT; AD-SoS) showed statistical significance, though the r value was 
low. The correlation coefficients between DXA and BTT were higher, ranging from 
0.341 to 0.462 (p<0.05), compared to correlation coefficients between DXA and 
AD-SoS, ranging from 0.291 to 0.345 (p<0.05). In comparison, boys showed a 
statistically significant and slightly higher correlation, which was not found for girls 
(boys: 0.468-0.585, p<0.05 versus girls: 0.008-0.335, p>0.05). Nevertheless, the 
differences found between boys and girls, calculated with the Fisher’s r-to-Z 
transformation, were not statistically significant, except for lumbar spine BMD and 
AD-SoS (p=0.039).  
 Table 3 presents the correlation coefficients for the Z-scores. AD-SoS Z-score (age) 
and BTT Z-score (age) showed a statistically significant but weak correlation with DXA 
Z-scores (0.327-0.401, p=<0.05). The correlation coefficients for BTT Z-scores (age) 
were higher than those for AD-SoS Z-scores (age). Since the Z-scores (height) showed 
no statistically significant correlation coefficients, they were not further evaluated. In 
comparison, the Z-scores (age) of boys showed a statistically significant correlation 
coefficient in contrast to girls (boys: 0.436-0.520,p<0.05 versus girls: -0.026-0.274, 
p>0.05). In general, the difference found between boys and girls, calculated with the 
Fisher’s r-to-Z transformation, was not statistically significant, except for lumbar spine 
Z-score and AD-SoS Z-score (age) (p=0.027). 
 As an example, Figure 1 illustrates an overlay scatterplot of the correlation 
coefficients between the AD-SoS Z-score (age) and the whole body Z-score for boys 
Table 1   Baseline characteristics and bone parameters for participants
Total (n=60) Boys (n=31) Girls (n=29) p-value
Age (y) 10.0 ± 0.5 9.9 ± 0.5 10.0 ± 0.6 0.78
Gestational age (weeks) 29.4 ± 1.7 29.2 ± 1.4 29.6 ± 1.9 0.27
Weight (kg) 31.1 ± 5.5 30.9 ± 4.4 31.3 ± 6.5 0.79
Height (cm) 139.3 ± 5.9 139.8 ± 6.3 138.7 ± 5.4 0.45
BMI (kg/m2) 16.0 ± 2.3 15.7 ± 1.4 16.2 ± 3.0 0.43
Tanner stage pubic hair (n/stage) 46/I; 13/II; 1/III 25/I; 6/II 21/I; 7/II; 1/III 0.64
Tanner stage mammae 22/I; 6/II, 1/III - 22/I; 6/II, 1/III -
DXA measurements Total (n=60) Boys (n=31) Girls (n=29) p-value
Whole body BMC (g) 1123.5 ± 145.0 1136.8 ± 156.4 1109.3 ± 133.0 0.47
Whole body BMD (g/cm2) 0.851 ± 0.064 0.859 ± 0.061 0.842 ± 0.066 0.29
Whole body Z-score 0.4 ± 1.0 0.5 ± 1.0 0.3 ± 1.0 0.49
Lumbar spine BMC (g) 24.5 ± 4.2 24.2 ± 4.5 24.8 ± 4.0 0.57
Lumbar spine BMD (g/cm2) 0.601 ± 0.084 0.580 ± 0.085 0.623 ± 0.078 0.05
Lumbar spine Z-score -0.1 ± 1.1 -0.2 ± 1.3 0.1 ± 1.0 0.32
pQUS measurements Total (n=60) Boys (n=31) Girls (n=29) p-value
AD-SoS (m/s) 1830.9 ± 72.7 1814.2 ± 75.8 1848.8 ± 65.8 0.07
AD- SoS Z-score (age) -2.3 ± 1.7 -2.7 ± 1.9 -2.0 ± 1.5 0.15
AD-SoS Z-score (height) -2.2 ± 1.8 -2.5 ± 2.1 -1.9 ± 1.6 0.23
BTT (μsec) 0.8 ± 0.3 0.8 ± 0.3 0.7 ± 0.3 0.57
BTT Z-score (age) -0.9 ± 1.5 -0.9 ± 1.7 -0.8 ± 1.2 0.77
BTT Z-score (height) -1.0 ± 1.4 -1.0 ± 1.6 -1.0 ± 1.3 0.95
All data are presented as  mean ± SD. P-values of the difference between boys and girls were calculated 
using an unpaired T-test.
AD-SoS, amplitude-dependent speed of sound; BTT, bone transit time; BMC, bone mineral content; BMD, 
bone mineral density; Z-score (age), Z-score adjusted for sex and age; Z-score (height), Z-score adjusted 
for sex and height. 
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and girls. Other pQUS and DXA measurements revealed comparable scatterplots. 
Partial correlation
Table 4 presents the original correlation coefficients and the partial correlation 
coefficients adjusted for gestational age, height and BMI for the continuous values 
and the Z-scores (age). The adjustment for the three confounders induced a further 
decrease of the correlation coefficients. On average, the remaining coefficients, 
although significant, were very weak. 
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Figure 1   Overlay scatterplot
Scatterplot for the correlation coefficients between AD-SoS Z-score (age) and whole body Z-score for boys 
and girls. The circles and the continuous line represent boys. The squares and the broken line represent 
girls.
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Agreement
The agreement was considered for all parameters. Only the Bland-Altman plot of the 
whole body Z-score and the AD-SoS Z-score (age) will be presented, because the 
other plots showed comparable results (Figure 2). The agreement between the two 
techniques was low, based on the following results. First, the mean difference 
between the Z-scores as presented in figure 2 was 2.73 and thereby significantly 
different from zero determined using a paired T-test (p-value: 0.011). Thereby, the 
95%-limits of agreement in this figure had a large interval between -0.54 and 6.00. 
Lastly, the plot showed that the differences of the two Z-scores (whole body Z-score 
minus AD-SoS Z-score (age)) were negatively dependent on the mean. This means 
that the difference between DXA and pQUS Z-scores increased with a lower mean 
Z-score, leading to an increasing disagreement between the two techniques while 
assessing bone mineralization for lower Z-scores.
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Figure 2   Bland-Altman plot
The Bland- Altman plot presents the agreement between whole body Z-score measured by dual-energy 
X-ray absorptiometry and AD-SoS Z-score (age) measured by phalangeal quantitative ultrasound. The 
middle horizontal line represents the mean difference of the Z-score; the upper and lower horizontal lines 
represent the 95% limits-of-agreement.
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Cross tabulation
Cross tabulation was performed for all combinations of pQUS and DXA measurements. 
The number of pQUS measurements with a Z-score below -1.0 SDS was higher 
compared to DXA. The sensitivity for all measurements ranged from 33% to 92%. The 
specificity ranged from 16% to 68%. The positive and negative predictive values 
ranged from 4% to 38% and 82% to 97%, respectively.
 As an example, Table 5 shows a cross table for the BTT Z-score (age) and the 
lumbar spine Z-score. This table revealed the best agreement of all measurements, 
but the specificity, sensitivity, positive predictive value and negative predictive value 
in general, were low. The sensitivity and specificity for BTT Z-score (age) in comparison 
with lumbar spine Z-score were 69% and 68%, respectively, and for the positive and 
negative predictive value this was 38% and 89%, respectively. Overall, we found a 
large discrepancy between the two methods for discriminating a patient with a 
normal or reduced bone mineralization. 
Discussion
This study evaluated two different diagnostic techniques for bone development in 
former preterm born children, who are at risk for impaired bone mineralization. Four 
statistical tests showed that the results of dual-energy X-ray absorptiometry scan 
(DXA) and phalangeal quantitative ultrasound (pQUS) had a significant weak 
correlation that further decreased after adjustment for confounders. In addition, 
there was a low agreement between the two techniques and a discrepancy in differ-
entiating the same children with normal or reduced bone mineralization. 
 The correlation coefficients were calculated for the continuous values as well as 
for the standard deviation scores (Z-scores) based on reference data. According to 
Baroncelli et al (9) the Z-score is the more appropriate value to express bone 
mineralization in children. The DXA Z-scores were available adjusted for sex and age, 
while the pQUS presented two types of Z-scores, either adjusted for sex and age 
(Z-score (age)) or sex and height (Z-score (height)). In our study the continuous values 
and Z-scores (age) showed statistically significant but weak correlations with DXA 
measurements, whereas correlation coefficients between DXA Z-scores and pQUS 
Z-scores (height) revealed to be non-significant. This is in accordance with the 
reference data provided by Barkmann et al (44), who found that the QUS signals 
correlated less with height compared to age. Therefore the Z-scores (height ) were left 
out for further analysis. 
 Our analysis showed different results for boys and girls. Only boys had statistically 
significant correlations for continuous values as well as Z-scores when comparing 
pQUS and DXA. This is in agreement with the study of Halaba et al (28), who found a 
significant correlation between QUS and DXA in boys (0.40-0.47, p=0.000) and no 
correlation in girls. They evaluated 150 healthy Caucasian patients aged from 14 to 19 
years. According to Halaba et al, the gender-related bone differences could be related 
to puberty development and influence of bone size as a result of earlier skeletal 
maturation in girls compared to boys. Our children had a lower age range and were 
mainly prepubertal. We do not have an explanation for this phenomenon and 
therefore suggest that these gender differences should be further investigated.
 The association between QUS and DXA has previously been evaluated in a 
number of studies. (10, 12-33, 45, 46) Table 6 presents an overview of these studies. The 
results are inconsistent and difficult to compare to our study, partly because a number 
of studies investigated different populations or used different measurement sites of 
QUS. Seven studies used the same equipment as we did, comparing pQUS to DXA. (14, 
16, 18, 22, 23, 28, 46) The correlation coefficients between pQUS and DXA found by 
Pluskiewicz et al (18) and Di Mase et al (14) are in agreement with our calculations 
(0.45-0.56 and 0.42-0,52, respectively). As mentioned above, Halaba et al (28) found 
positive correlations only in boys using continuous values, comparable to our study. 
In contrast to our results, Halaba et al found no correlation for both sexes using the 
Z-scores. Nevertheless, in agreement with our analyses these studies found 
comparable poor correlation coefficients and thereby questioning the equivalence of 
pQUS and DXA. In contrast, two other studies found relatively stronger correlations 
for the continuous values (0.59-0.74, p<0.05), but no significant correlations while 
comparing Z-scores, except for the AD-SoS Z-score and whole body Z-score which had 
a poor significant correlation coefficient (0.31, p<0.02). (16, 22) These five studies 
evaluated children and adults at an age ranging from 4-27 years, while Catalano et al 
(23, 46) evaluated postmenopausal women. The younger and smaller age range in our 
group could be an explanation for the different results we found.  
 Furthermore, Table 6 gives an overview of the authors’ conclusion per study, 
showing different interpretations for in general a relatively low correlation between 
Table 5   Cross table of the BTT Z-score (age) measured by pQUS and the lumbar 
spine Z-score measured by DXA 
DXA – Lumbar spine Z-score
pQUS – BTT Z-score (age) Z-score ≤-1 Z-score >-1
Z-score ≤-1 9 15
Z-score >-1 4 32
Cut-off value = -1.0 SDS (≤ -1: reduced bone mineralization; >-1: normal bone mineralization)
pQUS, phalangeal quantitative ultrasound; DXA, dual-energy X-ray absorptiometry; BTT, bone transit 
time; Z-score (age), Z-score adjusted for sex and age.
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Table 6   Literature study of studies investigating the association between  
the measurements of DXA and QUS
Author (yr)
QUS Age (yr) Sample 
size
Morbidity Statistical method Outcome Pearson’s correlation 
coefficients (r)
Authors’ 
conclusionQUS DXA
Pluskiewicz (2002) (18) Phalanges 9 - 23 30 ESRF LCC, SCC AD-SoS LS/TB BMD, Z-scores 0.45-0.56 +
Halaba (2005) (28) Phalanges 14 - 19 150 Healthy LRA, MRA AD-SoS, Z-score LS/TB BMD, TB BMC, Z-scores M: 0.40-0.47, F/Z-scores: NS -
Di Mase (2012) (14) Phalanges 4 - 18 25 Idiopathic SH PCC, MRA AD-SoS, BTT, Z-scores LS BMD, Z-score 0.42-0.52 +
Catalano (2013) (46) Phalanges 43 - 78 80 Postmenopause SCC AD-SoS, BTT, UBPI, T-scores FN BMD T-score, LS BMD 
T-score
FN T-score: 0.61, LS T-score: 
0.55
+
Gonçalves (2014) (16) Phalanges 6 - 27 70 21-OHD PCC, SCC, CT, ROC AD-SoS, BTT, UBPI, Z-scores LS/TB BMD, Z-scores 0.59-0.72, Z-scores: no 
correlation
+/-
Bąk-Drabik (2016) (22) Phalanges 10 - 15 51 IBD PCC, SCC AD-SoS, Z-score LS/TB BMD, Z-scores Continuous: 0.69-0.74, TB 
Z-scores: 0.31, LS Z-scores: NS
-
Catalano (2017) (23) Phalanges 60 - 70 60 Postmenopause, BC  SCC, MRA AD-SoS, BTT, UBPI LS/FN BMD AD-SoS/FN BMD: 0.32 +
Olzynski (2015) (24) Radius/tibia/
phalanges
30 - 97 4123 Healthy PCC SOS FN, hip, LS BMD 0.21-0.29 -
Hartman (2004) (17) Radius/tibia 4 - 18 40 CRD PCC, LRA SOS, Z-score LS BMD, Z-score Radius: 0.54, Tibia: NS +
Hartman (2004) (32) Radius/tibia 5 - 18 41 Celiac disease LRA, MRA SOS, Z-score LS BMD, Z-score 0.3 -
Zuckerman-Levin (2007) (25) Radius/tibia 11 - 39 27 Turner’s syndrome PCC SOS, Z-score LS/FN/TB BMD, Z-scores 0.46-0.63 -
Gianni (2008) (10) Radius/tibia 4 - 6 45 Ex-preterm PCC SOS, Z-score LS BMD, Z-score NS -
Mora (2009) (26) Radius/tibia 4 - 22 88 HIV-infection MRA, X2 test SOS, Z-score LS/TB BMD/BMC, Z-scores 0.58-0.66 +
Christoforidis (2010) (30) Radius/tibia 4 - 18 27 Hemophilia A PCC, Cк SOS, Z-score LS BMD, Z-score Tibia: NS, Radius: -0.019 -
Christoforidis (2011) (31) Radius/tibia 2 - 16 20 CKD PCC, SCC, MRA SOS, Z-score LS BMD, Z-scores Tibia: 0.129, Radius: 0.022 -
Williams (2012) (33) Radius/tibia 5 - 20 621 Healthy, CF, obese CT, BAA SOS, Z-score LS BMD, BMAD, Z-scores - -
De Schepper (2012) (45) Radius 12 - 38 64 CF LRA, MRA SOS, Z-score TB BMC/BMD, Z-scores 0.39-0.44, Z-scores: NS -
Chong (2015) (29) Radius 7 - 11 134 Healthy CT, BAA, ROC SOS, Z-score TB BMD, Z-score - -
Van Rijn (2000)(13) Tibia 7 - 23 146 Healthy MRA SOS LS/TB BMD, BMAD 0.63-0.81 +
Tuna (2008) (12) Tibia 40 - 72 200 Postmenopause LRA, SCC, CT, ROC SOS LS/FN BMD 0.29-0.36 -
Sundberg (1998) (20) Calcaneus 11 - 16 280 Healthy PCC SOS, BUA, SI TB, LS, FN  BMD 0.44-0.70 -
Falcini (2000) (15) Calcaneus 6 - 18 53 Juvenile arthritis PCC, LRA BUA, Z-score LS BMD, Z-score 0.83 +
Sani (2011) (19) Calcaneus 6 - 17 8 Thalassemia PCC SOS, BUA TB/LS BMD BUA: 0.492-0.507, SOS: NS +/-
Xu (2014) (21) Calcaneus 5 - 19 392 Healthy PCC SOS, BUA, SI TB BMC/BMD 0.690-0.693 +
Weeks (2016) (27) Calcaneus 4 - 18 389 Healthy PCC, LRA, MRA BUA TB/LS/FN BMD, BMC 0.47-0.56 -  to +/-
Numbers in brackets behind the author names reflect the reference. Morbidity: ESRF, End-stage renal failure; 
Idiopathic SH, Idiopathic subclinical hypothyroidism; BC: breast cancer; CRD, Chronic rheumatic disease; 
IBD, Inflammatory bowel disease; CF, Cystic fibrosis; 21-OHD, 21-hydroxylase deficiency; CKD, Chronic 
kidney disease. 
Statistical methods: PCC, Pearson’s correlation coefficient; LCC, linear correlation coefficient; SCC, Spearman’s 
correlation coefficient; CT, cross tabulation; ROC, receiver operating characteristic analysis; LRA, linear 
regression analysis; MRA, multiple regression analysis; BAA, Bland-Altman analysis; Cк, Cohen к analysis.
Outcome: LS, lumbar spine; TB, total body; FN, femoral neck; AD-SoS, amplitude-dependent speed of 
sound; SOS, speed of sound; BTT, bone transit time; UBPI, ultrasound bone profile index; BUA, broadband 
ultrasound attenuation; SI, stiffness index; BMC, bone mineral content; BMD, bone mineral density;  BMAD, 
bone mineral apparent density; NS, not significant; F, female; M, male.
Author’s conclusion: +, good association; +/-, moderate association ; -, weak/poor association.
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QUS and DXA. An advantage of our study was that, besides the small range of age of 
the participants, more statistical tests were used to compare both techniques, leading 
to a more reliable overall conclusion.
 The partial correlation coefficient was used to evaluate the effect of possible 
confounders on the original correlation. To our knowledge only a few studies that 
evaluated the association between pQUS and DXA looked at the influence of possible 
confounding factors with regard to correlation coefficients. Halaba et al (28) and Di 
Mase et al (14) performed a multiple linear regression analysis to evaluate the effect of 
anthropometric characteristics on DEXA or QUS measurements using confounders 
such as age, sex, weight, height and BMI. 
 Only four studies used other statistical tests such as the Bland-Altman analysis 
(29, 33) and cross tabulation. (12, 16, 29, 33) Although these studies looked at tibial and 
radial QUS, their conclusions are consistent with our findings of poor agreement 
between the two techniques and a large discrepancy in differentiating the same 
children as having normal or reduced bone mineralization. 
 The overall absence of an association between DXA and pQUS for continuous 
values and Z-scores could be explained by the fact that measurements were influenced 
by different bone composition and bone mineralization at different sites. In addition, 
children may be in different growth phases and some bones may grow faster than 
others, which potentially could have an effect on the bone development and thereby 
may have affected the results. Quantitative ultrasound can be applied on various 
parts of the extremities, such as the phalanx, radius, tibia and calcaneus. Recent 
studies suggest that the phalanges may be the most appropriate measurement site, 
because this site is sensitive to changes in bone status. (47-49)
 For the assessment of pQUS we chose the DXA scan as the golden standard for 
comparison.  Quantitative Computed Tomography (QCT), or peripheral QCT may have 
been good alternatives and may have provided more accurate results and additional 
information on bone strength. (50) However, QCT uses a relatively high radiation dose, 
especially for young children in research settings, and for both methods normative 
data for a pediatric population are lacking. (50,51) DXA has been recommended as an 
appropriate method for clinical densitometry of infants and young children by the 
International Society for Clinical Densitometry (ISCD) in 2013. (52) The advantage of 
QUS is the ability to easily repeat measurements, giving the opportunity to follow the 
development of bone over time, especially under circumstances were diagnostic 
tools as DXA are not possible or available. Our results were limited to a single 
measurement per child. Therefore intra-individual repeated measurements with QUS 
should be further evaluated with regard to the reliability to predict the intra- individual 
development of bone over a longer time period.  
 Our study had several limitations. The number of patients was limited. Firstly, this 
limited the number of confounders we were able to use for calculation of the partial 
correlation coefficient. Secondly, low bone mineralization with a significant Z-score 
below 2.0 SD was only found in 2 out of 60 children for lumbar spine measurements, 
and none for  the whole body measurements. To increase the number of children with 
deviant bone mineralization we chose a cut-off value of -1.0 SDS for determination of 
normal or low bone mineralization, in contrast to general practice. This is in accordance 
with the study of Gianni et al, who evaluated the prevalence of Z-scores < -1.0 SDS for 
tibial or radial QUS (10), because the QUS values were higher in comparison with DXA. 
According to the literature a similar cut-off value can be used for AD-SoS and BTT. (14, 41) 
 In general, the Z-scores were based on reference data derived from different 
populations. The reference data of the DXA Z-scores were based on an U.S. population, 
while the reference data for the pQUS Z-scores were recorded from an Italian 
population. It is not known whether the populations are comparable to our population 
and theoretically this might explain some of our differences. 
Conclusion
This study demonstrated a weak association between DXA and pQUS measurements, 
established from a statistically significant weak correlation, a poor agreement and a 
discrepancy in differentiating the same children with normal or reduced bone 
mineralization. Therefore, pQUS measurements are not equivalent to DXA for the 
evaluation of bone health and cannot replace the DXA in former preterm born 
children at the age of 9 to 10 years.
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General discussion
As described in chapter 1 (Part 1), preterm birth is a critical event for the infant, with 
major impact on health directly after birth, but also with high risk of unfavorable 
long-term development. (1) The survival of preterm infants has increased significantly 
during the last decennia, consequently it is important to further improve postnatal 
treatment to achieve the best possible development.(2) During the third trimester, the 
fetus exhibits an exponential development of all organ systems leading to optimal 
growth, neurodevelopment and bone development. Ideally, after birth, the treatment 
of preterm infants should aim to continue the intra-uterine development, to achieve 
growth and functional development comparable to healthy term born infants. (3, 4) 
 Nutrition in the early postnatal period has been recognized as a key determinant 
for neonatal outcomes. (5, 6) For this thesis we evaluated nutritional interventions in 
very low birth weight infants, comprising the group of very, and extreme preterm 
infants, with emphasis on the early postnatal period because this has been shown to 
be a critical period in the transition from constant rich flow of nutrient supply in 
healthy pregnancies, through the umbilical cord to enteral and parenteral supply of 
nutrients with risk of under- or overnutrition and consecutively impaired development. 
 The aim of the thesis was to study effects of nutritional interventions on growth, 
development and bone composition in very low birth weight infants. 
 Part 2 of this thesis presents the results of clinical studies on the effect of amino 
acid intake on growth and neurodevelopment, while the studies presented in Part 3 
assessed the calcium and phosphorus metabolism as determinant for bone mineralization 
and growth. 
Amino acids and postnatal growth 
Chapter 1 described that the preterm born infant has amino acid requirements 
comparable to the fetal requirements. Fetal amino acid concentrations are higher 
than maternal concentrations, mostly obtained by production within the placenta 
and based on an active, carrier-mediated transport. (7, 8) Quantitative balance studies 
showed that amino acid uptake exceeded the amount necessary for protein accretion, 
indicating that the human fetus oxidizes amino acids to generate energy. (9) Fetal 
amino acid requirements are high to provide sufficient substrate to enable a high 
protein synthesis rate with adequate growth during early gestation. (10) Animal studies 
have shown that protein deficits in fetuses lead to growth restriction, but also 
adversely affect organ development such as that of the kidney, pancreas and brain, 
thereby inducing changes with long-term consequences such as hypertension and 
diabetes and functional outcome. (11, 12)
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Chapter 3 compared a new feeding regimen with higher amounts of amino acids in 
parenteral nutrition, according to international recommendations, in combination 
with the intention of rapid increment of enteral feeding (Cohort 2), to the previous 
standard nutritional protocol with lower amounts of amino acids and energy (Cohort 
1). (4, 13-15) Very low birth weight infants were included prospectively during two 
consecutive years. We demonstrated that the new parenteral nutrition provided a 
significant higher amount of amino acids during the first week of life and this was 
associated with a significant higher weight gain in appropriate for gestational age 
born infants until week 5 postnatally. This short-term improvement was in agreement 
with the retrospective cohort study by Berry et al (1997) who determined that amino 
acid intake in the first two weeks of life in very low birth weight infants was an 
independent positive prognostic determinant of growth. (16) Olsen et al compared 
more than 500 preterm infants below 30 weeks gestational age from 6 different 
neonatal intensive care units. (17) They found that, even after adjustment for a number 
of clinical factors, differences in weight gain between units could be explained by the 
variation in nutritional intake. Altogether, these results indicate that the administration 
of a sufficient amount of amino acids, not only can reverse a negative nitrogen balance 
in preterm infants, as has been described by a number of studies, but also has an 
effect on growth. (18-24) However, a further finding of our cohort study was that despite the 
higher weight gain rates from the second week onwards, all infants still demonstrated 
a steady decrease in standard deviation score (SDS) for weight that resulted in a mean 
loss of 2 SDS for both cohorts around term corrected age, indicating that our nutritional 
improvement still was insufficient. Infants in both cohorts developed cumulative deficits 
in protein and energy intake relative to the daily requirements, that were not compensated 
during the observational period of five weeks. Embleton et al. demonstrated that 
postnatal growth retardation in preterm infants was associated with a nutritional 
intake of protein and energy below the current recommendation during the first 
2 weeks of life. (25) 
 The insufficient nutritional intake as seen in our cohort, despite improvement of 
parenteral intake, can be explained by an insufficient (i.e. not meeting the 
requirements) amount of protein and energy provided with enteral feeding. According 
to our revised nutritional protocol full enteral feeding was achieved significantly 
earlier and consecutively the duration of parenteral nutrition was significantly shorter. 
Despite early fortification of human milk, Cohort 2 achieved the recommended intake 
of protein only at median day 10 (min-max: 4–35 days) while 16% of the cohort never 
reached a recommended enteral protein intake of 3.8 gram/kg/day. More than 90% of 
infants in both cohorts received mother’s own milk (MOM). The exact composition of 
MOM was not known and therefore exact protein intake could not be calculated, a 
limitation of our study. As elaborated in chapter 1 the composition of human milk is 
dependent on the gestational age of the infant and the duration of lactation. During 
the last 30 years several studies have tried to define reference values for the 
composition of human milk. Most of them evaluated human milk provided by mothers 
of more mature preterm infants than nowadays treated and most of them analysed 
only a small number of samples and at different times. (26-52) Furthermore the method 
of protein determination may influence the results. (41) This may explain the great 
diversity of data concerning the composition of human milk. For the study presented 
in chapter 3 we used the reference of Anderson et al since this has frequently been 
cited as reference for the composition of human milk and therefore facilitates the 
comparison with other publications. (36) Anderson et al. evaluated, besides term and 
donor milk, human milk from mothers of 14 preterm infants born between 28 and 36 
weeks GA. Samples were taken at day 3, 7 and 14 after birth. Anderson et al also 
recognized, as many other studies, a decreasing amount of protein during the 
lactation period with an assumed protein content of 1.4 g/dl after two weeks. (36) In 
contrast, more recent data presented by Bauer et al investigated a large sample (102) 
of mothers of preterm infants with a gestational age between 23 and 33 weeks who 
were followed according to a standardized procedure for 8 weeks. (50) Both studies 
used 24 h samples. Analyses of milk samples performed by Bauer et al during the first 
postnatal week revealed a mean protein content of 2.8 – 2.2 g/dl depending on the 
gestational age and a decrease in protein content during the lactation period with a 
mean protein concentration of 2.1 g/dl for preterm infants after eight weeks. To rule 
out an underestimation of nutritional intake, the intake for both cohorts was also 
calculated using the data provided by Bauer et al. with a varying protein intake 
between 2.5 and 2.0 gram. This resulted in higher nutritional intakes and shorter time 
to achieve the recommended intake, however for both cohorts the cumulative deficits 
were not resolved by the end of the observational period of five weeks. Therefore the 
conclusion was that optimal nutritional intake, as actually recommended, cannot be 
achieved with currently available standard human milk fortifiers. We suggest that 
standardized human milk fortifiers should provide a higher amount of protein, or 
otherwise that protein content of human milk should be adapted to the individual 
requirements of the infant based on individual analyses of MOM.
 In contrast to our findings two recent observational studies, evaluating comparable 
cohorts of preterm infants, demonstrated that it was possible to prevent cumulative 
nutritional deficits in the early postnatal period and that this was associated with less 
postnatal growth restriction. (53-55) To understand the differences in outcomes 
compared to our results, it is necessary to look in detail at differences between the 
nutritional protocols as well as the interpretation of the data. Senterre et al evaluated 
a cohort of 102 preterm infants with birth weight below 1250 grams. The first study 
was a description of weight changes until discharge in relation to nutritional intake 
with a sub-categorization of infants into appropriate (AGA) and small (SGA) for 
gestational age. (53) The second study evaluated 84 infants of the same cohort with a 
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subdivision of infants according to gestational age at birth below 28 weeks or 
between 28 and 30 weeks. (54) Infants in this study experienced a negligible cumulative 
protein deficit during the first two weeks and had the maximum decrease of 0.9 SDS 
for weight by the second week that improved to a loss around -0.5 SDS for weight 
after six postnatal weeks. Infants of this study received significantly higher protein 
intakes during the first month than infants of studies that previously related postnatal 
nutritional intake to postnatal growth retardation. (25, 56, 57) 
 Maas et al compared two historical cohorts, evaluating an enhanced volume 
increase of enteral feeding and consecutively shorter duration of parenteral nutrition 
administration. (55) Both cohorts had a decrease of –0.15 SDS for weight. Recently 
Maas et al. presented a comparable cohort study evaluating the same nutritional 
intervention exclusively in extremely preterm infants. (58) All of these studies have in 
common that the first week nutritional intake affected growth at discharge, and 
differences in outcome, among other things, compared to our results, can be 
explained by differences in nutritional protocols.  
 In comparison to the studies presented by Senterre et al., our cohorts started 
enteral nutrition on the first day of life (mean 0.96 ± 0.39 vs. 0.91± 0.22 days), while for 
the total Senterre cohort enteral feeding was introduced at a mean of 3.9 ± 4.2 and 2.9 
± 4.2 days for AGA and SGA infants respectively. Our infants received parenteral 
nutrition (PN) for a mean duration of 12.8 ± 3.8 vs. 10.6 ± 3.6 days, while full enteral 
feeds were achieved by a mean of 13.6 ± 3.4 vs. 11.6 ± 3.6 days. According to Senterre, 
PN was discontinued at a mean age of 28.6 ± 18.8 and 21.3 ± 15.1 days. (53) In the 
second study evaluating infants born below 30 weeks’ gestation introduction of 
enteral feeding occurred even later and duration of PN was even longer. (54) Therefore 
the higher nutritional intake in the Senterre cohort was predominantly achieved by 
PN. Twelve infants of the Senterre group (about 10 % of the total study group) received 
individualized fortification after human milk analysis. It remains unclear how these 
analyses were used in the calculation of the nutritional intake. One may speculate that 
this may have had a substantial effect (in combination with continuing PN intake) on 
the improved weight gain of their patients compared to our patients. Maas et al., in 
comparison to the cohorts studied in this thesis, provided a higher amount of protein 
and energy with human milk fortifier (protein: 1.1 – 1.6 vs. 0.8 g/dl; energy: 15 - 20 vs. 
15 kcal/dl). (55, 58) In this way, we conclude that higher supplementation of protein is 
needed with early increment of enteral feeding to prevent postnatal growth 
retardation. Finally, the differences in nutritional management used in all the above 
mentioned studies, reveal the essential scientific question concerning optimal 
feeding for preterm infants. It is not known what the optimal way of feeding is, either 
by parenteral or enteral route. As explained in the introduction, both ways have their 
(dis)-advantages. Most studies demonstrate a positive effect of human milk as 
stimulation of gastrointestinal maturation, support of infant host defence, improved 
neurodevelopment, as well as protection against necrotizing enterocolitis. (59, 60) 
Therefore we suggest that improvements of enteral feeding strategies with human 
milk need to be further investigated.
 A second aspect of differences in the results among the above mentioned studies 
is based on the fact that AGA and SGA infants seem to have a different growth pattern. 
We performed sub-group analyses for AGA and SGA infants of both cohorts. 
Nutritional intake was not different between the sub-groups. The sub-groups of AGA 
infants for different gestational ages within a cohort showed no differences in growth 
pattern, while SGA infants, comprising 16 and 18 percent of both cohorts, showed the 
highest weight gain and a lower decrease in SDS for weight until term corrected age 
(TCA) compared to AGA infants. (chapter 3, figure 2) A comparable growth pattern 
was seen for SGA infants (20%) in the Senterre study, even ending up with a positive 
change in SDS for weight at discharge. (53) For the second study, Senterre et al 
included SGA in the subdivided cohorts according to gestational age, thus combining 
AGA and SGA infants in one group. This may have had a positive effect on the changes 
in SDS score for the total subgroup. The historical cohorts evaluated by Maas et al 
comprised a comparable number of SGA infants, but sub-group analyses where not 
performed. (55, 58) In addition to the retrospective studies, Maas et al. presented a 
small randomized trial that evaluated postnatal growth in relation to a further 
increment of protein in human milk fortifiers. (61) In this study a higher increase of 
protein did not further enhance the growth, while the lower protein intake group 
seemed to have none significant better weight changes. Nearly 40 percent of this 
group were classified as SGA. We speculate that in this randomized trial, the relatively 
lower protein intake for SGA infants may have been sufficient for an optimal catch-up 
growth and thereby may have biased differences resulting from nutritional intake. 
Appropriate for GA infants have demonstrated a normal growth potential until birth, 
therefore this sub-group of preterm infants should serve as a reference for the 
evaluation of optimal postnatal growth, while sub-group analysis of SGA infants is 
necessary as well, to define optimal growth in this group without increased risk of 
long-term negative consequences. (62) We conclude that AGA and SGA preterm 
infants have different protein requirements for optimal growth. Specific nutritional 
needs of SGA preterm infants are currently not known. We suggest that nutritional 
intervention studies, trying to specify the requirements of sub groups of AGA and 
SGA preterm infants, are needed.
 Chapter 4 presents the results of the long-term follow up of the same cohorts, 
evaluating changes in length and BMI. We were unable to demonstrate an effect of 
the first week nutritional intake on growth at age of nine to 10 years. Both cohorts 
were already able to catch up in length to standard deviation scores (SDS) within the 
range for the Dutch reference population and slightly lower BMI SDS by six months of 
corrected age with no further significant increment at the age of nine to 10 years. The 
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subgroup of SGA children needed more time, but showed a full catch-up in length at 
age nine to 10. Our findings are in contrast with a number of studies, among which the 
Dutch nationwide prospective study POPS, that followed growth development of 
very and extreme preterm infants. (63-68) These follow-up studies showed that weight 
and length until young childhood and early adulthood of AGA born children who 
developed an extra-uterine growth retardation remained small, and SGA children as 
well showed persistent stunting. Fast postnatal weight gain was associated with 
increase in BMI at young adulthood, thus a risk factor for development of metabolic 
syndrome. (69) Children evaluated for these studies were born between the 70ies and 
90ies of the last century and outcome was not related to nutritional intake. We 
speculate that the differences in outcome compared to our cohort may reflect in 
general, improvement of neonatal intensive care treatment, but also improvement in 
nutritional practices. However, despite the fact that growth of children in our cohorts 
approached the range of the reference population, AGA children remained below 
their initial birth SDS, indicating that further improvement of the nutritional protocol 
is needed. 
Amino acids and neurodevelopment
Chapter 5 describes the evaluation of infants of the above mentioned cohorts at 
corrected age of 24 months with emphasis on neurodevelopmental outcome, 
postnatal weight gain and head circumference in relation to the first week nutritional 
intake of protein and energy. Specifically boys who had received more protein and 
energy demonstrated a short-term improvement in postnatal weight gain, while 
catch-up growth in head circumference seemed to be improved as well. We found 
differences in the developmental scores between boys and girls. 
 The Bayley Scales of Infant Development (BSID II) were used for assessment of the 
cognitive (MDI) as well as motor (PDI) development. (70) Adequate testing requires on 
the one hand specifically trained and experienced psychologists and physical 
therapists and on the other hand the persisting cooperation of a small child. Thus, 
failure to reveal a test score can either be the result of lack of cooperation of an 
otherwise normal child or lack of ability to pay attention or capability to fulfill the 
tasks, both indicating a subnormal development. For 10 infants, comprising 18% of 
cohort 1, we were unable to define a MDI score. Based on written observations of the 
investigators (in addition to some available scoring results) and the parents’ concerns 
about child behavior we decided to categorize these infants into the group of 
sub-normal development (MDI/PDI < 85) and consecutively were able to include 
them in the logistic regression. Since the continuous scores were not available, these 
infants are missing in the linear regression analysis. Since all 10 children derived from 
the cohort with lower nutritional intake, there is a chance of underestimation of the 
effect of nutritional intake on the continuous scores. However, in clinical practice and 
for the individual child, the categorization into normal or sub-normal development 
may be more relevant, thus we suggest that the logistic regression analysis in our 
study represents the more relevant results. 
 Postnatal weight gain and head growth have been positively associated with 
mental and psychomotor development. (71-76) Improvement in head growth has 
specifically been associated with higher amino acids intake. (74, 77, 78) However, until 
now it has been difficult to prove the relationship between higher amino acid intake 
and improvement of neurodevelopment. There is no consensus on the positive effect 
of amino acids on neurological outcome. (79, 80) The comparison of different studies is 
hampered by diversity of nutritional interventions and various neurodevelopmental 
outcome measures. In contrast to most other studies we were able to directly relate 
the psychomotor indices to the individual nutritional intake of the first week. (79)
 Various multi-center follow-up studies have reported impaired functional 
outcome and a higher incidence of disabilities in preterm compared to term born 
children. (81-88) Numerous risk factors are known to negatively affect neurodevelop-
ment among which perinatal morbidities. For our cohorts the diagnosis and treatment 
of patent ductus arteriosus (PDA) was, together with male sex, the greatest negative 
determinant of neurodevelopment. The association of PDA with impaired neurode-
velopment has been a subject of a number of epidemiological studies. (89-91) While a 
validated explanation for the association currently is missing, none of the studies 
accounted for the nutritional intake of infants with PDA. A conservative measure of 
treatment of a PDA is fluid restriction and cautious enteral feeding, often at the 
expense of the daily required amount of nutritional intake. In our study group, infants 
with PDA received statistically significant less protein and energy during the first two 
weeks compared to infants without PDA. We speculate that not the PDA itself, but 
undernutrition in a period of rapid brain growth is an important determinant of the 
impaired outcome. The same may hold true for other perinatal diseases such as sepsis 
or necrotizing enterocolitis that in clinical practice often lead to a reduction in 
nutritional intake despite high nutritional needs. We suggest that evaluation of 
outcome in relation to prematurity related diseases should take into account the 
individual nutritional intake. 
 Besides perinatal conditions, gender has been reported to be an important 
determinant for outcome after preterm birth. In general, long-term follow-up 
evaluations of preterm infants have shown that boys are more at risk for unfavorable 
outcome than girls. (64, 92-94) Hintz et al. evaluated risk factors for adverse neurodevel-
opmental outcomes of preterm born children and found male gender to be an 
independent risk factor for severe impairment of psychomotor development at two 
years of age. (95) In accordance with these findings, boys in our cohorts had lower 
developmental scores than girls. However, the first week increase in protein and 
energy intake was associated with an increase in PDI score and significantly increased 
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the chance of having a normal PDI, specifically in boys. For girls higher protein and 
energy intake of the first week significantly increased the chance of normal MDI. 
Several nutritional intervention studies already indicated that boys may take more 
advantage of improvements of nutritional intake than girls. Lucas et al found that 
preterm boys fed preterm formula after discharge had a greater head circumference 
compared to preterm boys fed term formula, although this was not related to 
improvement in developmental scores. (96) Poindexter found that a higher intake of 
parenteral amino acids during the first postnatal week resulted in significantly less 
impaired growth of head circumference in male infants at 18 months corrected age. 
(97) Frondas-Chauty et al evaluated a French cohort of very preterm infants and found 
an association between in-hospital growth velocity and neurological outcome at 2 
years of corrected age. The association between early growth and neurodevelop-
ment was significantly stronger for boys than for girls, even after adjustment for a 
great number of different determinants of neurodevelopment. (98) This study did not 
include nutritional management in the statistical analyses, therefore a suggestion of 
gender specific benefits in relation to nutritional interventions in the early postnatal 
period based on the results of this study remains speculative. Van den Akker et al. 
assessed very preterm infants at the corrected age of two years after participation in 
a randomized trial that provided either parenteral glucose or glucose in combination 
with amino acids during the first three days after birth. (99) In this study boys had 
significantly more often a normal neurodevelopmental outcome if they had received 
amino acids from birth onwards. While girls tend to have a more favorable outcome 
compared to boys, girls who participated in this study showed no improvement in 
relation to the intervention. (99) 
 All of these studies indicate that specific nutritional interventions may be 
advantageous for male infants, especially when they are compared with groups that 
are underfed. The physiology of gender-specific nutritional requirements is not well 
understood yet. Boys and girls grow differently and experience a different metabolic 
and endocrine environment. (100-102) Male vulnerability has been related to faster 
growth and hence greater substrate demands compared to females, different exposure 
to sex steroids, impaired adaptive response to stress, as well as altered speed in 
maturation. (92, 103, 104) Further, studies demonstrated gender-specific differences in 
early brain maturation. (105-107) Animal studies evaluating perinatal insults demonstrated 
different effects in male and female offspring, for example a low protein intake 
resulted in increased blood pressure predominantly in male offspring, while a high fat 
diet caused high blood pressure in females and insulin resistance in male off-spring. (108) 
Different feeding regimens for male and female preterm infants have not been 
studied, and only few studies, as mentioned above, reported outcome after nutritional 
interventions separately for gender. These studies reported benefits of nutritional 
interventions only for boys, while girls seemed not to be affected. In contrast, girls in 
our study had an increased chance of normal development with higher intake of 
protein and energy. Our results indicate that both female as well as male infants are 
vulnerable to nutritional deficits, but with different needs. Furthermore our study 
comprised a short-term intervention with a positive effect on weight, as well as on 
neurodevelopment. In agreement with our study, Belfort et al found in a cohort of 
former preterm infants, that early linear growth was associated with better cognition, 
but also with an increased risk of overweight or obesity later in childhood. (109) 
 In summary, these findings indicate that short-term nutritional interventions can 
effect outcome positively in male as well as in female preterm infants, but the optimal 
nutrient composition, the amount and timing of nutritional intake, to achieve further 
improvement are currently unknown. There may be a critical window for nutritional 
interventions to achieve optimal neurodevelopment without increasing the risk for 
obesity. We suggest that further research is needed to evaluate gender specific 
nutritional requirements in preterm infants, while studies in general should take into 
account differences in outcome between boys and girls and therefore need to be 
adequately powered to detect a gender effect. Future studies should investigate the 
effect of gender specific nutritional protocols on growth and neurodevelopment. 
Calcium and phosphorus metabolism in the early postnatal period  
of preterm infants
Nutritional intake of calcium (Ca) and phosphorus (P) in general, aims to provide 
adequate amounts of minerals to achieve optimal bone mineralization, specifically in 
preterm infants who have the highest requirements during the immediate postnatal 
period. (110, 111) Inadequate intake of Ca and P increases the risk for impaired bone 
development and consecutively metabolic bone disease (MBD). (112, 113) Studies tried 
to define nutritional requirements, but it is often uncertain whether the nutritional 
intake of Ca and P provided to preterm infants is sufficient and is actually used for 
bone mineralization. (114-118) In daily clinical practice it is impossible to directly evaluate 
the effect of mineral intake on bone development, therefore biochemical parameters 
of the Ca - P homeostasis in blood and urine are frequently used to evaluate nutritional 
intake.
 Chapter 6 presents an observational descriptive study of Ca and P metabolism in 
the cohort of preterm infants that received improved parenteral mineral intake. 
Changes in biochemical parameters in urine and blood during the first five weeks 
after birth are described. Mineral imbalances as hypercalcemia, hypophosphatemia, 
hypercalciuria and high tubular phosphate reabsorption during the first week after 
birth were observed as well as an increasing alkaline phosphatase (ALP) and hyper-
phosphaturia in the following period, indicating insufficient supply of phosphorus as 
well as unfavorable ratios of calcium and phosphorus supplementation. Infants in this 
cohort received amounts of Ca and P within the recommendations of the guidelines 
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for parenteral and enteral intake for very low birth weight infants presented by the 
ESPGHAN. (4, 14) A number of studies demonstrated that adding Ca and P to the PN 
solution caused a positive mineral balance and increasing the amount of Ca and P 
increased the retention of both minerals. (119-124) None of these studies provided 
amounts that would equal the fetal accretion rate, probably because of limited 
solubility of parenteral fluids. The use of sodium-glycero-phosphate enabled us to 
obtain a stable PN solution with the recommended amount of Ca and P. (125) However, 
the mineral disturbances as seen in this study indicate that the composition of 
minerals may not have been adequate. The PN used for this study contained Ca and P 
with a molar ratio of Ca:P of 1.56:1. All of the above mentioned studies used varying 
ratios (0.9:1, 1.3:1, 1.7:1, 2:1). (119, 121, 122, 126) The Ca:P ratio for PN as recommended by the 
ESPGHAN varies between 1.3- 1.7:1 and is based on the fetal mineral accretion ratio 
(1.7:1) and the fixed ratio for hydroxyl-apatite (1.67:1). (127) In contrast, the American 
Society for Clinical Nutrition and Tsang et al. recommended ratios between 1:1 and 
1.3:1, thus comparatively higher intakes of P. (13, 128) Since the PN used in our study 
provided an amount and ratio of Ca and P according to ESPGHAN recommendations, 
the findings of this study indicate that the European recommendation needs to be 
adapted to higher P intake, thus lower ratios. Our results are in agreement with a 
recently published study by Mulla et al. who compared two PN regimens with different 
Ca:P ratios. (129) Reverting the molar ratio of Ca:P in PN from 1.3 -1.5:1 to 1.0:1 was 
associated with a lower incidence and severity of hypophosphatemia and 
hypercalcemia. (129) Higher requirements of P may be explained by the fact that 
besides being an essential mineral for bone mineralization, P also plays an important 
role in energy metabolism and cellular functions. (130) In addition, the higher amino 
acid intakes provided, resulting in higher protein synthesis rates, may increase the 
need for additional P. We suggest that a ratio as recommended by the American 
Society for Clinical Nutrition is more appropriate. (128) 
 Minerals provided by PN are directly available for metabolism in contrast to the 
dependency on intestinal absorption of enterally supplemented nutrients. 
Consecutively enteral daily requirements are assumed to be higher than parenteral 
needs and molar Ca:P ratios are assumed to be different. (4, 13, 117, 131) Balance studies 
estimated a significant variability of intestinal absorption of Ca (40 - 70 %) and P (60 - 
95%) among preterm infants. (114, 132-136) The efficacy of recommended Ca:P ratios for 
enteral intake has not been evaluated systematically. Only a few studies, mostly 
dating back to more than two decennia ago, looked at different mineral intakes in 
either human milk or preterm formula. (116, 137-145) Most studies evaluated small 
numbers of infants, either at term age or higher gestational age than currently cared 
for in neonatal intensive care units. These studies showed varying results, but mostly 
found that higher intake was related to improved bone mineralization. However, 
nowadays in clinical practice, very low birth weight infants rarely receive exclusively 
either parenteral or enteral nutrition in the direct postnatal period. Parenteral 
nutrition is started directly after birth, while enteral intake starts with small amounts 
several hours after birth with gradual daily increase. Therefore, we suggest that future 
guidelines should provide recommendations for a combined parenteral and enteral 
intake. Furthermore, taking into account the variability of intestinal absorption, we 
speculate that it may be difficult to guarantee sufficient intake even while providing 
amounts of minerals in adequate ratios according to recommendations. Subsequently, 
we suggest that supply of a calculated mineral intake may not guarantee adequate 
real intake and therefore monitoring of mineral homeostasis could be a tool to adapt 
nutritional supply to guarantee that Ca and P are sufficiently supplemented to support 
cell metabolism as well as bone mineralization. Thus we suggest that guidelines for 
nutritional intake of Ca and P could be improved by not only recommend a certain 
amount of minerals, but also define a target range of biochemical parameters that will 
guarantee optimal bone mineralization. However, neither the optimal amount of 
minerals, nor target ranges for biochemical parameters, that may indicate sufficient 
bone mineralization in VLBW infants, are currently known. 
 Pohlandt et al. recommended to use a ‘small surplus’ of phosphorus and calcium 
in spot urine as indicator for sufficient supplementation of minerals necessary for 
optimal bone mineralization. (146) Hypophosphatemia in our cohort was treated with 
additional P supplementation. As demonstrated in the sub-analysis, we observed 
urinary excretion of P above the recommended surplus, independent of additional 
supplementation, in combination with low serum P and an increasing Alkaline 
Phosphatase (ALF). Therefore based on the results in chapter 6 we question the 
reliability of the ‘small surplus’ of P and Ca in spot urine as instrument to guide optimal 
mineral supplementation. 
 The evaluation of Ca–P homeostasis generally occurs under the assumption 
that biochemical parameters within the normal range will lead to optimal bone 
mineralization and is standard of care in many neonatal units as elaborated in chapter 7. 
However, the appropriateness of either parameter, frequency of measurements or 
reference values in relation to bone development have yet not been defined and 
there is lack of consensus and variation in practices regarding screening methods for 
metabolic bone disease. (147-149) Currently, it has not been proven whether biochemical 
parameters are able to indicate sufficiency of nutritional intake. Chapter 7 presents 
the attempt to understand changes in biochemical markers in relation to nutritional 
intake. We performed an observational study in very low birth weight infants of 
initially three randomized groups that received different amounts of enteral Ca and P 
intake during the first 10 days of life. We found no differences between the groups. 
However the linear regression mixed model analyses showed that Ca intake 
significantly was associated with an increase in urinary excretion of Ca, renal tubular P 
reabsorption and a decrease in ALP, while P intake was significantly associated with 
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increase in serum P concentration, urinary excretion of P and ALP. Furthermore, higher 
protein intake was associated with decrease in serum P concentration, while low 
gestational age and male gender were associated with increased renal excretion of P. 
 This study not only confirmed but also quantified the increased needs of P in 
combination with high intake of amino acids. (150, 151) We calculated that 1 mmol/kg/
day of P was needed for every extra gram/kg/day of protein to keep the serum 
phosphorus concentration unchanged. We also confirmed the finding of our previous 
study concerning high renal excretion of P, irrespective of low serum P concentrations 
and independent of P intake. In agreement with the regression analysis, a sub-analysis, 
not presented in chapter 7, revealed that high renal excretion mostly was found in 
infants with a gestational age below 28 weeks. Low tubular reabsorption of P has 
been related to immaturity of the kidneys. (152) Current recommendations for 
nutritional intake do not take into account differences in renal function based on 
gestational age. Minerals lost through renal excretion will not be available, neither for 
cell metabolism nor bone mineralization and therefore this loss should be 
compensated. Standardized repeated measurements, as used in our clinical practice, 
enabled us to individually adept mineral supply. We used an increasing concentration 
of ALP as marker for P insufficiency and the necessity to increase P supplementation. 
This policy is in agreement with our study results. Despite high P intake we recognized 
an increasing ALP concentration, probably related to an increasing intake of protein. 
 The exact role of ALP in bone mineralization has not completely been elucidated, 
but experimental data based on studies using chicken and rat embryonic bones 
indicate a catalyzing activity linked to the initial mineralization process.  (153-160) ALP is 
a tissue-nonspecific membrane-bound metalloenzyme that is present in high 
amounts in matrix vesicles of bone tissue. In developing bone the matrix vesicles are 
released from chondro- and osteoblasts and deposited within the newly formed 
osteoid under the mineral facing surfaces of osteoblasts. Matrix vesicles are the initial 
site of calcification in cartilage and bone. The initial mineralization occurs in a biphasic 
pattern. The first phase is under tight control regulated by enzymes within the matrix 
vesicle, while the second phase mainly takes place in the extracellular matrix. Studies 
showed that ALP is needed to initiate calcification, while P is needed to activate the 
enzyme function of ALP. Phosphate molecules are brought into the matrix vesicle by 
ALP, while the intravesicular Ca concentration is increased by its affinity for lipids and 
Ca-binding proteins of the interior vesicle membrane. This results in deposition of 
CaPO4 and initial crystal forming. Crystals built within the matrix vesicles finally 
perforate the vesicle membranes and then serve as templates for further crystal 
proliferation. Mineral particles keep growing and ultimately fill the extracellular 
matrix.  It is not known whether these experimental results may be extrapolated to 
the human situation. An increase in ALP has been associated with growth in pubertal 
children as well as accelerated growth in height after growth hormone therapy. (161) In 
preterm infants high serum ALP levels usually have been associated with impaired 
bone mineralization as a result of insufficient supply of mineral intake. In contrast to 
the above mentioned pubertal children, preterm infants often reach serum levels far 
above the normal range. We reported increases in ALP in Chapter 6 and Chapter 7 in 
very low birth weight infants during the early postnatal period despite relatively high 
mineral intake. Taking into account the results of the experimental studies described 
above, we propose a ‘two step’ explanation for increases in ALP seen in the early 
postnatal period. The initial small increase may indicate activation of bone 
mineralization, comparable to changes as seen in children with growth spurt. This 
may be seen as a positive phenomenon. Further increase in ALP may occur after 
perforation of matrix vesicles without full activation of ALP by P, then entering the 
extracellular fluid and increasing the serum concentration. This probably may indicate 
insufficiency of P supply. In case of the study presented in chapter 7 and as described 
above, the intake of protein was significantly associated with a decrease in serum P 
concentration, while protein further was associated with a significant increase in  ALP. 
All together this may be interpreted as a relatively insufficiency of P for bone 
mineralization.  Thus, we regard ALP as a useful indicator for mineral supply for the 
benefit of bone mineralization in the early postnatal period.
 The statement that ALP is useful for the evaluation of bone mineralization is 
controversial. (147, 148, 162, 163) Lucas et al. found an association between high ALP and 
impaired growth in length in childhood, whereas Tinnion and Embleton stated that 
serum P, Ca and ALP may be normal, while the bone actually is osteopenic. (147, 162) 
They also found ALP not useful to predict the need to start treatment for MBD or 
predict MBD at discharge. The systematic review by Visser et al., analyzing the validity 
of biochemical markers in metabolic bone disease in preterm infants, found conflicting 
results concerning a correlation between high serum ALP and MBD. (148) All of these 
studies looked at biochemical parameters as markers for MBD and in case of ALP 
either looked at an incidental measurement or the maximum concentration. We used 
standardized repeated measurements of biochemical parameters to optimize 
nutritional supply of minerals with the aim to achieve bone mineralization comparable 
to term born infants. None of our patients developed signs of MBD, whereas a recent 
cohort study reported an incidence of MBD in preterm infants below 1000 grams of 31 
% of which 34 % developed spontaneous fractures. (164) According to our opinion the 
provision of adequate intake of Ca and P from the first week of life onwards can 
prevent MBD even in the smallest infants, but monitoring of intake is necessary to 
account for increased requirements of P in combination with high amino acid intakes 
and renal (or fecal) losses related to immaturity. We conclude that changes in 
biochemical parameters are associated with nutritional intake. 
 Careful follow up of biochemical parameters has also been proposed in recent 
studies evaluating mineral homeostasis in relation to parenteral and enteral nutrition 
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in preterm infants. (129, 165) However, none of the studies, including our own, has 
sufficiently defined target values of biochemical parameters to aim for. Research is 
needed to provide a concept of target values for biochemical parameters to guarantee 
sufficient intake of Ca and P. As an example we suggest that urinary P excretion 
should be further studied to define an upper range of mineral excretion to enable the 
differentiation between immature tubular reabsorption or over dosage of mineral 
supply. Under the assumption that protein and mineral intake is provided according to 
the recommendations, urinary excretion of P in combination with a low concentration 
of ALP may indicate sufficiency and thereby define the upper range of P excretion. 
Additional studies are needed to define this range with special attention to differences 
in gestational ages. 
Growth and bone mineralization of preterm infants
Chapter 4 evaluates the long-term follow up of growth and bone mineralization of 
children at the age of nine to 10 years who previously participated in the observational 
cohorts 1 and 2. We hypothesized that improved nutritional intake would lead to 
improved length and bone mineralization. The outcome in length has been discussed 
under section ‘amino acids and growth’. The mean standard deviation score (SDS) for 
bone mass measured for whole body (WB) and lumbar spine (LS) was within the 
normal range for the reference population, while bone mass seemed not to be related 
to the nutritional intake of the first two weeks. As previously discussed, our studies 
revealed that the improved nutritional protocol did not prevent nutritional deficits 
and infants demonstrated a severe extra-uterine growth retardation at term corrected 
age (TCA). However, at nine to 10 years, the bone mass SDS was within the normal 
range of the reference population for both cohorts. Several studies indicated a 
positive effect of human milk on bone mineralization despite low mineral content. 
(166, 167) More than 90% of all infants in both cohorts received MOM. For cohort 1 the 
use of MOM may have compensated for the low mineral intake. Furthermore this 
study indicates that preterm infants may have the capability for catch-up in bone 
mineralization. Several follow-up studies reported catch-up in bone mineralization in 
former preterm infants over the years. (168, 169) In contrast, a recent Chinese cohort 
study evaluated more than 2000 term and preterm newborn infants, including 149 
extremely preterm infants, repeatedly during the first 12 months after birth. During 
this first year all preterm infants remained significantly smaller in weight and length 
and bone mineral density compared to the reference of term born infants, with the 
group of extremely preterm infants having the lowest scores during the whole period. 
(170) In this study the preterm infants demonstrated a significant higher increase in 
bone mineral density compared to the reference, even after adjustment for 
well-known determinants of growth, but did not achieve a full catch-up. We speculate 
that despite the capability to catch-up in bone mineralization, special attention is 
needed for nutritional intake even in the post-discharge period, especially in relation 
to severe postnatal growth retardation. Van de Lagemaat et al. demonstrated that a 
mineral-enriched post discharge formula compared to standard formula was 
associated with improved gain in bone mineral content until six months of corrected 
age. (171) 
 Chapter 8 describes a randomized study in very and extreme preterm infants 
who were randomly assigned to one of three groups that differed by enteral Ca and P 
intake until day 10. The aim of the study was to evaluate bone mineralization and 
growth at term corrected age (TCA). We hypothesized that higher intake would lead 
to improved growth and bone mineralization at TCA. In contrast to our assumption 
the outcomes for bone mineral content (BMC), bone mineral density (BMD), weight 
and length were similar across the groups. The nutritional intake of Ca, P and protein 
was not associated with an effect on weight. P intake was associated with a small 
positive effect on length, whereas Ca intake was associated with a decrease in BMC. 
The volume of human milk intake during the first 10 days was significant positively 
associated with BMC. The effect sizes found in this study were small. While one would 
expect that nutritional intake of Ca and P would influence each other, testing of the 
interaction of both minerals was negative for all outcomes except for BMD. Any 
interpretation based on the results of this study should be performed with caution 
since the results may be distorted by the small amount of patients investigated with 
DXA scans. A limitation of this study was that we were unable to include the intended 
number of patients and that a considerable number of disapprovals of dual-ener-
gy-x-ray absorptiometry (DXA) scans led to low numbers of scans per group. This may 
have led to overestimation of observed effects, as well as perhaps having missed 
certain effects. However, since there is a limited number of studies with a randomized 
design evaluating this subject in very, and extremely preterm infants, it may be 
considered that this study provides an important contribution to the research. 
 In agreement with the study protocol the groups differed significantly in the 
amount of Ca and P intake, based on the enteral supplementation. However all groups 
received more than 50% of the total intake as parenteral supplement according to the 
PN protocol. Further, based on blood and urine analyses additional parenteral mineral 
supplementation was permitted since we felt it would be unethical to withhold 
standard of care to high risk patients. Parenteral nutrients are directly available for 
metabolism, while intake by the enteral route is also determined by the amount of 
intestinal absorption. (114, 122) This possibly has ameliorated the differences between 
the three groups and possibly decreased the size of any effect of Ca and P intake. 
 At term corrected age anthropometric data were available for all 93 surviving 
infants. This study was performed about 8 years after the first observational cohort 
study and patients included had lower gestational age and birth weight. While infants 
of Cohort 1 and 2 developed a decrease of about 2 SDS for weight by the time they 
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reached TCA, participants of the more recent study had a decrease in SDS between 
-0.75 and -0.41 for weight and -0.69 and -0.33 for length. We speculate that the smaller 
decrease in SDS will enable these infants to achieve a full catch up to birth SDS, in 
contrast to the previous cohorts. 
 The lower decrease in SDS until TCA may be interpreted as an improvement in 
nutritional management. However, the nutritional protocol basically remained 
unchanged, using the same standard PN solution, preterm formula and human milk 
fortifier. The only additional product that was used was an enteral supplement of 
protein. Practically, this improvement may also be related to more adherence to the 
protocol, availability of daily calculated nutritional intake in combination with 
consequent registration of growth into digital growth curves which were used to 
adapt the nutritional intake in case of impaired growth. Further improvement 
probably could be achieved by individual fortification of human milk based on 
determination of the actual nutritional content of mother’s own milk. (172, 173)
 In agreement with the anthropometric results bone mineralization was comparable 
between the groups. As elaborated above, this may be a result of the relatively high 
amount of minerals provided by PN, but also the short intervention period. 
Independent of group assignment, the percentage of MOM was very high in this 
study. Previous studies that evaluated bone mineralization in relation to enteral 
feeding found the highest weight gain and BMC with preterm formula. (174, 175) We did 
not include a group with exclusively preterm formula because our general practice is 
to provide preferably mother’s own milk. A positive effect of human milk on bone 
mineralization has previously been reported and is confirmed by our analyses. (176, 177) 
This may support our assumption that even for very, and extreme preterm infants it 
should be possible to achieve adequate bone mineralization at TCA in combination 
with human milk. According to the references for body composition in appropriate 
and small for gestational age infants as presented by Lapillonne et al. the participants 
of our study achieved a median BMC comparable to 38-39 weeks gestation at term 
corrected age. (178) Taking into account the results of our long-term follow up of the 
previous cohort study, we speculate that infants who participated in the last study 
gained sufficient weight, length and bone mineralization during the early postnatal 
period to achieve a full catch-up growth to birth SDS during early childhood. 
Diagnostic tools and bone mineralization
Metabolic bone disease (MBD) often is defined as decreased bone mineral content 
relative to the expected level of mineralization of an infant of a comparable size in 
combination with either biochemical or radiographic changes. (179) Impaired bone 
mineralization is asymptomatic in most infants, therefore screening seems necessary 
for a timely diagnosis or prevention of MBD. Currently there is no consensus on 
diagnosis, treatment or timing of initiation of treatment. This is partly based on the 
lack of evidence based parameters to evaluate bone status. (147-149) Besides biochemical 
parameters as discussed in the previous section, screening methods currently used 
also include imaging and quantitative ultrasound. While radiographic signs of 
impaired bone mineralization or fractures are usually late signs, they are also not 
quantifiable. Dual-energy-x-ray absorptiometry (DXA) currently is recognized as the 
gold standard and regarded as a sensitive method to detect and quantify small 
changes in body composition and specifically bone mass. (180) Both methods use 
radiation and are not suitable for daily screening, while also the availability of a DXA 
scan is limited. Quantitative ultrasound (QUS) has been proposed as an easy to use, 
portable, and radiation free alternative. The method is based on the idea that changes 
in ultrasound are related to changes in bone mineral density and bone structure. (181) 
 Chapter 9 presents a statistical assessment of DXA and QUS results collected 
during the long-term follow up study of former preterm infants at nine to 10 years of 
age. We evaluated whether both techniques are equivalent in diagnosing the state of 
bone mineralization. Equivalent results would allow to replace DXA by QUS as 
diagnostic tool for the evaluation of bone mineralization and would provide a method 
to evaluate changes of bone mineralization in daily clinical practice. In contrast to our 
expectations we found statistically significant weak correlations and poor agreement 
between the methods and a discrepancy in differentiating the same children with 
normal or reduced bone mineralization. Thus according to our analysis we cannot 
recommend to replace DXA scans by QUS for the evaluation of bone mineralization. 
However, reference values and standard deviation scores for both methods were 
derived from different countries, thus different populations. (182-184) Different pubertal 
stages at different ages, depending on the population cannot be excluded. This may 
have affected our results. Furthermore we evaluated a single measurement and did 
not investigate whether QUS may be useful to evaluate changes over time, irrespective 
of any comparison with DXA. Two studies performed repeated measurements in 
preterm infants during hospital stay and analyzed a possible association with markers 
of bone health and severe illness. (185, 186) Fewtrell et al. found the QUS signal to be 
positively associated with gestational age, but markers of impaired bone mineralization 
and severe illness were not related to changes in QUS signal, while Betto et al. found 
significant weak correlations between the QUS signal and anthropometric data as 
well as a number of biochemical markers of bone mineralization. Both studies looked 
at incidental measurements with intervals of several weeks and thereby may have 
missed certain effects. Standardized repeated measurements in the early postnatal 
period in relation to nutritional interventions have yet not been performed. We would 
like to note that despite the fact that most children in this study achieved growth and 
bone mineralization within the range of the reference population, this was still below 
their initial birth SDS. Therefore, improvement in postnatal growth development for 
preterm infants is still needed.  This means that growth and bone mineralization need 
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to be evaluated in follow up and pQUS may serve as a simple, non-invasive, cheap 
tool. Despite the lack of agreement between DXA and QUS, we suggest that the 
usefulness of QUS for direct clinical evaluation in very preterm infants should be 
further evaluated since this method provides the possibility to observe changes in 
bone development in high risk infants directly from birth onwards, while a negative 
impact for the infant is low. Ideally, repetitive measurements in the early postnatal 
period may be used to evaluate the adequacy of nutritional interventions and 
consecutively limit blood and urine sampling. However, before the implementation 
of QUS as diagnostic tool is possible, further research is needed to better understand 
the nature of changes of ultrasound in growing bone of very preterm infants. 
Future perspectives
Our studies comprised interventions in preterm infants during the first days after 
birth. We demonstrated that small changes in nutritional supply during this period 
had impact on later development. However, many issues concerning optimal 
nutritional management in preterm infants still remain unclear and need further 
investigations. This has been discussed throughout this chapter. In this paragraph we 
will summarize our suggestions for future research. 
 The nutritional management presented in this thesis focused among other things 
on standardized nutritional care. We discussed the positive effects. On the other 
hand, the requirements of preterm infants are neither ‘standard’ nor ‘equal’ for the 
individual infant. Extremely preterm infants have the highest nutritional needs that 
have to be provided in combination with the smallest volumes, while maturation and 
growth during the postnatal period will change the requirements and in case of use 
of human milk the protein content is variable and usually unknown. We demonstrated 
that adaptation of the nutritional intake according to the individual needs cannot be 
provided using current available multi-component human milk fortifiers. Therefore 
further improvements in nutritional care should investigate ‘standardized individualized’ 
supply of nutrients for enteral as well as parenteral nutrition. Further research should 
determine whether individualized enterally protein supplementation based on 
regular milk analyses of mother’s own milk leads to further improvement in growth 
and neurodevelopment. While the use of parenteral standardized multi-component 
solutions has the advantage of a well-balanced intake of nutrients and increases 
patient safety, these solutions are often unable to provide optimal intake with low 
volumes as required for extremely low birth weight infants. Concepts of adequate 
parenteral nutrition specifically for infants with a birth weight below 1000 grams 
need to be developed.  
We demonstrated a positive effect of early nutritional intake on neurodevelopmental 
outcome for boys and girls, as well as for appropriate and small for gestational age 
infants. However, we also showed that nutritional needs seem to be different. We 
speculate that male infants have higher nutritional needs than female infants. Our 
studies indicated that improvements were mainly associated with protein intake. We 
suggest that at first, research should define the specific requirements of boys as well 
as for girls, which should include the effect of other nutrients. A next step would be to 
prove that a specified nutritional protocol for boys will lead to neurodevelopmental 
outcomes comparable to girls.  
 We also found an improved response to nutritional interventions in the subgroup 
of SGA children compared to AGA children indicating that SGA infants have lower 
protein requirements than AGA infants. Further studies should try to specify the 
nutritional requirements of SGA born infants aiming at nutritional intakes that allow 
optimal growth, while avoiding accelerated growth with high risk of developing 
obesity, diabetes and cardiovascular disease. Studies should look for and try to define 
the critical window for ‘healthy catch up growth’. 
 We suggested that insufficient nutritional intake could be a cause of impaired 
neurodevelopmental outcome in relation to prematurity related diseases. Further 
studies are needed to evaluate whether adequate nutritional intake in combination 
with morbidities such as patent ductus arteriosus, sepsis, necrotizing enterocolitis 
and chronic lung disease will improve outcome. In addition, specific nutritional 
requirements in relation to certain diseases have yet not be defined. 
 Part 3 of this thesis evaluated Ca–P homeostasis and bone mineralization. Current 
recommendations for nutritional intake need to be adapted taking into account different 
requirements according to gestational age. The aim of adequate supplementation of 
Ca and P should not be the prevention of metabolic bone disease but the development 
of adequate bone mineralization comparable to term born infants. The efficacy of 
newly developed recommendations should be evaluated in long-term follow up that 
evaluates bone mineralization as well as side effects such as nephrocalcinosis. Non- 
invasive screening tools that reflect changes in bone mineralization during the early 
postnatal period need to be developed. We suggest to search for target ranges of 
biochemical parameters that indicate adequate nutritional intake, taking into account 
immature renal tubular reabsorption. Further study is needed to prove whether 
repeated measurements of quantitative ultrasound may serve as a non-invasive tool 
for early changes in skeletal development. 
 As mentioned in Chapter 1 bone mineralization or skeletal development is not 
only dependent on nutritional intake, but also driven by functional requirements. 
Active muscle contractions increase bone strength, while lack of mechanical challenge 
will decrease the need for bone formation. (187, 188) The studies presented in this 
thesis focused on nutritional intake, while nowadays standard care of preterm infants 
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does not stimulate active movements or muscle contractions comparable to the 
fetal situation. We speculate that ‘developmental care based physical training’ in 
combination with adequate intake will further improve the early postnatal 
development of bone mineralization. 
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Summary
Part 1
Chapter 1
Chapter 1 provides an introduction on the subject of this thesis, namely the effects of 
nutritional intake in the early postnatal period of very low birth weight (VLBW) infants 
on growth, neurodevelopment and bone mineralization. We describe the consequences 
of preterm birth as a critical event for the infant, with a major impact on health directly 
after birth, but also a high risk of unfavorable long-term development. The current 
knowledge of the role of nutrients for the preterm infant is described in detail, along 
with their requirements and the way to supply nutrition. Nutrition in the early postnatal 
period has been recognized as a key determinant for neonatal outcomes. While the 
aim of nutritional support for preterm infants is to achieve a postnatal growth rate 
similar to fetal growth combined with satisfactory functional development, comparable 
to term-born infants, preterm infants are known to experience growth retardation 
and impaired executive functioning. Nutritional intake has been associated with 
growth, neurodevelopment and bone mineralization. A description of the current 
knowledge of these three outcome parameters with specific attention being paid to 
nutritional interventions is provided.
Chapter 2
This chapter gives an outline of the thesis. For this thesis we evaluated nutritional 
interventions in VLBW infants, comprising the group of very and extreme preterm 
infants. Emphasis was placed on the early postnatal period because in healthy 
pregnancies, this has been shown to be a critical period in the transition from a 
constant rich flow of nutrient supply through the umbilical cord to an enteral and 
parenteral supply of nutrients with a risk of under- or overnutrition and consequently 
impaired development. The aim was to gain more knowledge concerning the efficacy 
of current recommendations for the nutrient supply for VLBW infants. Research 
questions focused on the effect of early postnatal amino acid intake on growth and 
neurodevelopment and calcium and phosphorus metabolism as determinants of 
bone development. 
Part 2
Chapter 3 
This chapter evaluates whether increasing the amount of amino acids and energy 
administered in parenteral nutrition combined with a rapid increase of enteral feeding 
would improve postnatal growth in preterm infants. The observational study analysed 
two consecutive year-cohorts of preterm infants admitted to the neonatal intensive 
care unit of the Radboudumc. A new feeding regimen that provided a higher amount 
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of amino acids with parenteral nutrition, according to international recommenda-
tions, in combination with the intention of a rapid increase of enteral feeding (Cohort 
2) was compared with the previous standard nutritional protocol with a lower amount 
of amino acids and energy (Cohort 1). The new parenteral nutrition was shown to 
provide a significantly higher amount of amino acids during the first week of life. This 
was associated with a significantly greater weight gain in appropriate for gestational 
age born infants (AGA) until week 5 postnatally. Small for gestational age (SGA) infants 
showed a greater weight gain compared with AGA infants, but growth in head 
circumference failed to improve. A further finding of this study was that, despite the 
positive weight gain from the second week onwards, all infants demonstrated a 
steady decrease in standard deviation score (SDS) for weight, which resulted in a 
mean loss of 2 SDS for both cohorts around the term-corrected age. We concluded 
that improved parenteral intake may lead to improved short-term postnatal weight 
gain, but a fast increase in enteral nutrition, specifically using fortified human milk, 
failed to prevent nutritional deficits.    
Chapter 4
In this chapter we describe the results of the long-term evaluation of the previously 
studied former preterm children at the age of 9 - 10 years. The aim of the study was to 
investigate whether increased nutritional supplementation of calcium, phosphate 
and protein in VLBW infants during the first 14 days after birth was associated with any 
improvement in length and bone development. The children who were born at 
gestational age below 32 weeks or had a birth weight below 1500 grams were invited 
for additional follow-up at 9 - 10 years of age. Anthropometric data were collected 
during standard follow-up visits until  five years of age and additionally at 9 - 10 years, 
including measurements of bone mineral content, bone mineral density of the whole 
body and lumbar spine determined by dual-energy X-ray absorptiometry. Long-term 
growth trajectories of both cohorts were evaluated separately for participants born 
appropriate (AGA) and small for gestational age (SGA), stratified by gender. Multivariate 
linear regression was used to examine the effect of nutritional intake and clinical 
covariates on length and bone mineralization. Both cohorts caught up in length  to 
SDS within the normal range by 6 months. Bone mineral content and density at 9 - 10 
years were within the normal range and did not differ between the cohorts. SGA 
children caught up in length at 5 years, with bone mineralization at 9 - 10 years being 
comparable to AGA children. There was no evidence of an association between early 
nutritional intake and bone mineralization at 9 - 10 years. We concluded that children 
born as AGA or SGA preterm infants are able to catch up in length after the postnatal 
period, and achieve a normal length and bone mineralization at age nine - ten years. 
An improvement of calcium and phosphate intake during the first 14 days after birth 
was not associated with an improvement in length and bone development. 
Chapter 5
The study described in this chapter assessed whether an increased amino acid and 
energy intake in preterm infants during the first week of life is associated with 
improved neurodevelopment at the corrected age (CA) of 24 months. The previously 
described cohorts were evaluated. Neurodevelopment was determined using the 
Bayley Scales of infant Development, 2nd Edition at 24 months CA. Linear and logistic 
regression analyses analyzed the association between nutritional intake and neuro-
development. We found that Cohort 2 received significantly higher nutritional intake 
during the first week compared to Cohort 1, and weight gain until week 5 was 
significantly higher, especially in boys. The mean Mental Developmental Index (MDI) 
scores did not differ between the groups, but Cohort 2 was associated with an 
increased chance of having an MDI ≥ 85, with an odds ratio of 6.4 and 95% confidence 
interval (CI) of 1.5-27.4. For all girls, this was associated with a higher protein intake 
(5.3, 1.2-23.3). For boys, the chance of having a Psychomotor Developmental Index ≥ 
85 was positively associated with increased protein intake. We concluded that higher 
nutritional intake was associated with different improvements in growth and neuro-
development in boys and girls. 
 A sub-analysis of our data showed that besides male sex, a patent ductus 
arteriosus was found to be the greatest negative determinant of neurodevelopment. 
Infants with patent ductus arteriosus received significantly less protein and energy 
intake during the first two weeks. Fluid restriction and cautious increase of enteral 
feeding are generally accepted measures of conservative treatment of patent ductus 
arteriosus. In many cases this is at the expense of the daily required nutritional intake. 
We speculate that the impaired outcome in relation to patent ductus arteriosus could 
be the consequence of undernutrition in a period of rapid brain growth and suggest 
that neurodevelopmental outcome of prematurity-related clinical conditions should 
also be evaluated in relation to nutritional intake. 
Part 3
Chapter 6
This chapter describes an observational study that analyzed the postnatal calcium 
(Ca) and phosphorus (P) metabolism in preterm infants who were included in cohort 
2. During a 5-week period, serum concentrations and the urinary excretion of calcium 
and phosphorus (Ca/P) were recorded and related to the intake of minerals and 
vitamin D. The recommended intake of minerals was achieved by day 5 and for 
vitamin D, by 4 weeks. Infants developed hypercalcaemia, hypercalciuria, and hypo-
phosphataemia during the first postnatal week, leading to additional P supplementa-
tion in more than half of the infants. The renal tubular reabsorption of P was > 95% 
until day 9 but decreased to < 70% after the second week. Alkaline phosphatase was 
normal at birth, increased to a maximum of 450 IU/L by day 14, and persisted above 
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the normal range for the remaining period. The conclusion of this study was that 
parenteral intake of P appeared to be too low, leading to mineral imbalances in the 
early postnatal period, and vitamin D intake was also below recommendations. 
Chapter 7
The study described in this chapter used data collected for the Early Supplementation 
Study (ESS), which was part of the ‘Early Nutrition Study’ (ENS), a multi-center, 
double-blind, randomized trial that evaluated the effects of human milk on survival 
and infections in preterm infants. The primary objective of the ESS was bone 
mineralization in preterm infants in relation to different mineral supplementation. 
The aim of this study was to evaluate changes in the biochemical parameters of the 
Ca-P homeostasis in blood and urine in relation to different nutritional intakes during 
the first 14 days of life in VLBW infants. Our hypothesis was that the nutritional intake 
of Ca and P would have an effect on the biochemical parameters of the Ca-P 
homeostasis. For this study we compared two groups of very and extremely low birth 
weight infants that differed by nutritional intake of Ca and P (High versus Low) during 
the first 14 days after birth.  Biochemical parameters such as serum (s)/urinary (u) Ca 
and P; alkaline phosphatase (ALP); tubular reabsorption of P (TrP); and urinary ratios 
for Ca/creatinine and P/creatinine were determined on postnatal days 1, 3, 5, 7, 10, and 
14. The daily median concentrations of the biochemical parameters did not differ 
between the groups, but the analyses showed that Ca intake was significantly 
associated with an increase in uCa and TrP and a decrease in ALP. Phosphorus intake 
was significantly associated with increase in sP, uP, uP/creat ratio and ALP and a 
decrease in TrP (p =0.00). Protein intake was associated with a decrease in sP, while 
low gestational age and male gender were associated with a significantly increased 
renal excretion of P. Standardized repeated measurements showed that the 
biochemical parameters were affected by nutritional intake, gestational age and 
gender. 
Chapter 8
This chapter presents the results of a randomized study that evaluated the effect of 
different enteral intakes of Ca and P on bone mineralization and growth at term 
corrected age in very and extremely preterm infants. Infants (n=109) with birth weight 
below 1500 grams were randomly assigned to one of three groups that differed by the 
nutritional protocols delivered until day 10: Group A - mother’s own milk (MOM) and 
donor milk (unfortified); Group B - MOM (unfortified) and preterm formula; Group C - 
MOM (start fortification > 50 ml/d) and preterm formula. The early stop of patient 
inclusions led to lower numbers than the originally anticipated 65 infants per group. 
Thus, the study may be underpowered and unable to answer the research questions. 
This study found no difference in weight, length, bone mineral content (BMC) and 
bone mineral density (BMD) between three different intake groups of very and 
extremely preterm infants at term corrected age. The regression analysis further 
showed that group assignment was not associated with the studied outcome 
measures; however, we found significant positive associations between P intake and 
length, as well as the amount of human milk intake and BMC. In contrast, Ca intake 
was associated with a decrease in BMC that decreased further after the addition of P 
and protein in the analysis. On the basis of this study, there is no evidence that early 
high mineral intake through early fortification of human milk improves bone 
mineralization in combination with high parenteral mineral intake. The positive effect 
of human milk on bone mineral content needs to be evaluated further.  
Chapter 9
The study described in chapter 9 is a comparison of two diagnostic tools for the 
evaluation of bone mineralization. The study assessed whether Phalangeal 
Quantitative Ultrasound (pQUS) was equivalent to the golden standard dual-energy 
x-ray absorptiometry scan (DXA). Phalangeal Quantitative Ultrasound (pQUS) is an 
alternative technique that is inexpensive, easy to use and radiation-free. Sixty former 
preterm infants were investigated when aged between 9 and 10 years old using both 
methods on the same day. DXA measured bone mineral content (BMC) and bone 
mineral density (BMD) for total body and lumbar spine (L1-4), while pQUS measured 
the amplitude-dependent speed of sound (AD-SoS) and bone transit time (BTT) at 
metacarpals II-IV, providing continuous values and Z-scores based on age and sex. 
Four statistical methods evaluated the association between both techniques: 
Pearson’s correlation coefficients; partial correlation coefficients adjusted for 
gestational age, height and BMI; Bland-Altman analysis; and cross-tabulation. Both 
techniques showed a statistically significant weak correlation for continuous values as 
well as Z-scores (0.291-0.462, p<0.05). The correlation coefficients decreased further 
after adjustment for confounders. The Bland-Altman plots showed poor agreement, 
while sensitivity and specificity had wide ranges. According to these results, pQUS 
measurements are not equivalent to DXA for the evaluation of bone health and 
cannot replace the DXA in former preterm children at the age of 9 - 10 years. 
Chapter 10
The findings of the above-mentioned studies are discussed in the context of the 
relevant literature. In addition, suggestions for future research are provided. 
The main findings from the studies presented in this thesis:
• Increase in protein and energy intake during the first postnatal week improves 
postnatal weight gain in very preterm infants.
• The standardly available multicomponent fortification of human milk is insufficient 
to prevent postnatal growth retardation in very preterm infants. 
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• The first week nutritional intake affects neurodevelopmental outcome at 24 months 
differently in boys and girls. 
• AGA and SGA preterm infants have different protein requirements for optimal growth.
• Former preterm children are able to catch up in height comparable to the reference 
population, but remain below their initial birth standard deviation scores. 
• Current recommendations for nutritional intake of calcium and phosphorus are 
insufficient to achieve a stable calcium and phosphorus homeostasis.
• Calcium-phosphorus homeostasis is affected by nutritional intake, specifically 
protein intake, and gestational age.
• Improvement of bone mineralization in the early postnatal period needs further 
evaluation.
• Quantitative ultrasound cannot replace dual-energy x-ray absorptiometry scan for 
the evaluation of bone mineralization.
Samenvatting
Deel 1
Hoofdstuk 1
Hoofdstuk 1 geeft een inleiding in het onderwerp van dit proefschrift, namelijk het 
effect van voeding in de vroege fase na de geboorte van zeer kleine, te vroeg geboren 
kinderen. Een vroeggeboorte is vaak geassocieerd met negatieve gevolgen voor de 
gezondheid, zowel direct na de geboorte als in de latere ontwikkeling. De huidige 
kennis over de rol van voedingsstoffen voor te vroeg geborenen, de voedings-
behoefte en de toedieningsvormen wordt uitvoerig beschreven. Tegenwoordig 
wordt erkend dat de voeding die in de vroege fase na de geboorte toegediend wordt, 
een belangrijke factor voor de ontwikkeling is, ook op lange termijn. In algemene zin is 
het streven om na de geboorte met behulp van voeding, een groei te bereiken die 
vergelijkbaar is met de groei tijdens de zwangerschap en verder een goede functionele 
ontwikkeling te bereiken, vergelijkbaar met die van kinderen die à term geboren 
worden. Het blijkt echter, dat te vroeg geboren kinderen vaak kleiner blijven en minder 
goed functioneren dan hun op termijn geboren leeftijdsgenootjes. Voeding wordt 
over het algemeen in verband gebracht met groei, neurologische ontwikkeling en 
botmineralisatie. In dit hoofdstuk wordt de huidige kennis ten aanzien van voedings-
interventies in relatie tot deze drie uitkomstmaten beschreven. 
Hoofdstuk 2
Dit hoofdstuk beschrijft de indeling van het proefschrift, waarin voedingsinterventies 
in de vroege fase na de geboorte bij zeer kleine (< 1500 gram) en extreem kleine 
(< 1000 gram), te vroeg geboren kinderen worden bestudeerd. In deze fase vindt de 
overgang plaats van een constante rijke toevoer van voedingsstoffen via de navel - 
streng naar opname van voeding via het onrijpe maagdarmstelsel of kunstmatige 
voeding via een infuus. Hierbij bestaat de kans op zowel onder- als overvoeding en 
vervolgens een beperkte ontwikkeling. Het doel van dit proefschrift is om de 
effectiviteit van de huidige aanbevelingen ten aanzien van toediening van voeding 
aan te vroeg geborenen te onderzoeken. De onderzoeksvragen zijn toegespitst op 
het effect van aminozuren op de groei en de neurologische ontwikkeling, en op de 
invloed van de calcium-fosfaathuishouding op de botontwikkeling.
Deel 2
Hoofdstuk 3
In hoofdstuk 3 wordt onderzocht of een verhoogde toediening van aminozuren en 
energie in de parenterale voeding, in combinatie met sneller ophogen van enterale 
voeding, tot een verbeterde groei in de eerste fase na de geboorte leidt. Voor deze 
observationele studie werden gegevens verzameld van twee achtereenvolgende 
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jaargangen van kinderen die opgenomen werden op de neonatale intensive 
care-afdeling van het Radboudumc. Het nieuwe voedingsbeleid (Cohort 2), aangepast 
aan huidige aanbevelingen, werd vergeleken met het oude standaardbeleid (Cohort 
1). Bij het nieuwe beleid werd een significant grotere hoeveelheid eiwitten toegediend 
gedurende de eerste levensweek. Dit was geassocieerd met een grotere gewichts-
toename gedurende de eerste vijf weken. Kinderen die bij de geboorte te klein waren 
voor de zwangerschapsduur (small for gestational age, SGA) groeiden beter dan 
kinderen die een adequaat gewicht hadden (appropriate for gestational age, AGA). 
De toename van de schedelomtrek lag bij SGA-kinderen echter wel lager. Helaas liet 
deze studie ook zien dat alle kinderen uit beide groepen, ondanks verbeterde 
voeding, een groeivertraging van twee standaardafwijkingen hadden opgelopen 
rond de gecorrigeerde leeftijd van de uitgerekende termijn. De conclusie uit deze 
studie was dat met de nieuwe parenterale voeding weliswaar een kortdurende 
 gewichtstoename bereikt kon worden, maar met het snel ophogen van enterale 
voeding, zoals verrijkte moedermelk, ondervoeding niet voorkomen kon worden. 
Hoofdstuk 4
Hoofdstuk 4 beschrijft de langetermijnontwikkeling van de eerder onderzochte 
groep te vroeg geboren kinderen op de leeftijd van 9 tot 10 jaar. Het doel van de 
studie was te onderzoeken of een hogere toediening van calcium en fosfaat in de 
eerste twee weken na de geboorte geassocieerd was met een betere lengtegroei en 
botontwikkeling. Kinderen die voor de 32e zwangerschapsweek geboren waren of 
minder dan 1500 gram wogen bij de geboorte, werden rond de leeftijd van 9 -10 jaar 
uitgenodigd voor een additioneel vervolgonderzoek. Groeigegevens van de 
voorafgaande periode werden verkregen uit de standaard neonatale follow-up-
onderzoeken en tijdens het laatste onderzoek. Daarnaast werd met behulp van 
dual-energy X-ray-absorptiometrie (DXA-scan) het botgehalte en de dichtheid van 
het bot bepaald voor het hele lichaam en de lumbale wervelkolom. De langetermijn-
groei werd geanalyseerd voor beide cohorten en separaat voor kinderen met een 
normaal (AGA) en een te laag geboortegewicht (SGA) voor de zwangerschapsduur, 
alsook voor jongens en meisjes apart. Met behulp van een multivariate regressieanal-
yse werd het effect van de voeding op de lengtegroei en botmineralisatie bepaald. 
Beide cohorten bereikten een inhaalgroei ten opzichte van de Nederlandse populatie 
op de gecorrigeerde leeftijd van zes maanden. Op de leeftijd van 9 -10 jaar waren het 
botgehalte en -dichtheid eveneens normaal voor de leeftijd en verschilden niet 
tussen de groepen. SGA-kinderen bereikten pas op de leeftijd van vijf jaar een 
inhaalgroei met een normale botmineralisatie tijdens het laatste onderzoek. Er werd 
geen verband gevonden tussen de toediening van calcium en fosfaat gedurende de 
eerste twee weken en de botmineralisatie op de leeftijd van 9 tot 10 jaar. De conclusie 
uit dit onderzoek was dat te vroeg geborenen, zowel AGA- als SGA-kinderen, in staat 
waren de lengtegroei te normaliseren en dat de verhoogde mineralentoediening 
gedurende de eerste twee weken geen effect op lengtegroei en botmineralisatie had.
Hoofdstuk 5
In de studie die in dit hoofdstuk beschreven wordt, werd onderzocht of een hogere 
toediening van aminozuren en energie gedurende de eerste levensweek (Cohort 2) 
tot een verbeterde neurologische ontwikkeling op de gecorrigeerde leeftijd van 24 
maanden leidt bij te vroeg geborenen. De ontwikkeling werd bepaald met behulp 
van de ‘Bayley Scales of Infant Development- 2nd Edition’ bij 24 maanden. Het verband 
tussen de voedingsinname en de scores werd geanalyseerd met behulp van lineaire 
en logistische regressie. Uit de analyse bleek dat Cohort 2 in vergelijking met Cohort 
1 significant meer eiwitten en calorieën toegediend kreeg gedurende de eerste week 
en dat dit vooral voor jongens tot een significant grotere gewichtstoename gedurende 
de eerste vijf weken leidde. De gemiddelde mentale scores (MDI) verschilden niet 
tussen de groepen, maar kinderen in Cohort 2 hadden een significant hogere kans op 
een normale verstandelijke ontwikkeling (MDI ≥ 85), met een odds ratio van 6,4 en 
een 95% betrouwbaarheidsinterval van 1,5-27,4. Bij meisjes werd een hogere 
eiwitinname in verband gebracht met een hogere MDI (5,3; 1,2-23,3), terwijl de hogere 
eiwitinname bij jongens de kans op een normale motorische ontwikkeling (PDI ≥ 85) 
significant verhoogde. De conclusie uit dit onderzoek was dat een verhoging van de 
voedingsinname verschillende effecten had op groei en neurologische ontwikkeling 
bij jongens en meisjes.
 Een deelanalyse liet zien dat mannelijk geslacht en een persisterende ductus 
arteriosus (PDA) de belangrijkste factoren waren voor een beperkte neurologische 
ontwikkeling. Te vroeg geborenen in onze studie die een PDA hadden, kregen 
significant minder eiwitten en calorieën toegediend gedurende de eerste twee 
levensweken. Vochtbeperking en voorzichtige toediening van voeding hoort vaak bij 
de behandeling van een PDA. In veel gevallen gaat dit ten koste van de dagelijkse 
voedingsbehoefte. Wij suggereren dat de slechte neurologische ontwikkeling die 
vaak gezien wordt bij kinderen met PDA, niet gebaseerd is op de PDA maar het gevolg 
is van ondervoeding in een periode van snelle hersengroei. Wij stellen dat in de 
beoordeling van de neurologische ontwikkeling bij andere aan vroeggeboorte 
gerelateerde ziekten ook rekening gehouden moet worden met de voedingstoediening.
Deel 3
Hoofdstuk 6
Dit hoofdstuk beschrijft een observationele, beschrijvende studie waarin het calcium- 
fosfaatmetabolisme na de geboorte onderzocht werd bij de te vroeg geboren kinderen 
van Cohort 2. Gedurende de periode van de eerste vijf levensweken werden de 
concentraties calcium en fosfaat (Ca/P) in serum en urine geregistreerd en gerelateerd 
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aan de inname van mineralen en vitamine D. De aanbevolen hoeveelheid mineralen 
werd vanaf dag 5 toegediend, terwijl dit voor vitamine D pas na 4 weken bereikt werd. 
In de eerste levensweek werden hypercalciëmie, hypercalciurie en hypofosfatemie 
gezien, waarvoor meer dan de helft van de kinderen extra fosfaat toegediend kreeg. 
De renale terugresorptie van fosfaat was aanvankelijk zeer hoog (>95%) en daalde tot 
minder dan 70% na de tweede week. De alkalische fosfatase was normaal ten tijde 
van de geboorte, steeg tot een gemiddeld maximum van 450 IE/l op dag 14 en bleef 
daarna boven de normaalwaarde gedurende de observationele periode. De conclusie 
uit deze studie was dat de toediening van fosfaat in de voeding te laag was waardoor 
in de vroege postnatale periode een ontregeling van mineralen ontstond. Verder was 
de toediening van vitamine D lager dan de aanbevolen dosis. 
Hoofdstuk 7
De studie die in hoofdstuk 7 gepresenteerd wordt, maakte gebruik van de data-
verzameling van de ‘Early Supplementation Study’ (ESS), die deel uitmaakte van de 
‘Early Nutrition Study’ (ENS), een dubbelblinde, gerandomiseerde studie die het effect 
van moedermelk op de overleving en het ontstaan van infecties bij zeer kleine vroeg- 
geborenen onderzocht. Het belangrijkste doel van de ESS was het onderzoek naar de 
botmineralisatie bij te vroeg geborenen in relatie tot verschillende hoeveelheden 
toegediend calcium (Ca) en fosfaat (P). Het doel van de studie die in hoofdstuk 7 
beschreven wordt, was om veranderingen in biochemische parameters van de Ca/P- 
huishouding in bloed en urine te onderzoeken in relatie tot de voeding die gedurende 
de eerste 14 dagen toegediend werd. Onze hypothese was dat de inname van Ca en P 
een effect zou hebben op de biochemische parameters van het Ca/P-metabolisme. 
In deze studie werden twee groepen extreem kleine en zeer kleine prematuren die 
gedurende de eerste 14 dagen verschillende hoeveelheden calcium en fosfaat 
toegediend kregen (hoog, laag), met elkaar vergeleken. Biochemische parameters zoals 
serum/urine-Ca, P, alkalische fosfatase (ALP), renale terugresorptie P en de urine-
creatinine ratio van Ca en P werden op dag 1, 3, 5, 7, 10 en 14 na de geboorte bepaald. 
De dagelijkse mediane concentraties van de biochemische parameters waren niet 
verschillend tussen de groepen. Verdere analyse liet zien dat een verhoging van de 
Ca-inname significant geassocieerd was met een toename in de uitscheiding van Ca in 
de urine, een verbeterde terugresorptie van P en een daling van de ALP. De toediening 
van P was geassocieerd met een stijging van de P-concentratie in serum, een verhoogde 
uitscheiding van P in de urine, en een verhoging van de P creatinine ratio en de ALP. 
De renale terugresorptie daalde in relatie met de P-inname. De eiwitinname was 
geassocieerd met een daling van de serumconcentratie P, terwijl een korte zwanger-
schapsduur en mannelijk geslacht eveneens geassocieerd waren met een toename van de 
fosfaatuitscheiding. Gestandaardiseerde, herhaalde metingen lieten zien dat biochemische 
parameters beïnvloed worden door voeding, zwangerschapsduur en geslacht.
Hoofdstuk 8
Dit hoofdstuk presenteert de resultaten van een studie die het effect onderzocht van 
verschillende hoeveelheden Ca en P in de voeding op de botmineralisatie en groei 
rond de gecorrigeerde uitgerekende leeftijd bij zeer kleine en extreem kleine 
prematuren. Hiervoor werden 109 kinderen met een geboortegewicht onder de 1500 
gram na loting in een van drie groepen ingedeeld. Deze groepen verschillenden van 
elkaar ten aanzien van het voedingsprotocol gedurende de eerste 10 levensdagen. 
Groep A: moedermelk (MOM) of donormelk (niet verrijkt), Groep B: MOM (niet verrijkt) 
of kunstvoeding voor prematuren, Groep C: MOM (verrijkt vanaf 50 ml/dag) en 
kunstvoeding voor prematuren. Door een voortijdige stop van de patiëntinclusie 
werd het oorspronkelijk beoogde aantal kinderen per groep niet bereikt. Om deze 
reden heeft de studie waarschijnlijk onvoldoende power om alle onderzoeksvragen 
te kunnen beantwoorden. Op basis van het studieprotocol had groep C een significant 
hogere inname aan Ca en P gedurende de eerste 10 dagen. In deze studie werd geen 
verschil gevonden in gewicht, lengte, en botmineraalgehalte en -dichtheid tussen de 
drie groepen van zeer kleine en extreem kleine prematuren rond de gecorrigeerde à 
terme-leeftijd. De analyse toonde verder dat indeling in een van de groepen niet 
geassocieerd was met een van de uitkomstmaten, maar dat er een positief verband 
was tussen de inname van P en de lengtegroei, en tussen de hoeveelheid toegediende 
moedermelk en het botmineraalgehalte. Op basis van deze studie is er geen bewijs 
dat vroege verrijking van moedermelk in combinatie met hoge parenterale toediening 
van mineralen de botmineralisatie verbetert. Het positieve effect van moedermelk op 
de botmineralisatie zou verder onderzocht moeten worden. 
Hoofdstuk 9 
In hoofdstuk 9 wordt een studie beschreven die twee diagnostische methoden voor 
de beoordeling van de botmineralisatie vergelijkt. De studie onderzocht of ultragelu-
idsonderzoek (botecho) aan de vinger gelijkwaardig is aan de gouden standaard, 
namelijk dual-energy X-ray absorptiometrie-scan (DXA). De botecho is goedkoop, 
eenvoudig in gebruik en stralingsvrij. Zestig te vroeg geboren kinderen werden 
onderzocht op de leeftijd van 9 tot 10 jaar, waarvoor bij ieder kind beide onderzoeken 
op de zelfde dag verricht werden. DXA bepaalde het gehalte en de dichtheid van het 
bot van het hele lichaam en de lumbale wervelkolom en met de botecho werd de 
snelheid van geluid en de duur van het geluid door bot gemeten. Voor alle metingen 
werden continue waarden en Z-scores verkregen. Voor de vergelijking werden vier 
statische methoden gebruikt: Pearsons correlatie, partiële correlatie aangepast aan 
zwangerschapsduur, lengte en BMI, een Bland-Altman plot en kruistabellen. Beide 
technieken lieten een statistisch significant zwakke correlatie zien, die verder daalde 
na correctie voor mogelijke verstorende variabelen. Tevens liet de Bland-Altman plot 
zwakke overeenkomsten zien, terwijl de sensitiviteit en specificiteit een brede marge 
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hadden. Op basis van deze resultaten kan geconcludeerd worden dat de botecho niet 
gelijkwaardig is aan de DXA-scan voor de evaluatie van de botontwikkeling en 
daarmee de DXA-scan niet kan vervangen voor onderzoek bij prematuren op de 
leeftijd van 9 tot 10 jaar. 
Hoofdstuk 10
In dit hoofdstuk worden de bevindingen van bovengenoemde studies besproken in 
samenhang met de relevante literatuur. Daarnaast worden suggesties gegeven voor 
verder onderzoek. 
De belangrijkste bevindingen van dit proefschrift zijn:
• Een verhoging van de eiwit- en calorie-inname gedurende de eerste week na de 
geboorte verbetert de gewichtstoename na de geboorte bij zeer kleine vroeg - 
geboren kinderen.
• Met standaard multi-component moedermelkverrijker kan een postnatale groei-
retardatie niet worden voorkomen.
• De voedingsinname tijdens de eerste levensweek heeft verschillende uitwerkingen op 
de neurologische ontwikkeling van jongens en meisjes op de leeftijd van 24 maanden.
• Vroeggeboren kinderen met een te laag geboortegewicht hebben een andere eiwit- 
behoefte dan zij met een normaal gewicht bij de geboorte om een optimale groei 
te bereiken.  
• Vroeggeboren kinderen zijn in staat om een lengte en botmineralisatie te bereiken 
die vergelijkbaar zijn met de referentiebevolking maar blijven onder de initiële 
standaard deviatie scores ten tijde van de geboorte. 
• Huidige aanbevelingen voor de toediening van calcium en fosfaat aan vroeggeborenen 
zijn ontoereikend om een stabiele calcium-fosfaathuishouding te krijgen. 
• De calcium-fosfaathuishouding wordt beïnvloed door inname van mineralen met 
de voeding, de eiwittoediening en de gestatieleeftijd van het kind.
• Verbetering van de botmineralisatie in de vroege fase na een vroeggeboorte zou 
verder onderzocht moeten worden.
• De botecho kan de dual-energy x-ray absorptiometriescan niet vervangen voor de 
beoordeling van de botmineralisatie.
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Zusammenfassung
Teil 1
Kapitel 1
Das erste Kapitel gibt eine Einführung zum Thema der Studien, die in dieser Arbeit 
behandelt werden, nämlich die Auswirkungen der Ernährung in den ersten Wochen 
nach der Geburt bei sehr untergewichtigen Frühgeborenen. Eine Frühgeburt wird 
häufig assoziiert mit negativen Folgen für die Gesundheit, sowohl direkt nach der 
Geburt als auch bezüglich der späteren Entwicklung. Der heutige Kenntnisstand 
bezüglich der Rolle der Ernährung von Frühgeborenen, der Bedarf an Nährstoffen, als 
auch die verschiedenen Darreichungsformen werden besprochen. Heutzutage ist 
allgemein anerkannt, dass Nahrung, die in der frühen Phase nach der Geburt 
verabreicht wird, ein wichtiger Faktor für die weitere Entwicklung eines Frühgeborenen 
ist, auch auf lange Sicht gesehen. Im Allgemeinen ist das Streben, um mit Hilfe der 
Ernährung nach der Geburt ein Wachstum zu erreichen, dass dem Wachstum während 
der Schwangerschaft entspricht, und eine funktionelle Entwicklung zu erreichen, 
die vergleichbar ist mit der eines reifgeborenen Kindes. In der Praxis zeigt sich jedoch, 
dass Frühgeborene häufig wachstumsretardiert sind und weniger gut im Alltag zurecht - 
kommen als ihre zum Termin geborenen Altersgenossen. Wachstum, neurologische 
Entwicklung und Knochenmineralisation werden häufig als Maßstab für den Effekt 
von Nahrungsinterventionen gesehen. Dieses Kapitel beschreibt diesbezüglich den 
heutigen Kenntnisstand.
Kapitel 2
Dieses Kapitel beschreibt die Einteilung der gesamten Arbeit, in der Interventionen 
auf dem Gebiet der Ernährung in der frühen Phase nach der Geburt bei sehr unter-
gewichtigen (< 1500 gram) und extrem untergewichtigen (< 1000 gram) Frühgeborenen 
untersucht wurden. Nach der Geburt findet ein Übergang statt von der reichen, 
 kontinuierlichen Zufuhr an Nahrungsstoffen über die Nabelschnur zu einer Nahrungs-
aufnahme über den unreifen Magen-Darm Trakt oder künstliche Ernährung über 
eine Infusion. Daraus ergibt sich ein erhöhtes Risiko auf sowohl Unter- als auch 
Überernährung und in Folge eine mangelnde Entwicklung des Kindes. Die hier vor -
gestellten Arbeiten richten sich auf die Untersuchung des Effektes von Aminosäuren 
auf das Wachstum und die neurologische Entwicklung und den Einfluss des Calcium 
– Phosphat Haushaltes auf die Knochenmineralisation.
Teil 2
Kapitel 3
Kapitel 3 untersucht ob, mit einer höheren Zufuhr an Aminosäuren und Energie in der 
parenteralen Infusion, die Gewichtszunahme in den ersten Wochen nach der Geburt 
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verbessert werden kann. Für diese observationelle Studie wurden Daten gesammelt 
von zwei aufeinander folgenden Jahrgängen von Frühgeborenen, die auf der 
Neonatalen Intensive Care Abteilung (NICU) des Radboudumc aufgenommen wurden. 
Frühgeborene, behandelt mit einem erneuerten Ernährungsprotokoll (Cohort 2), 
wurden verglichen mit Frühgeborenen deren Nahrungsaufnahme basierte auf dem 
alten Protokoll (Cohort 1).  Mit dem neuen Protokoll erhielten die Patienten in der 
ersten Lebenswoche signifikant mehr Eiweiß. Dies war assoziiert mit einer höheren 
Gewichtszunahme während der ersten fünf Wochen. Frühgeborene, die bei der 
Geburt ein zu niedriges Gewicht entsprechend der Schwangerschaftsdauer (small for 
gestational age, SGA) hatten, zeigten eine höhere Gewichtszunahme als die Kinder, 
die ein adäquates Gewicht hatten (appropriate for gestational age, AGA). Die Zunahme 
des Kopfumfanges war bei den SGA Patienten jedoch geringer. Leider zeigte diese 
Studie auch, dass alle Frühgeborenen aus beiden Kohorten, trotz der verbesserten 
Nahrungszufuhr, zum korrigierten Zeitpunkt der errechneten Geburt, eine Wachstums-
retardierung von zwei Standardabweichungen erreicht hatten. Die Schlussfolgerung 
aus dieser Studie war, dass mit der neuen parenteralen Ernährungslösung wohl eine 
verbesserte Gewichtszunahme erreicht werden konnte, aber dass durch eine schnelle 
Erhöhung der enteralen Ernährung, mit angereicherter Frauenmilch, eine Unter-
ernährung nicht verhindert werden konnte. 
Kapitel 4      
Kapitel 4 beschreibt die Langzeitentwicklung der initial untersuchten Kohorte von 
Frühgeborenen im Alter von 9 bis 10 Jahren.  Das Ziel dieser Studie war zu untersuchen 
ob eine höhere Einnahme von Calcium und Phosphat während  der erste beiden 
Lebenswochen assoziiert werden konnte mit einem besseren Längenwachstum und 
verbesserter Knochenmineralisation. Kinder die vor der 32. Schwangerschaftswoche 
geboren waren und weniger als 1500 gram bei Geburt wogen, wurden im Alter von 
9 – 10 Jahren zu einer zusätzlichen Nachuntersuchung eingeladen.  Daten zum 
Wachstum der vorangegangen Jahre wurden registriert während der standardisier-
ten Nachsorgeuntersuchungen für Frühgeborene. Während der letzten Untersuchung 
wurde zur Bestimmung der Knochenmineralisation zusätzlich eine ‚Dual – Energy 
X-Ray Absorptiometry‘ Scan (DXA - Scan) durchgeführt, wobei der Knochengehalt 
und die Knochendichte des gesamten Körpers und der Lendenwirbelsäule bestimmt 
wurden. Die Langzeitentwicklung der Körperlänge wurde für beide Kohorte als auch 
separat für Kinder mit einem normalen (AGA) und einem zu niedrigem Geburtsgewicht 
(SGA) für die Schwangerschaft als auch für Jungen und Mädchen  analysiert. Mit Hilfe 
einer multivariaten Regressionsanalyse wurde der Effekt von ‚Nahrung‘ auf das 
Längenwachstum und die Knochenmineralisation bestimmt. Beide Kohorte zeigten 
ein Aufholwachstum und erreichten damit, im korrigierten Alter von sechs Monaten, 
eine normale Länge im Vergleich zur niederländischen Bevölkerung. Im Alter von 9 
bis 10 Jahren waren der Knochengehalt und -dichte ebenfalls normal für das Alter 
und wurde kein Unterschied zwischen den Kohorten gefunden. SGA - Kinder 
erreichten erst im Alter von fünf Jahren  ein Aufholwachstum und eine normale 
Knochen mineralisation zum Zeitpunkt der letzten Untersuchung. Es konnte kein 
Zusammenhang festgestellt werden zwischen der Höhe der Calcium und Phosphat 
Einnahmenahme und der Knochenmineralisation im Alter von 9 bis 10 Jahren. Die 
Schlussfolgerung dieser Studie war, dass sowohl AGA- als SGA Kinder in der Lage sind 
eine normale Körperlänge zu erreichen und dass in dieser Studie eine höhere Zufuhr 
an Mineralen während der ersten beiden Lebenswochen keinen Einfluss hatte auf 
Körperlänge und Knochenmineralisation.
Kapitel 5
In der Studie, die in diesem  Kapitel beschrieben wird, wurde untersucht ob eine 
höhere Einnahme von Aminosäuren und Energie in der ersten Lebenswoche (Cohort 
2) zu einer verbesserten neurologischen Entwicklung bei Frühgeborenen im 
korrigierten Alter von 24 Monaten führt. Der Entwicklungsstand wurde bestimmt mit 
Hilfe der ‚Bayley Scales of Infant Development - 2nd Edition. Der Zusammenhang 
zwischen Nahrungseinnahme und psycho-motorischen Testergebnissen wurde 
analysiert mittels linearer und logistischer Regression. Die Analyse der Daten ergab, 
dass Cohort 2 im Vergleich zu Cohort 1 signifikant mehr Eiweiß und Kalorien erhalten 
hatte und dass besonders die männlichen Frühgeborenen eine signifikant höhere 
 Gewichtszunahme in den ersten fünf Wochen zeigten. Die durchschnittlichen 
mentalen Entwicklungsindices (MDI) waren nicht unterschiedlich zwischen den 
Kohorten, aber Kinder aus Cohort 2 hatten eine signifikant höhere Wahrscheinlichkeit 
eine normale geistige Entwicklung zu erreichen, mit einer Odds Ratio von 6,4 und 
einem Konfidenzintervall von 1,5-27,4. Eine höhere Eiweißeinnahme war für Mädchen 
assoziiert mit einer höheren Wahrscheinlichkeit eine normale mentale Entwicklung 
zu erreichen (5,3; 1,2-23,3), während dies für Jungen signifikant die Wahrscheinlichkeit 
eine normale motorische Entwicklung zu erreichen, erhöhte. Die Schlussfolgerung 
dieser Studie war, dass eine Erhöhung der Nahrungseinnahme verschiedene 
Auswirkungen auf die neurologische Entwicklung von Jungen und Mädchen hat.  
 Eine Teilanalyse zeigte, dass männliches Geschlecht und ein persistierender 
Ductus Arteriosus (PDA) die wichtigsten Faktoren für eine ungünstige neurologische 
Entwicklung waren. Frühgeborene aus unserer Studie, die einen PDA hatten, erhielten 
während der ersten zwei Lebenswochen signifikant weniger Eiweiß und Kalorien. 
Eine Beschränkung der Flüssigkeitszufuhr und zurückhaltende Steigerung der 
enteralen Nahrung werden häufig zur Behandlung eines PDA angewandt. In vielen 
Fällen führt dies zu einer geringeren Einnahme von Nahrungsstoffen. Wir schlagen 
vor, dass eine ungünstige neurologische Entwicklung, so wie sie bei Kindern mit PDA 
häufig gesehen wird, nicht verursacht wird durch einen PDA, sondern die Folge ist 
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einer Unterernährung zum Zeitpunkt einer schnellen Entwicklung des Gehirns. 
Wir schlagen weiterhin vor, dass bei der Beurteilung der neurologischen Entwicklung 
im Zusammenhang mit anderen mit Frühgeburtlichkeit assoziierten Erkrankungen, 
die Nahrungseinnahme als Faktor mit einbezogen werden sollte.  
Teil 3
Kapitel 6
Dieses Kapitel beschreibt eine observationelle, deskriptive Studie, die den Kalzium- 
Phosphat Metabolismus von Frühgeborenen aus Cohort 2 untersuchte. Während der 
ersten fünf Wochen nach der Geburt wurden die Konzentrationen von Kalzium und 
Phosphat im Blut und Urin bestimmt und  in Zusammenhang gebracht mit der 
Einnahme von Mineralien und Vitamin D. Ab Tag 5 wurde die   empfohlene Menge an 
Mineralen verabreicht, während Vitamin D erst nach 4 Wochen in ausreichenden 
Mengen angeboten wurde. In der ersten Lebenswoche entwickelten die Früh -
geborenen eine Hyperkalzämie, Hyperkalziurie, Hypophosphatämie. Mehr als die 
Hälfte der Kinder bekam zusätzlich Phosphat verabreicht.  Die renale Reabsorption 
von Phosphat war anfänglich sehr hoch (> 95%), aber nahm  nach der zweiten Woche 
ab bis auf 70%. Die alkalische Phosphatase lag im Bereich de Normwerte zum 
Zeitpunkt der Geburt, stieg bis Tag 14 auf ein durchschnittliches Maximum von 
450 IE/L an und blieb danach oberhalb der Normalwerte während des gesamten 
 Beobachtungszeitraum. Die Schlussfolgerung aus dieser Studie war, dass der 
Phosphatgehalt in der verabreichten Nahrung zu niedrig war. Dies führte zu einer 
Verstörung des Kalzium-Phosphat Metabolismus. Weiterhin war die verabreichte 
Vitamin D Gabe unterhalb der empfohlenen  Dosierung. 
Kapitel 7  
Die Studie die in Kapitel 7 präsentiert wird, basiert auf den Daten die im Rahmen der 
‚Early Supplementation Study‘ (ESS) gesammelt wurden. Die ESS war eine Teilstudie 
der ‚Early Nutrition Study‘ (ENS), eine doppel-blind randomisierte Studie, die als Ziel 
hatte, den Effekt von Frauenmilch in Bezug auf Überleben und Vorkommen von 
Infektionen bei sehr untergewichtigen Frühgeborenen zu untersuchen. Die wichtigste 
Fragestellung der ESS war die Entwicklung der Knochenmineralisation im Zusammen- 
hang mit unterschiedlicher Einnahme von Kalzium (Ca) und Phosphat (P). Die Studie, 
die in Kapitel 7 beschrieben wird, untersuchte die Frage inwieweit Veränderungen 
der biochemischen Parameter des Ca-P Metabolismus, gemessen im Blut und Urin, 
abhängig sind von der Nahrungsaufnahme während der erste 14 Lebenstage. Unsere 
Hypothese war, dass die Aufnahme von Ca und P einen Effekt haben würde in Bezug 
auf biochemische Parameter des Ca-P Metabolismus. Für diese Studie wurden zwei 
Gruppen von sehr und extrem untergewichtigen Frühgeborenen, die jeweils unter-
schiedliche Mengen an Kalzium und Phosphat (viel/wenig) während der erste 14 Tage 
erhielten, miteinander verglichen. Biochemische Parameter wie Ca, P im Serum und 
Urin, Alkalische Phosphatase (ALP), renale Reabsorption on Phosphat und  die Urin 
Kreatinine Ratio für Ca und P wurden am Tag 1, 3, 5, 7 10 und 14 nach der Geburt 
bestimmt. Die täglichen medianen Konzentrationen der verschiedenen bio- 
chemischen Parameter beider Gruppen waren nicht unterschiedlich. Eine weitere 
Analyse zeigte, dass eine Erhöhung der Ca - Einnahme signifikant assoziiert war mit 
einer Zunahme der Ca Ausscheidung im Urin, einer verbesserten renale Rückresorption 
von P und einer Erniedrigung der ALP – Werte. Die Einnahme von P war assoziiert mit 
einer Erhöhung der P Konzentration im Serum, einer erhöhten Ausscheidung von 
P im Urin, der P - Kreatinine Ratio und der ALP. Die renale Rückresorption sank im 
Zusammenhang mit einer erhöhten P – Einnahme. Die Eiweißeinnahme war assoziiert 
mit einer Erniedrigung der P Konzentration im Blut, während eine kurze Schwanger-
schaftsdauer und männliches Geschlecht  ebenfalls assoziiert waren mit erhöhter P – 
Ausscheidung. Standardisierte, wiederholte Messungen zeigten, dass biochemische 
Parameter beeinflusst wurden durch Nahrungseinnahme, Gestationsalter und Geschlecht. 
Kapitel 8
Dieses Kapitel präsentiert die Ergebnisse einer Studie, die den Effekt  unterschiedlicher 
Konzentrationen von Kalzium und Phosphat in der Nahrung in Bezug auf die Kno-
chenmineralisation und das Wachstums sehr untergewichtiger Frühgeborener im 
korrigierten Alter eines reifgeborenen Kindes untersuchte. Für diese Studie wurden 
109 Kinder mit einem Geburtsgewicht unter 1500 gram im Losverfahren in drei 
Gruppen eingeteilt. Gruppe A: Muttermilch (MOM) oder Spendermilch (nicht 
angereichert), Gruppe B: MOM (nicht angereichert) oder Formula Nahrung für 
Frühgeborene, Gruppe C: MOM (angereichert ab 50 ml/d) und Formula Nahrung für 
Frühgeborene. Da der Einschluss von Patienten vorzeitig beendet werden musste, 
konnte die ursprüngliche geplante Anzahl von Kindern pro Gruppe nicht erreicht 
werden. Aus diesem Grunde hat die Studie wahrscheinlich eine unzureichende 
statistische Aussagekraft um alle Studienfragen zu beantworten. Aufgrund des 
Studien protokolls wurde in Gruppe C mit der Nahrung eine signifikant größere Menge 
an Ca und P während der ersten 10 Tage verabreicht. Es  wurde kein Unterschied in 
Gewicht, Körperlänge und Knochenmineralgehalt und -dichte zwischen den drei 
Gruppen von sehr und extrem kleinen Frühgeborenen zum korrigierten Zeitpunkt 
des errechneten Termines gefunden. Eine multivariate Regressionsanalyse zeigte, 
dass die Zugehörigkeit zu einer der drei Gruppen keinen Einfluss hatte auf Gewicht, 
Körperlenge oder Knochenmineralgehalt, aber es wurde eine positive Assoziation 
zwischen Phosphateinnahme und Längenwachstum und der Menge der verabreichten 
Muttermilch und dem Knochenmineralgehalt gefunden. Aufgrund der Ergebnisse 
dieser Studie gibt es keinen Beweis, dass eine frühe Anreicherung der Frauenmilch, 
in Kombination mit einer hohen parenteralen Zufuhr von Mineralien, die Knochen-
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mineralisation verbessert. Die positive Auswirkung der Muttermilch auf die Entwicklung 
der Knochenmineralisation sollte weiter untersucht werden.  
Kapitel 9
Kapitel 9 beschreibt eine Studie die zwei diagnostische Methoden zur Beurteilung der 
Knochenmineralisation vergleicht. Es wurde untersucht ob Ultraschall (Knochenschall) 
am Finger gleichwertig ist zum Goldstandard, der Dual- Energy X-Ray - Absorptiometry 
(DXA) Scan. Die Knochenschall Untersuchung ist preiswert, einfach in der Handhabung 
und hat keine radioaktive Strahlung. Bei 60 ehemaligen Frühgeborenen wurden 
im Alter von 9 bis 10 Jahren am gleichen Tag mit beiden Methoden Messungen 
durchgeführt. Mit dem DXA Scan wurde die Knochendichte für den gesamten Körper 
und die Lendenwirbelsäule bestimmt, während mit dem Knochenecho die 
Geschwindigkeit und die Zeitdauer des Schalls durch den Knochen gemessen wurde. 
Für alle Messungen wurden sowohl kontinuierliche als auch Z-Scores erhalten. Zum 
Vergleich wurden vier statistische Methoden angewendet: Pearsons Korrelation, 
Partielle Korrelation korrigiert für Schwangerschaftswoche bei Geburt, Körperlenge 
und BMI, Bland Altman Plot und Kontingenztafeln. Beide Methoden zeigten eine 
statistisch signifikant schwache Korrelation, die noch schwächer wurde nach Korrektur 
für mögliche verstörende Variablen. Die Bland-Altman Analyse zeigte eine schwache 
Übereinstimmung, während Sensitivität und Spezifizität eine sehr breite Spanne 
hatten. Aufgrund dieser Ergebnisse ist unsere Schlussfolgerung, dass ein Knochenecho 
einem DXA Scan nicht gleichwertig ist, und damit den DXA Scan zur Beurteilung der 
Knochenentwicklung bei ehemaligen Frühgeborenen im Alter von 9 bis 10 Jahren 
nicht ersetzen kann.
Kapitel 10
In diesem Kapitel werden die Erkenntnisse der oben beschriebenen Studien besprochen 
im Zusammenhang mit der relevanten wissenschaftlichen Literatur. Weiterhin werden 
Vorschläge gemacht für zukünftige Studien.
Die wichtigsten Erkenntnisse der hier vorgestellten Arbeiten sind: 
• Eine Erhöhung der Einnahme an Eiweiß und Kalorien in der ersten Lebenswoche 
verbessert bei sehr untergewichtigen Frühgeborenen die Gewichtszunahme nach 
der Geburt.
• Mit einem Standard Multi-Komponenten Supplement für Frauenmilch kann bei 
sehr untergewichtigen Frühgeborenen eine Wachstumsretardierung nach der 
Geburt nicht verhindert werden.
• Die Nahrungseinnahme während der ersten Lebenswoche hat unterschiedliche 
Auswirkungen auf die neurologische Entwicklung von Jungen und Mädchen im 
Alter von 24 Monaten.
• Frühgeborene mit einem zu niedrigem Geburtsgewicht haben, im Vergleich zu 
Frühgeborenen mit einem normalen Gewicht bei der Geburt, einen anderen Eiweiß- 
bedarf um ein optimales Wachstum zu erreichen. 
• Ehemalige Frühgeborene sind in der Lage eine Körperlenge und Knochen-
mineralisation zu erreichen, die der der Referenzpopulation entspricht, aber bleiben 
unterhalb der Standardabweichung zum Zeitpunkt der Geburt.
• Heutige Empfehlungen für Frühgeborene zum Bedarf an Kalzium und Phosphat 
sind unzureichend um einen stabilen Kalzium-Phosphathaushalt zu erreichen.
• Der Kalzium-Phosphat Metabolismus wird beeinflusst durch die Einnahme an 
Mineralien, Eiweiß, und dem Gestationsalter des Kindes. 
• Zur Verbesserung der Knochenmineralisation in der frühen Phase nach einer Früh- 
geburt sind  weitere Studien nötig.
• Der Knochenschall kann den Dual-Energy X-Ray Absorptiometry Scan zur Beurteilung 
der Knochenmineralisation nicht ersetzen.
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ABBREVIATIONS
Abbreviations 
AAP:  American Association of Pediatrics
AD-SoS Amplitude dependent speed of sound 
AGA:  Appropriate for gestational age
ALP:  Alkaline phosphatase
BMC: Bone mineral content
BMD: Bone mineral density
BMI:  Body mass index
BSDI -II:  Bayley Scales of Infant Development – Second Edition 
BTT: Bone transit time  
BW:  Birth weight 
Ca: Calcium 
CA:  Corrected age 
CLD:  Chronic lung disease 
Creat:  Creatinine 
CVC:  Central venous catheter 
DEXA:  Dual energy X-ray absorptiometry  
ELBW Extremely low birth weight 
ESPGHAN  European Society of Paediatric Gastroenterology Hepatology and Nutrition
GA:  Gestational age 
GI symptoms:  Gastrointestinal symptoms  
HC: Head circumference 
HMF: Human milk fortifier 
IQR : Inter quartile range 
IRDS:  Infant respiratory distress syndrome 
ISCD: International Society  of Clinical Densitometry 
IVH:  Intra-ventricular hemorrhage 
LBW: Low birth weight 
LS:  Lumbar spine scan 
MDI:  Mental developmental index 
MOM: Mother’s own milk 
MV:  Mechanical ventilation 
N-CPAP: Nasal continuous positive pressure support 
NEC:  Necrotizing enterocolitis 
P: Phosphorus 
PDA:  Patent ductus arteriosus 
PDI:  Psychomotor developmental index 
PN:  Parenteral nutrition 
pQUS: Phalangeal quantitative ultrasound 
QUS: Quantitative ultrasound  
ROP:  Retinopathy of prematurity  
sCa: Serum calcium 
sP: Serum phosphorus 
SDS:  Standard deviation score 
SGA:  Small for gestational age 
SOS: Speed of sound 
TCA:  Term corrected age 
TrP: Tubular reabsorption of phosphorus 
uCa: Urinary excretion of calcium 
uP: Urinary excretion of phosphorus  
VLBW infant:  Very low birth weight infant  
WB:  Whole body scan
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DANKWOORD
Dankwoord
Aan het einde van dit proefschrift kan ik alleen maar beamen wat velen voor mij aan 
het einde van hun boekje benoemd hebben: een dergelijk werk komt alleen tot stand 
door de samenwerking van heel veel mensen. Graag wil ik iedereen hartelijk danken 
dat ik door deze samenwerking niet alleen dit proefschrift heb kunnen schrijven 
maar ook dat ik hierdoor in de gelegenheid gesteld ben om zelf heel veel meer van 
mijn vak te leren en nog meer van mijn werk te genieten. Een speciale dank gaat uit 
naar alle betrokken patiënten en hun ouders. Voor dit proefschrift zijn data verzameld 
van ca 300 kinderen. Meer dan 200 aanstaande ouders hebben op een moment dat 
zij zichzelf in een ernstige stress situatie bevonden, er mee ingestemd naar mijn 
verhaal te luisteren en te overwegen of hun te vroeggeboren kindje mee zou mogen 
doen aan onderzoek. Voor veel ouders is deze beslissing heel begrijpelijk te zwaar. 
Ouders verwachten van hun arts dat hun kind ‘gewoon’ de beste behandeling krijgt. 
Dat willen wij vanzelfsprekend ook waarmaken maar de realiteit is dat de ‘beste 
behandeling’ niet altijd bekend is. De neonatologie kan zich alleen verder ontwikkelen 
als wij systematisch onze handelingen en beleid analyseren en hiervoor is onderzoek 
nodig. Daarom wil ik hierbij graag mijn respect en grote dank uitspreken aan de 
ouders, die ons op deze onzekere weg hun vertrouwen hebben gegeven en alle 
medewerking aan dit onderzoek hebben verleend. 
Verder zou ik mijn dank willen uitspreken aan de volgende personen:
Prof. Dr. K. Noordam. Beste promotor, beste Kees, ondanks het feit dat mijn onderzoek 
niet binnen het profiel van de afdeling valt heb ik wel steun en begrip gekregen, 
waarvoor ik jou hierbij zou willen bedanken.
Dr. A.F.J. van Heijst. Beste Copromotor, beste Arno, zonder jou was dit proefschrift er 
zeker niet gekomen. Twee belangrijke zaken heb jij met grote nadruk geprobeerd mij 
te leren, namelijk focussen en frustratietolerantie opbouwen. Voor iemand met brede 
interesses zoals ik, was dat een moeilijke opgave om aan te voldoen. Jouw advies was 
om de sereniteit en discipline van het kloosterleven na te streven. Dat is gedeeltelijk 
gelukt, maar ik verheug mij er wel op om uit mijn kloostercel te kunnen stappen en 
weer een wat bredere kijk op de wereld te krijgen. Hartelijk dank daarvoor, dat jij mij 
ook nog gesteund hebt nadat ik besloten had om met een onderwerp door te gaan 
dat niet bij het speerpunt van onze afdeling hoort. Hopelijk heb ik jou kunnen 
overtuigen dat, onafhankelijk van welk speerpunt dan ook, voeding voor onze 
patiënten een belangrijk item is.  
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Prof. Dr. J.B. van Goudoever. Beste Promotor, beste Hans, ik was enorm blij toen jij je 
bereid verklaarde om de begeleiding van mijn promotietraject op afstand er ook nog 
bij te nemen. De afstand is nooit een belemmering geweest. Emailverkeer schijnt tot 
in het diepste Azië te werken en reacties kwamen meestal al voor het opstaan. Dank 
voor alle positieve commentaren en opmerkingen. Op menig moment was dat nodig 
om enige frustratie weg te werken en weer verder te kunnen gaan. Met heel veel 
genoegen heb ik aan het traject van de ENS-ESS meegewerkt en heel veel geleerd 
hoe je een studie volgens de regels der kunst opzet en uitvoert. Eigenlijk smaakt dit 
naar meer, maar voorlopig hoop ik ook nog, dat de braakliggende data nog verwerkt 
zullen worden en dus dat de samenwerking met het afmaken van dit proefschrift nog 
niet beëindigd is. 
De leden van de manuscriptcommissie: Prof. Dr. M.W.G. Nijhuis - van der Sanden, 
Prof. Dr. J.P.H. Drenth en Prof. Dr. H.N. Lafeber. Hartelijk dank om mijn stuk zo snel 
en ook nog tijdens de feestdagen te beoordelen en natuurlijk ook dank voor de 
positieve beoordeling.
Prof. Dr. R. de Groot. Beste Ronald, als voormalig hoofd van de afdeling kindergenees-
kunde heb je initieel jouw goedkeuring gegeven voor mijn onderzoek en een rol 
gespeeld bij het regelen van geschikte begeleiding. Daarmee heb je mee aan de wieg 
gestaan van dit boek waarvoor ik je hierbij hartelijk wil bedanken.  
Prof. Dr. M. van de Bor. Beste Margot, onze samenwerking is langgeleden. Desalniet- 
temin heeft dit voor mij een belangrijke betekenis gehad, doordat ik met jou mijn eerste 
stappen op het gebied van onderzoek mocht zetten en jouw begeleiding hierbij 
uitstekend was en bepalend voor mijn verdere loopbaan. Tot dat moment was mijn 
streven om vooral een goede arts te worden. Gaandeweg heb ik voor mijzelf gemerkt 
dat het een het ander niet uitsluit.  De samenwerking was kort maar met veel 
genoegen herinner ik onze gezellige etentjes tijdens diverse congressen. 
Prof. Dr. H.N. Lafeber. Beste Harrie, als voorzitter van de werkgroep voeding voor 
pasgeborene heb jij misschien even aan mijn wat ‘stellige, kritische houding’ moeten 
wennen, waardoor mogelijk aanvankelijk sommige uitspraken van mij tot 
misverstanden geleidt hebben. Van mijn kant was het altijd goed bedoeld en had dit 
misschien meer met een wat ‘Duits communicatie probleem’ en enige mate van 
fanatisme te maken. Belangrijker is dat ik mij altijd door jou gewaardeerd en gesteund 
heb gevoeld. Dus, daarom hier ook nog een keer dank voor het feit dat ik mijn 
manuscript tijdens jouw vakantie in Twente mocht afleveren en wij gezellig de 
middag konden doorkletsen.
Leden van de werkgroep voeding. Onze gezamenlijke activiteiten gedurende de 
laatste jaren hebben er in hoge mate toe bij gedragen dat mijn belangstelling voor 
voeding voor prematuren is gestegen en er uiteindelijk toe geleidt hebben om er 
meer werk van te maken. Het afgelopen jaar ben ik meer af- dan aanwezig geweest. 
Ik hoop vanaf nu weer een actieve bijdrage te kunnen leveren. 
De basis voor alle studies, die in dit proefschrift gepubliceerd zijn, is gelegd door het 
werk van maar liefst 9 studenten die in hun vrije tijd met heel veel geduld en 
nauwkeurigheid alle statussen door gewerkt, IC-lijsten ontcijfert en alles in grote 
databestanden ingevoerd en uitgebreide intake berekeningen verricht hebben. 
Marjolein Engelkes, jij hebt als eerste in je eentje een opstap gemaakt om een 
complete jaargang uit te pluizen. Omdat jij dit werk ook wilde gebruiken voor je 
wetenschappelijke stage, was dat in feite het moment voor mij om na te denken wat 
er eigenlijk met al die gegevens moest gebeuren en welke vraagstellingen belangrijk 
waren. Het heeft jouw een presentatie op de NVK opgeleverd en ondertussen zijn de 
gegevens gebruikt voor publicaties. Vervolgens waren er opnieuw drie 2e jaars 
studenten die actief wilden kennis maken met de kindergeneeskunde, Reina Visser, 
Anne de Grauw en Mariëlle Schelle. Reina heeft naafloop van haar stage ook nog de 
lange termijn groeigegevens opgezocht bij alle omliggende ziekenhuizen. Die 
gegevens konden in meerdere publicaties gebruikt worden. Anne ontdekte als eerste 
dat er ondanks een hogere toediening aan calcium en fosfaat het metabolisme nog 
steeds niet in orde was en dit was aanleiding voor verdere studies. Ondertussen 
hebben jullie allen een eigen carrière in de kindergeneeskunde opgebouwd en ben ik 
trots aan het begin hiervan met jullie te hebben kunnen samen werken. De gegevens 
voor de ENS-ESS studie zijn door Michelle Körnmann, Charlotte  Gradussen en Laure 
Vorstenbosch ingevoerd. Charlotte heeft daarna met een indrukwekkende 
statistische analyse de relatie tussen voedingsintake en biochemische parameter 
aangetoond en deze resultaten zijn ondertussen ook gepubliceerd. Michelle heeft na 
haar wetenschappelijke stage de hele analyse met alle kinderen uit de studie 
overgedaan. De resultaten waren niet zo als wij gehoopt hadden maar het manuscript 
was wel binnen een maand geaccepteerd. Inge Vermeer en Carmen Lageweg 
hebben beiden mijn collega Mayke van der Putten ondersteund om de lange termijn 
gegevens in kaart te brengen en de kinderen uit de Cohorten 2004, 2005 op oudere 
leeftijd nog een keer te onderzoeken. De resultaten hiervan zijn onlangs gepubliceerd. 
Carmen heeft een mooie presentatie tijdens het NVK congres kunnen geven over de 
uitkomsten van haar stage project en dit is in een manuscript omgezet dat ondertussen 
eveneens geaccepteerd is. Ik ben jullie dankbaar voor jullie inzet en wens jullie veel 
succes  voor de toekomst. 
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Mayke van der Putten. Beste Mayke, ondertussen collega neonatoloog in het 
Maastricht UMC, met jouw fellow onderzoek heb jij mijn grote wens om de kinderen 
uit 2004 en 2005 nog een keer terug te zien voor een lange termijn follow up 
gerealiseerd. Dank voor de opzet, planning en realisatie van dit onderzoek, dat met 
twee publicaties uiteindelijk bekroond is. 
Buiten de afdeling neonatologie kon ik rekenen op medewerking van alle kanten. 
De apotheek: Lang geleden (2003, 2004) is er veel werk van gemaakt om op mijn 
aanvraag een nieuwe samenstelling voor de parenterale voeding samen te stellen. 
Drs. Nicole Vink- van Kimmenade en Dr. Anna de Goede hartelijk dank voor jullie 
constructieve samenwerking sindsdien. De afdeling Nucleaire Geneeskunde: Prof. 
M. Gotthardt. Beste Martin, hartelijk dank voor je ongecompliceerde en constructieve 
medewerking bij twee projecten. Daarnaast was het opmerkelijk hoe gastvrij en 
vriendelijk wij door alle medewerkers werden ontvangen, op een afdeling die zeker 
niet gewend is om met kleine pasgeboren kinderen om te gaan. Hartelijk dank Marjo 
van de Ven voor de technische ondersteuning bij de DXA scans en de constructieve 
medewerking en het geduld als kinderen niet stil wilden liggen tijdens het onderzoek. 
De Follow up Poli: naar alle bij de neonatale follow up betrokken personen zou ik 
graag mijn dank willen uitspreken voor de medewerking aan mijn projecten. Ik ben 
mij ervan bewust dat dit voor iedereen extra werk opgeleverd heeft zowel voor de 
fysiotherapeuten, de logopedisten als ook de psychologen, het secretariaat en de 
verpleegkundigen. Dr. A.J.W.M. Janssen, beste Anjo, veel dank, niet alleen voor het 
mogen gebruiken van jouw gegevens maar ook dank voor je waardevolle commentaar 
op alle manuscript versies en je uitleg over de interpretatie van Bayley Scores. Mirjam 
Jetten dank voor je bijzondere moeite om alle scores zo duidelijk mogelijk te noteren 
en je uitleg over verschillen tussen de diverse tests. Het PDRC: Jos Gilissen heeft 
ervoor gezorgd dat voor de ENS_ESS alle GCP regels werden aangehouden terwijl 
Wendy Janssen in de praktijk tijdens de studie de gang van zaken onder controle 
had, afspraken met ouders en poli maakte, monsters verzamelde, de administratie 
bijhield en de studenten gesuperviseerd heeft. Beste Wendy, heel veel dank voor je 
onmisbare inzet voor de ENS_ESS. De ENS – groep: Dank o.a. aan Willemijn Corpeleijn, 
Marita de Waard en Stefanie Kouwenhoven die meegedacht hebben over de 
studieopzet en de opbouw van de database voor de ESS. Veel succes met jullie eigen 
projecten de komende tijd. Last but not least, de afdeling Biostatistiek: Terwijl ik 
aanvankelijk dacht alle berekeningen zelf te kunnen uitvoeren, heb ik de afgelopen 
tijd toch nog menig statistisch consult nodig gehad. Dr. N. Roeleveld. Beste Nel, veel 
dank om het onderzoek door goede statistiek op een ander niveau te tillen, zoals jij 
beloofd had. Drs. T. Feuth. Beste Ton, als invaller bij de afdeling statistiek na je 
pensionering heb je Mayke en Carmen heel goed geholpen. Helaas, voor ons was je 
echt alleen maar invaller. Dr. L. Rodwell.  Dear Laura, while it was meant to be a five 
minute consultation, our first meeting led to quite sophisticated high level statistical 
analyses with finally two very easily accepted papers. Thank you for your dedicated 
cooperation, meaning that you performed most of the analyses in your free-time, 
your critical comments on my statements and your final language-checks. I would like 
to say that your efforts improved my knowledge in a ‘statistically significant’ way 
during this last year for which I am very grateful to you.  
Team Perinatologie: Eigenlijk was de ENS-ESS studie een eerste proeve hoe wij als 
afdeling neonatologie en verloskunde samen kunnen werken - en dat ging heel goed! 
De lactatiekundigen Vera van Haaren, Jessie Cremer en Kim van de Water hebben er 
met hun voorlichting aan ouders en verpleegkundigen voor gezorgd dat een 
ongekend hoog aantal moeders succesvol moedermelk aan hun te vroeg geboren 
kinderen kon geven terwijl de kraamverpleegkundigen moeders ondersteunden om 
het ‘witte goud’ zo snel mogelijk bij de neonatologie af te kunnen leveren. Voor de 
neo-verpleegkundigen betekende de studie dat zij in plaats van zo maar een voed-
ingsspuitje pakken eerst naar het randomisatieschema moesten kijken en vooral alle 
intakes en de groei heel goed bij moesten houden, dus nog meer administratie. 
Iedereen heeft enthousiast meegewerkt, arts-assistenten, verpleegkundigen, zorg- 
hulpen, en secretaresses, te veel om alle namen te noemen. Apart wil ik nog wel de 
dames van de voedingskeuken noemen: Yolanda Dekker-Peters, Silvia Houkes, 
Jet Huijding-van Buren, Sonja Janssen, Heidi Lamers-Bosman, Leona Paas en 
Carlijn Thijssen en Ricky van Zuijlen-van den Broek. Terwijl jullie zeker niet 
aangenomen zijn voor wetenschappelijk onderzoek, waren jullie wel de spil van de 
studie, gezien het feit dat jullie de enige waren die wisten welke voeding een patiënt 
zou moeten krijgen en daarmee het studieresultaat ook van jullie betrouwbare 
werkwijze afhankelijk was. Jullie enthousiasme was geweldig. Heel veel dank voor 
jullie toegewijde medewerking aan deze studie. 
Lieve collega’s neonatologen. De afgelopen jaren hebben jullie mij veel ruimte 
gegeven om mijn ‘eigen ding’ te doen en vooral de afgelopen maanden heel veel 
vrijgespeeld om dit boekje af te kunnen maken. Beste Djien, Arno, Willem, Sabine, 
Katerina, Tim, René, Marije, Maresa, Robin, Mathijs, Elske en Joanne, voor mij betekent 
samenwerking met jullie, dat ten aanzien van het speerpunt ‘hemo-dynamiek’ binnen 
onze groep vooral het woord ‘dynamiek’ van toepassing is, namelijk een flexibel en 
vooral heel collegiaal team. Heel bijzonder om hierop te kunnen vertrouwen. Veel 
dank voor jullie bijdrage aan de inclusie van patiënten voor de ENS-ESS. Naar de 
follow up dokters: dank voor het invullen van extra-lijstjes voor de ENS-ESS patiënten 
en Katerina, dank voor het realiseren van extra poli-capaciteit voor de ENS-2 jaar 
follow up en dank aan Tim die met het opschrijven van het algoritme van de 
voedingsintake een analyse van de gegevens pas mogelijk gemaakt heeft.  
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Lieber Vati und liebe Mutti. Sowohl während der Schulzeit, des Studiums und der 
Ausbildung zum Kinderarzt konnte ich immer auf eure Unterstützung und euer 
Interesse an meiner Arbeit rechnen. Eure Enttäuschung war groß, als Peter und ich in 
die Niederlande umgezogen sind, aber ihr habt dies akzeptiert und selbst versucht 
die Sprache zu lernen. Lieber Vati, obwohl deine Welt in den letzten Jahren kleiner 
wurde, hast Du bis zuletzt versucht den Inhalt meiner Publikationen zu begreifen und 
mit mir darüber zu reden. Deine Art zu zuhören, aber auch kritische Fragen zu stellen 
habe ich immer bewundert. Fast genau auf den Tag, vor vier Jahren, haben wir 
Abschied genommen und Mutti ist dir zwei Jahre später um die gleiche Zeit gefolgt. 
Ich weiß, dass ihr euch sehr gefreut hättet dieses Buch zu sehen und bei den Feierlich-
keiten dabei zu sein. In meinen Gedanken seid ihr seid ihr meine Ehrengäste. 
Mijn Paranimfen. Mijn kinderen, lieve Lennaert en Wieke, vaak ben ik afwezig, veel 
aan het werk en nog meer achter mijn bureau, dus niet echt gezellig en soms wel een 
‘moppermama’ die op het laatste moment nog overal commentaar op moet geven. 
En toch tonen jullie altijd positieve belangstelling en begrip voor mijn werk en hebben 
jullie beiden op jullie manier een bijdrage aan dit boekje geleverd. Lennaert, 
waarschijnlijk heb jij zelf helemaal niet door hoeveel frustratie jij mij afgenomen 
hebt door alle verzamelde literatuur op gegeven moment over te zetten naar mijn 
reference manager. Wieke, dank je wel om mij af en toe voor een gezellige moeder- 
dochter filmavond achter het bureau weg te slepen. Het feit dat jullie op deze dag 
naast mij staan betekent dat ik helemaal op jullie vertrouw en dat ik supertrots ben 
op jullie. Het komt goed door jullie en met jullie. 
Liefste Peter. Aan het einde van deze opsomming sta jij als de voor mij meest 
vertrouwde persoon. Vanaf mijn komst naar Nederland ben jij degene die mij het 
meest support, het leren van de Nederlandse taal, bijles voor alle vakken in het eerste 
jaar (in feite heb jij wel de propedeuse geneeskunde gehaald), met humor tegen 
twijfels en frustraties ingaan. Jij bent mijn baken. Zo goed als  40 jaar zijn wij een goed 
team en ieder jaar wordt leuker en nu helemaal.........
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Viola Christmann was born on the 10th of September 1956 in Hamburg, Germany. 
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